[
    {
        "id": "unstructured-Biomarker_Clinical_Trials_in_Lung_Cancer.pdf-3d873136",
        "document": "This review article discusses the design, logistics, challenges, and practical considerations of biomarker clinical trials in lung cancer.  It covers the evolution of lung cancer treatment from histology-focused chemotherapy to biomarker-driven therapy, highlighting the shift towards precision medicine.  The authors provide an overview of trial designs across different drug development phases, including early-phase biomarker discovery, proof-of-concept trials (adaptive designs, basket trials), and definitive phase II/III and phase III trials (umbrella trials).  Challenges such as sample size justification, stopping rules, and heterogeneity of responses across subgroups are addressed.  The article concludes with a discussion of future directions in clinical trial design, emphasizing the need for efficient and flexible approaches to keep pace with rapid advancements in biomarker discovery and therapy development.",
        "metadata": {
            "identifier": "Biomarker Clinical Trials in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:26:51.787716+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Biomarker Clinical Trials in Lung Cancer.pdf",
            "name": "Biomarker Clinical Trials in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Biomarker",
                "Clinical Trials",
                "Lung Cancer",
                "Targeted Therapies",
                "Precision Medicine",
                "Adaptive Designs",
                "Basket Trials",
                "Umbrella Trials",
                "Drug Development"
            ],
            "author": "Jennifer Le-Rademacher, Suzanne Dahlberg, J. Jack Lee, Alex A. Adjei, Sumithra J. Mandrekar",
            "timestamp": "September 4, 2018",
            "headings": [
                "Introduction",
                "Early-Phase Biomarker Discovery Trial Designs",
                "Proof-of-Concept Trials",
                "Phase II Trials",
                "Adaptive Trial Design",
                "Tissue Agnostic or Molecularly Defined Rather Than Organ-Defined Trials",
                "Basket Trial Design",
                "Definitive Trials",
                "Phase II/III Design",
                "Phase III Design",
                "Conclusions and Future Directions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Defining_a_standard_set_of_patient-centred_outcomes_for_lung_cancer.pdf-469aa5ce",
        "document": "This article details the development of a standardized set of patient-centered outcomes for lung cancer by the International Consortium for Health Outcomes Measurement (ICHOM).  An international working group, using a modified Delphi method, established a consensus recommendation for essential outcomes, including survival, treatment complications, and patient-reported quality of life measures.  The study aimed to improve the measurement of lung cancer treatment value and facilitate global collaboration in improving care. Case-mix variables were also defined to allow for risk adjustment in comparisons.  The resulting \"Lung Cancer Standard Set\" is intended to guide future initiatives and improve global lung cancer care.",
        "metadata": {
            "identifier": "Defining a standard set of patient-centred outcomes for lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:26:56.744341+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Defining a standard set of patient-centred outcomes for lung cancer.pdf",
            "name": "Defining a standard set of patient-centred outcomes for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Patient-centered outcomes",
                "Quality of life",
                "Standard Set",
                "ICHOM",
                "Delphi method",
                "Survival",
                "Treatment complications",
                "Case-mix variables",
                "Risk adjustment"
            ],
            "author": "Kimberley S. Mak et al.",
            "timestamp": "July 07, 2016",
            "headings": [
                "ORIGINAL ARTICLE",
                "LUNG CANCER",
                "ABSTRACT",
                "Introduction",
                "Materials and methods",
                "Results",
                "Conditions scope and treatments covered",
                "Lung Cancer Standard Set: outcomes",
                "Survival",
                "Complications",
                "Degree of health",
                "Other outcomes",
                "Case-mix variables",
                "Data collection",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Effect_of_Prior_Cancer_on_Outcomes_in_Lung_Cancer.pdf-517145d8",
        "document": "This study investigates the effect of prior cancer on outcomes in patients with advanced lung cancer.  Researchers analyzed data from the Surveillance, Epidemiology, and End Results–Medicare linked registry, focusing on patients over 65 with stage IV lung cancer.  Their findings indicate that prior cancer did not negatively impact survival; in fact, patients with a history of prior cancer showed slightly better all-cause and lung cancer-specific survival.  The authors suggest that broader inclusion of patients with prior cancer in clinical trials should be considered.",
        "metadata": {
            "identifier": "Effect of Prior Cancer on Outcomes in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:01.400205+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Effect of Prior Cancer on Outcomes in Lung Cancer.pdf",
            "name": "Effect of Prior Cancer on Outcomes in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Prior Cancer",
                "Survival Outcomes",
                "Clinical Trials",
                "SEER-Medicare Registry",
                "Propensity Score",
                "Hazard Ratio",
                "Clinical Trial Eligibility"
            ],
            "author": "Andrew L. Laccetti*, Sandi L. Pruitt*, Lei Xuan, Ethan A. Halm, David E. Gerber",
            "timestamp": "February 09, 2015",
            "headings": [
                "Abstract",
                "Background",
                "Methods",
                "Data Sources",
                "Study Population",
                "Measures",
                "Statistical Analysis",
                "Results",
                "Discussion",
                "Funding",
                "Notes",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Efficacy_and_safety_of_nivolumab_nivo_monotherapy_versus_chemotherapy_chemo_in_recurrent_small_cell_lung_cancer_SCLC_Results_from_CheckMate_331.pdf-76df2f83",
        "document": "This is a report on the CheckMate 331 clinical trial (NCT02481830), evaluating nivolumab versus chemotherapy in patients with recurrent small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.  The primary endpoint, overall survival, did not show a statistically significant improvement with nivolumab. However, the study observed a delayed separation of survival curves, suggesting potential long-term benefits in platinum-refractory settings.  Nivolumab demonstrated a lower rate of adverse events compared to chemotherapy.  The authors acknowledge editorial assistance funded by Bristol-Myers Squibb.",
        "metadata": {
            "identifier": "Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC) Results from CheckMate 331.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:05.204447+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC) Results from CheckMate 331.pdf",
            "name": "Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC) Results from CheckMate 331.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "nivolumab",
                "chemotherapy",
                "small cell lung cancer (SCLC)",
                "CheckMate 331",
                "overall survival",
                "progression-free survival",
                "clinical trial",
                "platinum-resistant SCLC"
            ],
            "author": [
                "M. Reck",
                "D. Vicente",
                "T. Ciuleanu",
                "S. Gettinger",
                "S. Peters",
                "L. Horn",
                "C. Audigier-Valette",
                "N. Pardo",
                "O. Juan-Vidal",
                "Y. Cheng",
                "H. Zhang",
                "M. Shi",
                "J. Wolf",
                "S. J. Antonia",
                "K. Nakagawa",
                "G. Selvaggi",
                "C. Baudelet",
                "H. Chang",
                "D. R. Spigel"
            ],
            "timestamp": "December 2018",
            "headings": [
                "Table: LBA5 Efficacy outcomes with nivolumab vs chemotherapy in recurrent SCLC",
                "LBA5 Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331",
                "Background",
                "Methods",
                "Results",
                "Conclusions",
                "Editorial acknowledgement",
                "Clinical trial identification",
                "Legal entity responsible for the study",
                "Funding",
                "Disclosure"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Enrollment_Trends_and_Disparity_Among_Patients_With_Lung_cancer.pdf-24cd3dfb",
        "document": "This study analyzes enrollment trends and disparities in lung cancer clinical trials from 1990 to 2012, focusing on age, sex, and race/ethnicity.  Researchers compared data from 23,006 National Cancer Institute trial participants with 578,476 patients from the SEER registry.  While disparities decreased for elderly patients with non-small cell lung cancer and women overall, significant underrepresentation persisted for elderly patients with small cell lung cancer and minority groups.  The authors emphasize the need for continued efforts to improve representation in clinical trials to ensure generalizability of results and better target underrepresented patient groups.",
        "metadata": {
            "identifier": "Enrollment Trends and Disparity Among Patients With Lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:10.762007+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Enrollment Trends and Disparity Among Patients With Lung cancer.pdf",
            "name": "Enrollment Trends and Disparity Among Patients With Lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Clinical Trials",
                "Enrollment Disparities",
                "Age",
                "Sex",
                "Race/Ethnicity",
                "SEER Registry",
                "National Cancer Institute"
            ],
            "author": "Herbert H. Pang, Xiaofei Wang, Thomas E. Stinchcombe, Melisa L. Wong, Perry Cheng, Apar Kishor Ganti, Daniel J. Sargent, Ying Zhang, Chen Hu, Sumithra J. Mandrekar, Mary W. Redman, Judith B. Manola, Richard L. Schilsky, Harvey J. Cohen, Jeffrey D. Bradley, Alex A. Adjei, David Gandara, Suresh S. Ramalingam, and Everett E. Vokes",
            "timestamp": "September 19, 2016",
            "headings": [
                "Purpose",
                "Methods",
                "Data Sources",
                "Statistical Analysis",
                "Results",
                "Elderly and Women Patients",
                "Racial/Ethnic Minority Patients",
                "Elderly Patients by Lung Cancer Type",
                "Targeted Agents",
                "Discussion",
                "Authors’Disclosures of Potential Conflicts of Interest",
                "Author Contributions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Next_steps_to_improve_disparities_in_lung_cancer_treatment_clinical_trial_enrollment.pdf-81119bdf",
        "document": "This editorial discusses disparities in lung cancer clinical trial enrollment, focusing on underrepresentation of elderly patients, women, and racial/ethnic minorities.  It analyzes a study showing some improvement in enrollment of older patients with non-small cell lung cancer and women, but persistent disparities remain for other groups. The authors suggest multiple strategies to address these disparities, including policy changes, improved patient engagement, and realignment of research funding priorities.  They emphasize the need for a concerted effort involving various stakeholders to improve trial enrollment and ensure broader treatment effectiveness.",
        "metadata": {
            "identifier": "Next steps to improve disparities in lung cancer treatment clinical trial enrollment.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:13.732724+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Next steps to improve disparities in lung cancer treatment clinical trial enrollment.pdf",
            "name": "Next steps to improve disparities in lung cancer treatment clinical trial enrollment.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Clinical Trials",
                "Enrollment Disparities",
                "Racial Disparities",
                "Healthcare Disparities",
                "Personalized Medicine",
                "Cancer Treatment",
                "Research Funding"
            ],
            "author": "Leah L. Zullig, William R. Carpenter, Christina D. Williams",
            "timestamp": "December 20, 2016",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nivolumab_alone_and_nivolumab_plus_ipilimumab_in_lung_cancer.pdf-f9673826",
        "document": "This is a report on a phase 1/2 clinical trial (CheckMate 032) evaluating the safety and efficacy of nivolumab, alone and in combination with ipilimumab, for treating recurrent small-cell lung cancer (SCLC).  The study involved 216 patients across four treatment cohorts, assessing objective response rates and overall survival.  Results showed antitumor activity with both treatments, though the combination therapy demonstrated higher response rates.  The study highlights a potential new treatment approach for SCLC, warranting further investigation in larger, phase 3 trials.",
        "metadata": {
            "identifier": "Nivolumab alone and nivolumab plus ipilimumab in lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:20.379493+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Nivolumab alone and nivolumab plus ipilimumab in lung cancer.pdf",
            "name": "Nivolumab alone and nivolumab plus ipilimumab in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Small-cell lung cancer",
                "Nivolumab",
                "Ipilimumab",
                "Immunotherapy",
                "Clinical trial",
                "Phase 1/2",
                "Objective response",
                "Overall survival",
                "Adverse events",
                "PD-L1"
            ],
            "author": "Scott J Antonia, José A López-Martin, Johanna Bendell, Patrick A Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, M Catherine Pietanza, Dung T Le, Filippo de Braud, Michael A Morse, Paolo A Ascierto, Leora Horn, Asim Amin, Rathi N Pillai, Jeff ry Evans, Ian Chau, Petri Bono, Akin Atmaca, Padmanee Sharma, Christopher T Harbison, Chen-Sheng Lin, Olaf Christensen, Emiliano Calvo",
            "timestamp": "June 4, 2016",
            "headings": [
                "Summary",
                "Introduction",
                "Methods",
                "Study design and participants",
                "Procedures",
                "Outcomes",
                "Statistical analysis",
                "Results",
                "Discussion",
                "Contributors",
                "Declaration of interests",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Phase_I_Clinical_Trial_Design_in_Cancer_Drug_Development.pdf-83174c58",
        "document": "This article summarizes a workshop on Phase I clinical trial design in cancer drug development.  The main focus is on improving the efficiency and safety of these trials by exploring alternative methodologies to the traditional Fibonacci escalation scheme.  Discussions included higher starting doses, fewer patients per dose level, and statistically based dose escalation methods like the continual reassessment method (CRM). The goal is to reduce the number of patients exposed to subtherapeutic doses while ensuring patient safety and accurate phase II dose recommendations.",
        "metadata": {
            "identifier": "Phase I Clinical Trial Design in Cancer Drug Development.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:25.555768+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Phase I Clinical Trial Design in Cancer Drug Development.pdf",
            "name": "Phase I Clinical Trial Design in Cancer Drug Development.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Phase I clinical trial",
                "cancer drug development",
                "dose escalation",
                "maximum tolerated dose (MTD)",
                "Fibonacci escalation",
                "Continual Reassessment Method (CRM)",
                "toxicity",
                "pharmacokinetics"
            ],
            "author": "E.A. Eisenhauer, P.J. O’Dwyer, M. Christian, and J.S. Humphrey",
            "timestamp": "2000",
            "headings": [
                "SPECIAL ARTICLE",
                "PHASE I TRIAL design in cancer therapeutics",
                "GOALS OF PHASE I TRIALS OF CYTOTOXIC AGENTS",
                "LIMITATIONS OF STANDARD PHASE I DESIGN AND POTENTIAL SOLUTIONS",
                "STARTING DOSE LEVELS FOR PHASE I STUDIES",
                "PHARMACOKINETICS IN PHASE I TRIALS AND PHARMACOLOGICALLY GUIDED DOSE ESCALATION",
                "NOVEL DOSE-ESCALATION METHODS: STATISTICALLY BASED METHODS",
                "ACCELERATED TITRATION DESIGNS",
                "COMMENTARY AND DISCUSSION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Secondary_analysis_of_KeyNote-001_phase_1_trial.pdf-da9d0ab5",
        "document": "This secondary analysis of the KEYNOTE-001 phase 1 trial investigated the impact of prior radiotherapy on the efficacy and toxicity of pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients.  The study found that patients who had received prior radiotherapy experienced significantly longer progression-free and overall survival with pembrolizumab treatment.  While a higher incidence of treatment-related pulmonary toxicity was observed in patients with prior thoracic radiotherapy, the rate of grade 3 or worse toxicity remained similar between groups.  Further research is needed to optimize the combination therapy strategy for NSCLC.",
        "metadata": {
            "identifier": "Secondary analysis of KeyNote-001 phase 1 trial.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:31.488774+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Secondary analysis of KeyNote-001 phase 1 trial.pdf",
            "name": "Secondary analysis of KeyNote-001 phase 1 trial.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Pembrolizumab",
                "Radiotherapy",
                "Non-small-cell lung cancer (NSCLC)",
                "Immunotherapy",
                "Progression-free survival",
                "Overall survival",
                "Pulmonary toxicity",
                "KEYNOTE-001 trial"
            ],
            "author": "Narek Shaverdian*, Aaron E Lisberg*, Krikor Bornazyan, Darlene Veruttipong, Jonathan W Goldman, Silvia C Formenti, Edward B Garon†, Percy Lee†",
            "timestamp": "May 24, 2017",
            "headings": [
                "Summary",
                "Introduction",
                "Methods",
                "Study design and participants",
                "Procedures",
                "Outcomes",
                "Statistical analysis",
                "Results",
                "Discussion",
                "Contributors",
                "Declaration of interests",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Effect_of_Receiving_Treatment_Within_a_Clinical_Trial.pdf-91f80ec7",
        "document": "This study investigates the impact of clinical trial participation on survival and perceived quality of care among patients with advanced-stage non-small cell lung cancer (NSCLC).  Researchers analyzed data from the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) database, comparing survival outcomes and patient-reported quality of care between patients treated within and outside clinical trials.  The study found no significant survival benefit associated with clinical trial participation, although patients in trials perceived better quality of care.  These findings suggest that the perceived 'trial effect' may be primarily related to patient perception rather than a direct survival advantage.",
        "metadata": {
            "identifier": "The Effect of Receiving Treatment Within a Clinical Trial.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:35.622672+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\The Effect of Receiving Treatment Within a Clinical Trial.pdf",
            "name": "The Effect of Receiving Treatment Within a Clinical Trial.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "Clinical trials",
                "Survival",
                "Quality of care",
                "Trial effect",
                "CanCORS",
                "Chemotherapy"
            ],
            "author": "Taher Abu-Hejleh, Elizabeth A. Chrischilles, Thorvardur R. Halfdanarson, Christian Simon, Jane F. Pendergast, Dingfeng Jiang, Carmen J. Smith, Aaron T. Porter, Knute D. Carter, Robert B. Wallace, and Cancer Care Outcomes Research and Surveillance Consortium (CanCORS)",
            "timestamp": "2016",
            "headings": [
                "Objectives",
                "Materials and Methods",
                "Study Population",
                "Study Measures",
                "Statistical Analysis",
                "Results",
                "Discussion",
                "Conclusions",
                "ACKNOWLEDGMENT",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Impact_of_Clinical_Trials_on_the_Treatment_of_Lung_Cancer.pdf-d879d20c",
        "document": "This 1993 article investigates the impact of clinical trials on lung cancer treatment in the UK.  A survey of radiotherapists and medical oncologists revealed that large, multicenter randomized trials, particularly those from the MRC, significantly influenced clinical practice.  However, the study also highlights that a surprisingly small percentage of lung cancer patients participate in trials, raising concerns about access to specialized care and trial participation rates. The authors suggest improvements in trial design, publicity, and resource allocation to increase trial impact and patient participation.",
        "metadata": {
            "identifier": "The Impact of Clinical Trials on the Treatment of Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:40.736286+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\The Impact of Clinical Trials on the Treatment of Lung Cancer.pdf",
            "name": "The Impact of Clinical Trials on the Treatment of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Clinical Trials",
                "Radiotherapy",
                "Chemotherapy",
                "Medical Oncology",
                "Clinical Practice",
                "Multicenter Randomized Trials",
                "MRC",
                "UK"
            ],
            "author": "R. Stephens and D. Gibson",
            "timestamp": "1993",
            "headings": [
                "Abstract",
                "Introduction",
                "Methods",
                "Results",
                "Response to the Questionnaire",
                "Number of Patients Seen and Number of Patients Entered Into Trials",
                "The Impact of Lung Cancer Trials",
                "The Impact of Specific MRC Lung Cancer Trials",
                "Journals",
                "Discussion",
                "References",
                "Appendix A"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Treatment_of_Non-small_Cell_Lung_Cancer_Stage_I_and_Stage_II.pdf-0223f645",
        "document": "This text focuses on the treatment of non-small cell lung cancer (NSCLC), specifically stages I and II.  It discusses evolving surgical techniques, the role of adjuvant therapies (chemotherapy and radiation), and the importance of multidisciplinary care teams.  The text also highlights the use of evidence-based clinical practice guidelines from the American College of Chest Physicians (ACCP) and considers factors like age and comorbidity in treatment outcomes.  A minimally invasive technology for evaluating lung tissue is mentioned as a potential future diagnostic tool.",
        "metadata": {
            "identifier": "Treatment of Non-small Cell Lung Cancer Stage I and Stage II.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:43.155900+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Treatment of Non-small Cell Lung Cancer Stage I and Stage II.pdf",
            "name": "Treatment of Non-small Cell Lung Cancer Stage I and Stage II.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Lung cancer treatment",
                "Adjuvant therapy",
                "Chemotherapy",
                "Radiation therapy",
                "Surgical resection",
                "Multidisciplinary care",
                "Comorbidity",
                "Clinical trials"
            ],
            "author": [
                "L.T. Tanoue, MD",
                "Scott WJ, Howington J, Feigenberg S, et al",
                "Asmis TR, Ding K, Seymour L"
            ],
            "timestamp": [
                "2007",
                "2008"
            ],
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ALK_in_Lung_Cancer_Past_Present_and_Future.pdf-b6704a92",
        "document": "This scientific review article discusses anaplastic lymphoma kinase (ALK) in lung cancer, focusing on its discovery, current treatments, and future challenges.  The authors detail the history of ALK research, highlighting the effectiveness of crizotinib as an ALK inhibitor and its subsequent FDA approval.  The article also examines mechanisms of crizotinib resistance, including ALK mutations and the activation of bypass signaling pathways.  Finally, it explores promising new treatment strategies, such as next-generation ALK inhibitors and combination therapies, to overcome resistance and improve patient outcomes.",
        "metadata": {
            "identifier": "ALK in Lung Cancer Past, Present, and Future.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:47.881231+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\ALK in Lung Cancer Past, Present, and Future.pdf",
            "name": "ALK in Lung Cancer Past, Present, and Future.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Anaplastic Lymphoma Kinase (ALK)",
                "Lung Cancer",
                "Crizotinib",
                "ALK Inhibitors",
                "Drug Resistance",
                "Oncogene Addiction",
                "Targeted Therapy",
                "EML4-ALK"
            ],
            "author": "Alice T. Shaw and Jeffrey A. Engelman",
            "timestamp": "February 11, 2013",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "THE PAST: DISCOVERY OF ALK REARRANGEMENTS AS ONCOGENIC DRIVERS IN HUMAN CANCERS",
                "THE PRESENT: EFFICACY OF CRIZOTINIB IN TREATING PATIENTS WITH ADVANCED, ALK-POSITIVE NSCLC",
                "THE FUTURE: OVERCOMING CRIZOTINIB RESISTANCE",
                "Mechanisms",
                "New Treatment Strategies",
                "DISCUSSION",
                "REFERENCES",
                "AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST",
                "AUTHOR CONTRIBUTIONS"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Detection_of_Mutations_in_EGFR.pdf-f69ad70f",
        "document": "This research article from the New England Journal of Medicine details a study on detecting EGFR mutations in circulating lung cancer cells.  Researchers used a microfluidic device to isolate circulating tumor cells and a sensitive assay to detect EGFR mutations, finding that analysis of these cells is more sensitive than plasma DNA analysis.  The study showed a correlation between the presence of the T790M mutation and reduced progression-free survival.  Serial analysis revealed the emergence of additional EGFR mutations during treatment, highlighting the potential for monitoring tumor genotype changes non-invasively.",
        "metadata": {
            "identifier": "Detection of Mutations in EGFR.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:53.354128+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Detection of Mutations in EGFR.pdf",
            "name": "Detection of Mutations in EGFR.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "EGFR mutations",
                "circulating tumor cells",
                "lung cancer",
                "tyrosine kinase inhibitors",
                "T790M mutation",
                "drug resistance",
                "microfluidic device",
                "molecular analysis",
                "tumor genotyping"
            ],
            "author": "Maheswaran et al. (Haber)",
            "timestamp": "July 2, 2008",
            "headings": [
                "Abstract",
                "Background",
                "Methods",
                "Patients and Clinical Specimens",
                "Molecular Analysis",
                "Statistical Analysis",
                "Results",
                "Identification of Circulating Tumor Cells",
                "Detection of EGFR Mutations in Tumors",
                "Detection of EGFR Mutations in Circulating Tumor Cells",
                "Serial Measurements",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-EGFR_Mutations_in_Lung_Cancer.pdf-1c6cb115",
        "document": "This document presents two scientific research articles. The first explores the role of the FAMA gene in stomatal development in Arabidopsis plants, using microarray analysis and T-DNA insertion lines to identify genes involved in stomatal cell fate regulation. The second study investigates the correlation between EGFR mutations and the response to gefitinib therapy in non-small cell lung cancer (NSCLC) patients, finding a significant association between specific EGFR mutations and gefitinib sensitivity.  Both studies utilize genomic approaches to identify key genes and mutations impacting cellular processes and disease response.",
        "metadata": {
            "identifier": "EGFR Mutations in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:27:58.675080+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\EGFR Mutations in Lung Cancer.pdf",
            "name": "EGFR Mutations in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "FAMA gene",
                "stomatal development",
                "Arabidopsis",
                "EGFR mutations",
                "gefitinib",
                "lung cancer",
                "NSCLC",
                "microarray analysis",
                "T-DNA insertion",
                "autophagy"
            ],
            "author": [
                "J.A. Nadeau, F. Sack",
                "J. Guillermo Paez, Pasi A. Ja¨nne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson",
                "Li Yu, Ajjai Alva, Helen Su, Parmesh Dutt, Eric Freundt, Sarah Welsh, Eric H. Baehrecke, Michael J. Lenardo"
            ],
            "timestamp": [
                "28January2004;accepted7April2004",
                "16April2004;accepted21April2004"
            ],
            "headings": [
                "REPORTS",
                "ReferencesandNotes",
                "SupportingOnlineMaterial",
                "MaterialsandMethods",
                "EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy",
                "ReferencesandNotes",
                "SupportingOnlineMaterial",
                "MaterialsandMethods",
                "Regulation of an ATG7–beclin 1 Program of Autophagic Cell Death by Caspase-8"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-EML4-ALK_Mutations_in_Lung_Cancer.pdf-ed5e2cc3",
        "document": "This brief report from the New England Journal of Medicine details the discovery of two secondary mutations in the EML4-ALK gene in a lung cancer patient who relapsed after treatment with an ALK inhibitor.  These mutations, C1156Y and L1196M, were found to independently confer resistance to multiple ALK inhibitors.  The study used deep sequencing and in vitro assays to characterize the mutations and their impact on drug sensitivity.  The findings highlight a mechanism of acquired resistance to ALK inhibitors and suggest the need for next-generation inhibitors.",
        "metadata": {
            "identifier": "EML4-ALK Mutations in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:02.529117+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\EML4-ALK Mutations in Lung Cancer.pdf",
            "name": "EML4-ALK Mutations in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "EML4-ALK",
                "Lung Cancer",
                "ALK Inhibitors",
                "Drug Resistance",
                "Mutations",
                "C1156Y",
                "L1196M",
                "Tyrosine Kinase"
            ],
            "author": "Young Lim Choi, et al. for the ALK Lung Cancer Study Group",
            "timestamp": "October 28, 2010",
            "headings": [
                "SUMMARY",
                "Methods",
                "Results",
                "CASE REPORT",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Epidermal_growth_factor_receptor_EGFR_in_lung_cancer.pdf-d1e95e91",
        "document": "This review article discusses epidermal growth factor receptor (EGFR) in lung cancer, focusing on its role in tumorigenesis and the effectiveness of tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib.  EGFR mutations, particularly in exons 19 and 21, are associated with increased response to TKIs, although overall survival benefit is not always observed.  The article also explores the importance of EGFR gene amplification and the challenges in predicting TKI response using various assessment methods, including IHC, FISH, and PCR.  Further research is needed to standardize methodologies and improve patient selection for targeted therapies.",
        "metadata": {
            "identifier": "Epidermal growth factor receptor (EGFR) in lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:06.192224+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Epidermal growth factor receptor (EGFR) in lung cancer.pdf",
            "name": "Epidermal growth factor receptor (EGFR) in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "EGFR",
                "Tyrosine Kinase Inhibitors",
                "EGFR Mutations",
                "Gene Amplification",
                "Gefitinib",
                "Erlotinib",
                "IHC",
                "FISH",
                "PCR"
            ],
            "author": "Gillian Bethune, Drew Bethune, Neale Ridgway, Zhaolin Xu",
            "timestamp": "February 16, 2010",
            "headings": [
                "ABSTRACT",
                "EGFR function and its role in lung cancer",
                "EGFR receptor tyrosine kinase inhibitors",
                "Assessment of EGFR abnormalities",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-KRAS_Mutations_in_Non_Small_Cell_Lung_Cancer.pdf-bf58c701",
        "document": "This scientific article reviews the role of KRAS mutations in non-small cell lung cancer (NSCLC).  The authors discuss the discovery of RAS mutations, their association with clinical factors like smoking history, and their prognostic and predictive value in response to therapies.  KRAS mutations are shown to be negative predictors of benefit from adjuvant chemotherapy and anti-EGFR therapies.  The article concludes by highlighting the urgent need for therapies targeting KRAS mutant NSCLC.",
        "metadata": {
            "identifier": "KRAS Mutations in Non–Small Cell Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:10.248745+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\KRAS Mutations in Non–Small Cell Lung Cancer.pdf",
            "name": "KRAS Mutations in Non–Small Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "KRAS mutations",
                "non-small cell lung cancer",
                "NSCLC",
                "EGFR",
                "adjuvant chemotherapy",
                "targeted therapy",
                "cancer biomarkers",
                "prognosis",
                "smoking"
            ],
            "author": "Gregory J. Riely, Jenifer Marks, and William Pao",
            "timestamp": "November 19, 2008",
            "headings": [
                "KRAS Mutations in Non–Small Cell Lung Cancer",
                "RAS AND NON–SMALL CELL LUNG CANCER",
                "KRAS MUTATIONS AND CIGARETTESMOKING IN NSCLC",
                "KRAS MUTATIONS AS A PROGNOSTIC FACTOR IN NSCLC",
                "KRAS MUTATIONS AS A PREDICTIVE MARKER OF THERAPY FOR NSCLC",
                "CURRENT THERAPEUTIC APPROACHES BASED ON INHIBITION OF RAS-MEDIATED SIGNALING",
                "CONCLUSIONS"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Molecular_biology_of_lung_cancer.pdf-5a9b7dd8",
        "document": "This review article discusses the molecular biology of lung cancer, focusing on the genetic alterations in oncogenes and tumor suppressor genes.  It highlights the advancements in understanding the molecular pathogenesis of lung cancer, particularly in adenocarcinomas and squamous cell carcinomas. The authors detail common mutations in genes like KRAS, EGFR, BRAF, ALK, ROS1, and RET, along with the implications for targeted therapies.  The role of tumor suppressor genes like TP53 and PTEN is also explored, emphasizing the complexity and heterogeneity of lung cancer.",
        "metadata": {
            "identifier": "Molecular biology of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:16.897145+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Molecular biology of lung cancer.pdf",
            "name": "Molecular biology of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Oncogenes",
                "Tumor suppressor genes",
                "Mutations",
                "Targeted therapy",
                "KRAS",
                "EGFR",
                "ALK",
                "Genomics"
            ],
            "author": "Wendy A. Cooper, David C. L. Lam, Sandra A. O’Toole, John D. Minna",
            "timestamp": "August 1, 2013",
            "headings": [
                "Introduction",
                "KRAS",
                "EGFR mutations",
                "BRAF",
                "MEK",
                "MET",
                "HER2",
                "PI3K/AKT/mTOR",
                "ALK rearrangements",
                "ROS1",
                "RET",
                "FGFR1",
                "DDR2",
                "Tumour suppressor genes",
                "TP53",
                "PTEN",
                "LKB1 (STK11)",
                "The p16INK4a-cyclin D1-CDK4-RB pathway",
                "Molecular targeting in NSCLC",
                "Conclusions",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-MOLECULAR_PATHOGENESIS_OF_LUNG_CANCER.pdf-21c7b881",
        "document": "This scientific article reviews the molecular pathogenesis of lung cancer, focusing on genetic alterations in respiratory epithelial cells that lead to invasive and metastatic cancer.  The authors discuss various oncogenes and tumor suppressor genes involved, including RAS, MYC, p53, and RB, and their roles in cell growth, proliferation, and apoptosis.  The review also explores the molecular definition of individual susceptibility to tobacco smoke carcinogens and the development of mechanism-based therapies.  Finally, it highlights the clinical implications of these findings, emphasizing the potential for improved early detection, risk prediction, and targeted therapies.",
        "metadata": {
            "identifier": "MOLECULAR PATHOGENESIS OF LUNG CANCER.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:24.704899+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\MOLECULAR PATHOGENESIS OF LUNG CANCER.pdf",
            "name": "MOLECULAR PATHOGENESIS OF LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Molecular Pathogenesis",
                "Oncogenes",
                "Tumor Suppressor Genes",
                "Genetic Alterations",
                "Apoptosis",
                "Tobacco Smoke",
                "Chemoprevention",
                "Targeted Therapies"
            ],
            "author": "Kwun M. Fong, Yoshitaka Sekido, John D. Minna",
            "timestamp": "September 21, 1999",
            "headings": [
                "Molecular alterations in lung cancer cells",
                "Markers of genetic instability",
                "Specific molecular alterations in lung cancer cells",
                "Growth stimulation and oncogenes",
                "Gastrin-releasing peptide (GRP)/bombesin (BN) autocrine loop",
                "ERBB family",
                "Other membrane tyrosine kinases",
                "Nicotine and opioid receptors",
                "RAS",
                "MYC",
                "Tumor suppressor genes (TSGs)",
                "p53",
                "p16-cyclin D1-CDK4-RB pathway",
                "Other candidate TSGs",
                "Apoptosis",
                "Telomerase activity",
                "Aberrant methylation",
                "Angiogenesis and metastases",
                "Molecular alterations in normal and preneoplastic at-risk respiratory cells",
                "Inherited lung cancer susceptibility",
                "Clinical implications"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Ongoing_challenges_in_implementation_of_lung_cancer_screening.pdf-0a484ab9",
        "document": "This review article discusses the challenges in implementing lung cancer screening (LCS) programs, focusing on the selection of high-risk individuals, standardization of nodule classification, radiologist training, and optimization of screening intervals.  The authors also address the psychological impact of screening and the importance of smoking cessation.  Several studies demonstrating the effectiveness of LCS with low-dose computed tomography (LDCT) are reviewed, highlighting the need for careful consideration of false positives and overdiagnosis.  The article concludes by emphasizing the need for training, quality assurance, and addressing the psychological impact on patients.",
        "metadata": {
            "identifier": "Ongoing challenges in implementation of lung cancer screening.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:30.326921+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Ongoing challenges in implementation of lung cancer screening.pdf",
            "name": "Ongoing challenges in implementation of lung cancer screening.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Screening",
                "Low-dose Computed Tomography (LDCT)",
                "Nodule Management",
                "Overdiagnosis",
                "Smoking Cessation",
                "Psychological Impact",
                "Radiologist Training"
            ],
            "author": [
                "Katharina Martini",
                "Guillaume Chassagnon",
                "Thomas Frauenfelder",
                "Marie-Pierre Revel"
            ],
            "timestamp": "January 28, 2021",
            "headings": [
                "Abstract",
                "Introduction",
                "Adherence of high-risk individuals",
                "Optimization of the population to be screened",
                "Screening interval and duration of screening",
                "Quality of screening, radiologists’ expertise",
                "Management of screen-detected nodules, limitation of the overdiagnosis risk",
                "Impact on quality of life",
                "Management of ancillary findings",
                "Association to smoking cessation",
                "Conclusions",
                "Acknowledgments",
                "Footnote",
                "Conflicts of Interest",
                "Ethical Statement",
                "Open Access Statement",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Recent_Advances_in_Targeting_ROS1_in_Lung_Cancer.pdf-88879d1f",
        "document": "This accepted manuscript reviews recent advances in targeting ROS1 in lung cancer.  The authors discuss the biology and diagnosis of ROS1-rearranged non-small cell lung cancer (NSCLC), focusing on crizotinib and emerging treatment options.  Mechanisms of crizotinib resistance are explored, highlighting the need for novel ROS1 inhibitors.  The review concludes by outlining a current treatment approach and future research directions, emphasizing the importance of standardized diagnosis and treatment globally.",
        "metadata": {
            "identifier": "Recent Advances in Targeting ROS1 in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:38.585181+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Recent Advances in Targeting ROS1 in Lung Cancer.pdf",
            "name": "Recent Advances in Targeting ROS1 in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ROS1",
                "Lung Cancer",
                "NSCLC",
                "Crizotinib",
                "Tyrosine Kinase Inhibitors",
                "Cancer Therapy",
                "Drug Resistance",
                "ROS1 Inhibitors"
            ],
            "author": "Jessica J. Lin, MD, Alice T. Shaw, MD, PhD",
            "timestamp": "August 8, 2017",
            "headings": [
                "Recent Advances in Targeting ROS1 in Lung Cancer",
                "Abstract",
                "Introduction",
                "ROS1 Function",
                "ROS1 Gene Fusions in Cancer",
                "Clinicopathologic Characteristics of ROS1-Rearranged Lung Cancer",
                "Clinical Detection of ROS1 Fusions",
                "ROS1-Targeted Therapies in Lung Cancer",
                "Crizotinib",
                "Resistance to Crizotinib",
                "Other ROS1 Inhibitors in Development",
                "Ceritinib",
                "Brigatinib",
                "Lorlatinib",
                "Entrectinib",
                "Cabozantinib",
                "DS-6051b",
                "TPX-0005",
                "Our current approach",
                "Conclusions and Future Directions",
                "Grant Support",
                "References",
                "Figure Legends",
                "Table 1"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Recent_Trends_in_Lung_Cancer_Mortality_in_the_United_States.pdf-ab616f45",
        "document": "This study examines recent trends in lung cancer mortality in the United States from 1970 to 1997, focusing on birth cohorts after 1950.  Using age-period-cohort analyses, researchers found a surprising moderation in the decrease of lung cancer mortality for those born after 1950, potentially linked to increased teenage smoking initiation rates.  A statistically significant decrease in the calendar-period trend was also observed after 1990, possibly due to reduced tobacco carcinogens and increased smoking cessation.  The findings highlight the need for continued smoking cessation and prevention programs, especially for teenagers.",
        "metadata": {
            "identifier": "Recent Trends in Lung Cancer Mortality in the United States.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:43.837042+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Recent Trends in Lung Cancer Mortality in the United States.pdf",
            "name": "Recent Trends in Lung Cancer Mortality in the United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Mortality",
                "Birth Cohort",
                "Smoking",
                "Age-Period-Cohort Analysis",
                "Teenage Smoking",
                "Cancer Surveillance",
                "Tobacco Control"
            ],
            "author": "Ahmedin Jemal, Kenneth C. Chu, Robert E. Tarone",
            "timestamp": "February 21, 2001",
            "headings": [
                "Background",
                "SUBJECTS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "REFERENCES",
                "NOTES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Targeting_KRAS_in_non_small_cell_lung_cancer.pdf-0248e63b",
        "document": "This scientific article reviews recent progress and new approaches in targeting KRAS mutations, specifically the KRASG12C mutation, in non-small cell lung cancer (NSCLC).  The authors discuss the biology of KRAS, the history of targeting it (including past failures and recent successes with direct inhibitors), and ongoing efforts involving both monotherapies and combination strategies.  Key challenges remain, such as understanding resistance mechanisms and determining the optimal role of KRAS inhibitors in treatment regimens.  The article highlights promising new drugs like sotorasib and adagrasib, and explores various combination therapies to improve outcomes.",
        "metadata": {
            "identifier": "Targeting KRAS in non–small cell lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:51.045430+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Targeting KRAS in non–small cell lung cancer.pdf",
            "name": "Targeting KRAS in non–small cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "KRAS",
                "KRASG12C",
                "non-small cell lung cancer",
                "NSCLC",
                "targeted therapy",
                "cancer treatment",
                "sotorasib",
                "adagrasib",
                "combination therapy",
                "resistance mechanisms"
            ],
            "author": "M. Reck, D.P. Carbone, M. Garassino, F. Barlesi",
            "timestamp": "June 1, 2021",
            "headings": [
                "Highlights",
                "Abstract",
                "OVERVIEW OF RAS/KRAS-MUTANT LUNG CANCER",
                "KRAS biology: structure, function, and downstream effector pathways",
                "KRAS mutations in lung cancer",
                "Genetic heterogeneity",
                "Prognostic implications of KRAS mutations",
                "HISTORY OF TARGETING KRAS IN LUNG CANCER",
                "Direct targeting of KRAS",
                "Indirect targeting of KRAS",
                "Ongoing Efforts to Target KRAS in NSCLC",
                "Monotherapies",
                "Combination strategies for KRAS-mutant NSCLC",
                "Co-mutations of special interest",
                "WHAT LIES AHEAD?",
                "Table 1. Historical attempts to target KRAS in NSCLC",
                "Table 2. KRAS-targeting agents in clinical or preclinical development in NSCLC",
                "[Figure captions]"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Testing_for_ROS1_in_non-small_cell_lung_cancer.pdf-de5b60bc",
        "document": "This review article discusses the current state of molecular diagnostics for ROS1-positive non-small cell lung cancer (NSCLC).  It focuses on the detection of ROS1 gene rearrangements, a rare event in NSCLC,  and the effectiveness of crizotinib, an FDA-approved inhibitor of ROS1 kinase activity. The authors review various testing approaches, including fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and next-generation sequencing (NGS), providing recommendations for optimal ROS1 testing strategies.  The article concludes by suggesting an algorithm for integrating ROS1 testing into current clinical practice.",
        "metadata": {
            "identifier": "Testing for ROS1 in non-small cell lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:28:58.181821+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Testing for ROS1 in non-small cell lung cancer.pdf",
            "name": "Testing for ROS1 in non-small cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ROS1",
                "Non-small cell lung cancer (NSCLC)",
                "Crizotinib",
                "Fluorescence in situ hybridization (FISH)",
                "Immunohistochemistry (IHC)",
                "Next-generation sequencing (NGS)",
                "Biomarker",
                "Tyrosine kinase inhibitor"
            ],
            "author": "Lukas Bubendorf et al.",
            "timestamp": "2 August 2016",
            "headings": [
                "Abstract",
                "Introduction",
                "Rationale for targeting ROS1 fusions in NSCLC",
                "Efficacy and safety of ROS1 inhibitor therapy",
                "Detection of ROS1 gene rearrangements",
                "Fluorescence in situ hybridization",
                "Immunohistochemistry",
                "Non-in situ technologies",
                "Concordance between FISH, IHC and PCR",
                "General recommendations for ROS1 testing",
                "Guidance on the use of controls",
                "Pre-analytical variables and factors affecting quality of biopsies and surgical samples",
                "External quality assessment",
                "Integration of ROS1 into current testing algorithms",
                "Conclusions",
                "Acknowledgments",
                "Compliance with ethical standards",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_genetics_and_biology_of_KRAS_in_lung_cancer.pdf-dcdad3df",
        "document": "This review article from the Chinese Journal of Cancer focuses on KRAS mutations in lung cancer, exploring their clinical relevance, genetic basis, and implications for treatment.  The authors discuss the complex role of KRAS in tumorigenesis, highlighting the importance of both mutant and wild-type KRAS in cancer development.  They also review current challenges in developing effective KRAS-targeted therapies, including the limitations of existing approaches and the potential of novel strategies like synthetic lethality.  The article emphasizes the need for further research to bridge the gap between molecular understanding and clinical applications.",
        "metadata": {
            "identifier": "The genetics and biology of KRAS in lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:29:04.477770+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The genetics and biology of KRAS in lung cancer.pdf",
            "name": "The genetics and biology of KRAS in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "KRAS",
                "RAS",
                "lung cancer",
                "oncogene",
                "tumorigenesis",
                "mutations",
                "therapies",
                "mouse models",
                "synthetic lethality"
            ],
            "author": "Peter M. K. Westcott and Minh D. To",
            "timestamp": "2012-07-27",
            "headings": [
                "Abstract",
                "RAS Signaling",
                "KRAS Mutations in Human Lung Cancer",
                "Insights from Mouse Models of Kras-driven NSCLC",
                "The Tumor Suppressor Function of Kras and Implications for Lung Cancer Susceptibility",
                "Isoform-specific Functions of Kras in Lung Carcinogenesis",
                "The Challenges and Future of Therapeutics for KRAS-mutant NSCLC",
                "Conclusions",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_lung_microenvironment_regulator_of_tumor_growth.pdf-1ade7090",
        "document": "This review article discusses the lung tumor microenvironment (TME) and its crucial role in lung cancer growth and metastasis.  It highlights recent advancements in understanding how the TME, including cancer-associated fibroblasts, extracellular matrix, and immune cells, contributes to carcinogenesis and influences treatment responses. The authors summarize the latest findings on the TME's impact on both primary lung tumors and metastasis from other cancers, emphasizing the potential for developing novel targeted therapies.  The review also covers technological advances in studying the TME and the challenges in translating these findings into clinical practice.",
        "metadata": {
            "identifier": "The lung microenvironment regulator of tumor growth.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:29:25.258480+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The lung microenvironment regulator of tumor growth.pdf",
            "name": "The lung microenvironment regulator of tumor growth.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Tumor Microenvironment",
                "Metastasis",
                "Immunotherapy",
                "Angiogenesis",
                "Cancer-associated fibroblasts",
                "Immune checkpoint inhibitors",
                "Biomarkers"
            ],
            "author": "Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao, Jeffrey L. Port, Ashish Saxena, Brendon Stiles, Timothy McGraw, Vivek Mittal",
            "timestamp": "10 December 2018",
            "headings": [
                "Abstract",
                "Lung cancer is the leading cause of cancer-related mortality",
                "In the past decade, the central role of the tumour microenvironment (TME) in the initiation and progression of primary de novo lung carcinoma has been recognized",
                "In this Review, we summarize recent advances showing how the specialized lung TME supports both primary lung cancer and metastasis from extrapulmonary carcinoma and discuss how the mechanistic understanding of aberrant molecular signalling networks stimulated by tumour–stromal interactions has the potential to provide novel diagnostic, prognostic and therapeutic opportunities",
                "The altered TME landscape",
                "Cancer-associated fibroblasts",
                "Extracellular matrix",
                "Angiogenesis",
                "The immune TME",
                "The lung as a site of metastasis",
                "The lung TME as a target for therapy",
                "Antiangiogenic therapies",
                "Anti-inflammatory therapies",
                "Immunotherapies",
                "ICI monotherapy for metastatic NSCLC",
                "Combination therapy",
                "Resistance to immunotherapies",
                "Pre-metastatic niche targeting",
                "Technological advancements",
                "Developing better lung cancer models",
                "The pre-metastatic niche in the clinic",
                "The TME in precision medicine",
                "Conclusion",
                "Published online 10 December 2018"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Role_of_Tumor_Inflammatory.pdf-05cdff1b",
        "document": "This review article examines the role of the tumor inflammatory microenvironment (TME) in lung cancer development and metastasis.  It details the multifaceted link between inflammation and lung cancer, focusing on inflammatory cells (macrophages, neutrophils), cytokines (IL-1β, TNF-α, IL-6, TGF-β), and signaling pathways (NF-κB, STAT3). The authors discuss how the TME promotes immune escape, angiogenesis, and epithelial-mesenchymal transition (EMT), contributing to tumor progression.  Finally, the review explores potential therapeutic strategies targeting the inflammatory microenvironment for lung cancer treatment.",
        "metadata": {
            "identifier": "The Role of Tumor Inflammatory.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:29:32.417296+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The Role of Tumor Inflammatory.pdf",
            "name": "The Role of Tumor Inflammatory.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tumor Microenvironment",
                "Inflammation",
                "Lung Cancer",
                "Metastasis",
                "Immune Escape",
                "Angiogenesis",
                "Epithelial-Mesenchymal Transition",
                "NF-κB",
                "STAT3"
            ],
            "author": "Zhaofeng Tan, Haibin Xue, Yuli Sun, Chuanlong Zhang, Yonglei Song, Yuanfu Qi",
            "timestamp": "17 May 2021",
            "headings": [
                "REVIEW",
                "INTRODUCTION",
                "INFLAMMATION AND LUNG CANCER: A MULTIFACETED LINK",
                "INFLAMMATORY CELLS, CYTOKINES, AND PATHWAYS ASSOCIATED WITH LUNG CANCER",
                "Inflammatory Cells Associated With Lung Cancer",
                "Inflammatory Cytokines Associated With Lung Cancer",
                "Inflammation-Related Signal Pathways of Associated With Lung Cancer",
                "MECHANISMS OF TUMOR INFLAMMATORY MICROENVIRONMENT IN PROMOTING THE DEVELOPMENT AND METASTASIS OF LUNG CANCER",
                "Immune Escape",
                "Tumor Angiogenesis",
                "Epithelial-To-Mesenchymal Transition",
                "Anti-apoptosis",
                "PROGRESS IN THE TREATMENT OF LUNG CANCER BASED ON INFLAMMATION AND INFLAMMATORY MICROENVIRONMENT",
                "FUTURE OUTLOOK AND CONCLUSION",
                "AUTHOR CONTRIBUTIONS",
                "FUNDING",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Tumor_Microenvironment.pdf-b3526ab7",
        "document": "This scientific article reviews the tumor microenvironment (TME) in non-small-cell lung cancer (NSCLC), focusing on hypoxia and its impact on treatment response.  The authors discuss the significance of hypoxia in NSCLC progression and prognosis, exploring various methods for detecting tumor hypoxia, including imaging techniques.  They also examine strategies for targeting hypoxia, such as using hypoxic cell radiosensitizers and modulating the TME to enhance radiation response.  The article highlights the potential of imaging the TME to guide patient selection and treatment strategies.  Finally, it emphasizes the need for further clinical studies to validate the findings from preclinical models.",
        "metadata": {
            "identifier": "The Tumor Microenvironment.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:29:37.924585+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The Tumor Microenvironment.pdf",
            "name": "The Tumor Microenvironment.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tumor Microenvironment",
                "Non-small-cell lung cancer (NSCLC)",
                "Hypoxia",
                "Radiotherapy",
                "Angiogenesis",
                "EGFR Inhibitors",
                "PI3K/Akt Pathway",
                "Imaging",
                "HIF-1",
                "VEGF"
            ],
            "author": "Edward E. Graves, PhD, Amit Maity, MD, PhD, and Quynh-Thu Le, MD",
            "timestamp": "2010",
            "headings": [
                "The Tumor Microenvironment in Non–Small-Cell Lung Cancer",
                "Significance of Hypoxia in Lung Cancers",
                "Targeting Hypoxia in NSCLC",
                "Imaging the Microenvironment of Lung Cancer",
                "Perfusion and Angiogenesis Imaging",
                "Hypoxia Imaging",
                "Altering the TME to Increase Radiation Response",
                "HIF-1 and VEGF as Targets for Radiosensitization",
                "EGFR Inhibitors",
                "The Phosphatidylinositol 3-Kinase/Akt Pathway",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Updated_statistics_of_lung_and_bronchus_cancer_in_United_States.pdf-9704d09c",
        "document": "This editorial analyzes updated statistics on lung and bronchus cancer in the United States for 2018.  The authors highlight that lung cancer remains a leading cause of cancer mortality, with disparities observed across sex, race, and geographic location.  While incidence and mortality rates have shown a decline in recent decades, particularly among males, significant health disparities persist.  The authors emphasize the need for continued efforts in tobacco control and multi-dimensional interventions to address these disparities.",
        "metadata": {
            "identifier": "Updated statistics of lung and bronchus cancer in United States.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:29:40.335230+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Updated statistics of lung and bronchus cancer in United States.pdf",
            "name": "Updated statistics of lung and bronchus cancer in United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Bronchus Cancer",
                "Cancer Statistics",
                "Mortality Rates",
                "Incidence Rates",
                "Health Disparities",
                "Tobacco Control",
                "United States"
            ],
            "author": "Gabrielle Boloker, Cong Wang, Jianrong Zhang",
            "timestamp": "March 2018",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-US_Lung_Cancer_Trends_by_Histologic_Type.pdf-3492eadd",
        "document": "This study analyzes lung cancer incidence trends in the US from 1977 to 2010, using data from the Surveillance, Epidemiology, and End Results (SEER) program.  The researchers investigated trends by histologic type (e.g., squamous cell, adenocarcinoma), demographic characteristics (sex, race, age), and cigarette smoking prevalence.  Key findings include declining rates of squamous and small cell carcinomas, but a rise in adenocarcinoma rates, particularly among young women.  These trends reflect historical smoking patterns, cigarette composition changes, and advancements in lung cancer diagnosis and treatment.",
        "metadata": {
            "identifier": "US Lung Cancer Trends by Histologic Type.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:29:44.952314+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\US Lung Cancer Trends by Histologic Type.pdf",
            "name": "US Lung Cancer Trends by Histologic Type.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Incidence",
                "Histology",
                "Epidemiology",
                "Cigarette Smoking",
                "Trends",
                "SEER",
                "Adenocarcinoma",
                "Squamous Cell Carcinoma"
            ],
            "author": "Denise Riedel Lewis, David P. Check, Neil E. Caporaso, William D. Travis, Susan S. Devesa",
            "timestamp": "August 11, 2014",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "CONCLUSIONS",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "FUNDING SUPPORT",
                "CONFLICT OF INTEREST DISCLOSURES",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_metabolomic_approach_to_lung_cancer.pdf-c7ba0005",
        "document": "This scientific article details a metabolomic study on lung cancer, investigating serum and tissue metabolite changes in patients versus healthy controls.  Using gas chromatography-mass spectrometry (GC/MS), researchers identified significant alterations in various metabolites, including those involved in the TCA cycle and amino acid metabolism.  Partial least squares discriminant analysis (PLS-DA) was used to differentiate between disease stages and histological subtypes. The findings suggest that metabolite profiling could aid in lung cancer diagnosis and prognosis.",
        "metadata": {
            "identifier": "A metabolomic approach to lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:29:52.284014+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\A metabolomic approach to lung cancer.pdf",
            "name": "A metabolomic approach to lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Metabolomics",
                "GC/MS",
                "PLS-DA",
                "Biomarker",
                "Metabolite",
                "Tumor Markers",
                "TCA cycle"
            ],
            "author": "Suya Hori, Shin Nishiumi, Kazuyuki Kobayashi, et al.",
            "timestamp": "2011",
            "headings": [
                "1. Introduction",
                "2. Materials and methods",
                "2.1. Sample collection",
                "2.2. Serum collection and preparation",
                "2.3. Evaluation of the intra-day and inter-day variances for serum metabolites",
                "2.4. Tissue collection and preparation",
                "2.5. GC/MS analysis",
                "2.6. Data processing",
                "2.7. Statistics",
                "3. Results",
                "3.1. Subject characteristics",
                "3.2. Metabolite profiling of lung cancer",
                "3.3. Alterations in the levels of metabolites involved in the TCA cycle",
                "3.4. Alterations in the levels of amino acids and their derivatives",
                "3.5. Alterations in the levels of metabolites of fatty acids, nucleotides and others",
                "3.6. Serum metabolites characterizing disease stage",
                "3.7. Serum metabolites characterizing histological type",
                "3.8. Sensitivities of conventionally applied tumor markers and serum metabolites",
                "3.9. Evaluation of the intra-day and inter-day variances for serum metabolites",
                "4. Discussion",
                "5. Conclusion",
                "Funding source",
                "Conflict of interest statement",
                "Acknowledgments",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Advances_in_Lung_Cancer_Treatment_Using_Nanomedicines.pdf-93042da9",
        "document": "This review article discusses the advancements in lung cancer treatment using nanomedicines.  It focuses on various types of overexpressed receptors in lung cancer and the targeting approaches of nanoparticles for drug delivery.  The authors provide a comprehensive outline of different nanocarriers, including liposomes, polymeric nanoparticles, dendrimers, and others, highlighting their advantages and limitations in lung cancer therapy.  The review also covers diagnostic agents used for lung cancer and future perspectives in the field, emphasizing the potential of nanotechnology to improve treatment efficacy and reduce side effects.",
        "metadata": {
            "identifier": "Advances in Lung Cancer Treatment Using Nanomedicines.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:30:13.620403+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Advances in Lung Cancer Treatment Using Nanomedicines.pdf",
            "name": "Advances in Lung Cancer Treatment Using Nanomedicines.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Nanomedicine",
                "Drug Delivery",
                "Nanoparticles",
                "Targeted Therapy",
                "Theranostics",
                "Receptors",
                "Bioavailability"
            ],
            "author": "Akshansh Sharma, Devanshi Shambhwani, Sadanand Pandey, Jay Singh, Hauzel Lalhlenmawia, Murali Kumarasamy, Sachin Kumar Singh, Dinesh Kumar Chellappan, Gaurav Gupta, Parteek Prasher, Kamal Dua, and Deepak Kumar",
            "timestamp": "December 29, 2022",
            "headings": [
                "ABSTRACT",
                "1. INTRODUCTION",
                "2. OVEREXPRESSED RECEPTORS",
                "2.1. Epidermal Growth Factor Receptor (EGFR)",
                "2.2. Growth Hormone Receptor (GHR)",
                "2.3. Folate Receptors",
                "2.4. Vascular Endothelial Growth Factor Receptors (VEGFR)",
                "2.5. Luteinizing Hormone-Releasing Hormone Receptor (LHRHR)",
                "2.6. Fibroblast Growth Factor Receptor (FGFR)",
                "2.7. Cluster of Differentiation 44 (CD44)",
                "2.8. Integrins",
                "2.9. Mer or Axl as Receptor Tyrosine Kinase (RTK)",
                "2.10. Interleukin-22 Receptor",
                "2.11. Adenosine Receptors (AR)",
                "2.12. Chemotactic Cytokine CXCR4 Receptor",
                "2.13. Bombesin Receptor",
                "2.14. PETA-3/CD151",
                "2.15. Sigma (σ) Receptors",
                "2.16. Anaplastic Lymphoma Kinase (ALK) Receptors",
                "2.17. ROS Proto-oncogene 1, Tyrosine Kinase Receptor",
                "3. TARGETING APPROACH OF NANOCARRIER",
                "3.1. Receptor-Based Targeting",
                "3.2. Passive Targeting",
                "3.3. Stimuli-Responsive System-Based Targeting",
                "4. NANOCARRIER-MEDIATED DRUG DELIVERY SYSTEMS",
                "4.1. Liposomes",
                "4.2. Polymeric Nanoparticles",
                "4.3. Dendrimers",
                "4.4. Nanoemulsions",
                "4.5. Micelles",
                "4.6. Carbon Nanotubes (CNTs)",
                "4.7. Gold Nanoparticles (AuNPs)",
                "4.8. Magnetic Nanoparticles (MNPs)",
                "4.9. Solid Lipid Nanoparticles (SLNs)",
                "4.10. Hydrogels",
                "4.11. Quantum Dots (QDs)",
                "4.12. Inhalational",
                "5. DIAGNOSTIC AGENTS USED FOR LUNG CANCER",
                "6. DRUG DELIVERY CHANGES",
                "7. FUTURE PERSPECTIVES",
                "8. CONCLUSION",
                "AUTHOR INFORMATION",
                "Notes",
                "ACKNOWLEDGMENTS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-An_Overview_of_Lung_Cancer_Genomics_and_Proteomics.pdf-2a000b95",
        "document": "This translational review article examines the application of genomics and proteomics to understand lung cancer.  The authors review studies using microarray and proteomic technologies to classify lung tumors, identify molecular targets for diagnosis and therapy, and correlate gene/protein expression with clinical outcomes.  Key findings include the identification of gene expression profiles that predict patient survival and the potential for using these technologies to improve lung cancer diagnosis and treatment.  The review highlights the need for larger sample sizes and improved reproducibility in future studies.",
        "metadata": {
            "identifier": "An Overview of Lung Cancer Genomics and Proteomics.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:30:18.966223+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\An Overview of Lung Cancer Genomics and Proteomics.pdf",
            "name": "An Overview of Lung Cancer Genomics and Proteomics.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Genomics",
                "Proteomics",
                "Microarray",
                "Gene Expression",
                "Protein Expression",
                "Biomarkers",
                "Prognosis",
                "Diagnosis",
                "Therapy"
            ],
            "author": "Courtney A. Granville and Phillip A. Dennis",
            "timestamp": "December 16, 2004",
            "headings": [
                "Keywords",
                "THE OMICS OF LUNG CANCER",
                "Classification of Tumors: Class Prediction and Class Discovery",
                "Correlation of Gene and Protein Expression Profiles with Prognosis",
                "Correlation of Gene Expression Profiles with Smoking Status and Lung Cancer",
                "Identification of Novel Molecular Targets by Gene and Protein Expression Profiling",
                "Analysis of Relevant Murine Models",
                "Analysis of Lung Cancer Cells In Vitro",
                "DISCUSSION",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Comprehensive_genomic_profiles.pdf-1d9824fc",
        "document": "This research article presents a comprehensive genomic analysis of 110 small cell lung cancer (SCLC) tumors.  The study found that bi-allelic inactivation of TP53 and RB1 is obligatory in SCLC, with rare exceptions showing alternative mechanisms of Rb1 deregulation.  Recurrent somatic alterations were identified, including mutations in NOTCH family genes, suggesting a tumor suppressor role for NOTCH.  The findings uncover key biological processes and identify potential therapeutic targets for this aggressive cancer.",
        "metadata": {
            "identifier": "Comprehensive genomic profiles.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:30:31.536853+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Comprehensive genomic profiles.pdf",
            "name": "Comprehensive genomic profiles.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Small cell lung cancer",
                "SCLC",
                "TP53",
                "RB1",
                "NOTCH",
                "Genomic sequencing",
                "Tumor suppressor",
                "Oncogene",
                "Therapeutic targets",
                "Neuroendocrine"
            ],
            "author": "Julie George1*,Jing Shan Lim2*,Se Jin Jang3, et al.",
            "timestamp": "Published online 13 July 2015",
            "headings": [
                "ARTICLE",
                "Samples and clinical data",
                "Recurrent somatic alterations in SCLC",
                "Universal inactivation of TP53 and RB1",
                "Oncogenic genomic events affecting TP73",
                "Tumor suppressor roles of Notch in SCLC",
                "Discussion",
                "Methods"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-CRISPR_Cas9_molecular_tool_for_gene_therapy.pdf-9ef22df1",
        "document": "This review article discusses the use of CRISPR/Cas9 gene editing technology for the treatment of lung cancer.  The authors highlight the limitations of current lung cancer therapies, such as drug resistance and systemic toxicity, and propose CRISPR/Cas9 as a potential solution for targeted gene therapy.  The review details the mechanism of CRISPR/Cas9, its applications in gene modulation, and its potential for targeting both genomic and epigenomic alterations in lung cancer.  Future directions include further optimization of CRISPR/Cas9 for therapeutic applications and exploring its potential for treating heterogeneous tumors.",
        "metadata": {
            "identifier": "CRISPR Cas9 molecular tool for gene therapy.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:30:37.168783+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\CRISPR Cas9 molecular tool for gene therapy.pdf",
            "name": "CRISPR Cas9 molecular tool for gene therapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "CRISPR/Cas9",
                "Lung Cancer",
                "Gene Therapy",
                "Genome Editing",
                "Epigenome",
                "Targeted Therapy",
                "Drug Resistance",
                "Gene Modulation"
            ],
            "author": "M Sachdeva, N Sachdeva, M Pal, N Gupta, I A Khan, M Majumdar, A Tiwari",
            "timestamp": "23 October 2015",
            "headings": [
                "INTRODUCTION",
                "LUNG CANCER",
                "TYPE II CRISPR/Cas9 SYSTEM",
                "CRISPR/Cas9 SYSTEM AS A GENOME MODULATION TOOL IN HUMANS",
                "ENGINEERING dCas9",
                "VARIED UTILIZATION OF CRISPR/Cas9 IN CANCER STUDY AND TREATMENTS",
                "FUTURE DIRECTIONS",
                "CONFLICT OF INTEREST",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Delivery_of_genome-editing_biomacromolecules_for_treatment_of_lung.pdf-ce6d3c5e",
        "document": "This scientific article reviews the delivery of genome-editing biomacromolecules, specifically CRISPR/Cas9, for treating lung genetic disorders like cystic fibrosis (CF) and α-1 antitrypsin deficiency (AATD).  The authors discuss current treatment options, CRISPR-based strategies, and various administration routes (oral, intravenous, intratracheal/intranasal, inhalation).  Aerosol delivery is highlighted as a promising method for CRISPR/Cas9 delivery to the lungs.  Finally, the article addresses current challenges and future outlooks in this field.",
        "metadata": {
            "identifier": "Delivery of genome-editing biomacromolecules for treatment of lung.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:30:50.381738+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Delivery of genome-editing biomacromolecules for treatment of lung.pdf",
            "name": "Delivery of genome-editing biomacromolecules for treatment of lung.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "CRISPR/Cas9",
                "Genome Editing",
                "Lung Genetic Disorders",
                "Cystic Fibrosis",
                "α-1 Antitrypsin Deficiency",
                "Aerosol Delivery",
                "Gene Therapy",
                "Viral Vectors",
                "Non-viral Vectors"
            ],
            "author": "Tao Wan and Yuan Ping",
            "timestamp": "Accepted 8 May 2020",
            "headings": [
                "1. Introduction",
                "2. Lung genetic disorders and current therapeutic options",
                "2.1. Cystic fibrosis",
                "2.1.1. Current available therapeutic options",
                "2.1.2. Traditional gene therapy",
                "2.1.3. Repairing CFTR mutations: gene correction with genome-editing nucleases",
                "2.2. AATD",
                "2.2.1. Traditional therapeutic approaches",
                "2.2.2. Recent development of genome editing for AATD",
                "2.3. Lung cancer",
                "2.3.1. CRISPR/Cas9-mediated genome-editing of proto-oncogenes",
                "2.3.2. CRISPR/Cas9-mediated genome-editing of tumor-suppressor genes",
                "2.3.3. CRISPR/Cas9-mediated genome-editing of chemotherapy resistance-related genes",
                "2.4. COPD and asthma",
                "2.4.1. Regaining steroid sensitivity in asthma and COPD",
                "3. Delivery technologies for genome editing",
                "3.1. Viral delivery of genome editing systems",
                "3.2. Non-viral delivery of genome editing systems",
                "3.2.1. Nanoparticle-mediated delivery",
                "3.2.2. Physical methods",
                "4. Delivery routes for genome editing of the lung genetic disorders",
                "4.1. Oral administration",
                "4.2. Intravenous injection",
                "4.3. Intratracheal/intranasal instillation",
                "4.4. Inhalation delivery",
                "5. Summary and future outlook",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Metabolomics_of_lung_cancer.pdf-c282bbc8",
        "document": "This review article focuses on the application of metabolomics in lung cancer research, specifically examining analytical platforms and their use in early detection, biomarker discovery, and mechanism exploration.  The authors summarize recent developments in lung cancer metabolomics using techniques like NMR, LC-MS, GC-MS, and CE-MS, highlighting their advantages and disadvantages.  Sample collection and metabolite extraction methods are also discussed, emphasizing the importance of pre-analytical factors for data quality.  The review concludes by summarizing the metabolic disturbances observed in lung cancer, including alterations in the TCA cycle, glycolysis, lipid metabolism, and amino acid metabolism.",
        "metadata": {
            "identifier": "Metabolomics of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:30:57.600353+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Metabolomics of lung cancer.pdf",
            "name": "Metabolomics of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Metabolomics",
                "NMR Spectroscopy",
                "LC-MS",
                "GC-MS",
                "CE-MS",
                "Biomarkers",
                "Metabolic Pathways"
            ],
            "author": "Hamada A. A. Noreldeen, Xinyu Liu, Guowang Xu",
            "timestamp": "January 2020",
            "headings": [
                "INTRODUCTION",
                "SAMPLE COLLECTION AND METABOLITE EXTRACTION METHODS FOR LUNG CANCER METABOLOMICS STUDY",
                "ANALYTICAL PLATFORMS OF METABOLOMICS",
                "3.1 NMR-based metabolomics",
                "3.2 LC–MS",
                "3.3 GC–MS",
                "3.4 CE–MS",
                "3.5 MALDI-MS",
                "DISTURBED METABOLISM IN LUNG CANCER",
                "4.1 TCA cycle and glycolysis",
                "4.2 Amino acid metabolism",
                "4.3 Lipid metabolism",
                "CONCLUDING REMARKS",
                "ACKNOWLEDGMENTS",
                "CONFLICT OF INTEREST",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-mRNA_Cancer_Vaccines.pdf-601e2e16",
        "document": "This scientific article reviews the use of mRNA cancer vaccines, focusing on the RNActive® technology and its applications.  The authors discuss the advantages of mRNA vaccines over DNA and protein-based vaccines, including their safety profile and flexible production process.  Different approaches are explored, such as personalized vaccines targeting neoantigens and cellular vaccines using mRNA-pulsed dendritic cells or CAR T cells.  Preclinical and clinical data from various trials are presented, highlighting the potential and ongoing research in this field.",
        "metadata": {
            "identifier": "mRNA Cancer Vaccines.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:03.968771+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\mRNA Cancer Vaccines.pdf",
            "name": "mRNA Cancer Vaccines.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "mRNA vaccines",
                "cancer immunotherapy",
                "neoantigens",
                "dendritic cells",
                "CAR T cells",
                "RNActive®",
                "tumor-associated antigens",
                "personalized medicine"
            ],
            "author": "Katja Fiedler, Sandra Lazzaro, Johannes Lutz, Susanne Rauch and Regina Heidenreich",
            "timestamp": "2016",
            "headings": [
                "1 mRNA Cancer Vaccines",
                "1.1 Introduction",
                "1.2 RNActive® Vaccines",
                "1.2.1 Induction of Antitumor Responses with RNActive® Vaccines",
                "1.2.2 Clinical Studies with RNActive® Vaccines",
                "1.2.3 Combination of RNActive® Vaccines with Chemotherapy or Radiation Therapy",
                "1.2.4 Clinical Study with RNActive® Vaccines in Combination with Radiotherapy",
                "1.2.5 Combination of RNActive® Vaccines with Immune Checkpoint Inhibitors",
                "1.3 Personalized mRNA Vaccines",
                "1.4 Cellular Vaccines: mRNA-Pulsed Dendritic Cells",
                "1.5 CAR T Cells",
                "2 Conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-mRNA_vaccine_for_cancer_immunotherapy.pdf-f0ef630e",
        "document": "This review article discusses the development and application of mRNA vaccines for cancer immunotherapy.  The authors detail recent advancements in mRNA structure modification and delivery methods, including lipid nanoparticles (LNPs) and polymers, to overcome challenges like instability and innate immunogenicity.  The review also covers self-amplifying mRNA (SAM) vaccines and their potential advantages.  Finally, it summarizes current clinical trials using mRNA vaccines for various cancers, highlighting promising therapeutic outcomes and future directions in the field.",
        "metadata": {
            "identifier": "mRNA vaccine for cancer immunotherapy.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:15.969287+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\mRNA vaccine for cancer immunotherapy.pdf",
            "name": "mRNA vaccine for cancer immunotherapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "mRNA vaccine",
                "cancer immunotherapy",
                "lipid nanoparticles (LNPs)",
                "self-amplifying mRNA (SAM)",
                "tumor antigens",
                "antigen-presenting cells (APCs)",
                "neoantigens",
                "personalized vaccine"
            ],
            "author": "Lei Miao, Yu Zhang and Leaf Huang",
            "timestamp": "2021",
            "headings": [
                "Abstract",
                "Introduction",
                "Basic mRNA pharmacology, limitations and advantages",
                "Immunogenicity of mRNA and paradoxical effects in Cancer immunotherapy",
                "Strategies to improve mRNA translation efficiency and overcome the innate immunogenicity",
                "Utilizing the impact of type IIFN for improved mRNA vaccination",
                "Self-amplifying mRNA vaccine, structure, advantages and deliveries",
                "Delivery of mRNA Cancer vaccine",
                "Ionizable lipid nanoparticles-based mRNA delivery system",
                "Polymer-based mRNA delivery system",
                "Peptide-based mRNA delivery system",
                "Other formulations used in mRNA delivery",
                "Injection routes mRNA Cancer vaccines",
                "Clinical overview of mRNA Cancer vaccines",
                "mRNA encoding Immunostimulants",
                "mRNA vaccine encoding tumor associated antigens",
                "mRNA vaccine encoding Neoantigen, personalized vaccine",
                "Conclusion and future perspectives",
                "Abbreviations",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Multi-omics_Data_Integration_Interpretation.pdf-e4e5b36c",
        "document": "This review article examines tools and methods for integrating multi-omics data to study complex biological processes.  The authors focus on tools that analyze multiple datasets simultaneously, integrating at least two omics datasets with overlapping samples.  Applications discussed include disease subtyping, biomarker prediction, and gaining insights into disease biology.  The review also covers multi-omics data repositories and visualization portals, highlighting challenges in data integration.",
        "metadata": {
            "identifier": "Multi-omics Data Integration, Interpretation.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:27.704214+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Multi-omics Data Integration, Interpretation.pdf",
            "name": "Multi-omics Data Integration, Interpretation.pdf",
            "document_type": "pdf",
            "domain_themes": "Bioinformatics",
            "keywords": [
                "multi-omics",
                "data integration",
                "disease subtyping",
                "biomarker prediction",
                "data repositories",
                "integrative analysis",
                "biological pathways",
                "cancer genomics"
            ],
            "author": "Indhupriya Subramanian, Srikant Verma, Shiva Kumar, Abhay Jere, Krishanpal Anamika",
            "timestamp": "2020",
            "headings": [
                "ABSTRACT",
                "Introduction",
                "Omics Data Types and Repositories",
                "Leveraging Multi-omics Data to Derive Actionable Insights",
                "Disease subtyping and classification of samples based on their omics profiles",
                "Bayesian approach",
                "Network approach",
                "Fusion-based approaches",
                "Similarity-based approaches",
                "Other multivariate approaches",
                "Prediction of biomarkers for various applications including diagnostics and driver genes for diseases",
                "Bayesian approach",
                "Network approach",
                "Other multivariate approaches",
                "Deriving insights into disease biology",
                "Bayesian approach",
                "Correlation-based approach",
                "Other multivariate approaches",
                "Other applications of integrating multi-omics data",
                "Comparative analysis and benchmarking of tools",
                "Portals for Visualization and Interpretation of Multi-omics Data Sets",
                "Challenges in Multi-omics Data Integration and Future Perspectives",
                "Conclusions",
                "Acknowledgements",
                "Author Contributions",
                "ReFeRenCeS"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nanomedicine_for_Treatment_of_Lung_Cancer.pdf-54a5812b",
        "document": "This scientific article discusses the use of nanomedicine, specifically nanoparticles, in the treatment of lung cancer.  The author highlights the advantages of nanoparticle-based drug delivery systems, such as improved bioavailability and targeted delivery, leading to increased therapeutic effectiveness and reduced toxicity.  Various nanoparticle formulations, including lipid-based, polymeric, and metal-based nanoparticles, are explored for their potential in lung cancer therapy.  The article also addresses challenges and future perspectives in this field, emphasizing the need for further research and regulatory considerations.",
        "metadata": {
            "identifier": "Nanomedicine for Treatment of Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:32.442810+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Nanomedicine for Treatment of Lung Cancer.pdf",
            "name": "Nanomedicine for Treatment of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Nanomedicine",
                "Lung Cancer",
                "Drug Delivery",
                "Nanoparticles",
                "Liposomes",
                "Polymeric Nanoparticles",
                "Targeted Therapy",
                "Toxicity"
            ],
            "author": "Sajid Hussain",
            "timestamp": "2016",
            "headings": [
                "Abstract",
                "Abbreviations",
                "1 Background",
                "2 Nanoparticle Drug Delivery for Lung Cancer Therapy",
                "2.1 Lipid-Based Nanoparticles",
                "2.2 Polymer Conjugates as Nanocarriers",
                "2.3 Other Nanoparticle Systems",
                "3 Challenges and Future Perspective",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nanotechnology_and_Nanomedicine_in_lung_cancer.pdf-44953d08",
        "document": "This scientific review article discusses the application of nanotechnology and nanomedicine in lung cancer diagnosis and therapy.  It highlights the use of nanoparticles (NPs) for improving early diagnosis through enhanced imaging techniques and the isolation of tumor-derived biomarkers.  The article also explores the potential of precision nanomedicine for targeted drug delivery, focusing on gold nanoparticles and mesoporous silica nanoparticles as drug delivery systems.  Challenges associated with clinical translation, such as toxicity and large-scale manufacturing, are also addressed.  The authors conclude by emphasizing the promising future of nanomedicine in revolutionizing lung cancer treatment.",
        "metadata": {
            "identifier": "Nanotechnology and Nanomedicine in lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:38.445855+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Nanotechnology and Nanomedicine in lung cancer.pdf",
            "name": "Nanotechnology and Nanomedicine in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Nanomedicine",
                "Lung Cancer",
                "Diagnosis",
                "Therapy",
                "Nanoparticles",
                "Drug Delivery",
                "Targeted Therapy",
                "Clinical Translation"
            ],
            "author": "Wei Yin, Feng Pan, Junjie Zhu, Junwu Xu, Diego Gonzalez-Rivas, Meinoshin Okumura, Zhiyong Tang, Yang Yang",
            "timestamp": "October 7, 2021",
            "headings": [
                "1.Introduction",
                "2.Personalized diagnosis of lung cancer",
                "2.1.Nanotechnology for the in vivo diagnosis of lung cancer",
                "2.2.Nanotechnology for the in vitro diagnosis of lung cancer",
                "2.2.1.Tumor-derived DNA in peripheral blood",
                "2.2.2.Tumor-derived DNA in PE",
                "2.2.3.Exosomes",
                "3.Precision nanomedicine for lung cancer",
                "3.1.Drug delivery",
                "3.1.1.Gold nanoparticles",
                "3.1.2.Mesoporous silica nanoparticles",
                "3.1.3.Nanoscale coordination polymers and nanoscale metal–organic frameworks",
                "3.2.Nanotheranostics",
                "4.Improvements in traditional lung cancer diagnosis methods using nanomedicine",
                "5.Improvements in traditional lung cancer treatment methods, using nanomedicine",
                "6.Perspective",
                "Acknowledgments",
                "Compliance with ethics guidelines",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Non-small_cell_lung_cancer_current_treatment_and_future_advances.pdf-84a44fbd",
        "document": "This review article discusses the current treatments and future advances in non-small cell lung cancer (NSCLC), the most common type of lung cancer.  It covers various treatment options, including surgery, chemotherapy, radiotherapy, and immunotherapy, highlighting the role of biomarker testing in personalizing treatment strategies.  The article also explores the use of immunotherapy, focusing on immune checkpoint inhibitors and vaccine development.  The poor prognosis of lung cancer and the importance of ongoing research are emphasized.",
        "metadata": {
            "identifier": "Non-small cell lung cancer current treatment and future advances.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:45.037080+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Non-small cell lung cancer current treatment and future advances.pdf",
            "name": "Non-small cell lung cancer current treatment and future advances.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Chemotherapy",
                "Immunotherapy",
                "Radiotherapy",
                "Biomarker testing",
                "Targeted therapy",
                "EGFR",
                "ALK"
            ],
            "author": "Cecilia Zappa, Shaker A. Mousa",
            "timestamp": "June 2016",
            "headings": [
                "Abstract",
                "Introduction",
                "Risk factors",
                "Current treatment options",
                "Surgery",
                "Adjuvant",
                "Chemotherapy",
                "Radiotherapy",
                "Biomarker testing",
                "Epidermal growth factor receptor (EGFR) gene",
                "KRAS",
                "Anaplastic lymphoma kinase (ALK)",
                "Role of immunotherapy in non-small cell lung cancer",
                "Cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) therapy",
                "Programmed cell death-1 (PD-1) and PD-L1",
                "Immunotherapy through vaccine development",
                "Tumor cell vaccines",
                "Antigen-specific vaccines",
                "Melanoma-associated antigen-A3 (MAGE-A3)",
                "Liposome BLP25 vaccine",
                "CIMAVax EGF",
                "TG4010 (MVA-MUC1-IL-2) vaccine",
                "Conclusions",
                "Acknowledgements",
                "Footnotes",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Proteomics_analysis_in_lung_cancer.pdf-e3acbb75",
        "document": "This review article discusses the application of proteomics analysis in lung cancer research.  The authors explore various proteomics technologies, including 2-D gel electrophoresis, mass spectrometry (MALDI-TOF, SELDI-TOF, shotgun proteomics), and protein microarrays, highlighting their strengths and limitations in identifying and quantifying proteins related to lung cancer.  The study emphasizes the potential of proteomics to discover new biomarkers for diagnosis, prognosis, and treatment of lung cancer, but also acknowledges the challenges in detecting low-abundance proteins and the need for technological advancements.  The ultimate goal is to improve the understanding of lung cancer and develop personalized therapies.",
        "metadata": {
            "identifier": "Proteomics analysis in lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:49.088023+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Proteomics analysis in lung cancer.pdf",
            "name": "Proteomics analysis in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Proteomics",
                "Lung Cancer",
                "Biomarkers",
                "Mass Spectrometry",
                "2-D Gel Electrophoresis",
                "Protein Microarrays",
                "Cancer Profiling",
                "Biomarker Discovery"
            ],
            "author": "Takefumi Kikuchi and David P. Carbone",
            "timestamp": "2007",
            "headings": [
                "INTRODUCTION",
                "TWO-DIMENSIONAL GELS",
                "MASS SPECTROMETRY INSTRUMENTS FOR PROTEIN PROFILING",
                "MALDI-TOF PROFILING",
                "SHOTGUN PROTEOMICS",
                "PROTEIN MICROARRAY",
                "SUMMARY",
                "ACKNOWLEDGEMENTS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Proteomics_as_a_Method_for_Early_Detection_of_Cancer.pdf-2e80c3b5",
        "document": "This review article examines the application of proteomics to the early detection of lung cancer, focusing on the use of exhaled breath condensate (EBC).  The authors discuss various proteomic technologies, including mass spectrometry and protein microarrays, and their potential for identifying protein biomarkers indicative of lung cancer.  EBC collection is highlighted as a simple, non-invasive method for obtaining lung samples.  While promising, challenges remain in standardizing EBC collection and analysis, as well as in validating identified biomarkers.",
        "metadata": {
            "identifier": "Proteomics as a Method for Early Detection of Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:31:53.488344+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Proteomics as a Method for Early Detection of Cancer.pdf",
            "name": "Proteomics as a Method for Early Detection of Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Proteomics",
                "Lung Cancer",
                "Exhaled Breath Condensate (EBC)",
                "Biomarkers",
                "Early Detection",
                "Mass Spectrometry",
                "Protein Microarrays",
                "Cancer Screening"
            ],
            "author": "Dean H. Conrad, Jesse Goyette, and Paul S. Thomas",
            "timestamp": "2007",
            "headings": [
                "BACKGROUND",
                "Proteins and Carcinogenesis",
                "Proteomic Technologies",
                "Proteomics and Lung Cancer Screening",
                "EXHALED BREATH CONDENSATE",
                "Collection of EBC",
                "Application of Proteomics to EBC and Lung Cancer",
                "CONCLUSIONS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Safety_and_feasibility_of_CRISPR-edited_T_cells.pdf-f2fcb957",
        "document": "This Nature Medicine article reports on a Phase I clinical trial evaluating the safety and feasibility of CRISPR-Cas9 gene-edited T cells in treating refractory non-small-cell lung cancer.  The trial met its primary endpoints, demonstrating safety and feasibility of the treatment.  Secondary endpoints, including efficacy, were also assessed, revealing a median progression-free survival of 7.7 weeks and a median overall survival of 42.6 weeks.  The study concludes that CRISPR-Cas9 gene-edited T cell therapy is safe and feasible, but suggests future trials should utilize improved gene editing techniques to enhance therapeutic efficacy.",
        "metadata": {
            "identifier": "Safety and feasibility of CRISPR-edited T cells.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:19.118114+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Safety and feasibility of CRISPR-edited T cells.pdf",
            "name": "Safety and feasibility of CRISPR-edited T cells.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "CRISPR-Cas9",
                "gene editing",
                "T cell therapy",
                "non-small-cell lung cancer",
                "PD-1",
                "safety",
                "feasibility",
                "clinical trial",
                "off-target effects"
            ],
            "author": "You Lu, Jianxin Xue, Tao Deng, et al.",
            "timestamp": "Published: xx xx xxxx",
            "headings": [
                "Articles",
                "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer",
                "Patients and treatment",
                "Preparation and evaluation of edited T cells",
                "To study the off-target impact of CRISPR–Cas9 on edited T cell genomes",
                "Safety and clinical outcomes",
                "In vivo tracking of edited T cells",
                "Peripheral TCR clonal diversity",
                "Clinical outcome of patient B-01",
                "Discussion",
                "Methods",
                "Study design and patients",
                "Study endpoints and assessments",
                "CRISPR plasmid construction",
                "Preparation of PD-1-edited T cells",
                "T7E1 cleavage assay and sequencing",
                "Flow cytometry",
                "Long-term cell culture",
                "Detection of off-target sites by WGS analysis",
                "Detection of off-target sites by NGS",
                "Efficiency validation and in vivo tracking of edited T cells",
                "Assessment of TCR clonal diversity",
                "Immunohistochemistry staining",
                "Detection of cytokines",
                "Statistical analysis",
                "Reporting Summary",
                "Data availability",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Cancer_Drug_Development_challenges_in_a_competitive_market.pdf-a03aa7ce",
        "document": "This article discusses the challenges and opportunities in cancer drug development, particularly focusing on the shift from traditional cytotoxic therapies to targeted and novel therapeutics.  It highlights the growth of the oncology market driven by factors like improved diagnostics, an aging population, and increased public awareness.  The authors use the development of bortezomib (Velcade) as a case study of a successful new approach.  The text emphasizes the collaborative nature of drug development and the need to navigate various pitfalls to achieve commercial success.",
        "metadata": {
            "identifier": "Cancer Drug Development challenges in a competitive market.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:21.665132+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Cancer Drug Development challenges in a competitive market.pdf",
            "name": "Cancer Drug Development challenges in a competitive market.pdf",
            "document_type": "pdf",
            "domain_themes": "Pharmaceutical Science",
            "keywords": [
                "cancer drug development",
                "oncology",
                "targeted therapy",
                "genotoxic drugs",
                "bortezomib",
                "Velcade",
                "drug approval",
                "FDA",
                "clinical trials",
                "commercial success"
            ],
            "author": "Barry Greene and Michael Kauffman",
            "timestamp": "N/A",
            "headings": [
                "INTRODUCTION",
                "A DOSE OF REALITY",
                "CIRCUMVENTING THE PITFALLS",
                "BORTEZOMIB: A CASE STUDY",
                "TEAM COMPOSITION",
                "A COLLABORATIVE ENTERPRISE"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ComparisonofSalesIncomeandResearchandDevelopmentCosts_for_FDA-ApprovedCancerDrugsSoldbyOriginatorDrugCompanies.pdf-029024e6",
        "document": "This observational study compares the income generated from sales of FDA-approved cancer drugs with their estimated research and development (R&D) costs.  The study found that median income significantly exceeded R&D costs, with many drugs generating billions in revenue.  The authors argue that these high prices restrict patient access and compromise healthcare system sustainability.  They conclude that lowering drug prices and increasing competition are crucial for improving patient access and fostering innovation.",
        "metadata": {
            "identifier": "ComparisonofSalesIncomeandResearchandDevelopmentCosts for FDA-ApprovedCancerDrugsSoldbyOriginatorDrugCompanies.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:27.151991+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\ComparisonofSalesIncomeandResearchandDevelopmentCosts for FDA-ApprovedCancerDrugsSoldbyOriginatorDrugCompanies.pdf",
            "name": "ComparisonofSalesIncomeandResearchandDevelopmentCosts for FDA-ApprovedCancerDrugsSoldbyOriginatorDrugCompanies.pdf",
            "document_type": "pdf",
            "domain_themes": "Health Policy",
            "keywords": [
                "Cancer Drugs",
                "Research and Development Costs",
                "Sales Income",
                "FDA Approval",
                "Drug Pricing",
                "Patient Access",
                "Healthcare Sustainability",
                "Return on Investment"
            ],
            "author": "Kiu Tay-Teo, André Ilbawi, Suzanne R. Hill",
            "timestamp": "January 4, 2019",
            "headings": [
                "Abstract KeyPoints",
                "Introduction",
                "Methods",
                "StudyDesign",
                "DataSources",
                "StatisticalAnalysis",
                "UncertaintyandAssumptions",
                "Results",
                "DataCharacteristics",
                "SalesIncomes",
                "ReturnsonInvestment",
                "SensitivityAnalyses",
                "Discussion",
                "Limitations",
                "Conclusions",
                "ARTICLEINFORMATION",
                "REFERENCES",
                "SUPPLEMENT"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Patent_trend_and_competitive_analysis_of_cancer.pdf-93a04751",
        "document": "This scientific article analyzes patent trends and competitive landscapes in cancer immunotherapy within the United States from 2006-2016.  The authors identified 2,229 patents across 13 subfields, revealing that patent growth in this area outpaces overall patent growth.  Amgen, Novartis, and Chugai Seiyaku are identified as leading patent holders, though the field remains relatively dispersed.  The analysis highlights the diverse strategies employed by major players and suggests future collaborations and consolidations are likely.",
        "metadata": {
            "identifier": "Patent trend and competitive analysis of cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:32.537635+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Patent trend and competitive analysis of cancer.pdf",
            "name": "Patent trend and competitive analysis of cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "cancer immunotherapy",
                "patent analysis",
                "competitive analysis",
                "patent landscape",
                "biopharmaceutical",
                "immune checkpoint inhibitors",
                "Amgen",
                "Novartis",
                "Chugai Seiyaku"
            ],
            "author": "Chia-Lin Pan & Feng-Chi Chen",
            "timestamp": "07 Sep 2017",
            "headings": [
                "Abstract",
                "Introduction",
                "Results and Discussion",
                "Patent trend",
                "Development strategies and relative strengths of the top 15 assignees",
                "Analysis and Perspective",
                "Concluding Remarks",
                "Methods",
                "Patent search and classification",
                "Patent quality analysis",
                "Relative strength analysis",
                "Author Contributions",
                "Declaration of competing interests",
                "Acknowledgement",
                "References",
                "Figure legends",
                "Tables"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pricing_in_the_Market_for_Anticancer_Drugs.pdf-37c20475",
        "document": "This Journal of Economic Perspectives article analyzes pricing trends in the US anticancer drug market from 1995-2013.  The authors find a significant increase in launch prices, even after adjusting for inflation and health benefits, attributing this to several factors. These include reference pricing, where new drug prices are set relative to existing ones, and government policies like the 340B program, which incentivize higher launch prices to offset discounts.  The study also discusses the role of generous third-party coverage and financial incentives for physicians in driving up prices. The authors conclude that these market dynamics contribute to the substantial increase in anticancer drug costs.",
        "metadata": {
            "identifier": "Pricing in the Market for Anticancer Drugs.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:39.309318+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Pricing in the Market for Anticancer Drugs.pdf",
            "name": "Pricing in the Market for Anticancer Drugs.pdf",
            "document_type": "pdf",
            "domain_themes": "Economics",
            "keywords": [
                "Anticancer Drugs",
                "Drug Pricing",
                "Health Economics",
                "Reference Pricing",
                "340B Program",
                "Medicare",
                "Survival Benefit",
                "Launch Prices",
                "Pharmaceutical Industry"
            ],
            "author": "David H. Howard, Peter B. Bach, Ernst R. Berndt, and Rena M. Conti",
            "timestamp": "Winter 2015",
            "headings": [
                "Pricing in the Market for Anticancer Drugs",
                "Drug Pricing Strategies",
                "Anticancer Drugs",
                "Policies Governing Drug Coverage and Reimbursement",
                "Trends in Launch Prices",
                "Price Per Life-Year Gained and Drug Attributes",
                "Sensitivity Checks",
                "Explaining Pricing Trends",
                "Reference Pricing",
                "Required Pricing Discounts",
                "Other Potential Causes of Price Increases",
                "Discussion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Review_of_Current_Policy_Strategies_to_Reduce_US_Cancer_Drug_Costs.pdf-9c70b85a",
        "document": "This article reviews current policy strategies in the US aimed at reducing the escalating costs of cancer drugs.  The authors focus on Medicare Part B and Part D, examining proposals for physician reimbursement reform, international price benchmarking, 340B drug discount program modifications, and waste reduction.  They also discuss reforms impacting Medicare Part D, including rebate and point-of-sale rebate reform, formulary flexibility, and price transparency measures.  Finally, the article explores the potential of value-based pricing and increased competition among biologic drugs to control costs.",
        "metadata": {
            "identifier": "Review of Current Policy Strategies to Reduce US Cancer Drug Costs.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:44.823801+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Review of Current Policy Strategies to Reduce US Cancer Drug Costs.pdf",
            "name": "Review of Current Policy Strategies to Reduce US Cancer Drug Costs.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Cancer Drugs",
                "Drug Pricing",
                "Medicare Part B",
                "Medicare Part D",
                "Value-Based Pricing",
                "Biosimilars",
                "340B Drug Discount Program",
                "Physician Reimbursement",
                "International Price Benchmarks",
                "Health Care Spending"
            ],
            "author": "Angela K. Green, MD, MSc; Jennifer A. Ohn, MPH; and Peter B. Bach, MD, MAPP",
            "timestamp": "December 5, 2019",
            "headings": [
                "Review of Current Policy Strategies to Reduce US Cancer Drug Costs",
                "REFORMS INFLUENCING MEDICARE PART B DRUG REIMBURSEMENT",
                "Physician Reimbursement Transaction (buy and bill) Reform",
                "International Drug Price Benchmarks",
                "340B Drug Discount Program Modification",
                "Discarded Cancer Drug Cost Recovery",
                "REFORMS INFLUENCING MEDICARE PART D DRUG REIMBURSEMENT",
                "Part D Rebate and Point-of-Sale Rebate Reform",
                "Other Part D Reforms",
                "COMPETITION AMONG BIOLOGIC DRUGS",
                "VALUE-BASED PRICING FOR CANCER DRUGS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_non-small-cell_lung_market.pdf-22ea8c6f",
        "document": "This news analysis article from Nature Reviews | Drug Discovery focuses on the non-small-cell lung cancer (NSCLC) drug market.  It details recent advancements in NSCLC treatments, including the approval of several new therapies in 2015, and discusses the late-phase pipeline of potential new drugs.  The authors, from Decision Resources Group, project significant market growth driven by these new agents, particularly immune checkpoint inhibitors.  The article highlights the increasing segmentation of the market based on tumor histology and molecular characteristics.",
        "metadata": {
            "identifier": "The non-small-cell lung market.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:47.971401+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\The non-small-cell lung market.pdf",
            "name": "The non-small-cell lung market.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small-cell lung cancer (NSCLC)",
                "Immune checkpoint inhibitors",
                "EGFR inhibitors",
                "ALK inhibitors",
                "Targeted therapies",
                "Drug market",
                "Clinical trials",
                "Oncology"
            ],
            "author": "Khurram Nawaz and Rachel M. Webster",
            "timestamp": "April 1, 2016",
            "headings": [
                "NEWS & ANALYSIS\nFROM THE ANALYST’S COUCH",
                "Current treatment advances",
                "Table 1 | Select therapies in the late-phase pipeline for NSCLC",
                "Market indicators",
                "Figure 1 | NSCLC markets"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Trends_in_Drug_Revenue_Among_Major_Pharmaceutical.pdf-4dd80aea",
        "document": "This 2021 study by Meyers et al. examines trends in drug revenue from 2010-2019 among ten major pharmaceutical companies.  The researchers found a 70% increase in revenue from cancer drugs, contrasting with an 18% decrease in non-oncology drug revenue.  Cancer drugs now constitute 25% of total revenue, raising concerns about industry profit versus patient outcomes.  The study highlights the need for further research to assess the impact of increased spending on patient care.",
        "metadata": {
            "identifier": "Trends in Drug Revenue Among Major Pharmaceutical.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:51.918895+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Trends in Drug Revenue Among Major Pharmaceutical.pdf",
            "name": "Trends in Drug Revenue Among Major Pharmaceutical.pdf",
            "document_type": "pdf",
            "domain_themes": "Pharmaceutical Economics/Healthcare",
            "keywords": [
                "drug revenue",
                "cancer drugs",
                "pharmaceutical industry",
                "oncology",
                "financial toxicity",
                "health economics",
                "drug pricing",
                "patient outcomes"
            ],
            "author": "Daniel E. Meyers, MD, MSc; Benjamin S. Meyers, BComm; Timothy M. Chisamore, MSc; Kristin Wright, MD; Bishal Gyawali, MD, PhD; Vinay Prasad, MD, MPH; Richard Sullivan, MD, PhD; Christopher M. Booth, MD",
            "timestamp": "October 6, 2021",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "CONCLUSIONS",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "AUTHOR CONTRIBUTIONS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Trends_in_the_Cost_of_Cancer_Care.pdf-3ec02024",
        "document": "This article reviews trends in the cost of cancer care in the US, which is exceeding other healthcare sectors and overall economic growth.  The authors analyze cost drivers, including technology adoption, overuse and underuse of services, and hospital consolidation.  They explore various models aimed at improving value, such as Accountable Care Organizations (ACOs), Centers of Excellence (COEs), and consumerism in cancer care.  The article concludes that multi-stakeholder interventions are needed to ensure appropriate and cost-effective cancer care.",
        "metadata": {
            "identifier": "Trends in the Cost of Cancer Care.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:32:56.650185+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Trends in the Cost of Cancer Care.pdf",
            "name": "Trends in the Cost of Cancer Care.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Cancer Care",
                "Healthcare Costs",
                "Value-Based Care",
                "Accountable Care Organizations (ACOs)",
                "Centers of Excellence (COEs)",
                "Technology Diffusion",
                "Hospital Consolidation",
                "Consumerism",
                "Cost-Effectiveness"
            ],
            "author": "Aaron A. Laviana, MD; Amy N. Luckenbaugh, MD; Matthew J. Resnick, MD, MPH, MMHC",
            "timestamp": "December 5, 2019",
            "headings": [
                "INTRODUCTION",
                "APPROPRIATENESS OF CARE",
                "Understanding Costs",
                "Improving Underuse of Cancer Care Services",
                "Reducing Overuse of Cancer Care Services",
                "HOSPITAL CONSOLIDATION",
                "MODELS TO IMPROVE VALUE",
                "Accountable Care Organizations",
                "Oncology Care Model",
                "Centers of Excellence",
                "Consumerism in Cancer Care",
                "In conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-What_patents_tell_us_about_drug_repurposing_for_cancer_A_landscape_analysis.pdf-20c62afc",
        "document": "This review article analyzes international patents related to drug repurposing for cancer treatment, focusing on disclosures published between 2014 and 2019.  The study reveals that patenting activity in this area has remained relatively constant, with universities and corporations as the main applicants.  Many patented repurposing ideas are not yet reflected in peer-reviewed literature, highlighting the importance of examining patents for a comprehensive understanding of the field.  The analysis also identifies a surprising contribution from non-academic research institutes and foundations, suggesting broader participation than previously assumed.  The study emphasizes the value of patent documents as a source of information beyond their legal function.",
        "metadata": {
            "identifier": "What patents tell us about drug repurposing for cancer  A landscape analysis.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:00.295106+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\What patents tell us about drug repurposing for cancer  A landscape analysis.pdf",
            "name": "What patents tell us about drug repurposing for cancer  A landscape analysis.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Drug Repurposing",
                "Cancer",
                "Patents",
                "Intellectual Property",
                "Neoplasms",
                "Vaccine",
                "Small Molecules"
            ],
            "author": "Hermann A.M. Mucke",
            "timestamp": "September 17, 2019",
            "headings": [
                "1. Introduction",
                "2. Methods",
                "3. Results",
                "4. Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_herbal_medicine_for_the_treatment_of_lung_cancer.pdf-26fce5ec",
        "document": "This scientific article investigates the anti-cancer properties of Rasagenthi Lehyam (RL), a traditional Indian medicine, specifically its chloroform fraction (cRL), on lung cancer cells.  Researchers found that cRL significantly inhibited cell proliferation and induced apoptosis in lung cancer cell lines (A-549 and H-460) without harming normal bronchial epithelial cells.  The mechanism involves up-regulation of pro-apoptotic genes (p53 and Bax) and down-regulation of the pro-survival gene Bcl-2, leading to caspase-3 activation.  Further research is needed to translate these findings into mainstream medicine.",
        "metadata": {
            "identifier": "A herbal medicine for the treatment of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:06.182583+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\A herbal medicine for the treatment of lung cancer.pdf",
            "name": "A herbal medicine for the treatment of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Rasagenthi Lehyam",
                "Apoptosis",
                "p53",
                "Bax",
                "Bcl-2",
                "Caspase-3",
                "Herbal medicine",
                "Chemotherapy",
                "Radio-sensitization"
            ],
            "author": "Rama S. Ranga, Srinivasan Sowmyalakshmi, Ravshan Burikhanov, Mohammed A. Akbarsha, Damodaran Chendil",
            "timestamp": "2005",
            "headings": [
                "Abstract",
                "Introduction",
                "Materials and methods",
                "Extraction of RL",
                "Cell cultures",
                "Irradiation",
                "MTT assay",
                "Clonogenic inhibition assay",
                "Cell cycle analysis",
                "Western Blot analysis",
                "Quantitation of apoptosis",
                "Flourimetric assays for caspase-3/7 activation",
                "Indirect immunofluorescence",
                "Statistical analysis",
                "Results",
                "cRL-induced cytotoxicity in A-549 and H-460 lung cancer cells",
                "cRL-induced apoptosis in lung cancer cells",
                "cRL induces p53 and Bax and down-regulates Bcl-2 proteins in lung cancer cells",
                "Nuclear export of p53 in lung cancer cell lines by cRL",
                "The cRL enhances radio-sensitisation effect on lung cancer cell lines",
                "Caspase-3 activation in lung cancer cell lines by cRL",
                "cRL-released radiation-induced G2/M phase block of cell cycle in lung cancer cell lines",
                "Discussion",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_Review_of_Patient-Reported_Outcomes_Labeling_for_Oncology_drugs_approved_by_FDA_and_EMA.pdf-21d399fb",
        "document": "This study compares US Food and Drug Administration (FDA) and European Medicines Agency (EMA) labeling for patient-reported outcomes (PROs) in oncology drugs approved between 2012 and 2016.  The EMA approved PRO labeling for significantly more indications than the FDA, often based on open-label studies and broader concepts like health-related quality of life.  The FDA emphasized evidence from controlled trials with minimal missing data and easily measurable endpoints.  Key differences in evidentiary standards and preferred PRO measures between the agencies are highlighted, offering guidance for sponsors' PRO strategies.",
        "metadata": {
            "identifier": "A Review of Patient-Reported Outcomes Labeling for Oncology drugs approved by FDA and EMA.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:10.918923+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\A Review of Patient-Reported Outcomes Labeling for Oncology drugs approved by FDA and EMA.pdf",
            "name": "A Review of Patient-Reported Outcomes Labeling for Oncology drugs approved by FDA and EMA.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Patient-reported outcomes",
                "Oncology drugs",
                "FDA",
                "EMA",
                "Drug labeling",
                "Clinical trials",
                "PRO measures",
                "Regulatory approval"
            ],
            "author": "Ari Gnanasakthy, Amy Barrett, Emily Evans, Denise D'Alessio, Carla (DeMuro) Romano",
            "timestamp": "2019",
            "headings": [
                "Abstract",
                "Introduction",
                "Methods",
                "Results",
                "Discussion",
                "FDA and EMA: Areas of Misalignment",
                "Study design",
                "Concepts assessed",
                "Missing data",
                "PRO data in context",
                "Assessmentschedules",
                "Conclusions",
                "Acknowledgment",
                "Supplemental Materials",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_study_of_new_drug_approval_pattern_of_a_Southeast_Asian_developed.pdf-86c467ef",
        "document": "This pharmacoepidemiological study analyzes new drug approvals in Singapore from 2017 to 2021, revealing a total of 418 approvals.  The majority of approvals (30.86%) were for anti-neoplastic and immunomodulating agents, aligning with trends observed in the US and UK.  The study classifies approvals by active ingredient, date, application category, indication, and WHO ATC classification.  The findings provide baseline data on Singapore's drug approval patterns, highlighting the significant growth in anti-cancer drug development.",
        "metadata": {
            "identifier": "A study of new drug approval pattern of a Southeast Asian developed.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:14.808947+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\A study of new drug approval pattern of a Southeast Asian developed.pdf",
            "name": "A study of new drug approval pattern of a Southeast Asian developed.pdf",
            "document_type": "pdf",
            "domain_themes": "Pharmacology",
            "keywords": [
                "New Drug Approval",
                "Singapore",
                "Pharmacoepidemiology",
                "Anti-neoplastic",
                "Immunomodulating agents",
                "Health Science Authority (HSA)",
                "WHO ATC Classification",
                "Drug Development",
                "NDA"
            ],
            "author": "Nilesh Chavda, Nirav Patel, Jatin V Dhanani, Priti Solanky",
            "timestamp": "June 20, 2022",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "CONCLUSION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Alectinib_for_the_Treatment_of_Metastatic_ALK-Positive_Non_Small_Cell_Lung_Cancer.pdf-00f38a1e",
        "document": "This FDA approval document details the accelerated approval of alectinib (ALECENSA) for treating metastatic ALK-positive non-small cell lung cancer (NSCLC) patients who have progressed on or are intolerant to crizotinib.  The approval is based on two single-arm trials showing objective response rates of 38% and 44%, with median durations of response of 7.5 and 11.2 months.  The document also discusses the drug's safety profile, including common adverse reactions and laboratory abnormalities, and the need for a confirmatory trial to verify clinical benefit.  Alectinib demonstrated efficacy in treating CNS metastases, a significant factor in this patient population.",
        "metadata": {
            "identifier": "Alectinib for the Treatment of Metastatic ALK-Positive Non–Small Cell Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:19.641800+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Alectinib for the Treatment of Metastatic ALK-Positive Non–Small Cell Lung Cancer.pdf",
            "name": "Alectinib for the Treatment of Metastatic ALK-Positive Non–Small Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Alectinib",
                "ALECENSA",
                "ALK-positive NSCLC",
                "Crizotinib",
                "FDA Approval",
                "Metastatic Lung Cancer",
                "CNS Metastases",
                "Objective Response Rate",
                "Adverse Reactions"
            ],
            "author": "Erin Larkins, Gideon M. Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney Helms, Stacy Shord, Jingyu Yu, Hong Zhao, Gina Davis, Amy E. McKee, Patricia Keegan, and Richard Pazdur",
            "timestamp": "December 11, 2015",
            "headings": [
                "Abstract",
                "Introduction",
                "Chemistry, Manufacturing, and Control",
                "Nonclinical Pharmacology and Toxicology",
                "Clinical Pharmacology",
                "Clinical Trial Design",
                "Efficacy",
                "Safety",
                "Discussion",
                "References",
                "Table 1",
                "Table 2",
                "Table 3",
                "Table 4",
                "Table 5"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Alectinib_versus_Crizotinib.pdf-6940626a",
        "document": "This article reports on a phase 3 clinical trial (ALEX) comparing the efficacy and safety of alectinib versus crizotinib in treating previously untreated, advanced ALK-positive non-small-cell lung cancer (NSCLC).  Alectinib demonstrated significantly superior progression-free survival and a lower risk of CNS progression compared to crizotinib.  The study also found alectinib had a more favorable safety profile with fewer grade 3-5 adverse events.  These findings suggest alectinib is a superior first-line treatment option for ALK-positive NSCLC.",
        "metadata": {
            "identifier": "Alectinib versus Crizotinib.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:24.624616+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Alectinib versus Crizotinib.pdf",
            "name": "Alectinib versus Crizotinib.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Alectinib",
                "Crizotinib",
                "ALK-positive NSCLC",
                "Non-small-cell lung cancer",
                "Progression-free survival",
                "CNS metastases",
                "Phase 3 trial",
                "Clinical trial",
                "Cancer treatment"
            ],
            "author": "Solange Peters et al. for the ALEX Trial Investigators",
            "timestamp": "June 6, 2017",
            "headings": [
                "ABSTRACT",
                "BACKGROUND",
                "METHODS",
                "Patients",
                "Trial Oversight",
                "Trial Design and Treatment",
                "Assessments",
                "Statistical Analysis",
                "RESULTS",
                "Patients",
                "Efficacy",
                "Safety",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-An_appraisal_of_drug_development_timelines_in_the_Era_of_precision_oncology.pdf-59ee950b",
        "document": "This research paper analyzes drug development timelines for oncology drugs approved by the FDA between 1998 and 2014, comparing those developed with and without a personalized (biomarker-based) strategy.  The study found that personalized drug development was associated with faster clinical development but similar approval times.  Targeted agents, particularly those with a biomarker-based approach, were developed faster than cytotoxic agents.  Response rates in early trials correlated with both registration trial response rates and total drug development time.",
        "metadata": {
            "identifier": "An appraisal of drug development timelines in the Era of precision oncology.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:29.427461+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\An appraisal of drug development timelines in the Era of precision oncology.pdf",
            "name": "An appraisal of drug development timelines in the Era of precision oncology.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "drug development",
                "precision oncology",
                "biomarkers",
                "FDA approval",
                "personalized medicine",
                "oncology drugs",
                "clinical trials",
                "pharmacoeconomics"
            ],
            "author": "Denis Leonardo Jardim, Maria Schwaederle, David S. Hong, Razelle Kurzrock",
            "timestamp": "Published: July 13, 2016",
            "headings": [
                "AbstrAct",
                "INtrODUctION",
                "rEsULts",
                "Personalized therapy was associated with faster clinical development",
                "Access to FDA special programs",
                "response rates (rr) in early trials and drug approval time",
                "DIscUssION",
                "MAtErIALs AND MEtHODs",
                "search strategy",
                "Data extraction",
                "statistical analysis",
                "cONFLIcts OF INtErEst",
                "GrANt sUPPOrt",
                "rEFErENcEs"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Biosimilars_in_Oncology_in_the_United_States.pdf-cfb82c63",
        "document": "This JAMA Oncology review article examines biosimilars in oncology within the United States, focusing on their regulatory pathways, cost implications, and potential for healthcare savings.  The authors highlight key differences between biosimilars and generic drugs, emphasizing the more complex approval process for biosimilars due to their biological nature.  The article discusses the potential cost savings associated with biosimilars, although the magnitude of these savings remains uncertain.  Finally, the authors address the impact of policy changes and the need for further research to fully understand the role of biosimilars in oncology.",
        "metadata": {
            "identifier": "Biosimilars in Oncology in the United States.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:34.495458+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Biosimilars in Oncology in the United States.pdf",
            "name": "Biosimilars in Oncology in the United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Biosimilars",
                "Oncology",
                "Generic Drugs",
                "Healthcare Costs",
                "FDA Regulation",
                "Value-Based Care",
                "Biologic Agents",
                "Cost Savings",
                "Extrapolation"
            ],
            "author": "Chadi Nabhan, MD, MBA; Sandeep Parsad, PharmD; Anthony R. Mato, MD, MSCE; Bruce A. Feinberg, DO",
            "timestamp": "July 20, 2017",
            "headings": [
                "IMPORTANCE",
                "OBSERVATIONS",
                "CONCLUSIONS AND RELEVANCE",
                "Commonly Asked Questions",
                "What Are the Regulatory Requirements to Approve a Biosimilar in the United States?",
                "Is Extrapolation to Additional Indications Appropriate?",
                "Can the Use of Biosimilars and Generics Save Money?",
                "How Are Biosimilars Paid For?",
                "Would Policy Changes in the United States Affect Biosimilars?",
                "Discussion",
                "Conclusions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Challenges_in_lung_cancer_therapy_during_the_COVID-19_pandemic.pdf-2d31d769",
        "document": "This document comprises two articles published in The Lancet Respiratory Medicine in 2020, focusing on the challenges of lung cancer treatment during the COVID-19 pandemic.  The first article discusses the difficulties in distinguishing lung cancer progression from COVID-19 infection due to overlapping symptoms and radiological findings, emphasizing the need for careful clinical management and SARS-CoV-2 testing. The second article explores the potential benefits of immunomodulatory treatments, such as IL-6 inhibition, to control the hyperinflammatory response in severe COVID-19 cases. Both articles highlight the urgent need for effective strategies to manage cancer care and COVID-19 concurrently.",
        "metadata": {
            "identifier": "Challenges in lung cancer therapy during the COVID-19 pandemic.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:37.967403+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Challenges in lung cancer therapy during the COVID-19 pandemic.pdf",
            "name": "Challenges in lung cancer therapy during the COVID-19 pandemic.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical",
            "keywords": [
                "COVID-19",
                "Lung Cancer",
                "Immunomodulation",
                "SARS-CoV-2",
                "Pneumonia",
                "Hyperinflammation",
                "Treatment Challenges",
                "Radiological Findings",
                "Cytokine Storm"
            ],
            "author": "Luana Calabrò, Solange Peters, Jean-Charles Soria, Anna Maria Di Giacomo, Fabrice Barlesi, Alessia Covre, Maresa Altomonte, Virginia Vegni, Cesare Gridelli, Martin Reck, Naiyer Rizvi, Michele Maio",
            "timestamp": "April 9, 2020 and May 4, 2020",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Comparison_of_FDA_accelerated_vs_regular_pathway.pdf-81af4c5a",
        "document": "This research article compares FDA accelerated and regular pathway approvals for lung cancer treatments between 2006 and 2018.  The study analyzed FDA data to assess differences in study design, sample size, outcome measures, and effect size between the two pathways and the impact of Breakthrough Therapy Designation (BTD).  The findings reveal that accelerated pathway approvals rely more on single-arm studies with smaller sample sizes and surrogate endpoints, although effect sizes were not significantly different.  The authors conclude that the criteria for accelerated approval and BTD lack clarity and that faster approvals often involve uncertainties requiring cautious interpretation and patient communication.",
        "metadata": {
            "identifier": "Comparison of FDA accelerated vs regular pathway.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:43.474234+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Comparison of FDA accelerated vs regular pathway.pdf",
            "name": "Comparison of FDA accelerated vs regular pathway.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "FDA",
                "lung cancer",
                "accelerated approval",
                "regular pathway",
                "Breakthrough Therapy Designation (BTD)",
                "surrogate endpoints",
                "sample size",
                "effect size",
                "clinical trials",
                "evidence quality"
            ],
            "author": "Tatiane Bomfim Ribeiro, Lewis Buss, Cole Wayant, Moacyr Roberto Cuce Nobre",
            "timestamp": "July 24, 2020",
            "headings": [
                "Abstract",
                "Introduction",
                "Methods",
                "Data collection",
                "Magnitude of effect",
                "Statistical analysis",
                "Results",
                "Regulatory characteristics",
                "Study characteristics",
                "Elements related to the quality of evidence in lung cancer approvals",
                "Accelerated vs regular pathway",
                "Breakthrough therapy designation",
                "Discussion",
                "Limitations",
                "Conclusion",
                "Supporting information",
                "AuthorContributions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Drug_Resistance_Mechanisms_in_Non-Small_Cell_Lung_Carcinoma.pdf-18b2c662",
        "document": "This scientific review article examines drug resistance mechanisms in non-small cell lung carcinoma (NSCLC), the most common type of lung cancer.  The authors discuss resistance to both targeted therapies (like EGFR and ALK inhibitors) and conventional chemotherapeutics, focusing on molecular mechanisms such as secondary mutations, pathway crosstalk, and the role of multidrug resistance proteins (ABC transporters).  The review highlights the importance of understanding these mechanisms to improve treatment efficacy and patient outcomes.  The authors also discuss the challenges and future directions of research in this area, including the need for more effective pharmacogenetic testing and the development of specific inhibitors for ABC transporters.",
        "metadata": {
            "identifier": "Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:33:55.241271+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.pdf",
            "name": "Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "EGFR",
                "EML4-ALK",
                "Tyrosine kinase inhibitors",
                "Drug resistance",
                "ABC transporters",
                "Chemotherapy",
                "Targeted therapy"
            ],
            "author": "Janet Wangari-Talbot and Elizabeth Hopper-Borge",
            "timestamp": "2013 October 31",
            "headings": [
                "Abstract",
                "Keywords",
                "INTRODUCTION",
                "RESISTANCE TO TARGETED AGENTS IN NSCLC",
                "Epidermal Growth Factor Receptor (EGFR)",
                "Increased PI3K/AKT Signaling",
                "Insulin-Like Growth Factor Receptor 1 (IGFR-1) Crosstalk",
                "KRAS Mutations",
                "Secondary Mutations in Acquired Resistance",
                "Epithelial to Mesenchymal Transition",
                "MET Amplification",
                "Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase (EML4-ALK)",
                "EML4-ALK Secondary Mutations",
                "ALK Copy Number Gain and Emergence of ALK - Fusion Negative Tumors",
                "Heat Shock Protein (Hsp90) Targeting in EMK4-ALK Positive Tumors",
                "Role of Multidrug Resistance Proteins in NSCLC",
                "ABCB1/MDR1/Pgp",
                "ABCC1/MRP1",
                "ABCC10/MRP7",
                "ABCG2/BCRP",
                "CONCLUSION",
                "Acknowledgments",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Drug_resistance_to_targeted_therapeutic_strategies_in_non-small_cell.pdf-388e1d18",
        "document": "This journal pre-proof article reviews drug resistance mechanisms in non-small cell lung cancer (NSCLC) targeted therapies.  The authors discuss on-target resistance (mutations in the targeted oncogene) and off-target resistance (changes in other signaling pathways).  Key oncogenes like EGFR, ALK, ROS1, and BRAF are examined, along with less common ones.  The review also covers epigenetic alterations (DNA methylation, histone modifications) and tumor microenvironment heterogeneity (CAFs, endothelial cells, immune cells) as contributors to drug resistance.",
        "metadata": {
            "identifier": "Drug resistance to targeted therapeutic strategies in non-small cell.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:34:12.536456+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Drug resistance to targeted therapeutic strategies in non-small cell.pdf",
            "name": "Drug resistance to targeted therapeutic strategies in non-small cell.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "Drug resistance",
                "Targeted therapy",
                "Oncogenes",
                "Epigenetic alterations",
                "Tumor microenvironment",
                "EGFR",
                "ALK",
                "ROS1",
                "BRAF"
            ],
            "author": "Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu",
            "timestamp": "2019",
            "headings": [
                "Abstract",
                "Keywords",
                "Abbreviations",
                "1. Introduction",
                "2. Gene alterations associated with drug resistance",
                "2.1 EGFR-TKIs",
                "2.2 ALK-TKIs",
                "2.3 Other targetable molecular mutations",
                "2.3.1 Oncogenic ROS1 gene rearrangement",
                "2.3.2 Oncogenic BRAF mutation",
                "2.3.3 MET alteration",
                "2.3.4 KRAS mutation",
                "2.3.5 HER2 mutation",
                "2.3.6 Rearranged during transfection (RET)",
                "2.3.7 Neurotrophic tyrosine receptor kinase (NTRK)",
                "3. Epigenetic alterations and drug resistance",
                "3.1 DNA methylation",
                "3.2 Histone acetylation",
                "3.3 Histone methylation",
                "3.4 Chromosomal heterogeneity",
                "3.5 Noncoding RNA",
                "4. Tumor microenvironment heterogeneity and drug resistance",
                "4.1 Drug resistance induced by cancer-associated fibroblast",
                "4.2 Drug resistance induced by vascular and lymphatic endothelial cells",
                "4.3 Immune system-mediated drug resistance",
                "4.4 Cancer stem cell-mediated drug resistance",
                "5. Other therapeutic strategies",
                "6. Future perspectives",
                "Acknowledgments",
                "Contributions",
                "Conflict of interest statement",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Durvalumab_for_the_treatment_of_non-small_cell_cancer.pdf-9b2dd097",
        "document": "This expert review article focuses on durvalumab, an anti-PD-L1 antibody, and its use in treating non-small cell lung cancer (NSCLC).  The article covers durvalumab's pharmacological properties, clinical efficacy as a monotherapy and in combination with other drugs, and its safety profile.  Key clinical trials, including PACIFIC, MYSTIC, ARCTIC, and NEPTUNE, are discussed, highlighting durvalumab's success as a maintenance therapy after chemoradiotherapy for unresectable stage III NSCLC but mixed results in first-line treatment.  The article concludes by discussing the need for further research to identify optimal biomarkers for patient selection and treatment strategies.",
        "metadata": {
            "identifier": "Durvalumab for the treatment of non-small cell cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:34:19.155658+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Durvalumab for the treatment of non-small cell cancer.pdf",
            "name": "Durvalumab for the treatment of non-small cell cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Durvalumab",
                "Non-small cell lung cancer (NSCLC)",
                "Immune checkpoint inhibitors",
                "PD-L1",
                "Immunotherapy",
                "Chemotherapy",
                "Clinical trials",
                "Biomarkers",
                "Tumor mutational burden (TMB)"
            ],
            "author": "Shuji Murakami",
            "timestamp": "2019-11-29",
            "headings": [
                "Abstract",
                "Article highlights",
                "1. Introduction",
                "2. Overview of the market",
                "3. Introduction to durvalumab",
                "3.1. Chemistry",
                "3.2. Pharmacodynamics",
                "3.3. Pharmacokinetics and metabolism",
                "3.4. Clinical efficacy",
                "3.4.1. Second-line or Later Treatment",
                "3.4.2. First-line treatment",
                "3.4.3. Consolidation after Chemoradiotherapy",
                "3.4.4. Biomarkers",
                "3.5. Regulatory affairs",
                "4. Conclusion",
                "5. Expert opinion",
                "References",
                "Table 1. Ongoing phase II and III studies of durvalumab as monotherapy or in combination with other drugs"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Emerging_insights_of_tumor_heterogeneity_and_drug_resistance_mechanisms_in_lung_cancer_targeted_therapy.pdf-60463fd2",
        "document": "This review article discusses emerging insights into tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.  The authors focus on the challenges of acquired drug resistance, highlighting the role of minimal residual disease (MRD) cells and intratumoral heterogeneity.  They explore various resistance mechanisms, including secondary mutations, bypass pathways, and phenotypic transformation, and propose the use of advanced technologies like single-cell methods and liquid biopsies to identify and target MRD cells.  The ultimate goal is to develop more effective, preemptive strategies to combat drug resistance and improve patient outcomes.",
        "metadata": {
            "identifier": "Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:34:27.160624+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.pdf",
            "name": "Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tumor heterogeneity",
                "Drug resistance",
                "Lung cancer",
                "Targeted therapy",
                "Minimal residual disease",
                "EGFR",
                "Liquid biopsy",
                "Single-cell analysis"
            ],
            "author": "Zuan-Fu Lim and Patrick C. Ma",
            "timestamp": "2019",
            "headings": [
                "Abstract",
                "Introduction",
                "Mechanisms of acquired drug resistance to lung cancer targeted therapy",
                "Understanding intratumoral heterogeneity in tumor evolution: the driving force behind minimal residual disease and drug tolerance-resistance",
                "Previous limitations and novel methods for linking intratumoral heterogeneity and drug resistance",
                "Molecular profiling for tumor-agnostic, driver-specific targeted therapy",
                "Conclusion",
                "Abbreviations",
                "Acknowledgments",
                "Authors’ contributions",
                "Funding",
                "Availability of data and materials",
                "Ethics approval and consent to participate",
                "Consent for publication",
                "Competing interests",
                "Author details",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Global_research_landscape_and_trends_of_lung_cancer.pdf-adba1f5c",
        "document": "This bibliometric analysis examines the global research landscape and trends in lung cancer immunotherapy from 2010 to July 1, 2022, using data from the Web of Science.  The study analyzes 2,941 publications, identifying key publications, journals, countries, institutions, and authors.  It reveals that anti-PD-(L)1 therapy has become a major focus since 2015, with significant contributions from researchers in the USA and China. The analysis also highlights recent research hotspots, such as combined therapies and neoadjuvant treatments, and suggests future research directions.",
        "metadata": {
            "identifier": "Global research landscape and trends of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:34:39.606249+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Global research landscape and trends of lung cancer.pdf",
            "name": "Global research landscape and trends of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "bibliometric analysis",
                "lung cancer",
                "immunotherapy",
                "PD-1/PD-L1",
                "clinical trials",
                "nivolumab",
                "pembrolizumab",
                "tumor mutation burden",
                "SCLC",
                "NSCLC"
            ],
            "author": "Yanhao Liu, Xu Cheng, Xiaona Han, Xi Cheng, Shu Jiang, Yaru Lin, Zhen Zhang, Linlin Lu, Baozhen Qu, Yuxian Chen, and Xiaotao Zhang",
            "timestamp": "01 December 2022",
            "headings": [
                "Introduction",
                "Methods",
                "Database and paper selection",
                "Statistical analysis",
                "Results",
                "Journals",
                "Countries/regions",
                "Institutions",
                "Authors",
                "Keywords",
                "Research trends",
                "Anti–PD–(L)1 for NSCLC",
                "Anti–PD–(L)1 for previously treated advanced NSCLC",
                "First–line anti–PD–(L)1 therapy for advanced NSCLC",
                "Novel immunotherapy for advanced NSCLC",
                "Adjuvant anti–PD–(L)1 therapy",
                "Neoadjuvant anti–PD–(L)1 therapy",
                "Anti–PD–(L)1 for SCLC",
                "Anti–PD–(L)1 for previously treated extensive–stage SCLC",
                "First–line anti–PD–(L)1 for extensive–stage SCLC",
                "Anti–PD–(L)1 for limited–stage SCLC",
                "Other immunotherapies",
                "Journals, countries, institutions, and authors",
                "Research trends and hotspots",
                "Limitations",
                "Conclusions",
                "Data availability statement",
                "Publisher’s note",
                "Supplementary material",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_cancer_costs_by_treatment_strategy_and_phase_of_care_among.pdf-673112fb",
        "document": "This research article analyzes lung cancer treatment costs among Medicare patients in the US from 1998-2013.  Using the SEER-Medicare database, the authors allocated costs across different phases of care (prediagnosis, staging, surgery, initial, continuing, and terminal), considering treatment strategies, age, diagnosis stage, and histology.  Key findings reveal trends in costs over time for each phase and treatment, highlighting the need for updated cost estimates in cost-effectiveness analyses of lung cancer interventions. The study's comprehensive cost data enables more accurate assessments of the economic impact of lung cancer control strategies.",
        "metadata": {
            "identifier": "Lung cancer costs by treatment strategy and phase of care among.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:34:46.030671+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Lung cancer costs by treatment strategy and phase of care among.pdf",
            "name": "Lung cancer costs by treatment strategy and phase of care among.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Healthcare Costs",
                "Treatment Costs",
                "Medicare",
                "SEER-Medicare Database",
                "Cost-Effectiveness Analysis",
                "Phase of Care",
                "Treatment Strategy"
            ],
            "author": [
                "Deirdre F. Sheehan",
                "Steven D. Criss",
                "Yufan Chen",
                "Andrew Eckel",
                "Lauren Palazzo",
                "Angela C. Tramontano",
                "Chin Hur",
                "Lauren E. Cipriano",
                "Chung Yin Kong"
            ],
            "timestamp": "14 August 2018",
            "headings": [
                "Abstract",
                "1 | INTRODUCTION",
                "2 | MATERIALS AND METHODS",
                "2.1 | SEER‐Medicare data",
                "2.2 | Treatment strategies",
                "2.3 | Phases of care",
                "2.4 | Cancer‐attributable costs",
                "2.5 | Prescription drug costs",
                "2.6 | Statistical analysis",
                "3 | RESULTS",
                "3.1 | Costs during the prediagnosis and staging phases",
                "3.2 | Cost of initial cancer treatment",
                "3.3 | Costs during the continuing and terminal phases",
                "3.4 | Prescription drug costs",
                "4 | DISCUSSION",
                "ACKNOWLEDGMENTS",
                "CONFLICT OF INTEREST",
                "ORCID",
                "REFERENCES",
                "SUPPORTING INFORMATION"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_cancer_research_and_its_citation_on_clinical_practice_guidelines.pdf-4fd5e899",
        "document": "This research article analyzes the citation patterns of lung cancer research papers within clinical practice guidelines (CPGs) from 16 countries and the Cochrane Collaboration.  The study compares the characteristics of papers cited in CPGs with the broader body of lung cancer research, revealing that CPG-cited papers are more clinically focused and often originate from smaller Northern European countries, though leading institutions are primarily from the USA.  The analysis highlights the underrepresentation of certain research areas like genetics and palliative care in CPGs.  The authors propose CPG citation analysis as an alternative research evaluation method, offering insights into a research's clinical impact.",
        "metadata": {
            "identifier": "Lung cancer research and its citation on clinical practice guidelines.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:34:52.866832+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Lung cancer research and its citation on clinical practice guidelines.pdf",
            "name": "Lung cancer research and its citation on clinical practice guidelines.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Clinical Practice Guidelines",
                "Research Citation Analysis",
                "Bibliometrics",
                "Clinical Trials",
                "Treatment Modalities",
                "Research Impact",
                "CPGs"
            ],
            "author": "Elena Pallari, Magnus Eriksson, Annika Billhult, Tommy Billhult, Ajay Aggarwal, Grant Lewison, Richard Sullivan",
            "timestamp": "5 February 2021",
            "headings": [
                "1. Introduction",
                "1.1. The burden from the disease, and previous studies",
                "1.2. Methods for research evaluation",
                "1.3. What this paper does",
                "2. Methodology",
                "2.1. Two sets of lung cancer research papers and means of analysis",
                "2.2. The clinical impact® and the KCL databases",
                "2.3. Description of analyses",
                "2.4. The comparison cohort of lung cancer research papers",
                "2.5. Statistical analysis",
                "3. Results",
                "3.1. Numbers of papers",
                "3.2. Countries of the researchers",
                "3.3. The leading research institutions in lung cancer",
                "3.4. The different types of lung cancer research",
                "3.5. The time gap between CPGs, and research papers, and their references",
                "4. Discussion",
                "5. Conclusions",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Mechanisms_of_immune_response_regulation_in_lung_cancer.pdf-64599410",
        "document": "This review article examines the mechanisms of immune response regulation in lung cancer, focusing on how the tumor microenvironment suppresses the host's anticancer immune response.  The article highlights the crucial roles of regulatory T cells (Tregs), Th17 cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) in this suppression.  It discusses various cytokines like TGFβ and IL-10, and their impact on immune cell function.  The authors emphasize the need for further investigation into these mechanisms to develop novel cancer treatments.",
        "metadata": {
            "identifier": "Mechanisms of immune response regulation in lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:34:56.997196+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Mechanisms of immune response regulation in lung cancer.pdf",
            "name": "Mechanisms of immune response regulation in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Immune response",
                "Regulatory T cells",
                "Th17 cells",
                "Myeloid-derived suppressor cells",
                "Tumor-associated macrophages",
                "TGFβ",
                "IL-10",
                "Immunotherapy"
            ],
            "author": "Joanna Domagala-Kulawik, Iwona Osinska, Grazyna Hoser",
            "timestamp": "2013-11-25",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Osimertinib_in_the_treatment_of_non-small-cell_lung_cancer_design_development_and_place_in_therapy.pdf-23e184d9",
        "document": "This 2017 review article, published in *Lung Cancer: Targets and Therapy*, focuses on osimertinib, a third-generation tyrosine kinase inhibitor (TKI) for treating non-small-cell lung cancer (NSCLC).  The authors detail osimertinib's design, development, and clinical efficacy, particularly in patients with the T790M mutation, a common mechanism of resistance to first- and second-generation TKIs.  The article also discusses mechanisms of resistance to osimertinib and explores ongoing clinical trials investigating its use in various settings and combinations with other therapies.  The review highlights osimertinib's significant improvement in the treatment of EGFR-mutated NSCLC, especially those with brain metastases.",
        "metadata": {
            "identifier": "Osimertinib in the treatment of non-small-cell lung cancer  design  development and place in therapy.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:05.596180+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Osimertinib in the treatment of non-small-cell lung cancer  design  development and place in therapy.pdf",
            "name": "Osimertinib in the treatment of non-small-cell lung cancer  design  development and place in therapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Osimertinib",
                "Non-small-cell lung cancer (NSCLC)",
                "EGFR",
                "T790M mutation",
                "Tyrosine kinase inhibitors (TKIs)",
                "Acquired resistance",
                "Targeted therapy",
                "Brain metastases",
                "Liquid biopsy",
                "ctDNA"
            ],
            "author": "Mariacarmela Santarpia, Alessia Liguori, Niki Karachaliou, Maria Gonzalez-Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla & Rafael Rosell",
            "timestamp": "2017-08-18",
            "headings": [
                "Abstract",
                "Introduction",
                "Targeting EGFR in NSCLC",
                "Mechanisms of resistance to first-line EGFR TKI therapy",
                "Therapeutic strategies targeting EGFR T790M",
                "Osimertinib",
                "Design and mechanism of action",
                "Pharmacokinetics (PK)",
                "Development of the drug",
                "Phase I and II studies",
                "Phase III studies",
                "Activity of osimertinib against CNS metastases",
                "Cell-free ctDNA genotyping for EGFR T790M mutation",
                "Place in therapy",
                "Mechanisms of resistance to osimertinib",
                "Future perspectives: ongoing studies, novel agents and combination strategies",
                "Conclusion",
                "Disclosure",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Safety_and_antitumour_activity_of_durvalumab_plus.pdf-a6c20061",
        "document": "This phase 1b clinical trial investigated the safety and antitumor activity of the combination of durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) in patients with advanced non-small cell lung cancer (NSCLC).  The study, conducted across five US cancer centers, found that the combination had manageable tolerability at certain doses, with antitumor activity observed regardless of PD-L1 status.  A specific dose combination (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg) was selected for further phase 3 trials based on its safety profile and clinical activity. The results suggest potential for this combination therapy in treating NSCLC patients, even those with PD-L1-negative tumors.",
        "metadata": {
            "identifier": "Safety and antitumour activity of durvalumab plus.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:11.721657+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Safety and antitumour activity of durvalumab plus.pdf",
            "name": "Safety and antitumour activity of durvalumab plus.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "durvalumab",
                "tremelimumab",
                "non-small cell lung cancer",
                "NSCLC",
                "PD-L1",
                "CTLA-4",
                "immunotherapy",
                "phase 1b study",
                "antitumor activity",
                "safety"
            ],
            "author": "Scott Antonia*, Sarah B Goldberg*, Ani Balmanoukian, Jamie E Chaft, Rachel E Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson J Karakunnel, Naiyer A Rizvi",
            "timestamp": "February 5, 2016",
            "headings": [
                "Summary",
                "Introduction",
                "Research in context",
                "Methods",
                "Study design and participants",
                "Procedures",
                "Outcomes",
                "Statistical analysis",
                "Role of the funding source",
                "Results",
                "Discussion",
                "Contributors",
                "Declaration of interests",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Study_on_Medication_Rules_of_Modern_Chinese_Herbal_Medicine.pdf-4cd4f3c9",
        "document": "This research article investigates the medication rules of modern Chinese herbal medicine in treating non-small cell lung cancer (NSCLC).  Using data mining techniques on a dataset from Beijing 301 Hospital (2010-2017), the study analyzed the frequency, efficacy, meridian tropism, and properties of herbs used in 231 prescriptions.  Key findings revealed frequently used herbs, dominant properties (heat-clearing, qi-tonifying), and common herb combinations.  The study concludes that NSCLC treatment in TCM focuses on clearing heat, detoxifying, tonifying the spleen, and regulating qi, aligning with the principles of strengthening the body and dispelling pathogens.",
        "metadata": {
            "identifier": "Study on Medication Rules of Modern Chinese Herbal Medicine.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:18.115720+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Study on Medication Rules of Modern Chinese Herbal Medicine.pdf",
            "name": "Study on Medication Rules of Modern Chinese Herbal Medicine.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Data mining",
                "Traditional Chinese Medicine (TCM)",
                "Non-small cell lung cancer (NSCLC)",
                "Chinese herbal medicine",
                "Medication rules",
                "Data analysis",
                "Herb combinations",
                "Treatment principles"
            ],
            "author": "Li-Ting Liu, Cui-Yun Zhao, Tong Wu, Zi-Yang Yu, Yuan Sun, Jie Li",
            "timestamp": "20-02-2020",
            "headings": [
                "Abstract",
                "Introduction",
                "Search Methods",
                "Chinese Medicine Compound Screening and Entry",
                "Data processing and analysis",
                "Results and Analysis",
                "Discussion",
                "Conclusion",
                "Financial support and sponsorship",
                "Conflicts of interest",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_role_of_generic_medicines_and_biosimilars.pdf-933e1e23",
        "document": "This research article examines the role of generic and biosimilar medicines in oncology within low-income countries, particularly focusing on Africa.  The authors highlight the potential cost savings these medications offer, significantly impacting cancer care accessibility.  However, challenges related to quality assurance, supply chain integrity, and safety monitoring are discussed.  The article advocates for improved regulation, quality control, and the development of cost-effective treatment guidelines tailored to low-resource settings.",
        "metadata": {
            "identifier": "The role of generic medicines and biosimilars.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:21.962037+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\The role of generic medicines and biosimilars.pdf",
            "name": "The role of generic medicines and biosimilars.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Generic Medicines",
                "Biosimilars",
                "Oncology",
                "Low-income countries",
                "Cancer Care",
                "Cost-effectiveness",
                "Quality Assurance",
                "Supply Chain",
                "Africa"
            ],
            "author": "L. Renner, F. A. Nkansah, A. N. O. Dodoo",
            "timestamp": "2013",
            "headings": [
                "The role of generic medicines and biosimilars in oncology in low-income countries",
                "challenges facing cancer control in Africa",
                "potential solutions to improve cancer control",
                "the case for generics",
                "potential problems with generics",
                "discussion",
                "disclosure",
                "references"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-TrendsinPricesofDrugsUsedtoTreatMetastaticNon_SmallCellLungCancer_intheUSFrom2015to2020.pdf-bde1be4b",
        "document": "This cross-sectional study analyzed price changes in brand-name drugs for metastatic non-small cell lung cancer (NSCLC) in the US from 2015 to 2020.  The researchers found that prices increased across all drug classes, with strong positive correlations between prices of drugs within the same class, indicating minimal price competition.  These increases outpaced inflation and the consumer price index for prescription drugs, raising concerns about affordability. The study suggests a need for drug pricing reform to address the rising costs of oncology medications.",
        "metadata": {
            "identifier": "TrendsinPricesofDrugsUsedtoTreatMetastaticNon–SmallCellLungCancer intheUSFrom2015to2020.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:25.616587+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\TrendsinPricesofDrugsUsedtoTreatMetastaticNon–SmallCellLungCancer intheUSFrom2015to2020.pdf",
            "name": "TrendsinPricesofDrugsUsedtoTreatMetastaticNon–SmallCellLungCancer intheUSFrom2015to2020.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "drug pricing",
                "oncology",
                "non-small cell lung cancer (NSCLC)",
                "price competition",
                "inflation",
                "affordability",
                "brand-name drugs"
            ],
            "author": "Aakash Desai, MBBS, MPH; Caleb Scheckel, DO; Chelsee J. Jensen, PharmD, RPh; Jacob Orme, MD, PhD; Colt Williams, MD; Nilay Shah, MPH; Konstantinos Leventakos, MD, PhD; Alex A. Adjei, MD, PhD",
            "timestamp": "January 25, 2022",
            "headings": [
                "Abstract KeyPoints",
                "Introduction",
                "Methods",
                "StatisticalAnalysis",
                "Results",
                "Discussion",
                "Limitations",
                "Conclusions",
                "ARTICLEINFORMATION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_Review_of_the_Role_of_MRI_in_Diagnosis_and_Treatment_of_Early_Stage.pdf-76078746",
        "document": "This review article examines the evolving role of magnetic resonance imaging (MRI) in the diagnosis and treatment of early-stage lung cancer.  While MRI has traditionally faced challenges due to lung tissue properties, advancements in technology, such as new sequences and functional MRI techniques (DWI, DCE), are increasing its clinical relevance.  The integration of MRI into radiation treatment delivery via MR-linacs offers real-time image guidance and adaptive radiotherapy, potentially improving treatment outcomes and reducing toxicities.  Despite limitations, MRI shows promise as a valuable tool for early lung cancer management.",
        "metadata": {
            "identifier": "A Review of the Role of MRI in Diagnosis and Treatment of Early Stage.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:31.403547+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\A Review of the Role of MRI in Diagnosis and Treatment of Early Stage.pdf",
            "name": "A Review of the Role of MRI in Diagnosis and Treatment of Early Stage.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Research",
            "keywords": [
                "MRI",
                "Lung Cancer",
                "Radiotherapy",
                "Image-Guided Radiotherapy",
                "Diffusion-Weighted Imaging",
                "Dynamic Contrast-Enhanced MRI",
                "MR-linac",
                "Early Stage Lung Cancer",
                "Treatment Response",
                "Diagnostic Imaging"
            ],
            "author": "Austin J. Sim, Evangelia Kaza, Lisa Singer, Stephen A. Rosenberg",
            "timestamp": "June 1, 2020",
            "headings": [
                "Abstract",
                "1. Introduction",
                "2. Barriers to lung MRI",
                "3. Advances in MRI technology",
                "4. Lung functional imaging",
                "5. MRI in radiation treatment",
                "6. Conclusion",
                "Figure Legends",
                "References",
                "Highlights"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Accuracy_of_Fine_Needle_Aspiration_Cytology_in_the_Pathological_Typing_of_Non-small_Cell_Lung_Cancer.pdf-ac8374dd",
        "document": "This research article investigates the accuracy of fine needle aspiration cytology (FNAC) in typing non-small cell lung cancer (NSCLC) compared to histology.  The study analyzed 186 NSCLC cases with both cytology and histology results, finding an 88% concordance rate between the two methods.  The positive predictive value of FNAC was high for both adenocarcinoma (92%) and squamous cell carcinoma (82%). The authors conclude that FNAC, especially when performed by experts, is a valuable tool for NSCLC typing and treatment planning, particularly when more invasive procedures are not feasible.",
        "metadata": {
            "identifier": "Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:35.384890+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer.pdf",
            "name": "Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Fine needle aspiration cytology",
                "FNAC",
                "Histology",
                "Adenocarcinoma",
                "Squamous cell carcinoma",
                "Accuracy",
                "Diagnosis",
                "Treatment planning"
            ],
            "author": "Rita Nizzoli, Marcello Tiseo, Francesco Gelsomino, Marco Bartolotti, Maria Majori, Lilia Ferrari, Massimo De Filippo, Guido Rindi, Enrico Maria Silini, Annamaria Guazzi, Andrea Ardizzoni",
            "timestamp": "March 2011",
            "headings": [
                "KeyWords",
                "Background",
                "Methods",
                "Results",
                "Conclusion",
                "Patients and Study Design",
                "Cytological Diagnosis",
                "Histological Diagnosis",
                "Statistical Analysis",
                "DISCUSSION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ALK-rearrangement_in_non-small-cell_lung_cancer_NSCLC_.pdf-226139f3",
        "document": "This invited review article focuses on ALK-rearrangement in non-small-cell lung cancer (NSCLC), a significant driver mutation in a subset of NSCLC patients.  The authors discuss the different types of ALK gene mutations (rearrangement, amplification, and point mutation), their detection methods (FISH, IHC, RT-PCR, and NGS), and the use of ALK tyrosine kinase inhibitors (TKIs) like crizotinib for treatment.  The review highlights the advantages and limitations of each detection method, emphasizing the importance of accurate diagnosis for effective targeted therapy.  Finally, the article explores the development of next-generation ALK inhibitors to overcome drug resistance.",
        "metadata": {
            "identifier": "ALK-rearrangement in non-small-cell lung cancer (NSCLC).pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:41.363895+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\ALK-rearrangement in non-small-cell lung cancer (NSCLC).pdf",
            "name": "ALK-rearrangement in non-small-cell lung cancer (NSCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ALK-rearrangement",
                "Non-small-cell lung cancer (NSCLC)",
                "ALK tyrosine kinase inhibitor (TKI)",
                "Crizotinib",
                "Fluorescence in situ hybridization (FISH)",
                "Immunohistochemistry (IHC)",
                "Reverse transcriptase-PCR (RT-PCR)",
                "Next-generation sequencing (NGS)",
                "EML4-ALK fusion"
            ],
            "author": "Xue Du, Yun Shao, Hai-Feng Qin, Yan-Hong Tai, Hong-Jun Gao",
            "timestamp": "2018",
            "headings": [
                "ALK-rearrangement in non-small-cell lung cancer (NSCLC)",
                "Types of oncogenesis in ALK",
                "ALK rearrangement in non-small cell lung cancer (NSCLC)",
                "ALK rearrangement detection methods in NSCLC patients",
                "ALK inhibitors",
                "Next generation ALK inhibitors",
                "Acknowledgment",
                "Disclosure",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ALK-rearrangements_and_testing_methods_in_non-small_cell_lung_cancer.pdf-bfa370ec",
        "document": "This scientific review article focuses on anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC).  It examines ALK-mediated signaling pathways and compares molecular diagnostic methods (IHC, FISH, PCR) for detecting ALK rearrangements. The review also discusses the use of crizotinib and second-generation ALK inhibitors, along with mechanisms of crizotinib resistance.  The authors conclude by highlighting the need for cost-effective ALK detection methods and the development of new inhibitors to improve treatment outcomes for ALK-positive NSCLC.",
        "metadata": {
            "identifier": "ALK-rearrangements and testing methods in non-small cell lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:48.670612+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\ALK-rearrangements and testing methods in non-small cell lung cancer.pdf",
            "name": "ALK-rearrangements and testing methods in non-small cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ALK",
                "Non-small cell lung cancer",
                "Crizotinib",
                "EML4-ALK fusion",
                "Tyrosine kinase inhibitor",
                "Molecular diagnostics",
                "Cancer therapy",
                "Drug resistance"
            ],
            "author": "Rodney E. Shackelford, Moiz Vora, Kim Mayhall, and James Cotelingam",
            "timestamp": "April 22, 2014",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "Anaplastic Lymphoma Kinase Gene Signaling",
                "ALK Mutations in Cancer",
                "ALK Activity in NSCLC",
                "Molecular Diagnostic Testing Methods for ALK-Fusions in NSCLC",
                "FISH",
                "ALK IHC",
                "PCR",
                "Other Methods of EML4-ALK Detection in NSCLC",
                "Alk-Inhibitor-Specific Therapy for NSCLC",
                "Molecular Mechanisms of Crizotinib Resistance",
                "Second Generation ALK Inhibitors",
                "HSP90 Inhibitors and EML-ALK Positive Lung Cancer",
                "CONCLUSION",
                "ACKNOWLEDGMENTS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Biomarkers_in_Lung_Cancer_Screening.pdf-6a7c05f4",
        "document": "This review article examines the use of molecular biomarkers in lung cancer screening, focusing on improving risk assessment and characterizing indeterminate pulmonary nodules (IPNs).  It outlines principles for optimizing biomarker discovery, summarizes the development status of promising candidates (autoantibodies, complement fragments, microRNAs, ctDNA, etc.), and discusses emerging technologies like exhaled breath analysis and metabolomics. The authors emphasize the importance of integrating different molecular technologies with imaging and artificial intelligence for improved diagnostic accuracy and propose a trial design to test the clinical utility of biomarker-based risk assessment.",
        "metadata": {
            "identifier": "Biomarkers in Lung Cancer Screening.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:35:56.887395+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Biomarkers in Lung Cancer Screening.pdf",
            "name": "Biomarkers in Lung Cancer Screening.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Biomarkers",
                "Lung Cancer",
                "Screening",
                "Indeterminate Pulmonary Nodules (IPNs)",
                "Risk Assessment",
                "ctDNA",
                "MicroRNAs",
                "Exhaled Breath Analysis",
                "Metabolomics",
                "Artificial Intelligence"
            ],
            "author": "Luis M. Seijo, MD, PhD; Nir Peled, MD, PhD; Daniel Ajona, PhD; Mattia Boeri, PhD; John K. Field, PhD; Gabriella Sozzi, PhD; Ruben Pio, PhD; Javier J. Zulueta, MD, PhD; Avrum Spira, MD, MSc; Pierre P. Massion, MD; Peter J. Mazzone, MD, MPH; Luis M. Montuenga, PhD",
            "timestamp": "December 4, 2018",
            "headings": [
                "REVIEW ARTICLE",
                "ABSTRACT",
                "Lung Cancer Screening Challenges: Is Imaging Sufficient for Successful Screening? The Unmet Needs",
                "What Is a Good Biomarker?",
                "Optimizing Discovery of Lung Cancer Biomarkers",
                "The Metrics of Success",
                "Current Promising Molecular Biomarkers",
                "Emerging Biomarkers, New Technologies to Follow, and Future Directions. The Power of Integration",
                "EB Biomarkers",
                "Sputum Cell–Based Image Analysis",
                "Metabolomics",
                "Genetic Predisposition to Lung Cancer",
                "Integration of Molecular Biomarkers with Radiomics and Artificial Intelligence",
                "Integration of Multiple NGS Analysis in ctDNA",
                "Future Research Challenges",
                "The Future of Molecular Biomarkers in the Context of Lung Cancer Screening",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Bronchoscopy_for_the_Diagnosis_and_Staging.pdf-cb6cbbe9",
        "document": "This article reviews bronchoscopic techniques for diagnosing and staging lung cancer.  It covers established methods like forceps and brush biopsies, bronchoalveolar lavage, and transbronchial needle aspiration, detailing their accuracy based on tumor characteristics.  The article also introduces newer technologies such as autofluorescence bronchoscopy, narrow band imaging, and endoscopic ultrasound, highlighting their roles in early detection and staging.  The authors emphasize the potential of these advancements, particularly in minimally invasive mediastinal sampling, and discuss the future of bronchoscopy in lung cancer diagnosis.",
        "metadata": {
            "identifier": "Bronchoscopy for the Diagnosis and Staging.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:02.415469+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Bronchoscopy for the Diagnosis and Staging.pdf",
            "name": "Bronchoscopy for the Diagnosis and Staging.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical",
            "keywords": [
                "Bronchoscopy",
                "Lung Cancer",
                "Diagnosis",
                "Staging",
                "Endobronchial Ultrasound",
                "Electromagnetic Navigation",
                "Autofluorescence Bronchoscopy",
                "Narrow Band Imaging"
            ],
            "author": "Ezzat El-Bayoumi, M.D. and Gerard A. Silvestri, M.D., M.S., F.C.C.P.",
            "timestamp": "2008",
            "headings": [
                "ABSTRACT",
                "BRONCHOSCOPIC TECHNIQUES for Endobronchial Disease",
                "ENDOBRONCHIAL DISEASE",
                "Bronchoscopy with Forceps Biopsy",
                "Bronchoscopy with Brush Biopsy",
                "Bronchoscopy with Bronchoalveolar Lavage or Wash",
                "Transbronchial Needle Aspiration",
                "Combining Techniques",
                "PERIPHERAL LUNG LESIONS",
                "Forceps Biopsy",
                "Brush Biopsy",
                "Bronchoscopy with Bronchoalveolar Lavage or Wash for Peripheral Lesions",
                "Computed Tomographic Fluoroscopy",
                "SAMPLING OF THE MEDIASTINUM",
                "Transbronchial Needle Aspiration for Sampling the Mediastinum",
                "Endoscopic Ultrasound with Fine Needle Aspiration",
                "Endobronchial ultrasound with Transbronchial Needle Aspiration",
                "EMERGING TECHNOLOGIES",
                "Autofluorescence Bronchoscopy",
                "Narrow Band Imaging Bronchoscopy",
                "Electromagnetic Navigation",
                "Optical Coherence Tomography and Confocal Laser Fluorescent Microscopy",
                "THE FUTURE",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Current_and_Future_Development_in_Lung_Cancer_Diagnosis.pdf-d537fd09",
        "document": "This review article from the International Journal of Molecular Sciences discusses current and future developments in lung cancer diagnosis.  The authors highlight the critical need for earlier diagnosis due to the high mortality rate associated with late-stage detection.  They analyze the advantages and disadvantages of current diagnostic methods, including imaging and biopsies, and explore the potential of body fluids as sources of biomarkers for early detection and prediction of cancer progression.  The review also covers various biomarker applications in clinical samples like sputum, bronchoalveolar lavage, peripheral blood, and urine.  Finally, the authors conclude by emphasizing the need for more reliable and less invasive diagnostic tests.",
        "metadata": {
            "identifier": "Current and Future Development in Lung Cancer Diagnosis.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:09.031248+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Current and Future Development in Lung Cancer Diagnosis.pdf",
            "name": "Current and Future Development in Lung Cancer Diagnosis.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "lung cancer",
                "diagnosis",
                "biomarkers",
                "liquid biopsy",
                "early detection",
                "screening",
                "imaging",
                "ctDNA",
                "precision medicine"
            ],
            "author": "Reem Nooreldeen and Horacio Bach",
            "timestamp": "Published: 12 August 2021",
            "headings": [
                "Abstract",
                "1. Introduction",
                "2. Lung Cancer Staging",
                "3. Classification",
                "4. SCLC",
                "5. NSCLC",
                "6. Traditional Diagnosis and Screening",
                "7. Lung Tissue Biopsies",
                "8. Transition to Biomarker Applications",
                "9. Liquid Biopsies Use in Lung Cancer",
                "10. Applications of Biomarkers in Clinical Samples",
                "11. Conclusions and Future Venues",
                "Author Contributions",
                "Funding",
                "Conflicts of Interest",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Current_Challenges_and_Future_Advances_in_Lung_Cancer.pdf-ce7f3e3d",
        "document": "This editorial by Giovanni Vicidomini reviews ten articles on recent advancements in lung cancer diagnosis and treatment.  The articles cover various aspects, including genetic mutations, novel biomarkers, targeted therapies like tyrosine kinase inhibitors (TKIs), and immunotherapy.  Challenges remain in treating rare lung cancers and overcoming resistance to existing therapies.  The review highlights the need for further research to improve prognosis and quality of life for lung cancer patients.",
        "metadata": {
            "identifier": "Current Challenges and Future Advances in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:12.365395+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Current Challenges and Future Advances in Lung Cancer.pdf",
            "name": "Current Challenges and Future Advances in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Targeted Therapy",
                "Immunotherapy",
                "Biomarkers",
                "Genetics",
                "Diagnosis",
                "Treatment",
                "Prognosis",
                "Tyrosine Kinase Inhibitors (TKIs)",
                "EGFR"
            ],
            "author": "Giovanni Vicidomini",
            "timestamp": "2023-07-21",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Development_of_PD-1PD-L1.pdf-b3241528",
        "document": "This scientific review article discusses the PD-1/PD-L1 pathway's role in non-small cell lung cancer (NSCLC) development and treatment.  The authors explore the pathway's mechanism in tumor immune escape and the development of various anti-PD-1 and anti-PD-L1 drugs.  Clinical trials and their results regarding these inhibitors, both as single agents and in combination therapies, are reviewed.  The article also addresses challenges and future research directions in this field, including the use of PD-L1 as a prognostic biomarker.",
        "metadata": {
            "identifier": "Development of PD-1PD-L1.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:18.115986+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Development of PD-1PD-L1.pdf",
            "name": "Development of PD-1PD-L1.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "PD-1",
                "PD-L1",
                "Non-small cell lung cancer (NSCLC)",
                "Tumor immune microenvironment",
                "Immunotherapy",
                "Checkpoint inhibitors",
                "Cancer treatment",
                "Clinical trials"
            ],
            "author": "Jiabei He, Ying Hu, Mingming Hu & Baolan Li",
            "timestamp": "August 17, 2015",
            "headings": [
                "Immune checkpoint pathways and cancer",
                "The biological characteristics of PD-1/PD-L1 pathway and its role in tumor",
                "The clinical significance of PD-1/PD-L1 pathway in NSCLC",
                "Drugs targeting PD-1, PD-L1 and combination with other cancer treatments",
                "Safety of drugs",
                "Prospects and problems",
                "Conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Fine-needle_aspiration_biopsy_versus_core-needle_biopsy_in_diagnosing_lung_cancer.pdf-cad5f757",
        "document": "This systematic review compares fine-needle aspiration biopsy (FNAB) and core-needle biopsy (CNB) for diagnosing lung cancer.  The study analyzed eleven studies, finding insufficient evidence to definitively favor one technique over the other for overall diagnosis.  However, CNB showed potentially higher specificity for benign lesions and accuracy in specific diagnosis.  Complication rates (pneumothorax, hemoptysis) were similar between the two methods.  Further research with better study designs is recommended.",
        "metadata": {
            "identifier": "Fine-needle aspiration biopsy versus core-needle biopsy in  diagnosing lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:24.285588+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Fine-needle aspiration biopsy versus core-needle biopsy in  diagnosing lung cancer.pdf",
            "name": "Fine-needle aspiration biopsy versus core-needle biopsy in  diagnosing lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Fine-needle aspiration biopsy",
                "Core-needle biopsy",
                "Lung cancer",
                "Diagnostic accuracy",
                "Systematic review",
                "Sensitivity",
                "Specificity",
                "Complications",
                "Pneumothorax",
                "Hemoptysis"
            ],
            "author": "X. Yao, M.M. Gomes, M.S. Tsao, C.J. Allen, W. Geddie, and H. Sekhon",
            "timestamp": "February 2012",
            "headings": [
                "ABSTRACT",
                "1. BACKGROUND",
                "2. METHODS",
                "2.1 Search Strategy",
                "2.2 Study Selection Criteria",
                "2.3 Data Abstraction",
                "2.4 Study Quality Assessment",
                "2.5 Data Analysis",
                "3. RESULTS",
                "3.1 Study Details and Quality",
                "3.2 Diagnostic Characteristics",
                "3.3 Overall Diagnostic Characteristics",
                "3.4 Specific Diagnostic Characteristics",
                "3.5 Image Guidance",
                "3.6 Lung Biopsy",
                "3.7 On-Site Cytopathologist",
                "3.8 FNAB and CNB Performed on the Same Patient",
                "3.9 Diagnostic Yields",
                "3.10 Complications",
                "4. DISCUSSION",
                "5. CONCLUSIONS",
                "6. ACKNOWLEDGMENTS",
                "7. CONFLICT OF INTEREST DISCLOSURES",
                "8. REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Liquid_biopsy_for_lung_cancer_early_detection.pdf-989e891a",
        "document": "This review article discusses the use of liquid biopsy for early detection of lung cancer.  It explores various circulating biomarkers, including cell-free circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and tumor-educated platelets (TEPs), and their potential roles in diagnosis.  The authors examine recent studies evaluating these biomarkers and the associated techniques, highlighting challenges in clinical application.  The article emphasizes the need for more specific, less invasive biomarkers to complement current diagnostic procedures like low-dose computed tomography (LDCT) screening.  Ultimately, the goal is to improve early detection and patient outcomes.",
        "metadata": {
            "identifier": "Liquid biopsy for lung cancer early detection.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:31.006188+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Liquid biopsy for lung cancer early detection.pdf",
            "name": "Liquid biopsy for lung cancer early detection.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Liquid Biopsy",
                "Early Detection",
                "Circulating Tumor DNA (ctDNA)",
                "Circulating Tumor Cells (CTCs)",
                "Exosomes",
                "Tumor-Educated Platelets (TEPs)",
                "MicroRNAs",
                "Biomarkers"
            ],
            "author": "Mariacarmela Santarpia, Alessia Liguori, Alessandro D’Aveni, Niki Karachaliou, Maria Gonzalez-Cao, Maria Grazia Daffinà, Chiara Lazzari, Giuseppe Altavilla, Rafael Rosell",
            "timestamp": "February 26, 2018",
            "headings": [
                "Abstract",
                "Introduction",
                "Clinical applications of liquid biopsy",
                "Circulating cell-free tumor DNA",
                "Gene methylation in cell-free tumor DNA",
                "CTCs",
                "microRNAs",
                "Exosomes",
                "Tumor educated platelets (TEPs)",
                "Conclusions",
                "Acknowledgements",
                "Footnote",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Liquid_biopsy_in_lung_cancer_significance.pdf-ce7385c8",
        "document": "This review article from *Molecular Cancer* (2022) discusses the use of liquid biopsy in lung cancer diagnostics, prediction, and treatment monitoring.  The authors detail the research progress and clinical applications of various liquid biopsy components, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and microRNAs.  The article highlights the advantages of liquid biopsy over traditional tissue biopsies, such as its non-invasive nature and ability for real-time monitoring.  The authors conclude that liquid biopsy holds significant promise for improving lung cancer care, but further research and standardization are needed.",
        "metadata": {
            "identifier": "Liquid biopsy in lung cancer significance.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:37.863627+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Liquid biopsy in lung cancer significance.pdf",
            "name": "Liquid biopsy in lung cancer significance.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Liquid Biopsy",
                "Circulating Tumor Cells (CTCs)",
                "Circulating Tumor DNA (ctDNA)",
                "Exosomes",
                "MicroRNAs (miRNAs)",
                "Diagnostics",
                "Treatment Monitoring",
                "Prognosis Prediction"
            ],
            "author": "Wen Li, Ji-Bin Liu, Li-Kun Hou, Fei Yu, Jie Zhang, Wei Wu, Xiao-Mei Tang, Feng Sun, Hai-Min Lu, Jing Deng, Jie Bai, Juan Li, Chun-Yan Wu, Qin-Lu Lin, Zhong-Wei Lv, Gao-Ren Wang, Geng-Xi Jiang, Yu-Shui Ma, Da Fu",
            "timestamp": "2022",
            "headings": [
                "Abstract",
                "Introduction",
                "Clinical application and technical research progress of liquid biopsy in lung cancer",
                "CTCs",
                "ctDNA",
                "Exosomes",
                "Other liquid biopsy components",
                "Conclusions",
                "Abbreviations",
                "Acknowledgements",
                "Authors’ contributions",
                "Funding",
                "Availability of data and materials",
                "Declarations",
                "Ethics approval and consent to participate",
                "Consent for publication",
                "Competing interests",
                "Author details",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Detection_using_CT_Scan_Images.pdf-359ea68f",
        "document": "This research paper evaluates computer-aided techniques for lung cancer detection using CT scan images.  The authors analyze existing methods, highlighting their limitations, particularly in accuracy and the lack of benign/malignant classification.  A new model is proposed that incorporates median and Gaussian filtering for noise reduction, watershed segmentation for nodule detection, and Support Vector Machine (SVM) for classification.  The results show improved accuracy compared to previous models, though further improvements are suggested for future work.",
        "metadata": {
            "identifier": "Lung Cancer Detection using CT Scan Images.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:42.618710+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Lung Cancer Detection using CT Scan Images.pdf",
            "name": "Lung Cancer Detection using CT Scan Images.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer Detection",
                "CT Scan Image",
                "Image Processing",
                "Machine Learning",
                "Support Vector Machine (SVM)",
                "Watershed Segmentation",
                "Computer-Aided Diagnosis",
                "Medical Imaging"
            ],
            "author": "Suren Makaju, P.W.C. Prasad, Abeer Alsadoon, A. K. Singh, A. Elchouemi",
            "timestamp": "2018",
            "headings": [
                "Abstract",
                "1. Introduction",
                "2. Literature Review",
                "3. Proposed Model",
                "3.2 Image Preprocessing",
                "3.3 Segmentation",
                "3.3 Features extraction",
                "3.4 Classification",
                "4. Implementation",
                "5. Result and Evaluation of Implementation",
                "6. Conclusion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Diagnosis_by_Fine_Needle.pdf-a930e719",
        "document": "This study investigates the impact of CT-guided fine needle aspiration (FNA) on the resection rate of nonmalignant lung nodules in patients undergoing evaluation for lung cancer.  Researchers found that preoperative FNA significantly reduced the resection rate of nonmalignant lesions (7.9% vs 25.9%).  The study highlights the high diagnostic accuracy of FNA (97%) compared to PET (65%), with a low rate of adverse events.  The findings suggest that frequent use of preoperative FNA can minimize unnecessary surgeries and improve resource allocation in lung cancer management.  Variability in FNA use among surgeons was also observed, emphasizing the importance of standardized protocols.",
        "metadata": {
            "identifier": "Lung Cancer Diagnosis by Fine Needle.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:47.321420+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Lung Cancer Diagnosis by Fine Needle.pdf",
            "name": "Lung Cancer Diagnosis by Fine Needle.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Fine Needle Aspiration (FNA)",
                "Surgical Resection",
                "Nonmalignant Nodules",
                "Diagnostic Accuracy",
                "Positron Emission Tomography (PET)",
                "Pneumothorax",
                "Sensitivity",
                "Specificity"
            ],
            "author": "Julie A. Barta, MD, Claudia I. Henschke, PhD, MD, Raja M. Flores, MD, Rowena Yip, MPH, David F. Yankelevitz, MD, and Charles A. Powell, MD",
            "timestamp": "November 7, 2016",
            "headings": [
                "Background",
                "Methods",
                "Results",
                "Patient Characteristics",
                "Diagnosis and Clinical Outcomes",
                "Diagnostic Accuracy of FNA",
                "Predictive Factors for Malignant Disease",
                "Characteristics of the Nonmalignant Disease at Resection Cohort",
                "Comment",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Screening_with_CT_Mayo_clinic_experience.pdf-32391380",
        "document": "This study evaluated the effectiveness of low-dose spiral computed tomography (CT) screening for lung cancer in a large cohort of high-risk individuals.  Over three years, 40 cases of lung cancer were diagnosed, with a high rate of early-stage detection.  However, the study also revealed a high rate of benign nodule detection (false positives), raising concerns about overdiagnosis and the potential for unnecessary procedures.  The authors conclude that while CT can detect early-stage lung cancers, its effectiveness as a widespread screening tool remains unproven and requires further investigation.",
        "metadata": {
            "identifier": "Lung Cancer Screening with CT Mayo clinic experience.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:52.142431+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Lung Cancer Screening with CT Mayo clinic experience.pdf",
            "name": "Lung Cancer Screening with CT Mayo clinic experience.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "CT Screening",
                "Low-dose Spiral CT",
                "Early Detection",
                "Overdiagnosis",
                "False Positives",
                "Pulmonary Nodules",
                "Cancer Staging"
            ],
            "author": [
                "Stephen J. Swensen, MD",
                "James R. Jett, MD",
                "Thomas E. Hartman, MD",
                "David E. Midthun, MD",
                "Jeff A. Sloan, PhD",
                "Anne-Marie Sykes, MD",
                "Gregory L. Aughenbaugh, MD",
                "Medy A. Clemens, CCRP"
            ],
            "timestamp": "July 25, 2002",
            "headings": [
                "PURPOSE",
                "MATERIALS AND METHODS",
                "Participants",
                "Follow-up and Recommendations",
                "Imaging and Image Review",
                "RESULTS",
                "Enrollment",
                "DISCUSSION",
                "False-Positive Findings",
                "Overdiagnosis",
                "Potential Harms from False-Positive Findings and Overdiagnosis",
                "Additional Findings",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Magnetic_resonance_imaging_in_precision_radiation_therapy_for_lung_cancer.pdf-19f41ca8",
        "document": "This review article discusses the use of magnetic resonance imaging (MRI) in precision radiation therapy for lung cancer.  It explores MRI's role in improving diagnostic staging, target volume delineation, and treatment adaptation. The authors highlight the challenges of using MRI in the thorax, such as motion artifacts, but also discuss advancements like 4D MRI and MR-guided radiotherapy units (MR-Linacs).  The article emphasizes the potential of MR-Linacs to enable real-time treatment adaptation and improve outcomes for lung cancer patients.",
        "metadata": {
            "identifier": "Magnetic resonance imaging in precision radiation therapy for lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:36:58.739232+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Magnetic resonance imaging in precision radiation therapy for lung cancer.pdf",
            "name": "Magnetic resonance imaging in precision radiation therapy for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung cancer",
                "Radiotherapy",
                "Magnetic Resonance Imaging (MRI)",
                "MR-Linac",
                "Treatment planning",
                "Image-guided radiotherapy",
                "Adaptive radiotherapy",
                "Disease staging"
            ],
            "author": "Hannah Bainbridge, Ahmed Salem, Rob H. N. Tijssen, Michael Dubec, Andreas Wetscherek, Corinne Van Es, Jose Belderbos, Corinne Faivre-Finn, Fiona McDonald",
            "timestamp": "May 17, 2017 (Submitted); Sep 08, 2017 (Accepted)",
            "headings": [
                "Abstract",
                "Background Searching strategy and selection criteria",
                "Disease staging and patient selection",
                "Target and OAR delineation",
                "Treatment planning",
                "Treatment verification",
                "Daily treatment plan adaptation",
                "Real-time target tracking",
                "Early assessment of treatment response",
                "Conclusions",
                "Acknowledgements",
                "Footnote",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-PD-L1_Expression_in_Lung_Cancer.pdf-4500bd33",
        "document": "This article reviews the state-of-the-art research on PD-L1 expression in lung cancer, focusing on its role as a biomarker for predicting response to immunotherapy.  The authors discuss the challenges in harmonizing PD-L1 detection methods due to variations in antibodies, scoring systems, and positivity cutoffs across different clinical trials.  They highlight the need for standardized methods and definitions to improve patient care and avoid misleading comparisons.  The review also explores other potential biomarkers, such as PD-L2 expression and tumor mutation burden, which may further refine the prediction of immunotherapy response.",
        "metadata": {
            "identifier": "PD-L1 Expression in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:05.229246+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\PD-L1 Expression in Lung Cancer.pdf",
            "name": "PD-L1 Expression in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "PD-L1",
                "Lung Cancer",
                "Immunotherapy",
                "Biomarker",
                "Immunohistochemistry",
                "Clinical Trials",
                "PD-L2",
                "Tumor Mutation Burden"
            ],
            "author": "Hui Yu, MD, PhD; Theresa A. Boyle, MD, PhD; Caicun Zhou, MD, PhD; David L. Rimm, MD, PhD; Fred R. Hirsch, MD, PhD",
            "timestamp": "April 23, 2016",
            "headings": [
                "Introduction",
                "PD-L1 Expression Emerges as a Biomarker in Early Studies",
                "Challenges and Pitfalls in Detecting PD-L1 by IHC Analysis",
                "Comparison of Different Antibodies",
                "Definitions of Positivity",
                "Challenges with Characterization of PD-L1 Expression by Cell Type",
                "Heterogeneity and Associated Risks for False-Positive and False-Negative Results",
                "Effect of Tissue Processing on PD-L1 Expression",
                "The Impact of Different Therapies on the Expression of PD-L1",
                "Role of Other PD-L1 Biomarkers",
                "Conclusion",
                "Acknowledgments",
                "References",
                "Update",
                "Erratum"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-PET_CT_imaging_in_different_types_of_lung_cancer.pdf-4027eb62",
        "document": "This review article from the European Journal of Radiology (2012) examines the applications of PET/CT imaging in various types of lung cancer.  The authors discuss the use of different PET tracers, such as 18F-FDG, 68Ga-DOTA-peptides, and 18F-DOPA, for staging, treatment planning, and monitoring response to therapy in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bronchioloalveolar carcinoma (BAC), lung neuroendocrine tumors (NET), and solitary pulmonary nodules (SPN).  The review highlights the advantages and limitations of PET/CT compared to conventional imaging techniques like CT.  The overall aim is to provide an overview of the clinical applications and accuracy of PET/CT in the diagnosis and management of lung cancer.",
        "metadata": {
            "identifier": "PET,CT imaging in different types of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:14.691409+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\PET,CT imaging in different types of lung cancer.pdf",
            "name": "PET,CT imaging in different types of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "PET/CT",
                "18F-FDG",
                "68Ga-DOTA-peptides",
                "18F-DOPA",
                "NSCLC",
                "SCLC",
                "Staging",
                "Treatment Response"
            ],
            "author": "Valentina Ambrosini, Silvia Nicolini, Paola Carolia, Cristina Nanni, Arianna Massaro, Maria Cristina Marzola, Domenico Rubello, Stefano Fanti",
            "timestamp": "2012",
            "headings": [
                "1. Introduction",
                "2. Non-small cells lung cancer (NSCLC)",
                "2.1. PET/CT for T detection",
                "2.2. PET/CT for N detection",
                "2.3. PET/CT for M detection",
                "2.4. Radiation therapy planning",
                "3. Small cell lung cancer",
                "4. Bronchioloalveolar carcinoma (BAC)",
                "5. Solitary pulmonary nodule (SPN)",
                "6. Neuroendocrine tumours (NET) of the lung",
                "7. Conclusions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-PET_CT_Versus_MRI_for_Diagnosis.pdf-9598b674",
        "document": "This review article compares PET/CT and MRI for diagnosing, staging, and following up lung cancer.  PET/CT, combining metabolic and morphologic data, shows higher sensitivity and accuracy for lung nodule characterization and metastasis detection than conventional methods. MRI, while initially challenging, is becoming a useful alternative with advancements in techniques like diffusion-weighted MRI (DWI) for distinguishing benign and malignant nodules and evaluating treatment response.  The article also explores the potential of PET/MRI hybrid systems, offering higher soft-tissue contrast and reduced radiation exposure.  Finally, the role of both modalities in early lung cancer detection is discussed.",
        "metadata": {
            "identifier": "PET,CT Versus MRI for Diagnosis.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:21.692470+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\PET,CT Versus MRI for Diagnosis.pdf",
            "name": "PET,CT Versus MRI for Diagnosis.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "PET/CT",
                "MRI",
                "Diagnosis",
                "Staging",
                "Follow-up",
                "Metastasis",
                "Treatment Response"
            ],
            "author": "Hyun Su Kim, MD, Kyung Soo Lee, MD, Yoshiharu Ohno, MD, PhD, Edwin J.R. van Beek, MD, PhD, and Juergen Biederer, MD",
            "timestamp": "September 27, 2014",
            "headings": [
                "PET/CT Versus MRI for Diagnosis, Staging, and Follow-up of Lung Cancer",
                "Evaluation of patients with suspected lung cancer comprises PET/CT in Lung Cancer",
                "PET/CT in Solitary Pulmonary Nodule (SPN) Tissue Characterization",
                "Volume-Based Assessment of PET/CT in Lung Cancer",
                "PET/CT as a Follow-up Imaging Tool",
                "MRI in Lung Cancer",
                "Available Protocols",
                "MRI for the Detection of Pulmonary Nodules",
                "MRI for the Assessment of Malignancy and Tumor Viability",
                "Implementation of Lung MRI Into Hybrid Systems",
                "MRI as a Potential Tool for Early Detection of Lung Cancer",
                "PET/CT Versus MRI in Lung Cancer Staging",
                "TUMOR STAGING",
                "NODAL STAGING",
                "METASTASIS STAGING",
                "Performance Comparison in Cancer Staging Between PET/CT and WB MRI",
                "Conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Sensitivity_and_Specificity_of_Chest_X-Ray_Screening.pdf-0096e5e5",
        "document": "This review article by Gavelli and Giampalma examines the effectiveness of chest X-ray screening for early lung cancer detection.  While randomized controlled trials haven't shown a reduction in mortality rates, the authors argue that screening leads to earlier diagnosis and improved survival due to better disease staging and increased resectability.  They contend that despite limitations in sensitivity and specificity, chest X-ray screening remains the most valid method for secondary prevention in high-risk smokers.  The article also discusses challenges in radiologic interpretation and the potential of CT scans as an alternative screening method.",
        "metadata": {
            "identifier": "Sensitivity and Specificity of Chest X-Ray Screening.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:24.831347+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Sensitivity and Specificity of Chest X-Ray Screening.pdf",
            "name": "Sensitivity and Specificity of Chest X-Ray Screening.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Research",
            "keywords": [
                "Lung Cancer",
                "Chest X-Ray Screening",
                "Early Detection",
                "Mortality Rate",
                "Survival Rate",
                "Sensitivity",
                "Specificity",
                "Secondary Prevention",
                "Radiography"
            ],
            "author": "Giampaolo Gavelli, M.D. and Emanuela Giampalma, M.D.",
            "timestamp": "June 19, 2000",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Sensitivity_of_chest_X-ray_for_detecting_lung_cancer_in_people_presenting_with_symptoms.pdf-41045a60",
        "document": "This systematic review assesses the sensitivity of chest X-rays in detecting lung cancer among symptomatic individuals.  The researchers analyzed 21 studies, finding that high-quality studies suggest a sensitivity of 77-80%, meaning chest X-rays miss lung cancer in at least 20% of cases.  This highlights the need for further investigation in high-risk patients with negative chest X-rays and raises questions about the limitations of chest X-rays as the primary diagnostic tool for lung cancer. The authors suggest that increased access to CT scans may be necessary to improve early detection and outcomes.",
        "metadata": {
            "identifier": "Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:30.204526+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms.pdf",
            "name": "Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Chest X-ray",
                "Sensitivity",
                "Diagnostic Accuracy",
                "Systematic Review",
                "Early Diagnosis",
                "Primary Care",
                "Computed Tomography (CT)",
                "False Negatives"
            ],
            "author": "Stephen H Bradley, Sarah Abraham, Matthew EJ Callister, Adam Grice, William T Hamilton, Rocio Rodriguez Lopez, Bethany Shinkins and Richard D Neal",
            "timestamp": "2 May 2019",
            "headings": [
                "Abstract",
                "Background",
                "Aim",
                "Method",
                "Design and setting",
                "Databases",
                "Inclusion and exclusion criteria",
                "Study selection",
                "Data extraction",
                "Analysis",
                "RESULTS",
                "Summary of eligible studies",
                "Quality assessment",
                "DISCUSSION",
                "Summary",
                "Strengths and limitations",
                "Comparison with existing literature",
                "Implications for research and practice",
                "Funding",
                "Ethical approval",
                "Provenance",
                "Competing interests",
                "Acknowledgements",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Future_of_Bronchoscopy_in_treatment_and_diagnosis_of_lung_cancer.pdf-dcf84267",
        "document": "This 2006 thematic review article discusses the advancements and future directions of bronchoscopy in diagnosing, staging, and treating lung cancer.  It covers established techniques like forceps biopsy, needle aspiration, and brushing, as well as newer technologies such as endobronchial ultrasound and autofluorescence bronchoscopy.  The authors highlight the importance of multimodality treatment approaches and the need for greater collaboration between pulmonologists and oncologists.  The article also explores promising techniques like electromagnetic navigation and confocal fluorescence microendoscopy for improved diagnostic accuracy.",
        "metadata": {
            "identifier": "The Future of Bronchoscopy in treatment and diagnosis of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:35.668709+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\The Future of Bronchoscopy in treatment and diagnosis of lung cancer.pdf",
            "name": "The Future of Bronchoscopy in treatment and diagnosis of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Bronchoscopy",
                "Lung Cancer",
                "Diagnosis",
                "Staging",
                "Treatment",
                "Endobronchial Ultrasound",
                "Autofluorescence Bronchoscopy",
                "Electromagnetic Navigation",
                "Confocal Fluorescence Microendoscopy"
            ],
            "author": "Felix J.F. Herth, Ralf Eberhardt, Armin Ernst",
            "timestamp": "2006",
            "headings": [
                "Abstract",
                "Introduction",
                "Current Techniques in Diagnostic Bronchoscopy",
                "Forceps Biopsy",
                "Transbronchial Needle Aspiration",
                "Brushing and Aspiration Cytology",
                "Current Techniques in Therapeutic Bronchoscopy",
                "Laser Therapy",
                "Electrocautery and Cryotherapy",
                "Stenting",
                "Recent Developments in Bronchoscopy",
                "Endobronchial Ultrasound",
                "Autofluorescence Endoscopy",
                "Electromagnetic Navigation",
                "Promising Techniques",
                "Magnification",
                "Narrow-Band Imaging",
                "Confocal Fluorescence Microendoscopy",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Role_of_Artificial_Intelligence_in_Early_Cancer_Diagnosis.pdf-c4dc2c36",
        "document": "This review article examines the role of artificial intelligence (AI) in early cancer diagnosis.  The authors discuss how AI algorithms, particularly machine learning and deep learning techniques, can assist clinicians in screening asymptomatic patients, investigating symptomatic patients, and diagnosing cancer recurrence.  Various data types, including electronic health records, medical images, and biopsy samples, are analyzed using AI to improve risk stratification and early detection.  The article also addresses challenges and ethical considerations associated with implementing AI in clinical practice.",
        "metadata": {
            "identifier": "The Role of Artificial Intelligence in Early Cancer Diagnosis.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:45.826031+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\The Role of Artificial Intelligence in Early Cancer Diagnosis.pdf",
            "name": "The Role of Artificial Intelligence in Early Cancer Diagnosis.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Artificial Intelligence",
                "Machine Learning",
                "Deep Learning",
                "Early Cancer Diagnosis",
                "Cancer Screening",
                "Radiomics",
                "Digital Pathology",
                "Multi-Omics Data",
                "Clinical Workflow Triage"
            ],
            "author": "Benjamin Hunter, Sumeet Hindocha, Richard W. Lee",
            "timestamp": "Published: 16 March 2022",
            "headings": [
                "1. Introduction",
                "2. An Overview of Artificial Intelligence in Oncology",
                "2.1. Definitions and Model Architectures",
                "2.2. Data Types: Electronic Healthcare Records",
                "2.3. Data Types: Radiology",
                "2.4. Data Types: Digital Pathology",
                "2.5. Data Types: Multi-Omic Data",
                "3. Clinical Applications",
                "3.1. Risk-Stratified Screening of Asymptomatic Patients",
                "3.2. Symptomatic Patient Triage",
                "3.3. Diagnostic Workflow Triage",
                "3.4. Early Detection",
                "3.5. Early Detection of Recurrence",
                "4. Challenges and Future Directions",
                "5. Conclusions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_role_of_bronchoscopy_in_the_diagnosis_of_early_lung_cancer.pdf-f2d23d3a",
        "document": "This review article discusses the role of bronchoscopy in the early diagnosis of lung cancer.  It highlights the limitations of traditional white light bronchoscopy and explores newer techniques like autofluorescence bronchoscopy (AFB), narrow band imaging (NBI), high magnification bronchovideoscopy (HMB), optical coherence tomography (OCT), confocal laser endomicroscopy (CLE), and laser Raman spectroscopy (LRS) to improve diagnostic accuracy.  The authors analyze the effectiveness and limitations of each technique, emphasizing the need for further research in some areas. Early detection is crucial for improving patient outcomes, and these advanced bronchoscopic methods offer promising advancements in this field.",
        "metadata": {
            "identifier": "The role of bronchoscopy in the diagnosis of early lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:50.421988+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\The role of bronchoscopy in the diagnosis of early lung cancer.pdf",
            "name": "The role of bronchoscopy in the diagnosis of early lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Bronchoscopy",
                "Lung Cancer",
                "Early Diagnosis",
                "Autofluorescence Bronchoscopy",
                "Narrow Band Imaging",
                "Optical Coherence Tomography",
                "Confocal Laser Endomicroscopy",
                "Laser Raman Spectroscopy"
            ],
            "author": "Marco Andolfi, Rossella Potenza, Rosanna Capozzi, Valeria Liparulo, Francesco Puma, Kazuhiro Yasufuku",
            "timestamp": "October 20, 2016",
            "headings": [
                "Abstract",
                "Introduction",
                "AFB",
                "NBI",
                "HMB",
                "OCT",
                "CLE",
                "LRS",
                "EBUS",
                "Conclusions",
                "Acknowledgements",
                "Footnote",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Estimating_the_Prevalence_of_Cancer.pdf-81040396",
        "document": "This scientific article estimates the prevalence of cancer in the United States, using data from the Connecticut Tumor Registry.  The study found a significant increase in age-standardized prevalence rates between 1982 and 1994, particularly for breast, prostate, and lung cancers.  Based on Connecticut data, the authors project a substantial rise in the number of Americans who have ever been diagnosed with invasive cancer by 2030.  The study highlights the need for cancer prevention and further research on cancer survivors.",
        "metadata": {
            "identifier": "Estimating the Prevalence of Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:37:54.570908+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Estimating the Prevalence of Cancer.pdf",
            "name": "Estimating the Prevalence of Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "cancer prevalence",
                "cancer incidence",
                "cancer survival",
                "age-standardized rates",
                "Connecticut Tumor Registry",
                "breast carcinoma",
                "prostate carcinoma",
                "lung carcinoma",
                "cancer survivors"
            ],
            "author": "Anthony P. Polednak, Ph.D.",
            "timestamp": "March 7, 1997",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "DISCUSSION",
                "Problems in Estimating Cancer Prevalence",
                "Temporal Trends in Estimated Prevalence Rates",
                "Projections of Prevalence",
                "Implications",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Genetics_of_lung-cancer_susceptibility.pdf-6773d68f",
        "document": "This review article discusses the genetics of lung cancer susceptibility, focusing on the epidemiology of the disease, the role of tobacco smoking, and the identification of susceptibility genes through genome-wide association studies (GWAS).  The authors highlight three key susceptibility loci (5p15, 6p21, and 15q25) and discuss the implications of these findings for prevention, treatment, and personalized medicine.  While acknowledging the overwhelming influence of tobacco, the review emphasizes the importance of understanding the genetic contribution to lung cancer risk and its potential for improving outcomes. The article concludes by discussing future research directions, including larger GWAS and studies of rare variants.",
        "metadata": {
            "identifier": "Genetics of lung-cancer susceptibility.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:05.089765+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Genetics of lung-cancer susceptibility.pdf",
            "name": "Genetics of lung-cancer susceptibility.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Genetics",
                "Genome-Wide Association Studies (GWAS)",
                "Susceptibility Genes",
                "Tobacco Smoking",
                "Epidemiology",
                "Risk Factors",
                "Telomerase",
                "Nicotinic Acetylcholine Receptors"
            ],
            "author": "Paul Brennan, Pierre Hainaut, Paolo Boffetta",
            "timestamp": "October 14, 2010",
            "headings": [
                "Epidemiology of lung cancer",
                "Identifying genes for lung cancer",
                "Evidence of a genetic component",
                "Genes that affect lung-cancer risk",
                "Genome-wide association studies",
                "Association of the 15q25 locus with lung cancer",
                "Biological basis of susceptibility with CHRNA genes",
                "Lung cancer and 5p15 locus",
                "Search strategy and selection criteria",
                "Identifi cation of susceptible subgroups",
                "Future GWA studies of lung cancer and tobacco smoking",
                "Implications for treatment and survival"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Global_Epidemiology_of_Lung_Cancer.pdf-b6fce2b3",
        "document": "This review article examines the global epidemiology of lung cancer, focusing on international variations in incidence and mortality rates.  The authors analyze trends in industrialized and emerging economies, highlighting the significant role of smoking patterns and other risk factors like air pollution and occupational exposures.  The review also discusses the increasing incidence of adenocarcinoma, molecular profiling, targeted therapies, and the potential benefits of lung cancer screening.  Finally, it explores the epidemiology of lung cancer in specific populations, including women and never-smokers.",
        "metadata": {
            "identifier": "Global Epidemiology of Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:12.570542+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Global Epidemiology of Lung Cancer.pdf",
            "name": "Global Epidemiology of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Epidemiology",
                "Smoking",
                "Adenocarcinoma",
                "Mortality",
                "Risk Factors",
                "Screening",
                "Molecular Profiling",
                "Targeted Therapies"
            ],
            "author": "Julie A. Barta, Charles A. Powell, Juan P. Wisnivesky",
            "timestamp": "22 January 2019",
            "headings": [
                "Global Epidemiology of Lung Cancer",
                "Burden of Disease",
                "Industrialized Countries",
                "Emerging Economies",
                "Developing Countries",
                "Histopathology",
                "Histology",
                "Molecular Markers",
                "Risk Factors and Environmental Exposures",
                "Cigarette Smoking, Secondhand Smoking, and E-cigarettes",
                "Domestic Biomass Fuels",
                "COPD and other Pulmonary Conditions",
                "Occupational Exposures",
                "Ambient Air Pollution and Other Environmental Exposures",
                "Diet and Nutrition",
                "Genetic Factors",
                "Measures of Lung Cancer Risk and Impact on Early Diagnosis",
                "Special Populations",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Incidence_and_mortality.pdf-a5f30624",
        "document": "This scientific report analyzes global trends in lung cancer incidence and mortality, examining their correlation with socioeconomic factors.  The study uses data from GLOBOCAN and other sources to assess age-standardized rates and temporal patterns, revealing a strong correlation between lung cancer rates and the Human Development Index (HDI).  While declining trends are observed in men in many countries, increasing trends are prevalent among women, particularly in high-HDI nations.  The authors highlight the need for targeted preventive measures, especially in light of these gender disparities and the projected increase in global lung cancer burden.",
        "metadata": {
            "identifier": "Incidence and mortality.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:17.696955+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Incidence and mortality.pdf",
            "name": "Incidence and mortality.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Incidence",
                "Mortality",
                "Socioeconomic Status",
                "Human Development Index (HDI)",
                "Gross Domestic Product (GDP)",
                "Global Trends",
                "Gender Disparities"
            ],
            "author": "Martin C. S. Wong, Xiang Qian Lao, Kin-Fai Ho, William B. Goggins, Shelly L. A. Tse",
            "timestamp": "Published: xx xx xxxx",
            "headings": [
                "Received: 28 March 2017",
                "Accepted: 3 October 2017",
                "Methods",
                "Data Source",
                "Statistical Analysis",
                "Results",
                "Incidence and mortality of lung cancer in 2012",
                "The correlation between incidence/mortality of lung cancer and socioeconomic development",
                "Temporal trends in incidence of lung cancer",
                "Temporal trends in lung cancer mortality",
                "Discussion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_-_A_Review.pdf-17a15c44",
        "document": "This review article from the International Journal of Health Sciences and Research provides a comprehensive overview of lung cancer.  It covers the epidemiology, classification (small-cell and non-small-cell lung cancers), detection methods, metastasis, and treatment options for this leading cause of cancer death globally. The authors discuss various diagnostic techniques, including lymph node analysis and circulating tumor cell detection, and detail different treatment modalities such as surgery, chemotherapy, radiation, and targeted therapies.  The review emphasizes the importance of early detection and the challenges in treating advanced-stage lung cancer.",
        "metadata": {
            "identifier": "Lung Cancer - A Review.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:25.141629+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer - A Review.pdf",
            "name": "Lung Cancer - A Review.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "SCLC",
                "NSCLC",
                "Metastasis",
                "Chemotherapy",
                "Radiation Therapy",
                "Epidemiology",
                "Diagnosis",
                "Treatment"
            ],
            "author": [
                "V. Sankar",
                "R. Kothai",
                "N. Vanisri",
                "Akilandeswari. S",
                "G. Anandharaj"
            ],
            "timestamp": "October 2023",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "Classification of lung cancer",
                "Small cell lung cancer (SCLC)",
                "Non-small cell lung cancer (NSCLC)",
                "Adenocarcinomas",
                "Squamous Cell Carcinomas",
                "Large Cell Carcinomas",
                "Epidemiology",
                "Clinical manifestation of Lung Cancer",
                "Detection Strategies",
                "METASTASIS",
                "Regional Lymph Node Metastases",
                "Metastasis and Its impact",
                "Treatment of lung cancer",
                "Surgery",
                "Chemotherapy",
                "Alkylating agents (or) DNA- damaging agents",
                "Anti-metabolites",
                "Plant alkaloids and terpenoids",
                "Podophyllotoxin",
                "Taxanes",
                "Topoisomerase inhibitor",
                "Antitumour antibiotics",
                "Hormones",
                "Monoclonal antibodies",
                "Chemotherapy of lung cancer",
                "Chemotherapy for small cell lung cancer",
                "Chemotherapy for non-small cell lung cancer",
                "Chemotherapy after surgery",
                "Chemotherapy and radiotherapy",
                "Chemotherapy for locally advanced NSCLC or cancer that has spread",
                "Radiation",
                "CONCLUSION",
                "Declaration by Authors",
                "REFERENCE"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_and_Air_Pollution.pdf-43240b03",
        "document": "This 1995 Environmental Health Perspectives article by Cohen and Pope reviews epidemiological studies linking ambient air pollution, primarily from fossil fuel combustion, to increased lung cancer rates.  The authors analyze data from occupational groups, urban vs. rural populations, and cohort studies, finding consistent evidence of increased lung cancer risk associated with exposure to respirable particles.  They highlight the need for improved epidemiological research to better quantify this risk, considering factors like exposure measurement error and the interaction with other risk factors such as smoking.  The authors conclude that while the individual risk is small compared to smoking, the widespread exposure makes air pollution a significant public health concern.",
        "metadata": {
            "identifier": "Lung Cancer and Air Pollution.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:29.750247+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer and Air Pollution.pdf",
            "name": "Lung Cancer and Air Pollution.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Air pollution",
                "Fossil fuels",
                "Respirable particles",
                "Epidemiology",
                "Risk assessment",
                "Combustion",
                "Carcinogens"
            ],
            "author": "Aaron J. Cohen and C. Arden Pope",
            "timestamp": "1995",
            "headings": [
                "Introduction",
                "Occupational Exposure",
                "Environmental Exposure",
                "Case-Control and Recent Prospective Cohort Studies",
                "Plausibility ofAmbient Air Pollution-Lung Cancer Effect",
                "Epidemiology Research Needs",
                "Conclusions",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Epidemiology_Risk_Factors_and_Prevention.pdf-2d18c929",
        "document": "This article reviews the epidemiology, risk factors, and prevention strategies for lung cancer.  It highlights the strong correlation between lung cancer and cigarette smoking, emphasizing that adenocarcinoma rates have significantly increased in recent decades.  The text also discusses other risk factors such as environmental tobacco smoke, pollution, occupational exposures, genetic factors, and the role of HPV.  Finally, it explores prevention methods including tobacco cessation, tobacco-control legislation, vaccination against HPV, radon control, and dietary changes.",
        "metadata": {
            "identifier": "Lung Cancer Epidemiology, Risk Factors, and Prevention.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:35.943251+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer Epidemiology, Risk Factors, and Prevention.pdf",
            "name": "Lung Cancer Epidemiology, Risk Factors, and Prevention.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Epidemiology",
                "Risk Factors",
                "Prevention",
                "Cigarette Smoking",
                "Adenocarcinoma",
                "HPV",
                "Radon",
                "Environmental Tobacco Smoke",
                "Genetic Factors"
            ],
            "author": "Patricia deGroot, MD and Reginald F. Munden, MD, DMD, MBA",
            "timestamp": "2012",
            "headings": [
                "EPIDEMIOLOGY",
                "Trends in Incidence and Mortality",
                "Lung Cancer in Never-Smokers",
                "Histopathology of Lung Cancer",
                "RISK FACTORS",
                "Genetic Factors",
                "Heredity and genetic susceptibility",
                "Genomic instability",
                "Age",
                "Gender",
                "Race",
                "Behavioral Factors",
                "Tobacco and smoking",
                "Composition of tobacco smoke",
                "Nicotine",
                "Cannabis sativa",
                "Socioeconomic status",
                "Diet",
                "Macronutrients",
                "Micronutrients",
                "Preexisting lung disease",
                "Human papillomavirus",
                "Human immunodeficiency virus",
                "Environmental Factors",
                "Second-hand tobacco smoke",
                "Other environmental pollutants",
                "Radon",
                "Asbestos",
                "Other occupational exposures",
                "PREVENTION",
                "Tobacco Cessation",
                "Tobacco-Control Legislation",
                "Vaccination",
                "Radon Control",
                "Diet",
                "SUMMARY",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Risk_and_Workplace_Exposure.pdf-9e751f84",
        "document": "This scientific article presents a meta-analysis of 22 studies investigating the link between workplace exposure to environmental tobacco smoke (ETS) and lung cancer risk.  The analysis revealed a 24% increased lung cancer risk among workers exposed to ETS, rising to a 2-fold increase for those highly exposed. A strong correlation was found between lung cancer risk and duration of ETS exposure. The authors conclude that workplace ETS exposure is a significant risk factor for lung cancer, reinforcing public health concerns and supporting stricter workplace smoking regulations.",
        "metadata": {
            "identifier": "Lung Cancer Risk and Workplace Exposure.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:41.111066+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer Risk and Workplace Exposure.pdf",
            "name": "Lung Cancer Risk and Workplace Exposure.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Environmental Tobacco Smoke",
                "Workplace Exposure",
                "Meta-analysis",
                "Relative Risk",
                "Public Health",
                "Occupational Safety",
                "Case-Control Study"
            ],
            "author": "Leslie Stayner, James Bena, Annie J. Sasco, Randall Smith, Kyle Steenland, Michaela Kreuzer, and Kurt Straif",
            "timestamp": "March 2007",
            "headings": [
                "Objectives",
                "Methods",
                "Results",
                "Conclusions",
                "Data Abstraction",
                "Meta-regression",
                "Exposure–Response Analyses",
                "Sensitivity and Influence Analyses",
                "Evaluation of Publication Bias",
                "DISCUSSION",
                "Limitations",
                "Conclusions",
                "About the Authors",
                "Contributors",
                "Acknowledgments",
                "Institutional Review Board",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Molecular_and_Genetic_Aspects_of_Lung_Cancer.pdf-55c509a7",
        "document": "This scientific article reviews the molecular and genetic aspects of lung cancer, focusing on its cellular mechanisms and the role of environmental factors like cigarette smoking.  The authors discuss the involvement of cell cycle regulators, tumor suppressor genes (p53, Rb, p16), oncogenes (ras, myc), and telomeres in lung cancer development.  Diagnostic approaches, including sputum cytology and low-dose CT scans, are also examined.  Finally, the article explores the potential of gene therapy as a treatment for lung cancer.",
        "metadata": {
            "identifier": "Molecular and Genetic Aspects of Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:49.131926+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Molecular and Genetic Aspects of Lung Cancer.pdf",
            "name": "Molecular and Genetic Aspects of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Molecular Genetics",
                "Cell Cycle",
                "Tumor Suppressor Genes",
                "Oncogenes",
                "Gene Therapy",
                "Cigarette Smoking",
                "Telomeres",
                "Diagnosis"
            ],
            "author": "WILLIAM N. ROM, JOHN G. HAY, THEODORE C. LEE, YIXING JIANG, and KAM-MENG TCHOU-WONG",
            "timestamp": "September 24, 1999",
            "headings": [
                "Introduction",
                "Diagnosis (Clinical Approaches)",
                "Cigarette Smoking and Molecular Epidemiology of Lung Cancer",
                "Molecular Abnormalities in Lung Cancer: A Disease of the Cell Cycle",
                "Role of p53 as the Guardian of the Genome and Protector of the Lung from Environmental Carcinogens",
                "The p16 Tumor Suppressor Pathway",
                "Transforming Growth Factor-b Induces p15",
                "Role of Activated Oncogenic ras in the Genesis of Lung Cancer",
                "Oncogenic Pathways: c-Myc in Lung Cancer",
                "Chromosomal Abnormalities: Preneoplastic Changes in Bronchial Epithelial Cells",
                "Chromosomal Abnormalities: Telomeres and Telomerases in Lung Cancer",
                "Modeling Lung Cancer Genetic Lesions in Transgenic Mice",
                "Gene Therapy for Lung Cancer",
                "Gene Delivery Systems",
                "Monitoring, Therapeutics, and Delivering Toxins via Gene Therapy",
                "Summary: Cell Cycle Networking",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Non-small_cell_lung_cancer_NSCLC_.pdf-64bd4fc5",
        "document": "This narrative review article focuses on non-small cell lung cancer (NSCLC), the most common type of lung cancer.  It covers risk factors, diagnostic methods (including imaging and biopsies), and various treatment options such as surgery, radiation, chemotherapy, targeted therapies, and immunotherapy. The authors emphasize the importance of personalized treatment based on individual patient characteristics and the latest WHO classification for accurate subtyping.  The review highlights recent advancements in targeted therapies and immunotherapies, while acknowledging the persistent challenges in improving overall patient survival.",
        "metadata": {
            "identifier": "Non-small cell lung cancer (NSCLC).pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:38:53.683904+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Non-small cell lung cancer (NSCLC).pdf",
            "name": "Non-small cell lung cancer (NSCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Treatment",
                "Diagnosis",
                "Risk factors",
                "Immunotherapy",
                "Targeted therapy",
                "Chemotherapy",
                "Surgery",
                "Radiation therapy"
            ],
            "author": "Yaser Alduais, Haijun Zhang, Fan Fan, Jing Chen, Baoan Chen",
            "timestamp": "Received: 4 January 2023 / Accepted: 19 January 2023",
            "headings": [
                "Abstract",
                "Abbreviations",
                "Keywords",
                "1. Introduction",
                "2. Factors",
                "3. Classification",
                "4. Diagnosis",
                "5. Treatment",
                "6. Surgery",
                "7. Radiation therapy",
                "8. Chemotherapy",
                "9. Targeted therapy",
                "10. Immunotherapy",
                "11. Conclusions",
                "Acknowledgments",
                "Author contributions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-NoneSmall_Cell_Lung_Cancer.pdf-77de600d",
        "document": "This thematic review article focuses on non-small cell lung cancer (NSCLC), covering its epidemiology, screening, diagnosis, and treatment.  Significant advancements in NSCLC treatment are highlighted, including the introduction of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The article discusses various treatment strategies based on disease stage and molecular characteristics, emphasizing the role of surgery, chemotherapy, targeted therapy, and immunotherapy.  Finally, it addresses palliative care and survivorship considerations for NSCLC patients.",
        "metadata": {
            "identifier": "NoneSmall Cell Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:01.959175+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\NoneSmall Cell Lung Cancer.pdf",
            "name": "NoneSmall Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Oncology",
            "keywords": [
                "Non-small cell lung cancer (NSCLC)",
                "Tyrosine kinase inhibitors (TKIs)",
                "Immune checkpoint inhibitors (ICIs)",
                "EGFR mutations",
                "ALK translocations",
                "Chemotherapy",
                "Immunotherapy",
                "Screening",
                "Biomarkers",
                "Palliative care"
            ],
            "author": "Narjust Duma, MD; Rafael Santana-Davila, MD; and Julian R. Molina, MD, PhD",
            "timestamp": "8/1/2019",
            "headings": [
                "Epidemiology",
                "Classification",
                "Screening",
                "Diagnosis",
                "Treatment",
                "Surgery",
                "Neoadjuvant Chemotherapy",
                "Adjuvant Chemotherapy",
                "Immunotherapy Use in Unresectable Stage III NSCLC",
                "Oligometastatic Disease",
                "Metastatic NSCLC",
                "Chemotherapy for Advanced Disease",
                "Targeted Therapy",
                "Epidermal Growth Factor Receptor Inhibitors",
                "Resistance to EGFR TKIs",
                "Anti-EGFR Monoclonal Antibodies",
                "ALK and ROS1 Translocations",
                "Vascular Endothelial Growth Factor Receptor Inhibitors",
                "Other Targetable Alterations",
                "Immunotherapy",
                "Immunotherapy as First-Line Treatment",
                "Immunotherapy Monotherapy",
                "Combination Chemoimmunotherapy",
                "Combination Immunotherapy",
                "Immunotherapy for Progressive Disease After Chemotherapy",
                "Biomarkers of Activity",
                "Patients With Genetic Driver Abnormalities",
                "Brain Metastasis",
                "Patients With Preexisting Autoimmune Conditions",
                "Palliative Care and End of Life",
                "Survivorship",
                "Conclusion",
                "Abbreviations and Acronyms",
                "Potential Competing Interests",
                "Correspondence",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Occupational_exposure_and_lung_cancer.pdf-67008c6d",
        "document": "This mini-review article examines the link between occupational exposure to carcinogens and lung cancer.  It highlights lung cancer as a leading cause of cancer death globally, emphasizing the role of occupational and environmental factors beyond smoking. The authors discuss various carcinogenic agents identified by the International Agency for Research on Cancer (IARC), including asbestos, arsenic, and certain metals, and their association with lung cancer risk.  The article stresses the importance of detailed occupational history taking in lung cancer patients and advocates for comprehensive occupational hygiene policies, particularly in developing countries.",
        "metadata": {
            "identifier": "Occupational exposure and lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:06.141755+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Occupational exposure and lung cancer.pdf",
            "name": "Occupational exposure and lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Occupational exposure",
                "Carcinogens",
                "IARC",
                "Asbestos",
                "Environmental exposure",
                "Occupational disease",
                "Risk factors"
            ],
            "author": "Dionysios Spyratos, Paul Zarogoulidis, Konstantinos Porpodis, Kosmas Tsakiridis, Nikolaos Machairiotis, Nikolaos Katsikogiannis, Ioanna Kougioumtzi, Georgios Dryllis, Anastasios Kallianos, Aggeliki Rapti, Chen Li, Konstantinos Zarogoulidis",
            "timestamp": "July 4, 2013",
            "headings": [
                "ABSTRACT",
                "KEY WORDS",
                "Table 1. Classification of carcinogenetic agents according to the International Agency for Research on Cancer.",
                "Table 2. Carcinogenetic agents related with development of lung cancer according to IARC (first column: with sufficient evidence in humans; second: with limited evidence)."
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Occupational_Exposures_and_Lung_Cancer.pdf-912296b1",
        "document": "This article by David C. Christiani discusses the significant global public health issue of occupational lung cancer.  Two studies, analyzing a large pooled dataset, demonstrate increased lung cancer risks associated with diesel exhaust and crystalline silica exposure, even at low levels and in non-smokers.  The author emphasizes the need for primary prevention strategies, including identifying and eliminating carcinogenic agents in the workplace, to reduce the rising global burden of occupational lung cancer.  The article highlights the importance of understanding exposure-response relationships and interactions with other risk factors like smoking to develop effective control programs.",
        "metadata": {
            "identifier": "Occupational Exposures and Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:09.147843+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Occupational Exposures and Lung Cancer.pdf",
            "name": "Occupational Exposures and Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Occupational Exposures",
                "Diesel Exhaust",
                "Crystalline Silica",
                "Carcinogenesis",
                "Primary Prevention",
                "Risk Assessment",
                "Public Health",
                "Case-Control Studies",
                "Epidemiology"
            ],
            "author": "David C. Christiani, MD, MPH",
            "timestamp": "May 12, 2020",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pollution_and_regional_variations_of_lung_cancer_mortality_in_the_United.pdf-be413f81",
        "document": "This research article investigates regional variations in lung cancer mortality across the United States from 2004-2014.  The study identifies a 'lung cancer mortality belt' spanning from eastern Oklahoma through central Appalachia, characterized by high pollution levels, rural populations, and low socioeconomic status.  Geospatial autocorrelation methods were used to identify clustered counties with high mortality rates.  The findings highlight the association between particulate matter pollution and lung cancer mortality, even after adjusting for socioeconomic factors and healthcare access.",
        "metadata": {
            "identifier": "Pollution and regional variations of lung cancer mortality in the United.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:16.457194+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Pollution and regional variations of lung cancer mortality in the United.pdf",
            "name": "Pollution and regional variations of lung cancer mortality in the United.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Mortality",
                "Air Pollution",
                "Particulate Matter",
                "Geospatial Analysis",
                "Socioeconomic Factors",
                "Regional Disparities",
                "Public Health"
            ],
            "author": "Justin Xavier Moore, Tomi Akinyemiju, Henry E. Wang",
            "timestamp": "May 29, 2017",
            "headings": [
                "Introduction",
                "Methods",
                "2.1. Study design",
                "2.2. County-level particulate matter exposure",
                "2.3. County-level demographic characteristics",
                "2.4. County-level community characteristics",
                "2.5. Identification of lung cancer deaths",
                "2.6. Defining lung mortality clusters",
                "2.7. Statistical analysis",
                "2.8. Ethical statement",
                "Results",
                "3.1. LISA, EB, and GI* analyses",
                "3.2. Demographic characteristics",
                "3.3. Community characteristics",
                "3.4. Lung cancer mortality rates",
                "3.5. Odds of lung cancer mortality clustering",
                "3.6. Odds of lung cancer mortality clustering by urban status",
                "Discussion",
                "4.1. Conclusion",
                "Conflict of interest statement",
                "Author contributions",
                "Acknowledgements and funding",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Racial_and_Socioeconomic_Disparities_in_Lung_Cancer.pdf-a2d9babb",
        "document": "This systematic review examines racial and socioeconomic disparities in lung cancer screening (LCS) in the US.  The authors analyzed 21 studies, identifying disparities in eligibility, utilization, and post-screening care, particularly affecting Black and socioeconomically disadvantaged individuals.  Key findings highlight the limitations of current USPSTF guidelines and the need for improved interventions to increase screening rates and address disparities in outcomes.  The authors recommend prospective trials to evaluate eligibility criteria and interventions to improve utilization and follow-up care.",
        "metadata": {
            "identifier": "Racial and Socioeconomic Disparities in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:27.699849+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Racial and Socioeconomic Disparities in Lung Cancer.pdf",
            "name": "Racial and Socioeconomic Disparities in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer Screening",
                "Racial Disparities",
                "Socioeconomic Disparities",
                "Health Equity",
                "Lung Cancer Mortality",
                "USPSTF Guidelines",
                "Systematic Review",
                "Low-Dose Computed Tomography (LDCT)"
            ],
            "author": "Ernesto Sosa, Gail D’Souza, Aamna Akhtar, Melissa Sur, Kyra Love, Jeanette Duffels, Dan J. Raz, Jae Y. Kim, Virginia Sun, Loretta Erhunmwunsee",
            "timestamp": "2021",
            "headings": [
                "Abstract",
                "Introduction",
                "Methods",
                "Search Strategy",
                "Article Review Process",
                "Data Abstraction",
                "Study Quality Assessment",
                "Results",
                "LCS Eligibility",
                "LCS Utilization, Perception, and Utility",
                "LCS not offered or used",
                "Negative perceptions/understanding of LCS",
                "Late- stage diagnosis",
                "Postscreening Behavior and Care",
                "Failure to quit smoking",
                "Lack of follow- up care/loss to follow- up",
                "No surgery",
                "Post- LCS mortality",
                "Discussion",
                "Eligibility",
                "Utilization, Perception, and Utility",
                "Postscreening Behavior and Care",
                "Future Recommendations",
                "Address gaps in eligibility",
                "Address gaps in utilization and utility",
                "Address gaps in follow- up care",
                "Strengths and Limitations",
                "Conclusions",
                "Acknowledgments"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Rural-Urban_Differences_in_Cancer_Incidence_and_Trends_in_the_United_States.pdf-515d9446",
        "document": "This study analyzes rural-urban cancer incidence and trends in the US using data from the North American Association of Central Cancer Registries.  Researchers found that while overall cancer incidence was higher in urban areas, rural populations exhibited higher rates of tobacco- and HPV-associated cancers, as well as lung, colorectal, and cervical cancers.  These disparities were observed across various demographic and geographic factors. The study highlights the need for targeted interventions to address modifiable risk factors and improve cancer outcomes in rural communities.",
        "metadata": {
            "identifier": "Rural-Urban Differences in Cancer Incidence and Trends in the United States.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:34.121349+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Rural-Urban Differences in Cancer Incidence and Trends in the United States.pdf",
            "name": "Rural-Urban Differences in Cancer Incidence and Trends in the United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "cancer incidence",
                "rural health",
                "urban health",
                "cancer disparities",
                "tobacco",
                "HPV",
                "cancer screening",
                "epidemiology"
            ],
            "author": "Whitney E. Zahnd, Aimee S. James, Wiley D. Jenkins, et al.",
            "timestamp": "July 27, 2017",
            "headings": [
                "Abstract",
                "Introduction",
                "Materials and Methods",
                "Results",
                "Discussion",
                "Strengths and Limitations",
                "Conclusions",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "error-Small cell lung Cancer.pdf-no_content",
        "document": "No text content extracted.",
        "metadata": {
            "identifier": "Small cell lung Cancer.pdf",
            "full_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Small cell lung Cancer.pdf",
            "data_type": "error",
            "error": "No text content extracted",
            "source_type": "file"
        }
    },
    {
        "id": "unstructured-Small-cell_lung_cancer_SCLC_.pdf-7f21de46",
        "document": "This document presents ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of small-cell lung cancer (SCLC).  It covers various aspects, including staging, risk assessment, treatment strategies for localized and metastatic disease, and follow-up care.  The guidelines emphasize the importance of a multimodality approach, including chemotherapy and radiotherapy, tailored to the patient's stage and condition.  Smoking cessation is highlighted as a crucial factor in reducing the risk and improving outcomes.",
        "metadata": {
            "identifier": "Small-cell lung cancer (SCLC).pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:39.052219+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Small-cell lung cancer (SCLC).pdf",
            "name": "Small-cell lung cancer (SCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Small-cell lung cancer",
                "SCLC",
                "ESMO Clinical Practice Guidelines",
                "diagnosis",
                "treatment",
                "chemotherapy",
                "radiotherapy",
                "staging",
                "prognosis",
                "follow-up"
            ],
            "author": "M. Früh1, D. De Ruysscher2, S. Popat3, L. Crinò4, S. Peters5 & E. Felip6, on behalf of the ESMO Guidelines Working Group",
            "timestamp": "May 2013",
            "headings": [
                "incidence and epidemiology",
                "diagnosis and pathology/molecular biology",
                "staging and risk assessment",
                "management of localised disease",
                "management of metastatic disease",
                "first-line treatment",
                "second-line treatment",
                "personalised medicine",
                "follow-up and long-term implications",
                "note",
                "conflict of interest",
                "references"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_economic_burden_of_lung_cancer.pdf-6f0989d7",
        "document": "This study examines the economic burden of lung cancer in the United States using a large database of inpatient, outpatient, and pharmacy claims.  Researchers found significantly higher healthcare costs for lung cancer patients compared to a control group, with hospitalization and outpatient office visits being the main cost drivers.  Treatment failure was associated with dramatically increased costs, highlighting the need for preventative measures and new therapies. The study's findings underscore the significant economic impact of lung cancer on the US healthcare system.",
        "metadata": {
            "identifier": "The economic burden of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:43.770972+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\The economic burden of lung cancer.pdf",
            "name": "The economic burden of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Treatment Failure",
                "Healthcare Costs",
                "Economic Burden",
                "Hospitalization",
                "Outpatient Visits",
                "Case-Control Study",
                "Treatment Phases"
            ],
            "author": "Lucie Kutikova, Lee Bowman, Stella Chang, Stacey R. Long, Coleman Obasaju, William H. Crown",
            "timestamp": "Received 24 January 2005; accepted 14 June 2005",
            "headings": [
                "1. Introduction",
                "2. Methods",
                "2.1. Cancer severity",
                "2.2. Assignment by treatment phase",
                "2.3. Designation of treatment failure",
                "2.4. Study outcomes",
                "2.5. Statistical analysis",
                "3. Results",
                "3.1. Direct health care utilization and costs: patients versus controls",
                "3.2. Costs by treatment phase in lung cancer patients",
                "3.3. Costs of treatment failure",
                "4. Discussion",
                "5. Conclusion",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_epidemiology_of_lung_cancer.pdf-b6a0e2e2",
        "document": "This review article examines the epidemiology of lung cancer, focusing on incidence, mortality, and risk factors.  While lung cancer mortality is decreasing in the US due to tobacco control, it's rising globally.  The article details the significant role of smoking, highlighting disparities across demographics (race, socioeconomic status, gender) and geographic locations.  Emerging challenges include the legalization of marijuana and the rise of e-cigarettes, with limited long-term safety data available.",
        "metadata": {
            "identifier": "The epidemiology of lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:49.969690+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\The epidemiology of lung cancer.pdf",
            "name": "The epidemiology of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Epidemiology",
                "Smoking",
                "E-cigarettes",
                "Marijuana",
                "Risk factors",
                "Mortality",
                "Incidence"
            ],
            "author": "Patricia M. de Groot, Carol C. Wu, Brett W. Carter, Reginald F. Munden",
            "timestamp": "May 07, 2018",
            "headings": [
                "Introduction",
                "Lung cancer statistics",
                "Incidence",
                "Mortality and survival",
                "Global trends in lung cancer epidemiology",
                "Demographic factors in US lung cancer",
                "Race/ethnicity",
                "Geography",
                "Education/occupation/income",
                "Age",
                "Gender",
                "Behavioral risk factors for lung cancer",
                "Tobacco and smoking: historical perspective",
                "Tobacco and smoking: carcinogenesis",
                "Other smoking products",
                "Electronic nicotine delivery systems (ENDS)",
                "Environmental risk factors for lung cancer",
                "Radon",
                "Asbestos",
                "Pollution and air quality",
                "Infection",
                "Genetic risk factors for lung cancer",
                "Lung cancer in never smokers (LCINS)",
                "Conclusions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-_ALK_inhibitors_in_the_treatment.pdf-f342f218",
        "document": "This accepted manuscript reviews anaplastic lymphoma kinase (ALK) inhibitors used in treating ALK-driven lung cancers.  It details the structure and function of ALK, focusing on its role in oncogenesis and the mechanisms of action of various ALK inhibitors like crizotinib, ceritinib, and alectinib. The review also discusses the development of drug resistance and different strategies to overcome it, including the use of second-generation inhibitors.  Finally, it classifies protein kinase inhibitors based on their interaction with the enzyme's active site.",
        "metadata": {
            "identifier": "(ALK) inhibitors in the treatment.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:39:58.175658+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\(ALK) inhibitors in the treatment.pdf",
            "name": "(ALK) inhibitors in the treatment.pdf",
            "document_type": "pdf",
            "domain_themes": "Oncology/Pharmacology",
            "keywords": [
                "ALK inhibitors",
                "Lung cancer",
                "Crizotinib",
                "Ceritinib",
                "Alectinib",
                "Drug resistance",
                "Protein kinase",
                "Oncogenesis",
                "Targeted therapy"
            ],
            "author": "Robert Roskoski Jr.",
            "timestamp": "2017-01-06",
            "headings": [
                "Overview of lung cancers",
                "1.1 Incidence",
                "1.2 Small cell lung cancer",
                "1.3 Non-small cell lung cancer",
                "Role of ALK and ALK-fusion proteins in the pathogenesis of malignancies",
                "2.1 Discovery and architecture of Anaplastic Lymphoma Kinase (ALK)",
                "2.2 Primary structure of the ALK protein-tyrosine kinase domain",
                "2.3 Secondary and tertiary structure of ALK and the K/E/D/D signature",
                "2.4 The hydrophobic spines of inactive ALK and active insulin receptor protein kinase",
                "Structure of ALK-drug complexes",
                "Mechanisms of ALK-based drug resistance",
                "Classification of protein kinase-drug complexes",
                "Epilogue"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Chemotherapy_advances_in_small-cell_lung_cancer.pdf-c8c1013b",
        "document": "This review article discusses the advances in chemotherapy for small-cell lung cancer (SCLC), a disease with limited treatment progress in the past 30 years.  The authors provide a historical overview of chemotherapeutic regimens, focusing on the current standard platinum-etoposide doublet and emerging alternatives like amrubicin and belotecan.  Clinical trial data on these novel agents, including their efficacy and toxicity profiles, are presented. The review also covers second-line chemotherapy options and explores the potential of maintenance and consolidation therapies to improve outcomes for SCLC patients.",
        "metadata": {
            "identifier": "Chemotherapy advances in small-cell lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:04.377303+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Chemotherapy advances in small-cell lung cancer.pdf",
            "name": "Chemotherapy advances in small-cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Small cell lung cancer",
                "SCLC",
                "Chemotherapy",
                "Amrubicin",
                "Belotecan",
                "Picoplatin",
                "Relapsed SCLC",
                "Platinum-etoposide"
            ],
            "author": "Bryan A. Chan, Jermaine I. G. Coward",
            "timestamp": "July 30, 2013",
            "headings": [
                "Introduction",
                "SCLC: histology and staging",
                "Evolution of combination chemotherapy",
                "First-line chemotherapy",
                "Irinotecan",
                "Belotecan",
                "Amrubicin",
                "Maintenance and consolidation therapy",
                "Second-line chemotherapy",
                "Amrubicin",
                "Picoplatin",
                "Belotecan",
                "Future directions and closing remarks"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-COMPARISON_OF_FOUR_CHEMOTHERAPY_REGIMENS_FOR_ADVANCED_NON_SMALL-CELL_LUNG_CANCER.pdf-b6d1ecfd",
        "document": "This randomized clinical trial by the Eastern Cooperative Oncology Group (ECOG) compared four chemotherapy regimens for advanced non-small-cell lung cancer.  The study involved 1207 patients, evaluating cisplatin and paclitaxel against three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel.  No significant survival differences were found among the regimens, though cisplatin and gemcitabine showed a longer time to disease progression but with increased renal toxicity.  Patients with a performance status of 2 had significantly lower survival rates.",
        "metadata": {
            "identifier": "COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:08.992818+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER.pdf",
            "name": "COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "Chemotherapy",
                "Cisplatin",
                "Paclitaxel",
                "Gemcitabine",
                "Docetaxel",
                "Carboplatin",
                "Survival",
                "Toxicity",
                "ECOG"
            ],
            "author": "Joan H. Schiller, M.D., David Harrington, Ph.D., Chandra P. Belani, M.D., Corey Langer, M.D., Alan Sandler, M.D., James Krook, M.D., Junming Zhu, Ph.D., and David H. Johnson, M.D., FOR THE EASTERN COOPERATIVE ONCOLOGY GROUP",
            "timestamp": "January 10, 2002",
            "headings": [
                "ABSTRACT",
                "METHODS",
                "Stratification Variables",
                "Regimens",
                "Eligibility Criteria",
                "Statistical Analysis",
                "RESULTS",
                "DISCUSSION"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Comparison_of_gefitinib_erlotinib_and_afatinib_in_non-small_cell_lung.pdf-b651c3e6",
        "document": "This meta-analysis compares the efficacy and safety of three epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs): gefitinib, erlotinib, and afatinib, in treating non-small cell lung cancer (NSCLC).  The study synthesized data from 90 studies involving over 17,000 patients. Gefitinib and erlotinib showed comparable efficacy in first-line treatment of EGFR-mutant NSCLC, but gefitinib had a better safety profile. Afatinib demonstrated superior efficacy to erlotinib as a second-line treatment for advanced squamous cell carcinoma. These findings provide valuable insights for clinical decision-making in NSCLC treatment.",
        "metadata": {
            "identifier": "Comparison of gefitinib, erlotinib and afatinib in non-small cell lung.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:17.307016+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Comparison of gefitinib, erlotinib and afatinib in non-small cell lung.pdf",
            "name": "Comparison of gefitinib, erlotinib and afatinib in non-small cell lung.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Gefitinib",
                "Erlotinib",
                "Afatinib",
                "Non-small cell lung cancer",
                "EGFR TKIs",
                "Meta-analysis",
                "Efficacy",
                "Safety",
                "Adverse events"
            ],
            "author": "Zuyao Yang et al.",
            "timestamp": "N/A",
            "headings": [
                "Novelty and Impact",
                "ABSTRACT",
                "BACKGROUND",
                "METHODS",
                "Data sources and literature search",
                "Study selection",
                "Data extraction",
                "Risk of bias assessment",
                "Data synthesis and analysis",
                "RESULTS",
                "Study selection and characteristics",
                "Gefitinib versus erlotinib: efficacy",
                "Gefitinib versus erlotinib: safety",
                "Comparison of afatinib with gefitinib and erlotinib",
                "Subgroup, sensitivity and publication bias analyses",
                "DISCUSSION",
                "Funding support",
                "Conflicts of interest statement",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Crizotinib_A_comprehensive_review.pdf-5445701a",
        "document": "This article provides a comprehensive review of Crizotinib, a tyrosine kinase inhibitor used in treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).  The review details Crizotinib's mechanism of action, clinical trial results demonstrating its efficacy and safety, and common adverse effects.  It also discusses emerging resistance mechanisms and the development of second-generation ALK inhibitors to overcome resistance.  The authors highlight Crizotinib's significance as a targeted therapy for ALK-positive NSCLC and its potential applications in other ALK-positive cancers.",
        "metadata": {
            "identifier": "Crizotinib A comprehensive review.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:22.197615+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Crizotinib A comprehensive review.pdf",
            "name": "Crizotinib A comprehensive review.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Crizotinib",
                "ALK",
                "Non-small cell lung cancer",
                "Tyrosine kinase inhibitor",
                "Targeted therapy",
                "Cancer treatment",
                "Drug resistance",
                "Clinical trials"
            ],
            "author": "Arvind Sahu, Kumar Prabhash, Vanita Noronha, Amit Joshi, Saral Desai",
            "timestamp": "April-June 2013",
            "headings": [
                "Abstract",
                "Introduction",
                "Molecular pathogenesis",
                "Chemistry",
                "Mechanism of action",
                "Detection of EML4-ALK Mutation",
                "History",
                "Overview of Clinical Trials",
                "Indications",
                "Dosing",
                "In renal impairment",
                "In hepatic impairment",
                "Dose adjustment for toxicity",
                "Adverse reactions",
                "Resistance to crizotinib",
                "Future Possibilities (Ongoing Cinical Trials)",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Crizotinib_versus_Chemotherapy_in_Advanced_ALK-Positive_Lung_Cancer.pdf-ce37dce9",
        "document": "This New England Journal of Medicine article reports on a phase 3 clinical trial comparing crizotinib to standard chemotherapy in treating advanced ALK-positive non-small cell lung cancer.  The study found crizotinib significantly improved progression-free survival and response rates compared to chemotherapy. While overall survival showed no significant difference at the interim analysis, this was likely due to high crossover rates from the chemotherapy group. Crizotinib also led to better patient-reported outcomes, including symptom reduction and improved quality of life.",
        "metadata": {
            "identifier": "Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:27.135445+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.pdf",
            "name": "Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Crizotinib",
                "Chemotherapy",
                "ALK-positive lung cancer",
                "Non-small cell lung cancer",
                "Progression-free survival",
                "Response rate",
                "Clinical trial",
                "Phase 3",
                "Patient-reported outcomes"
            ],
            "author": "Alice T. Shaw et al.",
            "timestamp": "June 1, 2013",
            "headings": [
                "Background",
                "Methods",
                "Patients",
                "Study Oversight",
                "Study Design and Treatment",
                "Assessments",
                "Statistical Analysis",
                "Results",
                "Patients",
                "Efficacy",
                "Safety and Adverse Events",
                "Patient-Reported Outcomes",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-CURRENT_LANDSCAPE_OF_TARGETED_THERAPY_IN_LUNG_CANCER.pdf-8821ff99",
        "document": "This review article discusses the current state of targeted therapy in lung cancer treatment.  It highlights the success of biomarker-driven approaches, where patients are matched to therapies based on their tumor's genetic profile.  The article details various targeted therapies for oncogenic drivers like EGFR, ALK, ROS1, and BRAF mutations, outlining their efficacy, limitations, and ongoing research into overcoming resistance.  Challenges such as genetic heterogeneity and the development of drug resistance are addressed, along with strategies for combination and sequential therapies.  The authors emphasize the importance of molecular profiling in improving lung cancer treatment and patient outcomes.",
        "metadata": {
            "identifier": "CURRENT LANDSCAPE OF TARGETED THERAPY IN LUNG CANCER.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:32.413265+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\CURRENT LANDSCAPE OF TARGETED THERAPY IN LUNG CANCER.pdf",
            "name": "CURRENT LANDSCAPE OF TARGETED THERAPY IN LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Targeted Therapy",
                "Oncogenic Drivers",
                "Biomarker",
                "EGFR",
                "ALK",
                "ROS1",
                "BRAF",
                "Drug Resistance",
                "Molecular Profiling"
            ],
            "author": "Manasi K. Mayekar and Trever G. Bivona",
            "timestamp": "N/A",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "ACTIONABLE GENETIC ALTERATIONS",
                "EGFR-activating genetic lesions",
                "ALK rearrangements",
                "ROS1 rearrangements",
                "RET rearrangements",
                "NTRK rearrangements",
                "BRAF mutations",
                "OTHER ONCOGENIC ALTERATIONS",
                "HER2 mutations",
                "MET activating genetic lesions",
                "KRAS activating mutations",
                "DISCUSSION",
                "References",
                "Table 1"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Effectiveness_and_safety_of_nivolumab_in_advanced_non-small_cell_lung.pdf-91c4efc1",
        "document": "This real-world study evaluates the effectiveness and safety of nivolumab in treating advanced non-small cell lung cancer (NSCLC) in 260 Israeli patients.  The median overall survival was 5.9 months, lower than clinical trial results, with ECOG performance status being the most significant predictor of survival.  The safety profile was generally consistent with previous reports, although some new adverse events were observed.  The study highlights the need for real-world data to complement clinical trial findings in guiding treatment decisions, particularly for patients with poor prognoses.",
        "metadata": {
            "identifier": "Effectiveness and safety of nivolumab in advanced non-small cell lung.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:37.020955+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Effectiveness and safety of nivolumab in advanced non-small cell lung.pdf",
            "name": "Effectiveness and safety of nivolumab in advanced non-small cell lung.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Nivolumab",
                "Non-small cell lung cancer (NSCLC)",
                "Overall survival (OS)",
                "ECOG performance status",
                "Real-world data",
                "Safety",
                "Toxicity",
                "Immunotherapy"
            ],
            "author": "Elizabeth Dudnik et al.",
            "timestamp": "November 17, 2017",
            "headings": [
                "Introduction",
                "Materials and methods",
                "Results",
                "3.1. Patients",
                "3.2. Treatment",
                "3.3. Effectiveness",
                "3.4. Safety",
                "Discussion",
                "Conclusions",
                "Funding",
                "Conflict of interest",
                "Acknowledgments",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ESTIMATING_THE_NEED_FOR_RADIOTHERAPY_FOR_LUNG_CANCER.pdf-91d49b1b",
        "document": "This 2001 clinical investigation by Tyldesley et al. uses an evidence-based, epidemiologic approach to estimate the need for radiotherapy (RT) in lung cancer patients.  The study systematically reviewed literature to identify RT indications and their evidence levels, then estimated the incidence of each indication in a typical North American population.  Results showed a significant proportion of lung cancer patients requiring RT, varying by cancer type and stage.  The methodology provides a rational basis for long-term planning of radiation services and auditing access to RT at the population level.",
        "metadata": {
            "identifier": "ESTIMATING THE NEED FOR RADIOTHERAPY FOR LUNG CANCER.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:41.627406+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\ESTIMATING THE NEED FOR RADIOTHERAPY FOR LUNG CANCER.pdf",
            "name": "ESTIMATING THE NEED FOR RADIOTHERAPY FOR LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Radiotherapy",
                "Lung Cancer",
                "Needs Assessment",
                "Treatment Guidelines",
                "Epidemiology",
                "Small-Cell Lung Cancer",
                "Non-Small-Cell Lung Cancer",
                "Evidence-Based Medicine"
            ],
            "author": "Scott Tyldesley, Chris Boyd, Karleen Schulze, Hugh Walker, William J. Mackillop",
            "timestamp": "2001",
            "headings": [
                "Background and Objectives",
                "Methods",
                "Results",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Gefitinib_a_review_of_its_use_in_adults.pdf-506bfcd8",
        "document": "This article reviews the efficacy and tolerability of gefitinib, a selective EGFR tyrosine kinase inhibitor, in treating adults with advanced non-small cell lung cancer (NSCLC).  Large clinical trials demonstrate that gefitinib significantly prolongs progression-free survival and improves response rates in patients with activating EGFR mutations, particularly in never-smokers and Asian patients.  While overall survival wasn't significantly increased, this may be due to confounding post-study treatments. Gefitinib is generally well-tolerated, although interstitial lung disease is a potential, albeit rare, adverse effect.",
        "metadata": {
            "identifier": "Gefitinib a review of its use in adults.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:50.355099+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Gefitinib a review of its use in adults.pdf",
            "name": "Gefitinib a review of its use in adults.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Gefitinib",
                "EGFR",
                "Non-small cell lung cancer",
                "Tyrosine kinase inhibitor",
                "NSCLC",
                "EGFR mutation",
                "Progression-free survival",
                "Interstitial lung disease"
            ],
            "author": "Sohita Dhillon",
            "timestamp": "Received: 21 September 2014 / Accepted: 18 December 2014",
            "headings": [
                "Abstract",
                "Gefitinib in advanced NSCLC: a summary",
                "Introduction",
                "Pharmacodynamic properties",
                "Mechanism of action",
                "Predictors of efficacy",
                "Drug resistance",
                "Diagnostic studies",
                "Pharmacokinetic properties",
                "Therapeutic efficacy",
                "In chemotherapy-experienced patients",
                "Versus placebo",
                "Versus chemotherapy",
                "Versus docetaxel",
                "Versus pemetrexed",
                "Versus other EGFR TKIs",
                "In chemotherapy-naïve patients",
                "In clinically selected patients",
                "Versus carboplatin plus paclitaxel",
                "Versus gemcitabine plus cisplatin",
                "In patients with activating EGFR mutations",
                "Versus carboplatin plus paclitaxel",
                "Versus cisplatin plus docetaxel",
                "In Caucasian patients with activating EGFR mutations",
                "In patients with poor performance status and activating EGFR mutations",
                "Real-world evidence",
                "Tolerability",
                "General profile",
                "Versus chemotherapy",
                "Versus other EGFR TKIs",
                "Interstitial lung disease",
                "Place of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Introduction_to_Cancer_Chemotherapeutics.pdf-2be1c807",
        "document": "This Chemical Reviews issue focuses on cancer chemotherapeutics, exploring their development from the 1940s to current advancements.  The articles cover various aspects, including mechanisms of action of existing drugs, novel drug targets (e.g., angiogenesis inhibitors, cyclin-dependent kinases), and strategies to overcome drug resistance.  The authors discuss combination therapy, the challenges of targeting cancer cells while minimizing harm to normal cells, and the potential of new approaches like oncolytic viruses and nanotechnology. The overall goal is to inspire the development of new cancer treatments.",
        "metadata": {
            "identifier": "Introduction to Cancer Chemotherapeutics.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:40:52.957643+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Introduction to Cancer Chemotherapeutics.pdf",
            "name": "Introduction to Cancer Chemotherapeutics.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Cancer Chemotherapy",
                "Antimetabolites",
                "DNA Replication",
                "Drug Resistance",
                "Angiogenesis",
                "Combination Therapy",
                "Oncolytic Viruses",
                "Nanotechnology"
            ],
            "author": "Donna S. Shewach, Robert D. Kuchta",
            "timestamp": "07/08/2009",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_cancer_immunotherapy.pdf-d2bee17c",
        "document": "This review article from Molecular Cancer (2023) by Lahiri et al. focuses on the progress, challenges, and future prospects of lung cancer immunotherapy.  It covers various immunotherapeutic approaches, including cancer vaccines, immune checkpoint inhibitors (ICIs), adoptive cell therapies (CAR T, TCR, TIL), and oncolytic viruses.  The authors discuss the clinical trials and obstacles associated with each approach, highlighting the need for combination therapies and personalized medicine.  The role of nanomedicine and nutraceuticals in enhancing immunotherapy is also explored.",
        "metadata": {
            "identifier": "Lung cancer immunotherapy.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:08.262064+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Lung cancer immunotherapy.pdf",
            "name": "Lung cancer immunotherapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Immunotherapy",
                "Checkpoint Inhibitors",
                "Adoptive Cell Therapy",
                "Cancer Vaccines",
                "Nanomedicine",
                "SCLC",
                "NSCLC"
            ],
            "author": "Aritraa Lahiri, Avik Maji, Pravin D. Potdar, Navneet Singh, Purvish Parikh, Bharti Bisht, Anubhab Mukherjee, Manash K. Paul",
            "timestamp": "2023",
            "headings": [
                "Abstract",
                "Introduction",
                "NSCLC and immunotherapy",
                "Tumor-specific vaccines",
                "Peptide/protein vaccines",
                "DNA vaccines",
                "Vector vaccines",
                "Dendritic cell vaccines",
                "Allogeneic vaccines",
                "Adoptive cell therapy",
                "CAR T cell therapy and lung cancer targeting",
                "T-cell receptor (TCR) engineering and lung cancer",
                "Tumor-infiltrating lymphocyte (TIL) and lung cancer",
                "Oncolytic viruses for lung cancer immunotherapy",
                "Targeted antibodies for lung cancer",
                "Immune checkpoint inhibitors and NSCLC",
                "Immunotherapy in SCLC",
                "Antigen-specific vaccines and SCLC",
                "Immune-checkpoint inhibitors for SCLC",
                "Combination immunotherapy approaches",
                "Immunotherapy with Anti-angiogenic agents for targeting NSCLC",
                "Chemo-immunotherapy in NSCLC",
                "Pembrolizumab",
                "Atezolizumab",
                "Durvalumab",
                "Nivolumab with or without ipilimumab",
                "Chemo-immunotherapy in SCLC",
                "Radiation and immunotherapy",
                "Immunomodulatory nanomedicine for use in lung cancer",
                "Immunomodulatory nutraceuticals in lung cancer",
                "Ongoing clinical trials for immunotherapeutics",
                "Major obstacle and future perspective for lung cancer treatment",
                "Conclusion",
                "Abbreviations",
                "Acknowledgements",
                "Authors’ contributions",
                "Funding",
                "Availability of data and materials",
                "Declarations",
                "Ethics approval and consent to participate",
                "Consent for publication",
                "Competing interests",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_in_the_Era_of_Precision_Medicine.pdf-9f7c053e",
        "document": "This article discusses the advancements in lung cancer treatment in the era of precision medicine.  It highlights the importance of molecular profiling to identify actionable mutations and match patients to targeted therapies.  The authors emphasize the need for repeat biopsies to understand drug resistance mechanisms and the development of new clinical trial designs, such as basket and umbrella trials, to accelerate the development of effective treatments.  Despite progress, the authors acknowledge that metastatic lung cancer remains incurable, and further research is crucial to improve patient outcomes.",
        "metadata": {
            "identifier": "Lung Cancer in the Era of Precision Medicine.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:13.230563+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Lung Cancer in the Era of Precision Medicine.pdf",
            "name": "Lung Cancer in the Era of Precision Medicine.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Precision Medicine",
                "Molecular Profiling",
                "Targeted Therapies",
                "Drug Resistance",
                "Biomarkers",
                "Clinical Trials",
                "Repeat Biopsies",
                "EGFR Mutations",
                "Immunotherapy"
            ],
            "author": "Katerina Politi and Roy S. Herbst",
            "timestamp": "May 15, 2015",
            "headings": [
                "Abstract",
                "Introduction",
                "Molecular Profiling of Lung Cancer",
                "Is there a role for molecular profiling in lung squamous cell carcinoma and SCLC?",
                "Lung cancer-omics and new targets",
                "Beyond mutations: the future of molecular profiling for lung cancer",
                "Tackling Drug Resistance",
                "Repeat biopsies in lung cancer",
                "Incorporating rebiopsies at disease progression into clinical practice",
                "Clinical Trial Design in the Era of Precision Medicine",
                "Conclusions",
                "Disclosure of Potential Conflicts of Interest",
                "Authors' Contributions",
                "Grant Support",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nivolumab_for_the_Treatment_of_Metastatic_Non-Small_Cell_Lung_Cancer_With_Progression_On_or_After_Platinum-Based_Chemotherapy.pdf-37948e6f",
        "document": "This FDA approval summary details the results of the CheckMate 057 clinical trial, evaluating nivolumab's efficacy in treating metastatic non-small cell lung cancer (NSCLC) patients who progressed after platinum-based chemotherapy.  The trial demonstrated a statistically significant improvement in overall survival (OS) for nivolumab compared to docetaxel, with a median OS of 12.2 months versus 9.4 months.  While progression-free survival wasn't significantly different, a subgroup analysis suggested a greater benefit for patients with PD-L1-positive tumors.  The FDA approved nivolumab based on this favorable benefit-risk assessment, with caveats regarding patients with EGFR or ALK alterations.",
        "metadata": {
            "identifier": "Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:18.558025+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.pdf",
            "name": "Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Nivolumab",
                "Non-small cell lung cancer",
                "NSCLC",
                "PD-1 inhibitor",
                "Immunotherapy",
                "FDA approval",
                "CheckMate 057",
                "Overall survival",
                "Docetaxel",
                "PD-L1"
            ],
            "author": "Dickran Kazandjian, Daniel L. Suzman, Gideon Blumenthal, Sirisha Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur",
            "timestamp": "March 16, 2016",
            "headings": [
                "Regulatory Issues: FDA",
                "FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy",
                "Key Words",
                "ABSTRACT",
                "Implications for Practice",
                "INTRODUCTION",
                "Trial Design",
                "RESULTS",
                "DISCUSSION",
                "CONCLUSION",
                "AUTHOR CONTRIBUTIONS",
                "DISCLOSURES",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Osimertinib_As_First-Line_Treatment_of_EGFR.pdf-596090f1",
        "document": "This article reports on the AURA study, which investigated the efficacy and safety of osimertinib as a first-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC).  The study included two cohorts of treatment-naive patients receiving either 80mg or 160mg of osimertinib daily.  Results showed a robust objective response rate (ORR) and prolonged progression-free survival (PFS) across both dose groups, with no evidence of acquired EGFR T790M mutation.  The 80mg dose demonstrated better tolerability.  The findings suggest osimertinib is a promising first-line treatment option for this type of lung cancer.",
        "metadata": {
            "identifier": "Osimertinib As First-Line Treatment of EGFR.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:25.775978+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Osimertinib As First-Line Treatment of EGFR.pdf",
            "name": "Osimertinib As First-Line Treatment of EGFR.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Osimertinib",
                "EGFR",
                "Non-small-cell lung cancer (NSCLC)",
                "First-line treatment",
                "Objective response rate (ORR)",
                "Progression-free survival (PFS)",
                "EGFR T790M",
                "AURA study",
                "Clinical trial"
            ],
            "author": "Suresh S. Ramalingam, James C.-H. Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, and Pasi A. Ja¨nne",
            "timestamp": "March 20, 2018",
            "headings": [
                "Purpose",
                "Patients and Methods",
                "Results",
                "Conclusion",
                "INTRODUCTION",
                "ASSOCIATED CONTENT",
                "PATIENTS AND METHODS",
                "Patients",
                "Study Design and Treatment",
                "Study Assessments",
                "Clinical assessments",
                "Translational assessments",
                "Study Oversight",
                "StatisticalAnalysis",
                "RESULTS",
                "Patients and Treatment",
                "Clinical Activity",
                "Translational Analysis",
                "Baseline central tissue versus plasma EGFR genotyping",
                "Mechanisms of resistance to osimertinib",
                "Safety and AEs",
                "DISCUSSION",
                "AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST",
                "AUTHOR CONTRIBUTIONS",
                "REFERENCES",
                "Prior Presentation",
                "Acknowledgment"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Osimertinib_for_Patients_With_Non_Small-Cell.pdf-283259e9",
        "document": "This multicenter, open-label, phase II clinical trial (KCSG-LU15-09) investigated the efficacy and safety of osimertinib in treating non-small-cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations.  The study enrolled 37 patients, demonstrating an objective response rate of 50% and a median progression-free survival of 8.2 months.  Adverse events were mostly manageable, with the most common being rash, pruritus, and anorexia.  The results suggest that osimertinib may be a viable treatment option for NSCLC patients with uncommon EGFR mutations.",
        "metadata": {
            "identifier": "Osimertinib for Patients With Non–Small-Cell.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:30.113350+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Osimertinib for Patients With Non–Small-Cell.pdf",
            "name": "Osimertinib for Patients With Non–Small-Cell.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Osimertinib",
                "Non-small-cell lung cancer (NSCLC)",
                "Epidermal growth factor receptor (EGFR)",
                "Uncommon EGFR mutations",
                "Phase II clinical trial",
                "Objective response rate (ORR)",
                "Progression-free survival (PFS)"
            ],
            "author": "JangHo Cho et al.",
            "timestamp": "December 11, 2019",
            "headings": [
                "abstract",
                "INTRODUCTION",
                "PATIENTS AND METHODS",
                "Study Design and Participants",
                "Procedures",
                "Outcomes",
                "Statistical Analysis",
                "RESULTS",
                "Demographics",
                "Efficacy",
                "Safety",
                "DISCUSSION",
                "AFFILIATIONS",
                "CLINICAL TRIAL INFORMATION",
                "AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT",
                "AUTHOR CONTRIBUTIONS",
                "ACKNOWLEDGMENT",
                "REFERENCES",
                "APPENDIX"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pembrolizumab_for_the_Treatment_of_Non_Small-Cell_Lung_Cancer.pdf-7bb6138a",
        "document": "This New England Journal of Medicine article details a phase 1 clinical trial evaluating pembrolizumab, a PD-1 inhibitor, in treating advanced non-small-cell lung cancer.  The study assessed efficacy, safety, and the correlation between PD-L1 expression and treatment response.  Results showed pembrolizumab had an acceptable safety profile and demonstrated antitumor activity, with PD-L1 expression in at least 50% of tumor cells correlating with improved efficacy.  The study concludes that pembrolizumab is a promising treatment option for this cancer type, particularly for patients with high PD-L1 expression.",
        "metadata": {
            "identifier": "Pembrolizumab for the Treatment  of Non–Small-Cell Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:36.087586+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Pembrolizumab for the Treatment  of Non–Small-Cell Lung Cancer.pdf",
            "name": "Pembrolizumab for the Treatment  of Non–Small-Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Pembrolizumab",
                "Non-small-cell lung cancer",
                "PD-1 inhibitor",
                "PD-L1 expression",
                "Immunotherapy",
                "Clinical trial",
                "Antitumor activity",
                "Biomarker"
            ],
            "author": "Edward B. Garon, et al. for the KEYNOTE-001 Investigators",
            "timestamp": "April 19, 2015",
            "headings": [
                "Abstract",
                "Background",
                "Methods",
                "Results",
                "Conclusions",
                "Pembrolizumab for Non–Small-Cell Lung Cancer",
                "Study Oversight",
                "Study Design and Treatment",
                "Patients",
                "Study Assessments",
                "Biomarker Analysis for Patient Eligibility",
                "Biomarker Cutoff Selection",
                "Biomarker Validation",
                "Statistical Analysis",
                "Adverse Events",
                "Overall Efficacy",
                "Biomarker Selection",
                "Biomarker Validation",
                "Estimated Prevalence of PD-L1",
                "Longitudinal Outcomes on the Basis of PD-L1 Staining",
                "Discussion",
                "Appendix",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pembrolizumab_plus_Chemotherapy_in_Metastatic_Non_Small-Cell_Lung_Cancer.pdf-ee8eaaa4",
        "document": "This article reports on a phase 3 clinical trial (KEYNOTE-189) evaluating the efficacy and safety of pembrolizumab in combination with chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC).  The study found that adding pembrolizumab to standard chemotherapy significantly improved overall survival and progression-free survival compared to chemotherapy alone, regardless of PD-L1 expression levels.  While adverse events were common in both groups, the addition of pembrolizumab did not significantly increase the frequency of serious side effects.  These findings suggest that pembrolizumab plus chemotherapy is a valuable first-line treatment option for this type of lung cancer.",
        "metadata": {
            "identifier": "Pembrolizumab plus Chemotherapy  in Metastatic Non–Small-Cell Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:43.000466+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Pembrolizumab plus Chemotherapy  in Metastatic Non–Small-Cell Lung Cancer.pdf",
            "name": "Pembrolizumab plus Chemotherapy  in Metastatic Non–Small-Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Pembrolizumab",
                "Chemotherapy",
                "Non-small cell lung cancer (NSCLC)",
                "Metastatic cancer",
                "PD-L1",
                "Overall survival",
                "Progression-free survival",
                "KEYNOTE-189",
                "Clinical trial",
                "Immunotherapy"
            ],
            "author": "L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, et al. for the KEYNOTE-189 Investigators",
            "timestamp": "April 16, 2018",
            "headings": [
                "ABSTRACT",
                "BACKGROUND",
                "METHODS",
                "Patients",
                "Trial Design and Treatment",
                "Assessments",
                "End Points",
                "Trial Oversight",
                "Statistical Analysis",
                "RESULTS",
                "Patients and Treatment",
                "Overall Survival",
                "Progression-free Survival",
                "Tumor Response",
                "Adverse Events",
                "Discussion",
                "Appendix",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Personalized_medicine_for_lung_cancer.pdf-6303b7f0",
        "document": "This review article discusses the challenges and opportunities in personalized medicine for lung cancer, focusing on the importance of accurate subtyping of non-small-cell lung cancer (NSCLC).  The author highlights the limitations of traditional morphological diagnosis using small biopsy samples and advocates for the increased use of immunohistochemistry (IHC) to improve diagnostic accuracy.  Specific biomarkers and their association with various targeted therapies are examined, emphasizing the need for standardized testing methods and careful interpretation of results.  The article concludes by stressing the crucial role of pathologists in guiding treatment decisions through accurate diagnosis and biomarker testing.",
        "metadata": {
            "identifier": "Personalized medicine for lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:49.711640+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Personalized medicine for lung cancer.pdf",
            "name": "Personalized medicine for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Non-small-cell lung cancer (NSCLC)",
                "Personalized Medicine",
                "Immunohistochemistry (IHC)",
                "Biomarkers",
                "Targeted Therapy",
                "EGFR Mutation",
                "Pathology"
            ],
            "author": "Keith M Kerr",
            "timestamp": "2012",
            "headings": [
                "Introduction",
                "Subtyping NSCLC: why does it matter?",
                "Subtyping NSCLC: the challenges for pathologists",
                "NSCLC–NOS: how many cases?",
                "NSCLC–NOS: the solution becomes the problem",
                "What would be a reasonable rate for NSCLC–NOS diagnosis?",
                "Dealing with the morphological challenge: the NSCLC–NOS category",
                "Molecular predictive markers in NSCLC",
                "EGFR mutation testing",
                "Other mutations in adenocarcinomas",
                "Biomarkers and cytotoxic drugs",
                "Platinum-based agents",
                "Taxanes and vinca alkaloids",
                "Pemetrexed",
                "Gemcitabine",
                "Newer drug classes and biomarkers",
                "Delivering on this promise: challenges and opportunities for pathology",
                "Conclusion",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pneumonectomy_for_lung_cancer_Contemporary_national_early_morbidity_and_mortality_outcomes.pdf-b932d45a",
        "document": "This study analyzes contemporary early morbidity and mortality outcomes associated with pneumonectomy for lung cancer using a nationally representative French database (EPITHOR).  The researchers identified several risk factors for major adverse events, including age, low BMI, and ASA score.  Interestingly, induction therapy and overweight BMI were found to be protective factors, potentially due to selection bias and improved perioperative management.  The study highlights the importance of patient selection and perioperative care in minimizing risks associated with pneumonectomy.",
        "metadata": {
            "identifier": "Pneumonectomy for lung cancer Contemporary national early morbidity and mortality outcomes.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:41:54.534834+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Pneumonectomy for lung cancer Contemporary national early morbidity and mortality outcomes.pdf",
            "name": "Pneumonectomy for lung cancer Contemporary national early morbidity and mortality outcomes.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Pneumonectomy",
                "Lung Cancer",
                "Morbidity",
                "Mortality",
                "Risk Factors",
                "Induction Therapy",
                "BMI",
                "EPITHOR database",
                "Propensity Score Analysis"
            ],
            "author": "Pascal A. Thomas et al.",
            "timestamp": "October 16, 2014",
            "headings": [
                "Objective",
                "Methods",
                "Results",
                "Conclusions",
                "MATERIALS AND METHODS",
                "The French National Database EPITHOR",
                "Patient Population and Clinical Variables",
                "Outcome Definition",
                "Statistical Analysis",
                "RESULTS",
                "DISCUSSION",
                "Study Limitations",
                "CONCLUSIONS",
                "References",
                "Discussion",
                "EDITORIAL COMMENTARY"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Radiotherapy_treatment_for_lung_cancer.pdf-f7ef0fb8",
        "document": "This invited review article examines the current status and future directions of radiotherapy treatment for lung cancer.  It details advancements in radiotherapy technologies, such as stereotactic ablative body radiotherapy (SABR) and intensity-modulated radiotherapy (IMRT), leading to more precise and effective treatments with reduced side effects.  The review also discusses the role of radiotherapy in various stages of lung cancer, including stage I-II, stage III, and stage IV, highlighting clinical trial data and current treatment paradigms.  Finally, it explores promising future directions, including the combination of radiotherapy and immunotherapy, the use of MRI-linac technology, and the application of big data and machine learning in personalized radiotherapy decisions.",
        "metadata": {
            "identifier": "Radiotherapy treatment for lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:00.018162+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Radiotherapy treatment for lung cancer.pdf",
            "name": "Radiotherapy treatment for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Radiotherapy",
                "SABR",
                "IMRT",
                "Chemotherapy",
                "Immunotherapy",
                "Oligometastases",
                "Clinical Trials"
            ],
            "author": "Shalini K. Vinod and Eric Hau",
            "timestamp": "18 May 2020",
            "headings": [
                "ABSTRACT",
                "ADVANCES IN RADIOTHERAPY TECHNOLOGIES",
                "INTRODUCTION",
                "RADIOTHERAPY FOR STAGE I AND II NSCLC",
                "RADIOTHERAPY FOR STAGE III NSCLC",
                "RADIOTHERAPY FOR STAGE IV NSCLC",
                "RADIOTHERAPY FOR STAGE I–III (LIMITED STAGE) SCLC",
                "RADIOTHERAPY FOR STAGE IV (EXTENSIVE STAGE) SCLC",
                "FUTURE DIRECTIONS",
                "CONCLUSIONS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Segmentectomyor_lobectomy_forearlystage_lung_cancer.pdf-df60e1cf",
        "document": "This meta-analysis investigates the efficacy of segmentectomy versus lobectomy for early-stage lung cancer.  The study analyzed 22 observational studies, comparing overall and cancer-specific survival rates.  Results indicate that lobectomy is superior for Stage I, Stage IA, and Stage IA tumors larger than 2cm but smaller than 3cm. However, for tumors 2cm or smaller, segmentectomy showed equivalent survival to lobectomy.  The authors caution that these findings should be interpreted cautiously due to limitations inherent in meta-analyses of retrospective studies.",
        "metadata": {
            "identifier": "Segmentectomyor lobectomy forearlystage lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:04.839170+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Segmentectomyor lobectomy forearlystage lung cancer.pdf",
            "name": "Segmentectomyor lobectomy forearlystage lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Segmentectomy",
                "Lobectomy",
                "Survival",
                "Meta-analysis",
                "Early-stage lung cancer",
                "Tumor size",
                "Surgical treatment"
            ],
            "author": "Feichao Bao, Peng Ye, Yunhai Yang, Luming Wang, Chong Zhang, Xiayi Lv, and Jian Hu",
            "timestamp": "October 21, 2013",
            "headings": [
                "Summary",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "Eligibility criteria",
                "Collection of published studies",
                "Statistical analysis",
                "RESULTS",
                "Selected articles and description of the studies",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage I NSCLC patients",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage IA NSCLC patients",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage IA NSCLC patients with tumours larger than 2cm but smaller than 3cm",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage IA NSCLC patients with tumours of 2cm or smaller",
                "DISCUSSION",
                "Funding",
                "Conflict of interest"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Sleeve_Lobectomy_Versus_Pneumonectomy_for_Lung_cancer.pdf-6e3e763b",
        "document": "This study compares sleeve lobectomy (SL) and pneumonectomy (PN) for lung cancer treatment, analyzing survival rates and recurrence sites in 1230 patients.  SL showed significantly lower operative mortality (1.6% vs 5.3%) and better 5-year survival (52% vs 31%).  The study found that SL resulted in better long-term survival and local control, particularly in patients with stages I and II disease, when complete resection was achieved.  However, the authors acknowledge potential biases due to the retrospective nature of the study.",
        "metadata": {
            "identifier": "Sleeve Lobectomy Versus Pneumonectomy for Lung cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:08.678582+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Sleeve Lobectomy Versus Pneumonectomy for Lung cancer.pdf",
            "name": "Sleeve Lobectomy Versus Pneumonectomy for Lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Sleeve Lobectomy",
                "Pneumonectomy",
                "Lung Cancer",
                "Survival Rate",
                "Recurrence",
                "Operative Mortality",
                "NSCLC",
                "Oncology"
            ],
            "author": "Jean Deslauriers, MD, Jocelyn Gre´goire, MD, Louis F. Jacques, MD, Michel Piraux, MD, Liu Guojin, MD, and Yves Lacasse, MD",
            "timestamp": "2004",
            "headings": [
                "ORIGINAL ARTICLES: GENERAL THORACIC",
                "Background",
                "Methods",
                "Results",
                "Patient Profile",
                "Operative Risk",
                "Survival Rates",
                "Sites of Recurrences",
                "Comment",
                "References",
                "DISCUSSION"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Small_cell_lung_cancer_Treatment_review.pdf-08687ac6",
        "document": "This review article discusses the treatment of small cell lung cancer (SCLC), focusing on chemotherapy and radiotherapy.  The authors highlight the importance of considering various treatment options, including the choice of chemotherapy regimens and the timing of radiotherapy, while emphasizing that age should not be a contraindication to treatment for elderly patients.  Despite advancements in treatment, SCLC remains a significant challenge due to its aggressive nature and high risk of metastasis.  The article also touches upon the role of surgery in early-stage cases and the importance of considering quality of life in treatment decisions.",
        "metadata": {
            "identifier": "Small cell lung cancer Treatment review.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:13.823173+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Small cell lung cancer Treatment review.pdf",
            "name": "Small cell lung cancer Treatment review.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Small cell lung cancer",
                "SCLC",
                "Chemotherapy",
                "Radiotherapy",
                "Treatment",
                "Lung cancer",
                "Elderly patients",
                "Prognosis",
                "Survival"
            ],
            "author": "S Cooper and SG Spiro",
            "timestamp": "2006",
            "headings": [
                "PREVALENCE",
                "SYMPTOMS AND SIGNS",
                "STAGING AND PROGNOSTIC FACTORS",
                "TREATMENT",
                "CHEMOTHERAPY",
                "First-line chemotherapy",
                "Second-line chemotherapy",
                "Granulocyte colony stimulating factor",
                "Oral versus i.v. chemotherapy",
                "RADIOTHERAPY",
                "Dose",
                "Timing",
                "Prophylactic cranial irradiation",
                "SURGERY",
                "QUALITY OF LIFE",
                "ELDERLY",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Stereotactic_body_radiation_therapy_for_lung_metastases.pdf-99116a6d",
        "document": "This study evaluates the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for lung metastases.  Researchers retrospectively analyzed 61 patients treated between 2003 and 2009, finding high local control rates (89% at 2 years) and acceptable toxicity.  Overall survival and cancer-specific survival rates were also reported, with tumor volume significantly associated with survival outcomes.  The study concludes that SBRT is a safe and effective local treatment option for selected patients with lung metastases.",
        "metadata": {
            "identifier": "Stereotactic body radiation therapy for lung metastases.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:18.395738+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Stereotactic body radiation therapy for lung metastases.pdf",
            "name": "Stereotactic body radiation therapy for lung metastases.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Stereotactic body radiation therapy (SBRT)",
                "Lung metastases",
                "Oligometastases",
                "Local control",
                "Survival",
                "Toxicity",
                "Radiation oncology",
                "Cancer treatment"
            ],
            "author": [
                "Umberto Ricardi",
                "Andrea Riccardo Filippi",
                "Alessia Guarneri",
                "Riccardo Ragona",
                "Cristina Mantovani",
                "Francesca Giglioli",
                "Angela Botticella",
                "Patrizia Ciammella",
                "Cristina Iftode",
                "Lucio Buffoni",
                "Enrico Ruffini",
                "Giorgio Vittorio Scagliotti"
            ],
            "timestamp": "2011-04-26",
            "headings": [
                "Introduction",
                "Materials and methods",
                "2.1. Patients",
                "2.2. Treatment technique",
                "2.3. Follow-up and statistics",
                "3. Results",
                "4. Discussion",
                "5. Conclusion",
                "Conflict of interest statement",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-SURVIVAL_AND_FUNCTION_AFTER_SLEEVE_LOBECTOMY_FOR_LUNG_CANCER.pdf-794a4c87",
        "document": "This 1996 article by Gaissert et al. presents a retrospective study comparing sleeve lobectomy and pneumonectomy for lung cancer treatment.  The study analyzed 72 patients who underwent sleeve lobectomy between 1962 and 1991 and compared their outcomes to 56 patients who underwent pneumonectomy.  The findings suggest comparable survival rates between the two procedures, with sleeve lobectomy showing lower mortality and morbidity rates.  The authors conclude that sleeve lobectomy is a superior procedure for selected patients, particularly those with compromised lung function.",
        "metadata": {
            "identifier": "SURVIVAL AND FUNCTION AFTER SLEEVE LOBECTOMY FOR LUNG CANCER.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:21.711704+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\SURVIVAL AND FUNCTION AFTER SLEEVE LOBECTOMY FOR LUNG CANCER.pdf",
            "name": "SURVIVAL AND FUNCTION AFTER SLEEVE LOBECTOMY FOR LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Sleeve Lobectomy",
                "Pneumonectomy",
                "Lung Cancer",
                "Survival Rate",
                "Pulmonary Function",
                "Morbidity",
                "Mortality"
            ],
            "author": "Henning A. Gaissert, Douglas J. Mathisen, Ashby C. Moncure, Alan D. Hilgenberg, Hermes C. Grillo, John C. Wain",
            "timestamp": "1996",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Targeted_Therapies_in_Lung_Cancer.pdf-11277621",
        "document": "This review article discusses the mechanisms of tyrosine kinase inhibitor (TKI) resistance in oncogene-driven lung cancers, focusing on non-small cell lung cancer (NSCLC).  The authors explore both primary (intrinsic) and secondary (acquired) resistance mechanisms, including mutations within the target kinase, activation of bypass signaling pathways, and phenotypic transformations.  They highlight the complexity of TKI resistance, emphasizing the dynamic and heterogeneous nature of resistance evolution under selective pressure from therapy.  The review also discusses strategies to overcome TKI resistance, such as next-generation TKIs and combination therapies.",
        "metadata": {
            "identifier": "Targeted Therapies in Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:29.229895+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Targeted Therapies in Lung Cancer.pdf",
            "name": "Targeted Therapies in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tyrosine kinase inhibitors",
                "TKI resistance",
                "Lung cancer",
                "Non-small cell lung cancer",
                "Oncogene addiction",
                "Drug resistance mechanisms",
                "EGFR",
                "ALK"
            ],
            "author": "Jessica J. Lin and Alice T. Shaw",
            "timestamp": "July 2016",
            "headings": [
                "Resisting Resistance: Targeted Therapies in Lung Cancer",
                "TKI Resistance: A Pervasive Challenge",
                "Overview of Oncogenic Drivers in NSCLC",
                "Primary Resistance",
                "Secondary Resistance",
                "Target Amplification",
                "Bypass Signaling Pathway Activation",
                "Downstream Effector Activation",
                "Phenotypic and Histological Transformation",
                "Drug-Tolerant Persister Cells",
                "Heterogeneity and Polyclonal Resistance",
                "Strategies Targeting TKI Resistance",
                "Concluding Remarks",
                "Outstanding Questions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Ten-Year_Survey_of_Lung_Cancer.pdf-d502702c",
        "document": "This 1999 report from the American College of Surgeons Commission on Cancer and the American Cancer Society analyzes lung cancer treatment and survival in US hospitals from 1985-1995 using data from the National Cancer Data Base (NCDB).  The study reveals demographic trends like an increasing proportion of older, female, and African-American patients, and a rise in adenocarcinoma cases.  While there was a shift toward more complete staging, the overall 10-year relative survival rate remained low at 7%, highlighting the need for improved prevention and treatment.  The analysis also examines treatment patterns and their correlation with survival rates across different stages and histologic groups.",
        "metadata": {
            "identifier": "Ten-Year Survey of Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:33.508400+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Ten-Year Survey of Lung Cancer.pdf",
            "name": "Ten-Year Survey of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Treatment",
                "Survival",
                "National Cancer Data Base (NCDB)",
                "Adenocarcinoma",
                "Staging",
                "Chemotherapy",
                "Radiation Therapy",
                "Survival Rate"
            ],
            "author": "Willard A. Fry, Jerri Linn Phillips, Herman R. Menck",
            "timestamp": "1999",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "Patient Characteristics",
                "Treatment",
                "Survival Outcome",
                "DISCUSSION",
                "Demographic Trends",
                "Treatment Trends",
                "Survival Implications",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Treatment_of_Lung_Cancer.pdf-49b969b8",
        "document": "This article reviews the treatment of lung cancer, focusing on both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).  Treatment strategies for NSCLC vary depending on the stage of the disease, ranging from surgical resection for early stages to chemotherapy and radiotherapy for advanced stages.  Molecularly targeted therapies are also discussed for patients with specific genetic mutations.  For SCLC, the treatment goals and approaches are outlined, emphasizing combined modality therapy for limited-stage disease and chemotherapy for extensive-stage disease.  The article concludes by highlighting future directions in lung cancer research, including novel targeted agents and predictive biomarkers.",
        "metadata": {
            "identifier": "Treatment of Lung Cancer.pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:39.194514+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Treatment of Lung Cancer.pdf",
            "name": "Treatment of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Non-small cell lung cancer (NSCLC)",
                "Small cell lung cancer (SCLC)",
                "Chemotherapy",
                "Radiotherapy",
                "Surgery",
                "Molecular therapy",
                "Targeted therapy"
            ],
            "author": "Shirish M. Gadgeel, Suresh S. Ramalingam, Gregory P. Kalemkerian",
            "timestamp": "2012",
            "headings": [
                "NON–SMALL CELL LUNG CANCER",
                "Stage I/II NSCLC",
                "Surgery",
                "Nonsurgical therapy",
                "Adjuvant therapy",
                "Stage III NSCLC",
                "Stage IV NSCLC",
                "First-line chemotherapy",
                "Maintenance therapy",
                "Salvage chemotherapy",
                "Targeted therapy",
                "EGFR mutation",
                "ALK gene rearrangement",
                "Antiangiogenic therapy",
                "Future Directions",
                "SMALL CELL LUNG CANCER",
                "Treatment",
                "Radiotherapy",
                "Chemotherapy",
                "Recurrent disease",
                "Future Directions",
                "ACKNOWLEDGMENTS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Treatment_of_non-small_cell_lung_cancer_NSCLC_.pdf-e134c433",
        "document": "This review article discusses the treatment of non-small cell lung cancer (NSCLC), focusing on various stages and treatment strategies.  It covers surgical interventions, adjuvant therapies (chemotherapy and radiotherapy), and the role of targeted therapies like EGFR and VEGF inhibitors.  The article analyzes different chemotherapy regimens, including platinum-based combinations and newer agents, and their effectiveness based on clinical trial data.  Prognostic and predictive factors, such as ERCC1 and RRM1 expression, are also considered in tailoring treatment approaches.",
        "metadata": {
            "identifier": "Treatment of non-small cell lung cancer (NSCLC).pdf",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T08:42:44.610551+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Treatment of non-small cell lung cancer (NSCLC).pdf",
            "name": "Treatment of non-small cell lung cancer (NSCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Lung cancer",
                "Treatment",
                "Chemotherapy",
                "Radiotherapy",
                "Targeted therapy",
                "EGFR inhibitors",
                "VEGF inhibitors",
                "Clinical trials"
            ],
            "author": [
                "Konstantinos Zarogoulidis",
                "Paul Zarogoulidis",
                "Kaid Darwiche",
                "Efimia Boutsikou",
                "Nikolaos Machairiotis",
                "Kosmas Tsakiridis",
                "Nikolaos Katsikogiannis",
                "Ioanna Kougioumtzi",
                "Ilias Karapantzos",
                "Haidong Huang",
                "Dionysios Spyratos"
            ],
            "timestamp": "July 5, 2013",
            "headings": [
                "ABSTRACT",
                "Introduction",
                "Management of NSCLC according to the extent of the disease",
                "Early disease stage I-IIIA",
                "Stage IA",
                "Stage IB",
                "Stage II",
                "Locally advanced IIIA and selected IIIB",
                "Stage IIIB",
                "Management of advanced non-small cell lung cancer stage IIIB-IV",
                "Chemotherapy vs. best supportive care (BSC)",
                "Number of chemotherapy pts",
                "Concurrent vs. sequential chemo radiotherapy",
                "Treatment according to prognostic and predictive factors",
                "Excision repair cross-complementation group 1 and regulatory subunit of ribonucleotide reductase (ERCC1, RRM1)",
                "Thymidylate synthase expression (TS)",
                "Biological agents",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Biomarker_Clinical_Trials_in_Lung_Cancer.pdf-7188c76c",
        "document": "This review article discusses the design, logistics, challenges, and practical considerations of biomarker clinical trials in lung cancer.  It covers the evolution of lung cancer treatment from histology-focused chemotherapy to biomarker-driven therapy, highlighting the shift towards precision medicine.  The authors provide an overview of trial designs across different drug development phases, including early-phase biomarker discovery, proof-of-concept trials (adaptive designs, basket trials), and definitive phase II/III and phase III trials (umbrella trials).  Challenges such as sample size justification, stopping rules, and heterogeneity of responses across subgroups are addressed.  The article concludes with a discussion of future directions in clinical trial design for lung cancer.",
        "metadata": {
            "identifier": "2a127a63bc7ffbcd08d2af8cf7f20348625caa99b69e50ecd152dc61f008d41c",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:20.686351+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Biomarker Clinical Trials in Lung Cancer.pdf",
            "name": "Biomarker Clinical Trials in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Biomarker",
                "Clinical Trials",
                "Lung Cancer",
                "Targeted Therapies",
                "Precision Medicine",
                "Adaptive Designs",
                "Basket Trials",
                "Umbrella Trials",
                "Drug Development"
            ],
            "author": "Jennifer Le-Rademacher, Suzanne Dahlberg, J. Jack Lee, Alex A. Adjei, Sumithra J. Mandrekar",
            "timestamp": "September 4, 2018",
            "headings": [
                "Introduction",
                "Early-Phase Biomarker Discovery Trial Designs",
                "Proof-of-Concept Trials",
                "Phase II Trials",
                "Adaptive Trial Design",
                "Tissue Agnostic or Molecularly Defined Rather Than Organ-Defined Trials",
                "Basket Trial Design",
                "Definitive Trials",
                "Phase II/III Design",
                "Phase III Design",
                "Conclusions and Future Directions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Defining_a_standard_set_of_patient-centred_outcomes_for_lung_cancer.pdf-d5dbd6a7",
        "document": "This article details the development of a standardized set of patient-centered outcomes for lung cancer by the International Consortium for Health Outcomes Measurement (ICHOM).  An international working group, using a modified Delphi method, established a consensus on essential outcomes to track, including survival, treatment complications, and patient-reported quality of life measures.  The study aimed to improve the assessment of lung cancer treatments and the performance of healthcare institutions by providing a global standard for data collection and comparison.  The recommended set includes both clinical and patient-reported data, along with case-mix variables for risk adjustment.  This work is intended to facilitate value-based healthcare for lung cancer patients worldwide.",
        "metadata": {
            "identifier": "139455fb100ccade67b79306623948f99eae032f8d1c5e5a3151ad170614c0a8",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:25.391946+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Defining a standard set of patient-centred outcomes for lung cancer.pdf",
            "name": "Defining a standard set of patient-centred outcomes for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Patient-centered outcomes",
                "Quality of life",
                "Standard set",
                "ICHOM",
                "Delphi method",
                "Survival",
                "Treatment complications",
                "Case-mix variables",
                "Value-based healthcare"
            ],
            "author": "Kimberley S. Mak et al.",
            "timestamp": "July 07, 2016",
            "headings": [
                "ORIGINAL ARTICLE",
                "LUNG CANCER",
                "ABSTRACT",
                "Introduction",
                "Materials and methods",
                "Results",
                "Conditions scope and treatments covered",
                "Lung Cancer Standard Set: outcomes",
                "Survival",
                "Complications",
                "Degree of health",
                "Other outcomes",
                "Case-mix variables",
                "Data collection",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Effect_of_Prior_Cancer_on_Outcomes_in_Lung_Cancer.pdf-d0acd826",
        "document": "This study investigates the effect of prior cancer on outcomes in patients with advanced lung cancer.  Researchers analyzed data from the Surveillance, Epidemiology, and End Results–Medicare linked registry, finding that 14.7% of patients with stage IV lung cancer had a history of prior cancer.  Surprisingly, patients with prior cancer showed better all-cause and lung cancer-specific survival.  The authors conclude that broader inclusion of patients with prior cancer in clinical trials should be considered.",
        "metadata": {
            "identifier": "9bcbf816a5e4adb3507f88fdaa928d041c730f5570c4de3d0b6b71eb5bc43912",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:29.916151+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Effect of Prior Cancer on Outcomes in Lung Cancer.pdf",
            "name": "Effect of Prior Cancer on Outcomes in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Prior Cancer",
                "Clinical Trial Eligibility",
                "Survival Outcomes",
                "SEER-Medicare Registry",
                "Propensity Score",
                "Hazard Ratio",
                "Clinical Trial Accrual"
            ],
            "author": "Andrew L. Laccetti, Sandi L. Pruitt, Lei Xuan, Ethan A. Halm, David E. Gerber",
            "timestamp": "February 09, 2015",
            "headings": [
                "Abstract",
                "Background",
                "Methods",
                "Data Sources",
                "Study Population",
                "Measures",
                "Statistical Analysis",
                "Results",
                "Discussion",
                "Funding",
                "Notes",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Efficacy_and_safety_of_nivolumab_nivo_monotherapy_versus_chemotherapy_chemo_in_recurrent_small_cell_lung_cancer_SCLC_Results_from_CheckMate_331.pdf-64dbe9d0",
        "document": "This is a report on the CheckMate 331 clinical trial (NCT02481830), evaluating nivolumab versus chemotherapy in patients with recurrent small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.  The primary endpoint, overall survival, did not show a statistically significant improvement with nivolumab. However, the study observed a delayed separation of survival curves, suggesting potential long-term benefits in platinum-refractory settings.  Nivolumab demonstrated a lower rate of adverse events compared to chemotherapy.  The authors acknowledge writing and editorial assistance funded by Bristol-Myers Squibb.",
        "metadata": {
            "identifier": "477dcfe748e33ed8d03c51f78ef123f2109e9ee70117f7bd08029ac809762cef",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:33.710048+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC) Results from CheckMate 331.pdf",
            "name": "Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC) Results from CheckMate 331.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "nivolumab",
                "chemotherapy",
                "small cell lung cancer (SCLC)",
                "CheckMate 331",
                "overall survival",
                "progression-free survival",
                "clinical trial",
                "platinum-resistant SCLC"
            ],
            "author": [
                "M. Reck",
                "D. Vicente",
                "T. Ciuleanu",
                "S. Gettinger",
                "S. Peters",
                "L. Horn",
                "C. Audigier-Valette",
                "N. Pardo",
                "O. Juan-Vidal",
                "Y. Cheng",
                "H. Zhang",
                "M. Shi",
                "J. Wolf",
                "S. J. Antonia",
                "K. Nakagawa",
                "G. Selvaggi",
                "C. Baudelet",
                "H. Chang",
                "D. R. Spigel"
            ],
            "timestamp": "December 2018",
            "headings": [
                "Table: LBA5 Efficacy outcomes with nivolumab vs chemotherapy in recurrent SCLC",
                "LBA5 Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331",
                "Background",
                "Methods",
                "Results",
                "Conclusions",
                "Editorial acknowledgement",
                "Clinical trial identification",
                "Legal entity responsible for the study",
                "Funding",
                "Disclosure"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Enrollment_Trends_and_Disparity_Among_Patients_With_Lung_cancer.pdf-f9dcdcc0",
        "document": "This study analyzes enrollment trends and disparities in lung cancer clinical trials from 1990 to 2012, focusing on age, sex, and race/ethnicity.  Researchers compared data from 23,006 National Cancer Institute trial participants with 578,476 patients from the SEER registry.  While disparities decreased for elderly patients with non-small cell lung cancer and women overall, significant underrepresentation persisted for elderly patients with small cell lung cancer and minority groups.  The authors emphasize the need for continued efforts to improve representation in clinical trials to ensure generalizability of results and better target underrepresented patient groups.",
        "metadata": {
            "identifier": "0c3233d784f11e6076359158978815588d0093e42999bc4fd85f00dc9f98d823",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:38.778074+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Enrollment Trends and Disparity Among Patients With Lung cancer.pdf",
            "name": "Enrollment Trends and Disparity Among Patients With Lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Clinical Trials",
                "Enrollment Disparities",
                "Age",
                "Sex",
                "Race/Ethnicity",
                "SEER Registry",
                "National Cancer Institute"
            ],
            "author": "Herbert H. Pang, Xiaofei Wang, Thomas E. Stinchcombe, et al.",
            "timestamp": "September 19, 2016",
            "headings": [
                "Purpose",
                "Methods",
                "Data Sources",
                "Statistical Analysis",
                "Results",
                "Elderly and Women Patients",
                "Racial/Ethnic Minority Patients",
                "Elderly Patients by Lung Cancer Type",
                "Targeted Agents",
                "Discussion",
                "Authors’Disclosures of Potential Conflicts of Interest",
                "Author Contributions",
                "References",
                "Affiliations",
                "Acknowledgment"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Next_steps_to_improve_disparities_in_lung_cancer_treatment_clinical_trial_enrollment.pdf-400259a3",
        "document": "This editorial discusses disparities in lung cancer clinical trial enrollment, focusing on underrepresentation of elderly patients, women, and racial/ethnic minorities.  It analyzes a study showing improvements in some subgroups but persistent disparities in others, highlighting the need for multi-faceted solutions.  The authors suggest addressing these issues through policy changes, improved patient engagement, and realignment of research funding priorities.  They emphasize the importance of concerted efforts from various stakeholders to improve trial enrollment and ensure representative participant populations.",
        "metadata": {
            "identifier": "e2babeb4fc05b1bbf5ccd3be361b8acfb9998bff263d7640e3f089fce342434e",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:41.395218+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Next steps to improve disparities in lung cancer treatment clinical trial enrollment.pdf",
            "name": "Next steps to improve disparities in lung cancer treatment clinical trial enrollment.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Clinical Trials",
                "Enrollment Disparities",
                "Racial Disparities",
                "Healthcare Disparities",
                "Personalized Medicine",
                "Cancer Treatment",
                "Research Funding"
            ],
            "author": "Leah L. Zullig, William R. Carpenter, Christina D. Williams",
            "timestamp": "December 20, 2016",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nivolumab_alone_and_nivolumab_plus_ipilimumab_in_lung_cancer.pdf-9f66a539",
        "document": "This phase 1/2 multicenter trial assessed the safety and efficacy of nivolumab, alone and in combination with ipilimumab, in treating recurrent small-cell lung cancer (SCLC).  The study enrolled 216 patients who had progressed after at least one platinum-based chemotherapy regimen.  Objective responses were observed across all treatment groups, with the combination therapy showing higher response rates.  While manageable, treatment-related adverse events, including some serious ones, were reported.  The results suggest a potential new treatment approach for SCLC and warrant further investigation in phase 3 trials.",
        "metadata": {
            "identifier": "506b9d521f8a858d316bd1bbe33d8f0fa896921e58b3702c0f5739d964b9eec3",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:47.764566+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Nivolumab alone and nivolumab plus ipilimumab in lung cancer.pdf",
            "name": "Nivolumab alone and nivolumab plus ipilimumab in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Small-cell lung cancer",
                "Nivolumab",
                "Ipilimumab",
                "Immunotherapy",
                "Phase 1/2 trial",
                "Objective response",
                "Adverse events",
                "PD-L1",
                "ClinicalTrials.gov"
            ],
            "author": "Scott J Antonia, José A López-Martin, Johanna Bendell, et al.",
            "timestamp": "June 4, 2016",
            "headings": [
                "Summary",
                "Introduction",
                "Methods",
                "Study design and participants",
                "Procedures",
                "Outcomes",
                "Statistical analysis",
                "Results",
                "Discussion",
                "Contributors",
                "Declaration of interests",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Phase_I_Clinical_Trial_Design_in_Cancer_Drug_Development.pdf-28f62c3e",
        "document": "This article summarizes a workshop on Phase I clinical trial design in cancer drug development.  The main focus is on improving the efficiency and safety of these trials by exploring alternative methodologies to the traditional Fibonacci escalation scheme.  Discussions included higher starting doses, fewer patients per dose level, and statistically-based dose escalation methods like the continual reassessment method (CRM). The goal is to reduce the number of patients exposed to subtherapeutic doses while ensuring patient safety and accurately determining the recommended Phase II dose.",
        "metadata": {
            "identifier": "a2481ecec7dc280f97ec1ae4d4386a4792c23bc81e6814beacb00518cc55b330",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:52.735669+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Phase I Clinical Trial Design in Cancer Drug Development.pdf",
            "name": "Phase I Clinical Trial Design in Cancer Drug Development.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Phase I clinical trial",
                "cancer drug development",
                "dose escalation",
                "maximum tolerated dose (MTD)",
                "Fibonacci escalation",
                "continual reassessment method (CRM)",
                "toxicity",
                "pharmacokinetics",
                "clinical trial design"
            ],
            "author": "E.A. Eisenhauer, P.J. O’Dwyer, M. Christian, and J.S. Humphrey",
            "timestamp": "2000",
            "headings": [
                "SPECIAL ARTICLE",
                "PHASE I CLINICAL TRIAL DESIGN IN CANCER DRUG DEVELOPMENT",
                "GOALS OF PHASE I TRIALS OF CYTOTOXIC AGENTS",
                "LIMITATIONS OF STANDARD PHASE I DESIGN AND POTENTIAL SOLUTIONS",
                "STARTING DOSE LEVELS FOR PHASE I STUDIES",
                "PHARMACOKINETICS IN PHASE I TRIALS AND PHARMACOLOGICALLY GUIDED DOSE ESCALATION",
                "NOVEL DOSE-ESCALATION METHODS: STATISTICALLY BASED METHODS",
                "ACCELERATED TITRATION DESIGNS",
                "COMMENTARY AND DISCUSSION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Secondary_analysis_of_KeyNote-001_phase_1_trial.pdf-4ada9bf7",
        "document": "This secondary analysis of the KEYNOTE-001 phase 1 trial investigated the impact of prior radiotherapy on the efficacy and toxicity of pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients.  The study found that patients who had received prior radiotherapy experienced significantly longer progression-free and overall survival with pembrolizumab treatment.  While a higher incidence of treatment-related pulmonary toxicity was observed in patients with prior thoracic radiotherapy, the rate of grade 3 or worse toxicity remained similar between groups.  Further clinical trials are warranted to confirm these findings and optimize treatment strategies.",
        "metadata": {
            "identifier": "87269ca7d6eddccc895ecfcb03903f223ea866f5250353a6fef9fda3cc35debd",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:10:58.250429+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Secondary analysis of KeyNote-001 phase 1 trial.pdf",
            "name": "Secondary analysis of KeyNote-001 phase 1 trial.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Pembrolizumab",
                "Radiotherapy",
                "Non-small-cell lung cancer (NSCLC)",
                "Immunotherapy",
                "Progression-free survival",
                "Overall survival",
                "Pulmonary toxicity",
                "KEYNOTE-001"
            ],
            "author": "Narek Shaverdian*, Aaron E Lisberg*, Krikor Bornazyan, Darlene Veruttipong, Jonathan W Goldman, Silvia C Formenti, Edward B Garon†, Percy Lee†",
            "timestamp": "May 24, 2017",
            "headings": [
                "Summary",
                "Introduction",
                "Methods",
                "Study design and participants",
                "Procedures",
                "Outcomes",
                "Statistical analysis",
                "Results",
                "Discussion",
                "Contributors",
                "Declaration of interests",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Effect_of_Receiving_Treatment_Within_a_Clinical_Trial.pdf-157b9530",
        "document": "This study investigates the impact of clinical trial participation on survival and perceived quality of care among patients with advanced-stage non-small cell lung cancer (NSCLC).  Researchers analyzed data from the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) database, comparing survival outcomes and patient-reported quality of care between patients treated within and outside clinical trials.  The study found no significant survival benefit associated with clinical trial enrollment, although patients in trials perceived better quality of care.  These findings suggest that the perceived 'trial effect' may be primarily related to patient perception rather than a direct survival advantage.",
        "metadata": {
            "identifier": "2ef2df7ae05f74fdc6a9b8a4eb6c52997a8d6cad231891c16eb7e9039d02b807",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:02.461284+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\The Effect of Receiving Treatment Within a Clinical Trial.pdf",
            "name": "The Effect of Receiving Treatment Within a Clinical Trial.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "Clinical trials",
                "Survival outcomes",
                "Quality of care",
                "Trial effect",
                "CanCORS",
                "Chemotherapy",
                "Radiation therapy"
            ],
            "author": "Taher Abu-Hejleh, Elizabeth A. Chrischilles, Thorvardur R. Halfdanarson, Christian Simon, Jane F. Pendergast, Dingfeng Jiang, Carmen J. Smith, Aaron T. Porter, Knute D. Carter, Robert B. Wallace, and Cancer Care Outcomes Research and Surveillance Consortium (CanCORS)",
            "timestamp": "2016",
            "headings": [
                "Objectives",
                "Materials and Methods",
                "Results",
                "Discussion",
                "Conclusions",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Impact_of_Clinical_Trials_on_the_Treatment_of_Lung_Cancer.pdf-5c91b53d",
        "document": "This 1993 article investigates the impact of clinical trials on lung cancer treatment in the UK.  Researchers surveyed radiotherapists and medical oncologists, finding that large, multicenter randomized trials had the most significant influence on clinical practice.  While participation in trials increased the likelihood of adopting trial results, a considerable number of non-participants also changed their practices based on trial findings. The study also highlights the low percentage of lung cancer patients participating in trials and raises questions about referral patterns and trial design.",
        "metadata": {
            "identifier": "3e27f904341125d610de64df30170e8fb6c5a2cc1a9a293e5d07df99468cefb7",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:07.265438+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\The Impact of Clinical Trials on the Treatment of Lung Cancer.pdf",
            "name": "The Impact of Clinical Trials on the Treatment of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Clinical trials",
                "Radiotherapy",
                "Chemotherapy",
                "Clinical practice",
                "Multicenter randomized trials",
                "Impact",
                "UK Oncology"
            ],
            "author": "R. Stephens and D. Gibson",
            "timestamp": "1993",
            "headings": [
                "INTRODUCTION",
                "METHODS",
                "RESULTS",
                "Response to the Questionnaire",
                "Number of Patients Seen and Number of Patients Entered Into Trials",
                "The Impact of Lung Cancer Trials",
                "The Impact of Specific MRC Lung Cancer Trials",
                "The First MRC Palliative Radiotherapy Trial for Inoperable NSCLC",
                "The Fourth MRC Small Cell Trial",
                "Journals",
                "DISCUSSION",
                "References",
                "APPENDIX A"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Treatment_of_Non-small_Cell_Lung_Cancer_Stage_I_and_Stage_II.pdf-0777ad59",
        "document": "This text focuses on the treatment of non-small cell lung cancer (NSCLC), specifically stages I and II.  It discusses evolving surgical techniques, the role of adjuvant therapies (chemotherapy and radiation), and the importance of a multidisciplinary approach involving pulmonologists, surgeons, oncologists, and radiation specialists.  The text also highlights the use of evidence-based clinical practice guidelines and the consideration of patient age and comorbidities in treatment decisions.  A minimally invasive technology for evaluating lung tissue is mentioned as a potential future diagnostic tool.",
        "metadata": {
            "identifier": "8acc99cb4dfe4a49685a4711e427710d40a69b255824740aad18bb455a9a1d00",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:09.701937+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Clinical trial\\Treatment of Non-small Cell Lung Cancer Stage I and Stage II.pdf",
            "name": "Treatment of Non-small Cell Lung Cancer Stage I and Stage II.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Lung cancer treatment",
                "Adjuvant therapy",
                "Chemotherapy",
                "Radiation therapy",
                "Surgical resection",
                "Multidisciplinary approach",
                "Comorbidity",
                "Clinical trials"
            ],
            "author": [
                "L.T. Tanoue, MD",
                "Scott WJ, Howington J, Feigenberg S, et al",
                "Asmis TR, Ding K, Seymour L"
            ],
            "timestamp": [
                "2007",
                "2008"
            ],
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ALK_in_Lung_Cancer_Past_Present_and_Future.pdf-c289145f",
        "document": "This scientific review article discusses anaplastic lymphoma kinase (ALK) in lung cancer, focusing on its discovery, current treatment practices using crizotinib, and future challenges.  The authors detail the impressive initial success of crizotinib in treating ALK-positive non-small cell lung cancer (NSCLC), but also highlight the emergence of resistance mechanisms.  The review explores various resistance mechanisms, including ALK mutations and amplifications, as well as the activation of bypass signaling pathways like EGFR and c-KIT.  Finally, the authors discuss ongoing research into next-generation ALK inhibitors and combination therapies to overcome resistance.",
        "metadata": {
            "identifier": "3b1467d20a1cb1d3efb960ae352424d7e5261eed77f0f645ba5c16ab5bc4c2fb",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:15.308952+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\ALK in Lung Cancer Past, Present, and Future.pdf",
            "name": "ALK in Lung Cancer Past, Present, and Future.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ALK",
                "Lung Cancer",
                "Crizotinib",
                "NSCLC",
                "Drug Resistance",
                "EGFR",
                "c-KIT",
                "Oncogene Addiction",
                "Targeted Therapy"
            ],
            "author": "Alice T. Shaw and Jeffrey A. Engelman",
            "timestamp": "February 11, 2013",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "THE PAST: DISCOVERY OF ALK REARRANGEMENTS AS ONCOGENIC DRIVERS IN HUMAN CANCERS",
                "THE PRESENT: EFFICACY OF CRIZOTINIB IN TREATING PATIENTS WITH ADVANCED, ALK-POSITIVE NSCLC",
                "THE FUTURE: OVERCOMING CRIZOTINIB RESISTANCE",
                "Mechanisms",
                "New Treatment Strategies",
                "DISCUSSION",
                "REFERENCES",
                "AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST",
                "AUTHOR CONTRIBUTIONS"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Detection_of_Mutations_in_EGFR.pdf-a690ee53",
        "document": "This research article from the New England Journal of Medicine details a study on detecting EGFR mutations in circulating lung cancer cells.  Researchers used a microfluidic device to isolate circulating tumor cells and a sensitive assay to detect EGFR mutations, finding it more effective than plasma DNA analysis.  The study showed a strong correlation between the presence of the T790M mutation and reduced progression-free survival.  Serial analysis revealed the emergence of additional EGFR mutations during treatment, highlighting the dynamic nature of cancer evolution.  The findings suggest that monitoring circulating tumor cells could improve lung cancer treatment strategies.",
        "metadata": {
            "identifier": "e22321bb4b9721a2c0974e3d284c6ddeac9a03c62be6723534a3aab03f265bfd",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:21.195311+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Detection of Mutations in EGFR.pdf",
            "name": "Detection of Mutations in EGFR.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "EGFR mutations",
                "circulating tumor cells",
                "lung cancer",
                "tyrosine kinase inhibitors",
                "T790M mutation",
                "drug resistance",
                "microfluidic device",
                "molecular analysis",
                "cancer evolution",
                "progression-free survival"
            ],
            "author": "Maheswaran et al. (Haber)",
            "timestamp": "July 2, 2008",
            "headings": [
                "Abstract",
                "Background",
                "Methods",
                "Patients and Clinical Specimens",
                "Molecular Analysis",
                "Statistical Analysis",
                "Results",
                "Identification of Circulating Tumor Cells",
                "Detection of EGFR Mutations in Tumors",
                "Detection of EGFR Mutations in Circulating Tumor Cells",
                "Serial Measurements",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-EGFR_Mutations_in_Lung_Cancer.pdf-634b2b6c",
        "document": "This document presents two scientific research articles. The first article focuses on identifying genes responsible for stomatal development in Arabidopsis thaliana using microarray analysis and T-DNA insertion lines.  The second article investigates the correlation between epidermal growth factor receptor (EGFR) mutations and the response to gefitinib therapy in non-small cell lung cancer (NSCLC) patients.  Both studies utilize genomic approaches to understand the molecular mechanisms underlying biological processes and disease.  The findings have implications for plant biology and cancer treatment, respectively.",
        "metadata": {
            "identifier": "3f3ab8811e6b7166b14405e38b283175517a3b5f74ead81e3013351c7935b61d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:26.412700+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\EGFR Mutations in Lung Cancer.pdf",
            "name": "EGFR Mutations in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Arabidopsis thaliana",
                "stomatal development",
                "microarray analysis",
                "T-DNA insertion",
                "EGFR mutations",
                "gefitinib",
                "non-small cell lung cancer",
                "cancer therapy",
                "autophagy",
                "caspase-8"
            ],
            "author": "J. Guillermo Paez et al. and Li Yu et al.",
            "timestamp": "28 January 2004; accepted 7 April 2004 and 16 April 2004; accepted 21 April 2004",
            "headings": [
                "REPORTS",
                "ReferencesandNotes",
                "SupportingOnlineMaterial",
                "MaterialsandMethods",
                "REPORTS",
                "Fig.1.Sequencealignmentofselectedregions",
                "Fig.2.PositionsofmissensemutationsG719S",
                "Fig. 3. A lung adenocarcinoma cell line with EGFR receptor mutation",
                "ReferencesandNotes",
                "SupportingOnlineMaterial",
                "MaterialsandMethods"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-EML4-ALK_Mutations_in_Lung_Cancer.pdf-76b0b4fe",
        "document": "This brief report from the New England Journal of Medicine details the discovery of two secondary mutations in the EML4-ALK gene in a lung cancer patient who relapsed after treatment with an ALK inhibitor.  These mutations, C1156Y and L1196M, were found to independently confer resistance to multiple ALK inhibitors.  The study used deep sequencing and in vitro assays to characterize the mutations and their impact on drug sensitivity.  The findings highlight a potential mechanism of acquired resistance to ALK inhibitors and suggest the need for developing next-generation inhibitors.",
        "metadata": {
            "identifier": "2c086237d74110fd2fbc6b8a0ce7d88c34c387617fda33f8a8f0595e076855e8",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:30.286989+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\EML4-ALK Mutations in Lung Cancer.pdf",
            "name": "EML4-ALK Mutations in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "EML4-ALK",
                "Lung Cancer",
                "ALK Inhibitors",
                "Drug Resistance",
                "Mutations",
                "C1156Y",
                "L1196M",
                "Tyrosine Kinase"
            ],
            "author": "Young Lim Choi, et al. for the ALK Lung Cancer Study Group",
            "timestamp": "October 28, 2010",
            "headings": [
                "SUMMARY",
                "Methods",
                "Results",
                "CASE REPORT",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Epidermal_growth_factor_receptor_EGFR_in_lung_cancer.pdf-993fe61c",
        "document": "This review article discusses epidermal growth factor receptor (EGFR) in lung cancer, focusing on its role in tumor development and response to tyrosine kinase inhibitors (TKIs).  EGFR mutations, particularly in exons 19 and 21, are associated with increased sensitivity to TKIs like gefitinib and erlotinib, although the overall survival benefit is debated.  The article also explores the significance of EGFR gene amplification and the use of immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) in assessing EGFR abnormalities.  Standardization of testing methodologies is emphasized for better patient selection for TKI therapy.",
        "metadata": {
            "identifier": "a68c7f68c07240c4f314a90d39b921370e2dbabdea0a0d43868c1494e3aabb15",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:33.998446+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Epidermal growth factor receptor (EGFR) in lung cancer.pdf",
            "name": "Epidermal growth factor receptor (EGFR) in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "EGFR",
                "Tyrosine Kinase Inhibitors",
                "EGFR Mutations",
                "Gene Amplification",
                "Gefitinib",
                "Erlotinib",
                "Immunohistochemistry"
            ],
            "author": "Gillian Bethune, Drew Bethune, Neale Ridgway, Zhaolin Xu",
            "timestamp": "February 16, 2010",
            "headings": [
                "ABSTRACT",
                "EGFR function and its role in lung cancer",
                "EGFR receptor tyrosine kinase inhibitors",
                "Assessment of EGFR abnormalities"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-KRAS_Mutations_in_Non_Small_Cell_Lung_Cancer.pdf-570ff83d",
        "document": "This scientific article reviews the role of KRAS mutations in non-small cell lung cancer (NSCLC).  The authors discuss the discovery of RAS mutations, their association with clinical factors like smoking history, and their prognostic and predictive value in response to therapies.  They highlight that KRAS mutations are negative predictors of benefit from adjuvant chemotherapy and anti-EGFR therapies.  The review also covers current approaches to targeting KRAS mutant NSCLC, emphasizing the need for further research and development of effective therapies.",
        "metadata": {
            "identifier": "a635d4b081fb61abd8b0804bba37188fdab02f183c78502b4c64803a7548f7f4",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:38.176272+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\KRAS Mutations in Non–Small Cell Lung Cancer.pdf",
            "name": "KRAS Mutations in Non–Small Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "KRAS mutations",
                "non-small cell lung cancer",
                "NSCLC",
                "EGFR",
                "adjuvant chemotherapy",
                "targeted therapy",
                "cancer biomarkers",
                "prognosis",
                "smoking"
            ],
            "author": "Gregory J. Riely, Jenifer Marks, and William Pao",
            "timestamp": "November 19, 2008",
            "headings": [
                "KRAS Mutations in Non–Small Cell Lung Cancer",
                "RAS AND NON–SMALL CELL LUNG CANCER",
                "KRAS MUTATIONS AND CIGARETTESMOKING IN NSCLC",
                "KRAS MUTATIONS AS A PROGNOSTIC FACTOR IN NSCLC",
                "KRAS MUTATIONS AS A PREDICTIVE MARKER OF THERAPY FOR NSCLC",
                "CURRENT THERAPEUTIC APPROACHES BASED ON INHIBITION OF RAS-MEDIATED SIGNALING",
                "CONCLUSIONS"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Molecular_biology_of_lung_cancer.pdf-d70c124e",
        "document": "This review article discusses the molecular biology of lung cancer, focusing on the genetic alterations in oncogenes and tumor suppressor genes.  It highlights the advancements in understanding the molecular pathogenesis of lung cancer, particularly in adenocarcinomas and squamous cell carcinomas.  The authors detail common mutations in genes like KRAS, EGFR, BRAF, and ALK, and their implications for targeted therapies.  The role of tumor suppressor genes and the complexity of lung cancer's genetic heterogeneity are also addressed.  The ultimate goal is to improve patient outcomes by identifying and targeting key genetic aberrations.",
        "metadata": {
            "identifier": "4dbd46461d4c466191ef5be736498d413980208690b97f043dabe97b9efc011a",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:44.944293+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Molecular biology of lung cancer.pdf",
            "name": "Molecular biology of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Oncogenes",
                "Tumor suppressor genes",
                "Mutations",
                "Targeted therapy",
                "KRAS",
                "EGFR",
                "ALK",
                "Genomic analysis"
            ],
            "author": "Wendy A. Cooper, David C. L. Lam, Sandra A. O’Toole, John D. Minna",
            "timestamp": "August 1, 2013",
            "headings": [
                "Introduction",
                "KRAS",
                "EGFR mutations",
                "BRAF",
                "MEK",
                "MET",
                "HER2",
                "PI3K/AKT/mTOR",
                "ALK rearrangements",
                "ROS1",
                "RET",
                "FGFR1",
                "DDR2",
                "Tumour suppressor genes",
                "TP53",
                "PTEN",
                "LKB1 (STK11)",
                "The p16INK4a-cyclin D1-CDK4-RB pathway",
                "Molecular targeting in NSCLC",
                "Conclusions",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-MOLECULAR_PATHOGENESIS_OF_LUNG_CANCER.pdf-d446a05d",
        "document": "This scientific article reviews the molecular pathogenesis of lung cancer, focusing on genetic alterations in respiratory cells that lead to tumor development and metastasis.  The authors discuss various oncogenes and tumor suppressor genes involved, including RAS, MYC, p53, and RB, highlighting their roles in cell cycle regulation and apoptosis.  The review also explores the molecular basis of individual susceptibility to tobacco carcinogens and the implications for early detection, chemoprevention, and targeted therapies.  Finally, the clinical applications of these molecular findings are discussed, including improved risk prediction, diagnosis, prognosis, and treatment strategies.",
        "metadata": {
            "identifier": "db30b50101bfef0eb1164c646043bd901f5fb2cd87835fea9ea37e618b75c0ee",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:53.263712+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\MOLECULAR PATHOGENESIS OF LUNG CANCER.pdf",
            "name": "MOLECULAR PATHOGENESIS OF LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Molecular Pathogenesis",
                "Oncogenes",
                "Tumor Suppressor Genes",
                "Apoptosis",
                "Cell Cycle Regulation",
                "Tobacco Carcinogens",
                "Chemoprevention",
                "Targeted Therapies"
            ],
            "author": "Kwun M. Fong, Yoshitaka Sekido, John D. Minna",
            "timestamp": "September 21, 1999",
            "headings": [
                "Molecular alterations in lung cancer cells",
                "Markers of genetic instability",
                "Specific molecular alterations in lung cancer cells",
                "Growth stimulation and oncogenes",
                "Gastrin-releasing peptide (GRP)/bombesin (BN) autocrine loop",
                "ERBB family",
                "Other membrane tyrosine kinases",
                "Nicotine and opioid receptors",
                "RAS",
                "MYC",
                "Tumor suppressor genes (TSGs)",
                "p53",
                "p16-cyclin D1-CDK4-RB pathway",
                "Other candidate TSGs",
                "Apoptosis",
                "Telomerase activity",
                "Aberrant methylation",
                "Angiogenesis and metastases",
                "Molecular alterations in normal and preneoplastic at-risk respiratory cells",
                "Inherited lung cancer susceptibility",
                "Clinical implications"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Ongoing_challenges_in_implementation_of_lung_cancer_screening.pdf-b35aeaa8",
        "document": "This review article discusses the challenges in implementing lung cancer screening (LCS) programs, focusing on the selection of high-risk individuals, standardization of nodule classification, radiologist training, optimization of screening intervals, and the management of ancillary findings.  The authors highlight the importance of addressing the psychological impact of screening and the need for smoking cessation counseling.  Several studies demonstrating the efficacy of LCS with low-dose computed tomography (LDCT) are reviewed, along with various strategies for improving program implementation and reducing false positives. The article concludes by emphasizing the need for further research and standardization in LCS protocols.",
        "metadata": {
            "identifier": "fb2c0911c2062f5d7125646694e1a74f11e306b8f46c6aae1ee60424131c9c5b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:11:59.046318+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Ongoing challenges in implementation of lung cancer screening.pdf",
            "name": "Ongoing challenges in implementation of lung cancer screening.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Screening",
                "Low-dose Computed Tomography (LDCT)",
                "Nodule Management",
                "False Positives",
                "Smoking Cessation",
                "Quality of Life",
                "Radiologist Training"
            ],
            "author": [
                "Katharina Martini",
                "Guillaume Chassagnon",
                "Thomas Frauenfelder",
                "Marie-Pierre Revel"
            ],
            "timestamp": "January 28, 2021",
            "headings": [
                "Abstract",
                "Introduction",
                "Adherence of high-risk individuals",
                "Optimization of the population to be screened",
                "Screening interval and duration of screening",
                "Quality of screening, radiologists’ expertise",
                "Management of screen-detected nodules, limitation of the overdiagnosis risk",
                "Impact on quality of life",
                "Management of ancillary findings",
                "Association to smoking cessation",
                "Conclusions",
                "Acknowledgments",
                "Footnote",
                "Conflicts of Interest",
                "Ethical Statement",
                "Open Access Statement",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Recent_Advances_in_Targeting_ROS1_in_Lung_Cancer.pdf-cb4b1af8",
        "document": "This accepted manuscript reviews recent advances in targeting ROS1 in lung cancer.  The authors discuss the biology and diagnosis of ROS1-rearranged non-small cell lung cancer (NSCLC), focusing on crizotinib and emerging treatment options.  Mechanisms of crizotinib resistance are explored, highlighting the need for novel ROS1 inhibitors.  The review concludes by outlining a current treatment approach and future research directions, emphasizing the importance of standardized diagnosis and treatment globally.",
        "metadata": {
            "identifier": "ac1bc4e9454b968b27726f0221e1bbf93674fd5e785634543cbf068949b9c41a",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:12:07.787677+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Recent Advances in Targeting ROS1 in Lung Cancer.pdf",
            "name": "Recent Advances in Targeting ROS1 in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ROS1",
                "Lung Cancer",
                "NSCLC",
                "Crizotinib",
                "Tyrosine Kinase Inhibitors",
                "Drug Resistance",
                "Targeted Therapy",
                "Oncogene"
            ],
            "author": "Jessica J. Lin, MD, Alice T. Shaw, MD, PhD",
            "timestamp": "August 8, 2017",
            "headings": [
                "Recent Advances in Targeting ROS1 in Lung Cancer",
                "Abstract",
                "Introduction",
                "ROS1 Function",
                "ROS1 Gene Fusions in Cancer",
                "Clinicopathologic Characteristics of ROS1-Rearranged Lung Cancer",
                "Clinical Detection of ROS1 Fusions",
                "ROS1-Targeted Therapies in Lung Cancer",
                "Crizotinib",
                "Resistance to Crizotinib",
                "Other ROS1 Inhibitors in Development",
                "Ceritinib",
                "Brigatinib",
                "Lorlatinib",
                "Entrectinib",
                "Cabozantinib",
                "DS-6051b",
                "TPX-0005",
                "Our current approach",
                "Conclusions and Future Directions",
                "Grant Support",
                "References",
                "Figure Legends",
                "Table 1"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Recent_Trends_in_Lung_Cancer_Mortality_in_the_United_States.pdf-b3aab144",
        "document": "This study examines recent trends in lung cancer mortality in the United States from 1970 to 1997, focusing on birth cohorts after 1950.  Using age-period-cohort analyses, researchers found a surprising moderation in the decrease of lung cancer mortality for those born after 1950, possibly linked to increased teenage smoking initiation rates.  A statistically significant decrease in the slope of the calendar-period trend was also observed after 1990, potentially due to reduced tobacco carcinogens and increased smoking cessation.  The findings highlight the impact of teenage smoking and the long-term benefits of tobacco control programs.",
        "metadata": {
            "identifier": "84b8ea84926fa652796f124c063663adbe87f2be6d5fe1f46e9d151009c07e0c",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:12:12.805041+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Recent Trends in Lung Cancer Mortality in the United States.pdf",
            "name": "Recent Trends in Lung Cancer Mortality in the United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Mortality",
                "Birth Cohort",
                "Smoking",
                "Age-Period-Cohort Analysis",
                "Teenage Smoking",
                "Tobacco Control",
                "Cancer Trends",
                "Marijuana Smoking"
            ],
            "author": "Ahmedin Jemal, Kenneth C. Chu, Robert E. Tarone",
            "timestamp": "February 21, 2001",
            "headings": [
                "Background",
                "SUBJECTS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "REFERENCES",
                "NOTES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Targeting_KRAS_in_non_small_cell_lung_cancer.pdf-7686a1aa",
        "document": "This scientific article reviews recent progress and new approaches in targeting KRAS mutations, specifically the KRASG12C mutation, in non-small cell lung cancer (NSCLC).  The authors discuss the biology of KRAS, the history of targeting it (including past failures and recent successes with direct inhibitors), and ongoing efforts involving both monotherapies and combination strategies.  Key challenges remain, such as understanding resistance mechanisms and determining the optimal role of KRAS inhibitors in treatment regimens.  The article concludes by highlighting promising future directions in KRAS-targeted therapies for NSCLC.",
        "metadata": {
            "identifier": "0402a41a7fae36022da7a62090d6d38227fd89070a1538c3edf6d0da3b725d89",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:12:21.094021+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Targeting KRAS in non–small cell lung cancer.pdf",
            "name": "Targeting KRAS in non–small cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "KRAS",
                "KRASG12C",
                "Non-small cell lung cancer (NSCLC)",
                "Targeted therapy",
                "Cancer",
                "Oncogene",
                "Sotorasib",
                "Adagrasib"
            ],
            "author": "M. Reck, D.P. Carbone, M. Garassino, F. Barlesi",
            "timestamp": "June 1, 2021",
            "headings": [
                "Highlights",
                "Abstract",
                "OVERVIEW OF RAS/KRAS-MUTANT LUNG CANCER",
                "KRAS biology: structure, function, and downstream effector pathways",
                "KRAS mutations in lung cancer",
                "Genetic heterogeneity",
                "Prognostic implications of KRAS mutations",
                "HISTORY OF TARGETING KRAS IN LUNG CANCER",
                "Direct targeting of KRAS",
                "Indirect targeting of KRAS",
                "Ongoing Efforts to Target KRAS in NSCLC",
                "Monotherapies",
                "Combination strategies for KRAS-mutant NSCLC",
                "Co-mutations of special interest",
                "WHAT LIES AHEAD?",
                "Table 1. Historical attempts to target KRAS in NSCLC",
                "Table 2. KRAS-targeting agents in clinical or preclinical development in NSCLC",
                "[Figure captions]",
                "Figure 1.",
                "Figure 2.",
                "Figure 3.",
                "Acknowledgments",
                "Author Contributions",
                "Funding",
                "Conflict of interest",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Testing_for_ROS1_in_non-small_cell_lung_cancer.pdf-b27bc9b5",
        "document": "This review article discusses the current state of molecular diagnostics for ROS1-positive non-small cell lung cancer (NSCLC).  It focuses on the detection of ROS1 gene rearrangements, a rare event in NSCLC, and their clinical significance given the effectiveness of crizotinib, an FDA-approved inhibitor.  The authors review various detection methods, including fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and next-generation sequencing (NGS), providing recommendations for optimal testing strategies.  The article highlights the importance of accurate and timely ROS1 testing for optimal patient treatment and emphasizes the need for quality control measures in biomarker testing.",
        "metadata": {
            "identifier": "333c54890d2c47bf27182821550a7ddd166e3d28935741eba2fc1a441f24a689",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:12:28.839099+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Testing for ROS1 in non-small cell lung cancer.pdf",
            "name": "Testing for ROS1 in non-small cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ROS1",
                "Non-small cell lung cancer (NSCLC)",
                "Crizotinib",
                "Fluorescence in situ hybridization (FISH)",
                "Immunohistochemistry (IHC)",
                "Next-generation sequencing (NGS)",
                "Biomarker",
                "Tyrosine kinase inhibitor"
            ],
            "author": "Lukas Bubendorf et al.",
            "timestamp": "2 August 2016",
            "headings": [
                "Abstract",
                "Introduction",
                "Rationale for targeting ROS1 fusions in NSCLC",
                "Efficacy and safety of ROS1 inhibitor therapy",
                "Detection of ROS1 gene rearrangements",
                "Fluorescence in situ hybridization",
                "Immunohistochemistry",
                "Non-in situ technologies",
                "Concordance between FISH, IHC and PCR",
                "General recommendations for ROS1 testing",
                "Guidance on the use of controls",
                "Pre-analytical variables and factors affecting quality of biopsies and surgical samples",
                "External quality assessment",
                "Integration of ROS1 into current testing algorithms",
                "Conclusions",
                "Acknowledgments",
                "Compliance with ethical standards",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_genetics_and_biology_of_KRAS_in_lung_cancer.pdf-53534343",
        "document": "This review article from the Chinese Journal of Cancer focuses on KRAS mutations in lung cancer, exploring their clinical relevance, genetic basis, and implications for treatment.  The authors discuss the complex functions of KRAS in tumorigenesis, highlighting the importance of both mutant and wild-type KRAS in cancer development.  They also review current challenges in developing effective KRAS-targeted therapies, including the limitations of existing approaches and the potential of novel strategies like synthetic lethality.  The article emphasizes the need for further research to bridge the gap between molecular understanding and clinical applications.",
        "metadata": {
            "identifier": "7238bce8b7f5ed121f756d9754fcde005a9f6f3a68207cfda28f790c1339a51d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:12:35.296567+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The genetics and biology of KRAS in lung cancer.pdf",
            "name": "The genetics and biology of KRAS in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "KRAS",
                "RAS",
                "lung cancer",
                "oncogene",
                "tumorigenesis",
                "mutations",
                "therapies",
                "mouse models",
                "synthetic lethality"
            ],
            "author": "Peter M. K. Westcott and Minh D. To",
            "timestamp": "2012-07-27",
            "headings": [
                "Abstract",
                "RAS Signaling",
                "KRAS Mutations in Human Lung Cancer",
                "Insights from Mouse Models of Kras-driven NSCLC",
                "The Tumor Suppressor Function of Kras and Implications for Lung Cancer Susceptibility",
                "Isoform-specific Functions of Kras in Lung Carcinogenesis",
                "The Challenges and Future of Therapeutics for KRAS-mutant NSCLC",
                "Conclusions",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_lung_microenvironment_regulator_of_tumor_growth.pdf-c4044e97",
        "document": "This review article discusses the lung tumor microenvironment (TME) and its crucial role in lung cancer growth and metastasis.  It highlights recent advancements in understanding how the TME, including cancer-associated fibroblasts, extracellular matrix, and immune cells, contributes to carcinogenesis and influences responses to therapies. The authors also explore the potential of targeting TME components for developing novel diagnostic and therapeutic strategies against lung cancer.  Furthermore, the review examines the lung's role as a frequent site of metastasis from extrapulmonary cancers and the formation of pre-metastatic niches.",
        "metadata": {
            "identifier": "5f2e594c2ecee0d87ff0995293856bc79e7209d6466a3e1b3519686f5e9c80b0",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:12:56.595009+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The lung microenvironment regulator of tumor growth.pdf",
            "name": "The lung microenvironment regulator of tumor growth.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Tumor Microenvironment",
                "Metastasis",
                "Immunotherapy",
                "Angiogenesis",
                "Cancer-associated fibroblasts",
                "Immune checkpoint inhibitors",
                "Pre-metastatic niche"
            ],
            "author": "Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao, Jeffrey L. Port, Ashish Saxena, Brendon Stiles, Timothy McGraw, and Vivek Mittal",
            "timestamp": "Published online 10 December 2018",
            "headings": [
                "Abstract",
                "Lung cancer is the leading cause of cancer-related mortality",
                "In the past decade, the central role of the tumour microenvironment (TME) in the initiation and progression of primary de novo lung carcinoma has been recognized",
                "In this Review, we summarize recent advances showing how the specialized lung TME supports both primary lung cancer and metastasis from extrapulmonary carcinoma and discuss how the mechanistic understanding of aberrant molecular signalling networks stimulated by tumour–stromal interactions has the potential to provide novel diagnostic, prognostic and therapeutic opportunities.",
                "The altered TME landscape",
                "Cancer-associated fibroblasts",
                "Extracellular matrix",
                "Angiogenesis",
                "The immune TME",
                "The lung as a site of metastasis",
                "The lung TME as a target for therapy",
                "Antiangiogenic therapies",
                "Anti-inflammatory therapies",
                "Immunotherapies",
                "ICI monotherapy for metastatic NSCLC",
                "Combination therapy",
                "Resistance to immunotherapies",
                "Pre-metastatic niche targeting",
                "Technological advancements",
                "Developing better lung cancer models",
                "The pre-metastatic niche in the clinic",
                "The TME in precision medicine",
                "Conclusion",
                "Acknowledgements",
                "Author contributions",
                "Competing interests",
                "RElaTEd links",
                "Publisher’s note",
                "Supplementary information"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Role_of_Tumor_Inflammatory.pdf-b5987ecc",
        "document": "This review article examines the role of the tumor inflammatory microenvironment (TME) in lung cancer development and metastasis.  It details the involvement of inflammatory cells (macrophages, neutrophils), cytokines (IL-1β, TNF-α, IL-6, TGF-β), and signaling pathways (NF-κB, STAT3) in promoting tumor growth, angiogenesis, immune escape, and epithelial-mesenchymal transition (EMT). The authors discuss the link between chronic inflammation, infections, and lung cancer risk, highlighting potential therapeutic targets for cancer treatment based on modulating the inflammatory TME.  The review concludes by emphasizing the need for further research to develop effective anti-cancer therapies targeting the inflammatory microenvironment.",
        "metadata": {
            "identifier": "ea7226a8bfeb1371ed6fa92b128ef3194af7260a6d26cc30c4672f0d03a650ce",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:13:04.347987+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The Role of Tumor Inflammatory.pdf",
            "name": "The Role of Tumor Inflammatory.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tumor Microenvironment",
                "Inflammation",
                "Lung Cancer",
                "Metastasis",
                "Immune Escape",
                "NF-κB",
                "STAT3",
                "Cytokines",
                "Angiogenesis",
                "EMT"
            ],
            "author": "Zhaofeng Tan, Haibin Xue, Yuli Sun, Chuanlong Zhang, Yonglei Song, Yuanfu Qi",
            "timestamp": "17 May 2021",
            "headings": [
                "REVIEW",
                "INTRODUCTION",
                "INFLAMMATION AND LUNG CANCER: A MULTIFACETED LINK",
                "INFLAMMATORY CELLS, CYTOKINES, AND PATHWAYS ASSOCIATED WITH LUNG CANCER",
                "Inflammatory Cells Associated With Lung Cancer",
                "Inflammatory Cytokines Associated With Lung Cancer",
                "Inflammation-Related Signal Pathways of Associated With Lung Cancer",
                "MECHANISMS OF TUMOR INFLAMMATORY MICROENVIRONMENT IN PROMOTING THE DEVELOPMENT AND METASTASIS OF LUNG CANCER",
                "Immune Escape",
                "Tumor Angiogenesis",
                "Epithelial-To-Mesenchymal Transition",
                "Anti-apoptosis",
                "PROGRESS IN THE TREATMENT OF LUNG CANCER BASED ON INFLAMMATION AND INFLAMMATORY MICROENVIRONMENT",
                "FUTURE OUTLOOK AND CONCLUSION",
                "AUTHOR CONTRIBUTIONS",
                "FUNDING",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Tumor_Microenvironment.pdf-41066cee",
        "document": "This scientific article reviews the tumor microenvironment (TME) in non-small-cell lung cancer (NSCLC), focusing on hypoxia and its impact on treatment response.  The authors discuss the significance of hypoxia in NSCLC progression and the challenges in targeting hypoxic cells for therapeutic gain.  Various imaging modalities for assessing hypoxia and tumor vasculature are explored, along with strategies to modulate the TME to improve radiation response.  The article concludes by highlighting the need for further clinical studies to validate the findings from preclinical models.",
        "metadata": {
            "identifier": "14fef9ed7e5199230c06002795aa21cbdb48214aa8a45097ac81a20bf9b18feb",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:13:10.288429+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\The Tumor Microenvironment.pdf",
            "name": "The Tumor Microenvironment.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tumor Microenvironment",
                "Non-small-cell lung cancer (NSCLC)",
                "Hypoxia",
                "Radiotherapy",
                "Angiogenesis",
                "Imaging",
                "EGFR Inhibitors",
                "PI3K/Akt Pathway"
            ],
            "author": "Edward E. Graves, PhD, Amit Maity, MD, PhD, and Quynh-Thu Le, MD",
            "timestamp": "2010",
            "headings": [
                "The Tumor Microenvironment in Non–Small-Cell Lung Cancer",
                "Significance of Hypoxia in Lung Cancers",
                "Targeting Hypoxia in NSCLC",
                "Imaging the Microenvironment of Lung Cancer",
                "Perfusion and Angiogenesis Imaging",
                "Hypoxia Imaging",
                "Altering the TME to Increase Radiation Response",
                "HIF-1 and VEGF as Targets for Radiosensitization",
                "EGFR Inhibitors",
                "The Phosphatidylinositol 3-Kinase/Akt Pathway",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Updated_statistics_of_lung_and_bronchus_cancer_in_United_States.pdf-8e52a073",
        "document": "This editorial analyzes updated statistics on lung and bronchus cancer in the United States for 2018, highlighting it as the leading cause of cancer mortality globally.  The authors discuss the declining incidence rates in males and the persistent disparities based on sex, race, and geographic location.  Despite improvements in treatment, the 5-year survival rate remains low, emphasizing the need for continued tobacco control efforts and multi-dimensional interventions to address health disparities.  The data is sourced from the American Cancer Society and the Centers for Disease Control and Prevention.",
        "metadata": {
            "identifier": "6e1a86f8d44dadcabdd84601fcd1b594ec47b94cdace0aa1f4015b05a62cdaad",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:13:12.877441+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\Updated statistics of lung and bronchus cancer in United States.pdf",
            "name": "Updated statistics of lung and bronchus cancer in United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Bronchus Cancer",
                "Cancer Statistics",
                "Mortality Rates",
                "Tobacco Control",
                "Health Disparities",
                "Survival Rate",
                "United States"
            ],
            "author": "Gabrielle Boloker, Cong Wang, Jianrong Zhang",
            "timestamp": "March 2018",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-US_Lung_Cancer_Trends_by_Histologic_Type.pdf-2ba02d18",
        "document": "This study investigates US lung cancer incidence trends from 1977 to 2010, analyzing data by histologic type, demographic characteristics, and smoking prevalence.  Overall lung cancer rates are declining, but trends vary significantly by sex, race/ethnicity, and cancer type.  Squamous and small cell carcinoma rates declined, while adenocarcinoma rates increased after 2005.  The study highlights the impact of historical smoking patterns and changing cigarette composition on lung cancer incidence.",
        "metadata": {
            "identifier": "1dfbb331bf82da0e523207948b6aa047e2256897a00c286bf682d8808ad89a13",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:13:17.322054+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Current aspects\\US Lung Cancer Trends by Histologic Type.pdf",
            "name": "US Lung Cancer Trends by Histologic Type.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Incidence",
                "Histology",
                "Epidemiology",
                "Smoking",
                "Trends",
                "Adenocarcinoma",
                "Squamous Cell Carcinoma",
                "SEER"
            ],
            "author": "Denise Riedel Lewis, David P. Check, Neil E. Caporaso, William D. Travis, Susan S. Devesa",
            "timestamp": "August 11, 2014",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "CONCLUSIONS",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "FUNDING SUPPORT",
                "CONFLICT OF INTEREST DISCLOSURES",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_metabolomic_approach_to_lung_cancer.pdf-069fccbb",
        "document": "This scientific article details a metabolomic study on lung cancer, investigating serum and tissue metabolite alterations in patients compared to healthy controls.  Researchers used gas chromatography-mass spectrometry (GC/MS) to analyze samples, identifying significant changes in various metabolites related to the TCA cycle, amino acids, and fatty acids.  Partial least squares discriminant analysis (PLS-DA) was employed to distinguish between disease stages and histological subtypes. The findings suggest that metabolite patterns could serve as novel diagnostic tools for lung cancer.",
        "metadata": {
            "identifier": "47d49d279b971f50d80069c31390e4aea9e2f94e4b0d45e61d7e88254cbd65a8",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:13:24.821360+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\A metabolomic approach to lung cancer.pdf",
            "name": "A metabolomic approach to lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Metabolomics",
                "GC/MS",
                "PLS-DA",
                "Biomarker",
                "Metabolite",
                "Tumor Markers",
                "TCA cycle"
            ],
            "author": "Suya Hori, Shin Nishiumi, Kazuyuki Kobayashi, et al.",
            "timestamp": "2011",
            "headings": [
                "1. Introduction",
                "2. Materials and methods",
                "2.1. Sample collection",
                "2.2. Serum collection and preparation",
                "2.3. Evaluation of the intra-day and inter-day variances for serum metabolites",
                "2.4. Tissue collection and preparation",
                "2.5. GC/MS analysis",
                "2.6. Data processing",
                "2.7. Statistics",
                "3. Results",
                "3.1. Subject characteristics",
                "3.2. Metabolite profiling of lung cancer",
                "3.3. Alterations in the levels of metabolites involved in the TCA cycle",
                "3.4. Alterations in the levels of amino acids and their derivatives",
                "3.5. Alterations in the levels of metabolites of fatty acids, nucleotides and others",
                "3.6. Serum metabolites characterizing disease stage",
                "3.7. Serum metabolites characterizing histological type",
                "3.8. Sensitivities of conventionally applied tumor markers and serum metabolites",
                "3.9. Evaluation of the intra-day and inter-day variances for serum metabolites",
                "4. Discussion",
                "5. Conclusion",
                "Funding source",
                "Conflict of interest statement",
                "Acknowledgments",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Advances_in_Lung_Cancer_Treatment_Using_Nanomedicines.pdf-bf1a6dc4",
        "document": "This review article discusses the advancements in lung cancer treatment using nanomedicines.  It focuses on various types of overexpressed receptors in lung cancer and different nanoparticle targeting approaches for drug delivery.  The authors provide a comprehensive overview of nanocarrier-mediated drug delivery systems, including liposomes, polymeric nanoparticles, dendrimers, nanoemulsions, carbon nanotubes, gold nanoparticles, magnetic nanoparticles, solid lipid nanoparticles, hydrogels, and quantum dots.  The review highlights the advantages of nanotechnology in improving drug bioavailability, stability, and targeted delivery, ultimately aiming to enhance therapeutic efficacy and reduce side effects.",
        "metadata": {
            "identifier": "9bdc7806661586142a9bb3350fd5244db48ad3cd6c054c5631fbc3f1ca1037e8",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:13:50.750339+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Advances in Lung Cancer Treatment Using Nanomedicines.pdf",
            "name": "Advances in Lung Cancer Treatment Using Nanomedicines.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Nanomedicine",
                "Drug Delivery",
                "Nanoparticles",
                "Targeted Therapy",
                "Theranostics",
                "Receptors",
                "Bioavailability"
            ],
            "author": "Akshansh Sharma, Devanshi Shambhwani, Sadanand Pandey, Jay Singh, Hauzel Lalhlenmawia, Murali Kumarasamy, Sachin Kumar Singh, Dinesh Kumar Chellappan, Gaurav Gupta, Parteek Prasher, Kamal Dua, and Deepak Kumar",
            "timestamp": "December 29, 2022",
            "headings": [
                "INTRODUCTION",
                "OVEREXPRESSED RECEPTORS",
                "2.1. Epidermal Growth Factor Receptor (EGFR)",
                "2.2. Growth Hormone Receptor (GHR)",
                "2.3. Folate Receptors",
                "2.4. Vascular Endothelial Growth Factor Receptors (VEGFR)",
                "2.5. Luteinizing Hormone-Releasing Hormone Receptor (LHRHR)",
                "2.6. Fibroblast Growth Factor Receptor (FGFR)",
                "2.7. Cluster of Differentiation 44 (CD44)",
                "2.8. Integrins",
                "2.9. Mer or Axl as Receptor Tyrosine Kinase (RTK)",
                "2.10. Interleukin-22 Receptor",
                "2.11. Adenosine Receptors (AR)",
                "2.12. Chemotactic Cytokine CXCR4 Receptor",
                "2.13. Bombesin Receptor",
                "2.14. PETA-3/CD151",
                "2.15. Sigma (σ) Receptors",
                "2.16. Anaplastic Lymphoma Kinase (ALK) Receptors",
                "2.17. ROS Proto-oncogene 1, Tyrosine Kinase Receptor",
                "TARGETING APPROACH OF NANOCARRIER",
                "3.1. Receptor-Based Targeting",
                "3.2. Passive Targeting",
                "3.3. Stimuli-Responsive System-Based Targeting",
                "NANOCARRIER-MEDIATED DRUG DELIVERY SYSTEMS",
                "4.1. Liposomes",
                "4.2. Polymeric Nanoparticles",
                "4.3. Dendrimers",
                "4.4. Nanoemulsions",
                "4.5. Micelles",
                "4.6. Carbon Nanotubes (CNTs)",
                "4.7. Gold Nanoparticles (AuNPs)",
                "4.8. Magnetic Nanoparticles (MNPs)",
                "4.9. Solid Lipid Nanoparticles (SLNs)",
                "4.10. Hydrogels",
                "4.11. Quantum Dots (QDs)",
                "4.12. Inhalational",
                "DIAGNOSTIC AGENTS USED FOR LUNG CANCER",
                "DRUG DELIVERY CHANGES",
                "FUTURE PERSPECTIVES",
                "CONCLUSION"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-An_Overview_of_Lung_Cancer_Genomics_and_Proteomics.pdf-c14ae69d",
        "document": "This translational review article examines the application of genomics and proteomics to understand lung cancer.  The authors review studies using microarray and proteomic technologies to classify lung tumors, identify molecular targets, and correlate gene/protein expression with clinical outcomes.  Key findings include the identification of gene expression profiles that predict patient survival and the potential for improved diagnosis and treatment through molecular profiling.  The review highlights the need for larger sample sizes and validation studies to translate these findings into clinical practice.",
        "metadata": {
            "identifier": "95120e9e5229e72cc9fbe5d991525c028bfcf47c3ce0d0a8fa3aa82b81358635",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:13:56.164818+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\An Overview of Lung Cancer Genomics and Proteomics.pdf",
            "name": "An Overview of Lung Cancer Genomics and Proteomics.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Genomics",
                "Proteomics",
                "Microarray Analysis",
                "Gene Expression Profiling",
                "Biomarkers",
                "Prognosis",
                "Molecular Targets",
                "Classification",
                "Survival"
            ],
            "author": "Courtney A. Granville and Phillip A. Dennis",
            "timestamp": "December 16, 2004",
            "headings": [
                "Keywords",
                "THE OMICS OF LUNG CANCER",
                "Classification of Tumors: Class Prediction and Class Discovery",
                "Correlation of Gene and Protein Expression Profiles with Prognosis",
                "Correlation of Gene Expression Profiles with Smoking Status and Lung Cancer",
                "Identification of Novel Molecular Targets by Gene and Protein Expression Profiling",
                "Analysis of Relevant Murine Models",
                "Analysis of Lung Cancer Cells In Vitro",
                "DISCUSSION",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Comprehensive_genomic_profiles.pdf-eac38c21",
        "document": "This research article presents a comprehensive genomic analysis of small cell lung cancer (SCLC), a highly lethal form of cancer.  The study sequenced the genomes of 110 human SCLCs and discovered that nearly all tumors showed bi-allelic inactivation of TP53 and RB1.  Researchers identified somatic genomic rearrangements of TP73 creating an oncogenic version of this gene, and inactivating mutations in NOTCH family genes.  The findings uncover key biological processes and identify potential therapeutic targets for SCLC.",
        "metadata": {
            "identifier": "7440dcb441bb5f551cd174d408faad2c821f4452d36a01b3ad7547525b62bce9",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:14:09.262284+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Comprehensive genomic profiles.pdf",
            "name": "Comprehensive genomic profiles.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Small Cell Lung Cancer",
                "SCLC",
                "Genomic Sequencing",
                "TP53",
                "RB1",
                "TP73",
                "NOTCH",
                "Oncogene",
                "Tumor Suppressor",
                "Targeted Therapy"
            ],
            "author": "Julie George1*,JingShanLim2*,SeJinJang3, et al.",
            "timestamp": "Published online 13 July 2015",
            "headings": [
                "ARTICLE",
                "Samples and clinical data",
                "Recurrent somatic alterations in SCLC",
                "Universal inactivation of TP53 and RB1",
                "Oncogenic genomic events affecting TP73",
                "Tumour suppressor roles of Notch in SCLC",
                "Discussion",
                "Methods"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-CRISPR_Cas9_molecular_tool_for_gene_therapy.pdf-a8e4fdf0",
        "document": "This review article discusses the use of CRISPR/Cas9 gene editing technology for the treatment of lung cancer.  The authors highlight the limitations of current lung cancer therapies, emphasizing the need for novel approaches to improve patient survival rates.  CRISPR/Cas9 is presented as a potential tool for targeted gene therapy, offering the possibility of long-term repression or activation of genes involved in lung cancer development. The review explores various applications of CRISPR/Cas9, including gene knockout, activation, and epigenetic modulation, and discusses its potential advantages and challenges.",
        "metadata": {
            "identifier": "c90f3f69c8bbe4fa5d8dca17541bbf8ff8a2b55a7b76d78499306396a1d0a253",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:14:15.260536+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\CRISPR Cas9 molecular tool for gene therapy.pdf",
            "name": "CRISPR Cas9 molecular tool for gene therapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "CRISPR/Cas9",
                "Lung Cancer",
                "Gene Therapy",
                "Genome Editing",
                "Epigenome",
                "Targeted Therapy",
                "Gene Modulation",
                "Cancer Treatment"
            ],
            "author": "M Sachdeva, N Sachdeva, M Pal, N Gupta, I A Khan, M Majumdar, A Tiwari",
            "timestamp": "23 October 2015",
            "headings": [
                "INTRODUCTION",
                "LUNG CANCER",
                "TYPE II CRISPR/Cas9 SYSTEM",
                "CRISPR/Cas9 SYSTEM AS A GENOME MODULATION TOOL IN HUMANS",
                "ENGINEERING dCas9",
                "VARIED UTILIZATION OF CRISPR/Cas9 IN CANCER STUDY AND TREATMENTS",
                "FUTURE DIRECTIONS",
                "CONFLICT OF INTEREST",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Delivery_of_genome-editing_biomacromolecules_for_treatment_of_lung.pdf-bcaf126e",
        "document": "This scientific article reviews the delivery of genome-editing biomacromolecules, specifically CRISPR/Cas9, for treating lung genetic disorders like cystic fibrosis (CF) and α-1 antitrypsin deficiency (AATD).  The authors discuss current treatment options, CRISPR-based strategies, and various administration routes (oral, intravenous, intratracheal/intranasal, inhalation).  Aerosol delivery is highlighted as a promising method for CRISPR/Cas9 delivery to the lungs.  Finally, the article addresses current challenges and future outlooks in this field.",
        "metadata": {
            "identifier": "3beeee71ec253ca3a2eac3853a09c8edd9f66c7a028a2aa8d389bf492e830083",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:14:28.807498+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Delivery of genome-editing biomacromolecules for treatment of lung.pdf",
            "name": "Delivery of genome-editing biomacromolecules for treatment of lung.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "CRISPR/Cas9",
                "Genome Editing",
                "Lung Genetic Disorders",
                "Cystic Fibrosis",
                "α-1 Antitrypsin Deficiency",
                "Aerosol Delivery",
                "Gene Therapy",
                "Viral Vectors",
                "Non-viral Vectors"
            ],
            "author": "Tao Wan and Yuan Ping",
            "timestamp": "Accepted 8 May 2020",
            "headings": [
                "1. Introduction",
                "2. Lung genetic disorders and current therapeutic options",
                "2.1. Cystic fibrosis",
                "2.1.1. Current available therapeutic options",
                "2.1.2. Traditional gene therapy",
                "2.1.3. Repairing CFTR mutations: gene correction with genome-editing nucleases",
                "2.2. AATD",
                "2.2.1. Traditional therapeutic approaches",
                "2.2.2. Recent development of genome editing for AATD",
                "2.3. Lung cancer",
                "2.3.1. CRISPR/Cas9-mediated genome-editing of proto-oncogenes",
                "2.3.2. CRISPR/Cas9-mediated genome-editing of tumor-suppressor genes",
                "2.3.3. CRISPR/Cas9-mediated genome-editing of chemotherapy resistance-related genes",
                "2.4. COPD and asthma",
                "2.4.1. Regaining steroid sensitivity in asthma and COPD",
                "3. Delivery technologies for genome editing",
                "3.1. Viral delivery of genome editing systems",
                "3.2. Non-viral delivery of genome-editing systems",
                "3.2.1. Nanoparticle-mediated delivery",
                "3.2.2. Physical methods",
                "4. Delivery routes for genome editing of the lung genetic disorders",
                "4.1. Oral administration",
                "4.2. Intravenous injection",
                "4.3. Intratracheal/intranasal instillation",
                "4.4. Inhalation delivery",
                "5. Summary and future outlook",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Metabolomics_of_lung_cancer.pdf-608fd961",
        "document": "This review article focuses on the application of metabolomics in lung cancer research, specifically examining analytical platforms and their use in early detection, biomarker discovery, and mechanism exploration.  The authors discuss various sample collection and metabolite extraction methods, highlighting the importance of pre-analytical factors.  Different analytical platforms, including NMR spectroscopy, LC-MS, GC-MS, and CE-MS, are compared and contrasted in terms of their strengths and weaknesses for lung cancer metabolomics.  The review concludes by summarizing the metabolic disturbances observed in lung cancer and their potential as diagnostic and prognostic biomarkers.",
        "metadata": {
            "identifier": "fe1da4e0c30894c657ed3b540cce066daf1333d4e6659ad85eb6a8b1be285d29",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:14:36.301991+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Metabolomics of lung cancer.pdf",
            "name": "Metabolomics of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Metabolomics",
                "Biomarkers",
                "NMR Spectroscopy",
                "LC-MS",
                "GC-MS",
                "CE-MS",
                "Sample Preparation",
                "Metabolic Pathways"
            ],
            "author": "Hamada A. A. Noreldeen, Xinyu Liu, Guowang Xu",
            "timestamp": "January 2020",
            "headings": [
                "INTRODUCTION",
                "SAMPLE COLLECTION AND METABOLITE EXTRACTION METHODS FOR LUNG CANCER METABOLOMICS STUDY",
                "ANALYTICAL PLATFORMS OF METABOLOMICS",
                "3.1 NMR-based metabolomics",
                "3.2 LC–MS",
                "3.3 GC–MS",
                "3.4 CE–MS",
                "3.5 MALDI-MS",
                "DISTURBED METABOLISM IN LUNG CANCER",
                "4.1 TCA cycle and glycolysis",
                "4.2 Amino acid metabolism",
                "4.3 Lipid metabolism",
                "CONCLUDING REMARKS",
                "ACKNOWLEDGMENTS",
                "CONFLICT OF INTEREST",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-mRNA_Cancer_Vaccines.pdf-5f942357",
        "document": "This scientific article reviews the use of mRNA cancer vaccines, focusing on the RNActive® technology and its applications.  The authors discuss the advantages of mRNA vaccines over DNA and protein-based vaccines, including their safety profile and flexible production process.  Different approaches are explored, such as personalized vaccines targeting neoantigens and cellular vaccines using mRNA-pulsed dendritic cells or CAR T cells.  Preclinical and clinical data from various trials are presented, highlighting the potential and ongoing research in this field.",
        "metadata": {
            "identifier": "7a4fe5dccc381a016f9e9da308236ed2bbd97b9472fa1d446d94e47e6d046674",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:14:42.843752+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\mRNA Cancer Vaccines.pdf",
            "name": "mRNA Cancer Vaccines.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "mRNA vaccines",
                "cancer immunotherapy",
                "neoantigens",
                "dendritic cells",
                "CAR T cells",
                "RNActive®",
                "tumor-associated antigens",
                "personalized medicine"
            ],
            "author": "Katja Fiedler, Sandra Lazzaro, Johannes Lutz, Susanne Rauch and Regina Heidenreich",
            "timestamp": "2016",
            "headings": [
                "1 mRNA Cancer Vaccines",
                "1.1 Introduction",
                "1.2 RNActive® Vaccines",
                "1.2.1 Induction of Antitumor Responses with RNActive® Vaccines",
                "1.2.2 Clinical Studies with RNActive® Vaccines",
                "1.2.3 Combination of RNActive® Vaccines with Chemotherapy or Radiation Therapy",
                "1.2.4 Clinical Study with RNActive® Vaccines in Combination with Radiotherapy",
                "1.2.5 Combination of RNActive® Vaccines with Immune Checkpoint Inhibitors",
                "1.3 Personalized mRNA Vaccines",
                "1.4 Cellular Vaccines: mRNA-Pulsed Dendritic Cells",
                "1.5 CAR T Cells",
                "2 Conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-mRNA_vaccine_for_cancer_immunotherapy.pdf-c3f2e5b2",
        "document": "This review article discusses the development and application of mRNA vaccines for cancer immunotherapy.  The authors detail recent advancements in mRNA structure modification and delivery methods, including lipid nanoparticles (LNPs) and polymers, to overcome challenges like instability and innate immunogenicity.  The review also covers self-amplifying mRNA (SAM) vaccines and their potential advantages.  Finally, it summarizes current clinical trials using mRNA cancer vaccines, highlighting promising therapeutic outcomes and future directions for this field.",
        "metadata": {
            "identifier": "15181cb7fff027788e0f122e429a23e9de327aa2397201a6e216ab3bba56d4f2",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:14:55.556723+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\mRNA vaccine for cancer immunotherapy.pdf",
            "name": "mRNA vaccine for cancer immunotherapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "mRNA vaccine",
                "cancer immunotherapy",
                "lipid nanoparticles (LNPs)",
                "self-amplifying mRNA (SAM)",
                "tumor antigens",
                "antigen-presenting cells (APCs)",
                "neoantigens",
                "personalized vaccine"
            ],
            "author": "Lei Miao, Yu Zhang and Leaf Huang",
            "timestamp": "2021",
            "headings": [
                "Abstract",
                "Introduction",
                "Basic mRNA pharmacology, limitations and advantages",
                "Immunogenicity of mRNA and paradoxical effects in Cancer immunotherapy",
                "Strategies to improve mRNA translation efficiency and overcome the innate immunogenicity",
                "Utilizing the impact of type IIFN for improved mRNA vaccination",
                "Self-amplifying mRNA vaccine, structure, advantages and deliveries",
                "Delivery of mRNA Cancer vaccine",
                "LNP mRNA vaccine from formulation to manufacturing",
                "Polymer-based mRNA delivery system",
                "Peptide-based mRNA delivery system",
                "Other formulations used in mRNA delivery",
                "Injection routes mRNA Cancer vaccines",
                "Clinical overview of mRNA Cancer vaccines",
                "mRNA encoding Immunostimulants",
                "mRNA vaccine encoding tumor associated antigens",
                "mRNA vaccine encoding Neoantigen, personalized vaccine",
                "Conclusion and future perspectives",
                "Abbreviations",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Multi-omics_Data_Integration_Interpretation.pdf-58ee3b62",
        "document": "This review article examines tools and methods for integrating multi-omics data (genomics, transcriptomics, proteomics, metabolomics, etc.) to study complex biological processes.  The authors categorize these tools based on their approach (Bayesian, network, fusion, etc.) and application (disease subtyping, biomarker prediction, biological insight).  Several publicly available multi-omics data repositories and visualization portals are also discussed. The review highlights the challenges and future directions of multi-omics data integration, emphasizing the need for standardized workflows and improved interoperability.",
        "metadata": {
            "identifier": "d49bc7907b77df9f42bd02d7206f8951794f23c1de0484b9fa1641af30b9c8c2",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:15:07.998221+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Multi-omics Data Integration, Interpretation.pdf",
            "name": "Multi-omics Data Integration, Interpretation.pdf",
            "document_type": "pdf",
            "domain_themes": "Bioinformatics",
            "keywords": [
                "multi-omics",
                "data integration",
                "disease subtyping",
                "biomarker prediction",
                "data repositories",
                "integrative analysis",
                "biological pathways",
                "cancer genomics"
            ],
            "author": "Indhupriya Subramanian, Srikant Verma, Shiva Kumar, Abhay Jere, Krishanpal Anamika",
            "timestamp": "2020",
            "headings": [
                "ABSTRACT",
                "Introduction",
                "Omics Data Types and Repositories",
                "Leveraging Multi-omics Data to Derive Actionable Insights",
                "Disease subtyping and classification of samples based on their omics profiles",
                "Bayesian approach",
                "Network approach",
                "Fusion-based approaches",
                "Similarity-based approaches",
                "Other multivariate approaches",
                "Prediction of biomarkers for various applications including diagnostics and driver genes for diseases",
                "Bayesian approach",
                "Network approach",
                "Other multivariate approaches",
                "Deriving insights into disease biology",
                "Bayesian approach",
                "Correlation-based approach",
                "Other multivariate approaches",
                "Other applications of integrating multi-omics data",
                "Personalized medicines",
                "Clinical assessment predictions",
                "Risk prediction and clinical outcome",
                "Comparative analysis and benchmarking of tools",
                "Portals for Visualization and Interpretation of Multi-omics Data Sets",
                "Challenges in Multi-omics Data Integration and Future Perspectives",
                "Conclusions",
                "Acknowledgements",
                "Author Contributions",
                "ReFeRenCeS"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nanomedicine_for_Treatment_of_Lung_Cancer.pdf-67f84f33",
        "document": "This scientific article discusses the use of nanomedicine, specifically nanoparticles, in the treatment of lung cancer.  It explores various nanoparticle formulations, including lipid-based, polymeric, and metal-based nanoparticles, and their applications in drug delivery for lung cancer therapy. The article highlights the advantages of nanoparticles in targeted drug delivery, improved therapeutic efficacy, and reduced toxicity compared to traditional chemotherapy.  However, it also addresses challenges in nanomedicine, such as safety concerns and regulatory hurdles for clinical translation.",
        "metadata": {
            "identifier": "4857d79e4ec27155b360a18e96f3213c0a92ec688bb40fbb547f4d230e7aa75b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:15:12.586662+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Nanomedicine for Treatment of Lung Cancer.pdf",
            "name": "Nanomedicine for Treatment of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Nanomedicine",
                "Lung Cancer",
                "Nanoparticles",
                "Drug Delivery",
                "Chemotherapy",
                "Targeted Therapy",
                "Liposomes",
                "Polymeric Nanoparticles"
            ],
            "author": "Sajid Hussain",
            "timestamp": "2016",
            "headings": [
                "Abstract",
                "Abbreviations",
                "1 Background",
                "2 Nanoparticle Drug Delivery for Lung Cancer Therapy",
                "2.1 Lipid-Based Nanoparticles",
                "2.2 Polymer Conjugates as Nanocarriers",
                "2.3 Other Nanoparticle Systems",
                "3 Challenges and Future Perspective",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nanotechnology_and_Nanomedicine_in_lung_cancer.pdf-8e7c1e1c",
        "document": "This scientific review article discusses the use of nanotechnology and nanomedicine in lung cancer diagnosis and therapy.  It highlights the limitations of conventional methods and explores how nanoparticles (NPs) can improve early detection through enhanced imaging and the isolation of tumor-derived biomarkers.  The article also details the application of NPs in targeted drug delivery, improving the efficacy and reducing the toxicity of cancer treatments.  Challenges associated with clinical translation, such as toxicology and large-scale manufacturing, are also addressed.",
        "metadata": {
            "identifier": "cdfc19a9e6801cc72a4247035dbf4be97dcee1c30eccd1fb8f405171a3b72e48",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:15:19.113331+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Nanotechnology and Nanomedicine in lung cancer.pdf",
            "name": "Nanotechnology and Nanomedicine in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Nanomedicine",
                "Lung Cancer",
                "Diagnosis",
                "Therapy",
                "Nanoparticles",
                "Drug Delivery",
                "Imaging",
                "Biomarkers"
            ],
            "author": "Wei Yin, Feng Pan, Junjie Zhu, Junwu Xu, Diego Gonzalez-Rivas, Meinoshin Okumura, Zhiyong Tang, Yang Yang",
            "timestamp": "October 7, 2021",
            "headings": [
                "1. Introduction",
                "2. Personalized diagnosis of lung cancer",
                "2.1. Nanotechnology for the in vivo diagnosis of lung cancer",
                "2.2. Nanotechnology for the in vitro diagnosis of lung cancer",
                "2.2.1. Tumor-derived DNA in peripheral blood",
                "2.2.2. Tumor-derived DNA in PE",
                "2.2.3. Exosomes",
                "3. Precision nanomedicine for lung cancer",
                "3.1. Drug delivery",
                "3.1.1. Gold nanoparticles",
                "3.1.2. Mesoporous silica nanoparticles",
                "3.1.3. Nanoscale coordination polymers and nanoscale metal–organic frameworks",
                "3.2. Nanotheranostics",
                "4. Improvements in traditional lung cancer diagnosis methods using nanomedicine",
                "5. Improvements in traditional lung cancer treatment methods, using nanomedicine",
                "6. Perspective",
                "Acknowledgments",
                "Compliance with ethics guidelines",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Non-small_cell_lung_cancer_current_treatment_and_future_advances.pdf-d023abfd",
        "document": "This review article discusses the current treatments and future advances in non-small cell lung cancer (NSCLC), the most common type of lung cancer.  It covers various treatment options including surgery, chemotherapy, radiotherapy, and immunotherapy, highlighting the role of biomarker testing in personalizing treatment strategies.  The article also explores the use of immunotherapy, focusing on immune checkpoint inhibitors and vaccine development.  The poor prognosis of lung cancer and the importance of ongoing research are emphasized.",
        "metadata": {
            "identifier": "ec5aed618c0e7c1a4d05785f3d2efd78c11f52d0ff02a95ae6f1af4479073e59",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:15:25.783434+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Non-small cell lung cancer current treatment and future advances.pdf",
            "name": "Non-small cell lung cancer current treatment and future advances.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Chemotherapy",
                "Immunotherapy",
                "Radiotherapy",
                "Biomarker testing",
                "Targeted therapy",
                "EGFR",
                "ALK"
            ],
            "author": "Cecilia Zappa, Shaker A. Mousa",
            "timestamp": "June 2016",
            "headings": [
                "Abstract",
                "Introduction",
                "Risk factors",
                "Current treatment options",
                "Surgery",
                "Adjuvant",
                "Chemotherapy",
                "Radiotherapy",
                "Biomarker testing",
                "Epidermal growth factor receptor (EGFR) gene",
                "KRAS",
                "Anaplastic lymphoma kinase (ALK)",
                "Role of immunotherapy in non-small cell lung cancer",
                "Cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) therapy",
                "Programmed cell death-1 (PD-1) and PD-L1",
                "Immunotherapy through vaccine development",
                "Tumor cell vaccines",
                "Antigen-specific vaccines",
                "Melanoma-associated antigen-A3 (MAGE-A3)",
                "Liposome BLP25 vaccine",
                "CIMAVax EGF",
                "TG4010 (MVA-MUC1-IL-2) vaccine",
                "Conclusions",
                "Acknowledgements",
                "Footnotes",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Proteomics_analysis_in_lung_cancer.pdf-caf29e02",
        "document": "This review article discusses the application of proteomics analysis in lung cancer research.  The authors explore various proteomics technologies, including 2-D gel electrophoresis, mass spectrometry (MALDI-TOF, SELDI-TOF, shotgun proteomics), and protein microarrays, highlighting their strengths and limitations in identifying biomarkers and classifying lung cancer subtypes.  The challenges and opportunities in using proteomics for lung cancer diagnosis, prognosis, and treatment are discussed, emphasizing the need for technological advancements to improve sensitivity and comprehensiveness.  The ultimate goal is to develop individualized therapies based on proteomic profiles.",
        "metadata": {
            "identifier": "6b5816c4456c35c038b89d94106a4010cb20a5ade05f4a337d02e153f9e982d1",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:15:30.046137+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Proteomics analysis in lung cancer.pdf",
            "name": "Proteomics analysis in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Proteomics",
                "Lung Cancer",
                "Biomarkers",
                "Mass Spectrometry",
                "2-D Gel Electrophoresis",
                "Protein Microarrays",
                "Cancer Profiling",
                "Individualized Therapy"
            ],
            "author": "Takefumi Kikuchi and David P. Carbone",
            "timestamp": "2007",
            "headings": [
                "INTRODUCTION",
                "TWO-DIMENSIONAL GELS",
                "MASS SPECTROMETRY INSTRUMENTS FOR PROTEIN PROFILING",
                "MALDI-TOF PROFILING",
                "SHOTGUN PROTEOMICS",
                "PROTEIN MICROARRAY",
                "SUMMARY",
                "ACKNOWLEDGEMENTS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Proteomics_as_a_Method_for_Early_Detection_of_Cancer.pdf-2a38dcc3",
        "document": "This review article examines the application of proteomics to the early detection of lung cancer, focusing on the use of exhaled breath condensate (EBC).  The authors discuss various proteomic technologies, including mass spectrometry and protein microarrays, and their potential for identifying protein biomarkers indicative of lung cancer.  EBC collection is highlighted as a simple, non-invasive method for obtaining lung samples.  While promising, challenges remain in standardizing EBC collection and analysis, and further research is needed before widespread clinical application.",
        "metadata": {
            "identifier": "2aee7db4464a4e79833ddb30e6f605d68209071e458fe4b1f7b3c29b9b578e00",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:15:34.316145+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Proteomics as a Method for Early Detection of Cancer.pdf",
            "name": "Proteomics as a Method for Early Detection of Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Proteomics",
                "Lung Cancer",
                "Exhaled Breath Condensate (EBC)",
                "Biomarkers",
                "Early Detection",
                "Mass Spectrometry",
                "Protein Microarrays",
                "Cancer Screening"
            ],
            "author": "Dean H. Conrad, Jesse Goyette, and Paul S. Thomas",
            "timestamp": "2007",
            "headings": [
                "BACKGROUND",
                "Proteins and Carcinogenesis",
                "Proteomic Technologies",
                "Proteomics and Lung Cancer Screening",
                "EXHALED BREATH CONDENSATE",
                "Collection of EBC",
                "Application of Proteomics to EBC and Lung Cancer",
                "CONCLUSIONS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Safety_and_feasibility_of_CRISPR-edited_T_cells.pdf-efa41169",
        "document": "This Nature Medicine article reports on a Phase I clinical trial evaluating the safety and feasibility of CRISPR-Cas9 gene-edited T cells in treating refractory non-small-cell lung cancer.  The trial met its primary endpoints, demonstrating the treatment's safety and feasibility with mostly grade 1/2 adverse events.  Secondary endpoints, including efficacy, showed a median progression-free survival of 7.7 weeks and overall survival of 42.6 weeks.  The study concludes that CRISPR-Cas9 gene-edited T cell therapy is safe and feasible, but future trials should explore improved gene editing approaches to enhance therapeutic efficacy.",
        "metadata": {
            "identifier": "187f95c0602bc0f3b35b9af69755044ce4a898267b1b172f2868d77783a7fba9",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:00.077501+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Future aspects\\Safety and feasibility of CRISPR-edited T cells.pdf",
            "name": "Safety and feasibility of CRISPR-edited T cells.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "CRISPR-Cas9",
                "gene editing",
                "T cell therapy",
                "non-small-cell lung cancer",
                "PD-1",
                "safety",
                "feasibility",
                "clinical trial",
                "off-target effects"
            ],
            "author": "You Lu, Jianxin Xue, Tao Deng, et al.",
            "timestamp": "Published: xx xx xxxx",
            "headings": [
                "Articles",
                "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer",
                "Patients and treatment",
                "Preparation and evaluation of edited T cells",
                "To study the off-target impact of CRISPR–Cas9 on edited T cell genomes",
                "Safety and clinical outcomes",
                "In vivo tracking of edited T cells",
                "Peripheral TCR clonal diversity",
                "Clinical outcome of patient B-01",
                "Discussion",
                "Methods",
                "Study design and patients",
                "Study endpoints and assessments",
                "CRISPR plasmid construction",
                "Preparation of PD-1-edited T cells",
                "T7E1 cleavage assay and sequencing",
                "Flow cytometry",
                "Long-term cell culture",
                "Detection of off-target sites by WGS analysis",
                "Detection of off-target sites by NGS",
                "Efficiency validation and in vivo tracking of edited T cells",
                "Assessment of TCR clonal diversity",
                "Immunohistochemistry staining",
                "Detection of cytokines",
                "Statistical analysis",
                "Reporting Summary",
                "Data availability",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Cancer_Drug_Development_challenges_in_a_competitive_market.pdf-a474c031",
        "document": "This article discusses the challenges and opportunities in cancer drug development, particularly focusing on the shift from traditional cytotoxic therapies to targeted and novel therapeutics.  It highlights the growth of the oncology market driven by improved diagnostics, an aging population, and increased public awareness.  The authors use the development of bortezomib (Velcade) as a case study of a successful new approach.  The text emphasizes the collaborative nature of drug development and the need to navigate the complexities of the regulatory environment.",
        "metadata": {
            "identifier": "dbd1e00e68d272e46c4e6672fc64753645ff7de030363c84085569356955a696",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:02.596699+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Cancer Drug Development challenges in a competitive market.pdf",
            "name": "Cancer Drug Development challenges in a competitive market.pdf",
            "document_type": "pdf",
            "domain_themes": "Pharmaceutical Science",
            "keywords": [
                "cancer drug development",
                "oncology",
                "targeted therapy",
                "bortezomib",
                "Velcade",
                "FDA drug approval",
                "genotoxic drugs",
                "clinical trials",
                "pharmaceutical industry"
            ],
            "author": "Barry Greene and Michael Kauffman",
            "timestamp": "N/A",
            "headings": [
                "INTRODUCTION",
                "A DOSE OF REALITY",
                "CIRCUMVENTING THE PITFALLS",
                "BORTEZOMIB: A CASE STUDY",
                "TEAM COMPOSITION",
                "A COLLABORATIVE ENTERPRISE"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ComparisonofSalesIncomeandResearchandDevelopmentCosts_for_FDA-ApprovedCancerDrugsSoldbyOriginatorDrugCompanies.pdf-a7937c4f",
        "document": "This observational study compares the income generated from sales of FDA-approved cancer drugs with their estimated research and development (R&D) costs.  The study found that the median income return was significantly higher than the R&D costs, indicating substantial profits for originator companies.  High drug prices, while covering R&D, have limited patient access and impacted healthcare system sustainability. The authors suggest that lowering prices and increasing competition are crucial for improving patient access and fostering innovation.",
        "metadata": {
            "identifier": "c245031cff20b481719c4fc04fe341327b88ba25489fc925e423a78d1f23ed0e",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:08.126238+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\ComparisonofSalesIncomeandResearchandDevelopmentCosts for FDA-ApprovedCancerDrugsSoldbyOriginatorDrugCompanies.pdf",
            "name": "ComparisonofSalesIncomeandResearchandDevelopmentCosts for FDA-ApprovedCancerDrugsSoldbyOriginatorDrugCompanies.pdf",
            "document_type": "pdf",
            "domain_themes": "Health Policy",
            "keywords": [
                "Cancer Drugs",
                "Research and Development Costs",
                "Sales Income",
                "FDA Approval",
                "Drug Pricing",
                "Patient Access",
                "Healthcare Sustainability",
                "Return on Investment"
            ],
            "author": "Kiu Tay-Teo, André Ilbawi, Suzanne R. Hill",
            "timestamp": "January 4, 2019",
            "headings": [
                "Abstract KeyPoints",
                "Introduction",
                "Methods",
                "StudyDesign",
                "DataSources",
                "StatisticalAnalysis",
                "UncertaintyandAssumptions",
                "Results",
                "DataCharacteristics",
                "SalesIncomes",
                "ReturnsonInvestment",
                "SensitivityAnalyses",
                "Discussion",
                "Limitations",
                "Conclusions",
                "ARTICLEINFORMATION",
                "REFERENCES",
                "SUPPLEMENT"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Patent_trend_and_competitive_analysis_of_cancer.pdf-972d9518",
        "document": "This scientific article analyzes patent trends and competitive landscapes in cancer immunotherapy within the United States from 2006-2016.  The authors identified 2,229 patents across 13 subfields, revealing that patent growth in this area outpaces overall patent growth, particularly in cytokine therapies, immune checkpoint inhibitors, and natural killer cell therapies.  Amgen, Novartis, and Chugai Seiyaku are identified as leading patent holders, though the field remains relatively dispersed. The analysis suggests ongoing competition and potential for future collaborations and consolidation within the industry.",
        "metadata": {
            "identifier": "08e077c3830da697a1938a1dee636d2ac1c59a9b6f7121e5619c98f57eca204c",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:13.714237+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Patent trend and competitive analysis of cancer.pdf",
            "name": "Patent trend and competitive analysis of cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "cancer immunotherapy",
                "patent analysis",
                "competitive analysis",
                "patent landscape",
                "immune checkpoint inhibitors",
                "cytokine therapies",
                "biopharmaceutical companies",
                "Amgen",
                "Novartis"
            ],
            "author": "Chia-Lin Pan & Feng-Chi Chen",
            "timestamp": "07 Sep 2017",
            "headings": [
                "Abstract",
                "Introduction",
                "Results and Discussion",
                "Patent trend",
                "Development strategies and relative strengths of the top 15 assignees",
                "Analysis and Perspective",
                "Concluding Remarks",
                "Methods",
                "Patent search and classification",
                "Patent quality analysis",
                "Relative strength analysis",
                "Author Contributions",
                "Declaration of competing interests",
                "Acknowledgement",
                "References",
                "Figure legends",
                "Tables"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pricing_in_the_Market_for_Anticancer_Drugs.pdf-5d7b502a",
        "document": "This Journal of Economic Perspectives article analyzes pricing trends in the US anticancer drug market from 1995 to 2013.  The authors find a significant annual increase in launch prices, even after adjusting for inflation and health benefits. They explore several factors contributing to this trend, including reference pricing, generous third-party coverage, and policies that incentivize price increases to offset discounts. The study highlights the complex interplay between pricing strategies, regulatory policies, and the unique characteristics of the anticancer drug market.",
        "metadata": {
            "identifier": "6140760c23243cbbbfefbfbdcb0d5c1fec569c8e17f4c6fef916bc12b323c7d8",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:20.669152+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Pricing in the Market for Anticancer Drugs.pdf",
            "name": "Pricing in the Market for Anticancer Drugs.pdf",
            "document_type": "pdf",
            "domain_themes": "Economics",
            "keywords": [
                "Anticancer drugs",
                "Drug pricing",
                "Launch prices",
                "Health benefits",
                "Reference pricing",
                "Medicare",
                "Third-party payers",
                "Cost-effectiveness",
                "Market trends",
                "Pharmaceutical industry"
            ],
            "author": "David H. Howard, Peter B. Bach, Ernst R. Berndt, and Rena M. Conti",
            "timestamp": "Winter 2015",
            "headings": [
                "Pricing in the Market for Anticancer Drugs",
                "Drug Pricing Strategies",
                "Anticancer Drugs",
                "Policies Governing Drug Coverage and Reimbursement",
                "Trends in Launch Prices",
                "Price Per Life-Year Gained and Drug Attributes",
                "Sensitivity Checks",
                "Explaining Pricing Trends",
                "Reference Pricing",
                "Required Pricing Discounts",
                "Other Potential Causes of Price Increases",
                "Discussion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Review_of_Current_Policy_Strategies_to_Reduce_US_Cancer_Drug_Costs.pdf-84f14825",
        "document": "This article reviews current policy strategies in the US aimed at reducing the escalating costs of cancer drugs.  The authors focus on Medicare Part B and Part D, examining proposed reforms such as physician reimbursement reform, international drug price benchmarking, and modifications to the 340B drug discount program.  They also discuss the complexities of the Part D rebate system and the challenges of promoting biosimilar competition.  Finally, the article explores the potential of value-based pricing as a mechanism to align drug prices with clinical benefit.",
        "metadata": {
            "identifier": "d3a293ddeb66c022a7fe1e70d5d9af6e706bb874a98680166e9e967e97fada91",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:26.348834+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Review of Current Policy Strategies to Reduce US Cancer Drug Costs.pdf",
            "name": "Review of Current Policy Strategies to Reduce US Cancer Drug Costs.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Cancer Drugs",
                "Drug Pricing",
                "Medicare Part B",
                "Medicare Part D",
                "Biosimilars",
                "Value-Based Pricing",
                "340B Drug Discount Program",
                "Physician Reimbursement",
                "International Price Benchmarks",
                "Health Care Spending"
            ],
            "author": "Angela K. Green, MD, MSc; Jennifer A. Ohn, MPH; and Peter B. Bach, MD, MAPP",
            "timestamp": "December 5, 2019",
            "headings": [
                "Review of Current Policy Strategies to Reduce US Cancer Drug Costs",
                "REFORMS INFLUENCING MEDICARE PART B DRUG REIMBURSEMENT",
                "Physician Reimbursement Transaction (buy and bill) Reform",
                "International Drug Price Benchmarks",
                "340B Drug Discount Program Modification",
                "Discarded Cancer Drug Cost Recovery",
                "REFORMS INFLUENCING MEDICARE PART D DRUG REIMBURSEMENT",
                "Part D Rebate and Point-of-Sale Rebate Reform",
                "Other Part D Reforms",
                "COMPETITION AMONG BIOLOGIC DRUGS",
                "VALUE-BASED PRICING FOR CANCER DRUGS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_non-small-cell_lung_market.pdf-ac133ef6",
        "document": "This news analysis article from Nature Reviews | Drug Discovery focuses on the non-small-cell lung cancer (NSCLC) drug market.  It details recent advancements in NSCLC treatments, including the approval of several new therapies in 2015, and discusses the late-phase pipeline of potential new drugs.  The authors, from Decision Resources Group, project significant market growth driven by these new agents, particularly immune checkpoint inhibitors.  The article highlights the increasing segmentation of the market based on tumor histology and molecular characteristics.",
        "metadata": {
            "identifier": "491b5993a6f4c0a90025768b78f5016916e23af7c7028b24a9547164916665ce",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:29.256039+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\The non-small-cell lung market.pdf",
            "name": "The non-small-cell lung market.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small-cell lung cancer (NSCLC)",
                "Immune checkpoint inhibitors",
                "EGFR inhibitors",
                "ALK inhibitors",
                "Targeted therapies",
                "Drug market",
                "Clinical trials",
                "Oncology"
            ],
            "author": "Khurram Nawaz and Rachel M. Webster",
            "timestamp": "April 1, 2016",
            "headings": [
                "NEWS & ANALYSIS\nFROM THE ANALYST’S COUCH",
                "Current treatment advances",
                "Table 1 | Select therapies in the late-phase pipeline for NSCLC",
                "Market indicators",
                "Figure 1 | NSCLC markets"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Trends_in_Drug_Revenue_Among_Major_Pharmaceutical.pdf-9d352c69",
        "document": "This 2021 cohort study by Meyers et al. analyzes revenue trends from 2010-2019 among ten major pharmaceutical companies, focusing on the proportion of revenue generated by cancer drugs versus non-oncology drugs.  The study found a 70% increase in cancer drug revenue, reaching 25% of total revenue in 2019, while non-oncology drug revenue decreased by 18%.  The authors discuss the implications of these findings, highlighting the need for further research to determine if increased revenue translates to improved patient outcomes and whether the industry's financial gains are justified by societal benefits.  Limitations of the study include the potential for non-representativeness and data limitations.",
        "metadata": {
            "identifier": "0879308136de256294ec59260c38baf9b2c6c9731593fddb787f974b42fa9703",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:33.974801+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Trends in Drug Revenue Among Major Pharmaceutical.pdf",
            "name": "Trends in Drug Revenue Among Major Pharmaceutical.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Pharmaceutical Revenue",
                "Cancer Drugs",
                "Oncology",
                "Drug Pricing",
                "Health Economics",
                "Cohort Study",
                "Financial Toxicity",
                "Industry Profitability"
            ],
            "author": "Daniel E. Meyers, MD, MSc; Benjamin S. Meyers, BComm; Timothy M. Chisamore, MSc; Kristin Wright, MD; Bishal Gyawali, MD, PhD; Vinay Prasad, MD, MPH; Richard Sullivan, MD, PhD; Christopher M. Booth, MD",
            "timestamp": "October 6, 2021",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "CONCLUSIONS",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "AUTHOR CONTRIBUTIONS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Trends_in_the_Cost_of_Cancer_Care.pdf-e54d10c8",
        "document": "This article reviews trends in the cost of cancer care in the US, which is exceeding other healthcare sectors and overall economic growth.  The authors analyze cost drivers, including technology adoption, overuse and underuse of services, and hospital consolidation.  They explore various models aimed at improving value, such as Accountable Care Organizations (ACOs), Centers of Excellence (COEs), and consumerism in cancer care.  The article concludes that multi-stakeholder interventions are crucial to ensure appropriate and cost-effective cancer care.",
        "metadata": {
            "identifier": "83082b5a3bf986862eeff3b1d17f7bc34acece47f11e773247a78a96c3c67c97",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:38.692208+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\Trends in the Cost of Cancer Care.pdf",
            "name": "Trends in the Cost of Cancer Care.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Cancer Care",
                "Healthcare Costs",
                "Value-Based Care",
                "Accountable Care Organizations (ACOs)",
                "Centers of Excellence (COEs)",
                "Technology Diffusion",
                "Hospital Consolidation",
                "Consumerism",
                "Cost-Effectiveness"
            ],
            "author": "Aaron A. Laviana, MD; Amy N. Luckenbaugh, MD; Matthew J. Resnick, MD, MPH, MMHC",
            "timestamp": "December 5, 2019",
            "headings": [
                "INTRODUCTION",
                "APPROPRIATENESS OF CARE",
                "Understanding Costs",
                "Improving Underuse of Cancer Care Services",
                "Reducing Overuse of Cancer Care Services",
                "HOSPITAL CONSOLIDATION",
                "MODELS TO IMPROVE VALUE",
                "Accountable Care Organizations",
                "Oncology Care Model",
                "Centers of Excellence",
                "Consumerism in Cancer Care",
                "In conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-What_patents_tell_us_about_drug_repurposing_for_cancer_A_landscape_analysis.pdf-81adcab8",
        "document": "This review article analyzes international patents related to drug repurposing for cancer treatment, focusing on disclosures published between 2014 and 2019.  The study reveals that patenting activity in this area has remained consistent, with universities and corporations as major contributors.  Many patented repurposing ideas are not yet reflected in peer-reviewed literature, highlighting the value of patent databases as a supplementary research resource for oncologists and drug developers.  The analysis also identifies a surprising contribution from non-academic research institutes and foundations, indicating broader involvement than expected.  The study emphasizes the importance of considering patents alongside peer-reviewed publications for a comprehensive understanding of drug repurposing in oncology.",
        "metadata": {
            "identifier": "a60ea02314fdd7c5c326773a3708c5b33afdb3000e7cf8605d5d1ac1651a7203",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:42.424521+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Market and competitors\\What patents tell us about drug repurposing for cancer  A landscape analysis.pdf",
            "name": "What patents tell us about drug repurposing for cancer  A landscape analysis.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Drug Repurposing",
                "Cancer",
                "Patents",
                "Intellectual Property",
                "Oncology",
                "Small Molecules",
                "Vaccine Repurposing",
                "Peer Review Literature"
            ],
            "author": "Hermann A.M. Mucke",
            "timestamp": "September 17, 2019",
            "headings": [
                "1. Introduction",
                "2. Methods",
                "3. Results",
                "4. Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_herbal_medicine_for_the_treatment_of_lung_cancer.pdf-a5dc5515",
        "document": "This scientific article investigates the anti-cancer properties of Rasagenthi Lehyam (RL), a traditional Indian medicine, specifically its chloroform fraction (cRL), on lung cancer cells.  The study found that cRL significantly inhibited cell proliferation and induced apoptosis in lung cancer cell lines (A-549 and H-460) without harming normal bronchial epithelial cells.  cRL achieved this by upregulating pro-apoptotic genes (p53 and Bax) and downregulating the pro-survival gene Bcl-2, also enhancing the effects of radiation therapy. Further research is needed to translate these findings into mainstream medical practice.",
        "metadata": {
            "identifier": "c4a263a9830badd0bff632d22ef7005937b1ce3d48524bfa85d523aa68b30184",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:48.230372+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\A herbal medicine for the treatment of lung cancer.pdf",
            "name": "A herbal medicine for the treatment of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Rasagenthi Lehyam",
                "Apoptosis",
                "Herbal medicine",
                "p53",
                "Bax",
                "Bcl-2",
                "Chemotherapy",
                "Radio-sensitization",
                "Cancer treatment"
            ],
            "author": "Rama S. Ranga, Srinivasan Sowmyalakshmi, Ravshan Burikhanov, Mohammed A. Akbarsha, and Damodaran Chendil",
            "timestamp": "Received 21 March 2005; accepted 2 June 2005",
            "headings": [
                "Abstract",
                "Introduction",
                "Materials and methods",
                "Extraction of RL",
                "Cell cultures",
                "Irradiation",
                "MTT assay",
                "Clonogenic inhibition assay",
                "Cell cycle analysis",
                "Western Blot analysis",
                "Quantitation of apoptosis",
                "Flourimetric assays for caspase-3/7 activation",
                "Indirect immunofluorescence",
                "Statistical analysis",
                "Results",
                "cRL-induced cytotoxicity in A-549 and H-460 lung cancer cells",
                "cRL-induced apoptosis in lung cancer cells",
                "cRL induces p53 and Bax and down-regulates Bcl-2 proteins in lung cancer cells",
                "Nuclear export of p53 in lung cancer cell lines by cRL",
                "The cRL enhances radio-sensitisation effect on lung cancer cell lines",
                "Caspase-3 activation in lung cancer cell lines by cRL",
                "cRL-released radiation-induced G2/M phase block of cell cycle in lung cancer cell lines",
                "Discussion",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_Review_of_Patient-Reported_Outcomes_Labeling_for_Oncology_drugs_approved_by_FDA_and_EMA.pdf-b069070c",
        "document": "This study compares US Food and Drug Administration (FDA) and European Medicines Agency (EMA) labeling for patient-reported outcomes (PROs) in oncology drugs approved between 2012 and 2016.  The EMA approved PRO labeling for significantly more indications than the FDA, often based on open-label studies and broader concepts like health-related quality of life.  The FDA emphasized evidence from controlled trials with minimal missing data and easily measurable endpoints.  Key differences in evidentiary standards between the agencies are highlighted, offering guidance for sponsors' PRO strategies when seeking labeling.",
        "metadata": {
            "identifier": "a88e7e810c0f5c2d2831266188bcea9edd0344d19a3a8c71a30cc8151e6a2d40",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:52.992108+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\A Review of Patient-Reported Outcomes Labeling for Oncology drugs approved by FDA and EMA.pdf",
            "name": "A Review of Patient-Reported Outcomes Labeling for Oncology drugs approved by FDA and EMA.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Patient-reported outcomes",
                "Oncology drugs",
                "FDA",
                "EMA",
                "Drug labeling",
                "Clinical trials",
                "Regulatory approval",
                "Health-related quality of life",
                "Study design"
            ],
            "author": "Ari Gnanasakthy, Amy Barrett, Emily Evans, Denise D'Alessio, Carla (DeMuro) Romano",
            "timestamp": "2019",
            "headings": [
                "Abstract",
                "Introduction",
                "Methods",
                "Results",
                "Discussion",
                "FDA and EMA: Areas of Misalignment",
                "Study design",
                "Concepts assessed",
                "Missing data",
                "PRO data in context",
                "Assessmentschedules",
                "Conclusions",
                "Acknowledgment",
                "Supplemental Materials",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_study_of_new_drug_approval_pattern_of_a_Southeast_Asian_developed.pdf-f4b5d999",
        "document": "This pharmacoepidemiological study analyzes new drug approvals in Singapore from 2017 to 2021, revealing a total of 418 approvals.  The majority of approvals (30.86%) were for anti-neoplastic and immunomodulating agents, aligning with trends observed in the US and UK.  The study classifies approvals by active ingredient, date, application category, indication, and WHO ATC classification.  The findings provide baseline data on Singapore's drug approval patterns, highlighting the significant growth in anti-cancer drug development.",
        "metadata": {
            "identifier": "20525ff76e702fa85b8f264b53e07efac0089b7a38a78dee8bb3ab606b6fc276",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:16:56.796851+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\A study of new drug approval pattern of a Southeast Asian developed.pdf",
            "name": "A study of new drug approval pattern of a Southeast Asian developed.pdf",
            "document_type": "pdf",
            "domain_themes": "Pharmacology",
            "keywords": [
                "New Drug Approval",
                "Singapore",
                "Pharmacoepidemiology",
                "Anti-neoplastic",
                "Immunomodulating agents",
                "Health Science Authority (HSA)",
                "WHO ATC Classification",
                "Drug Development",
                "NDA Category"
            ],
            "author": "Nilesh Chavda, Nirav Patel, Jatin V Dhanani, Priti Solanky",
            "timestamp": "June 20, 2022",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "RESULTS",
                "DISCUSSION",
                "CONCLUSION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Alectinib_for_the_Treatment_of_Metastatic_ALK-Positive_Non_Small_Cell_Lung_Cancer.pdf-d476c49e",
        "document": "This FDA approval document details the accelerated approval of alectinib (ALECENSA) for treating ALK-positive metastatic non-small cell lung cancer (NSCLC) patients who have progressed on or are intolerant to crizotinib.  The approval is based on two single-arm trials showing objective response rates of 38% and 44%, with median durations of response of 7.5 and 11.2 months.  The document also discusses the drug's safety profile, including common adverse reactions and laboratory abnormalities, and the need for a confirmatory trial to verify clinical benefit.  Alectinib demonstrated efficacy in treating CNS metastases, a significant factor in this patient population.",
        "metadata": {
            "identifier": "2480816ca2091ca11e16d26d91af8df4466a1a3c21534d94941ce58ff2dde443",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:17:01.935176+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Alectinib for the Treatment of Metastatic ALK-Positive Non–Small Cell Lung Cancer.pdf",
            "name": "Alectinib for the Treatment of Metastatic ALK-Positive Non–Small Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Alectinib",
                "ALECENSA",
                "ALK-positive",
                "Non-small cell lung cancer (NSCLC)",
                "Crizotinib",
                "FDA approval",
                "Metastatic cancer",
                "CNS metastases",
                "Objective response rate (ORR)",
                "Adverse reactions"
            ],
            "author": "Erin Larkins, Gideon M. Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney Helms, Stacy Shord, Jingyu Yu, Hong Zhao, Gina Davis, Amy E. McKee, Patricia Keegan, and Richard Pazdur",
            "timestamp": "December 11, 2015",
            "headings": [
                "Abstract",
                "Introduction",
                "Chemistry, Manufacturing, and Control",
                "Nonclinical Pharmacology and Toxicology",
                "Clinical Pharmacology",
                "Clinical Trial Design",
                "Efficacy",
                "Safety",
                "Discussion",
                "References",
                "Table 1",
                "Table 2",
                "Table 3",
                "Table 4",
                "Table 5"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Alectinib_versus_Crizotinib.pdf-dc1acc0b",
        "document": "This article reports on a phase 3 clinical trial (ALEX) comparing the efficacy and safety of alectinib versus crizotinib in treating previously untreated, advanced ALK-positive non-small-cell lung cancer (NSCLC).  Alectinib demonstrated significantly superior progression-free survival and a lower risk of CNS progression compared to crizotinib.  The study also found that alectinib had a more favorable safety profile with fewer grade 3-5 adverse events.  These findings suggest that alectinib is a superior first-line treatment option for ALK-positive NSCLC.",
        "metadata": {
            "identifier": "3f399e09859c2b03ff1bc5b6db8782300f37edf8711f105b8666c475f9d30d7f",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:17:07.385153+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Alectinib versus Crizotinib.pdf",
            "name": "Alectinib versus Crizotinib.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Alectinib",
                "Crizotinib",
                "ALK-positive NSCLC",
                "Non-small-cell lung cancer",
                "Progression-free survival",
                "CNS metastases",
                "Phase 3 trial",
                "Clinical trial",
                "Cancer treatment"
            ],
            "author": "Solange Peters et al. for the ALEX Trial Investigators",
            "timestamp": "June 6, 2017",
            "headings": [
                "ABSTRACT",
                "BACKGROUND",
                "METHODS",
                "Patients",
                "Trial Oversight",
                "Trial Design and Treatment",
                "Assessments",
                "Statistical Analysis",
                "RESULTS",
                "Patients",
                "Efficacy",
                "Safety",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-An_appraisal_of_drug_development_timelines_in_the_Era_of_precision_oncology.pdf-8031296b",
        "document": "This research paper analyzes drug development timelines for oncology drugs approved by the FDA between 1998 and 2014, comparing those developed with and without a personalized (biomarker-based) strategy.  The study found that personalized drug development was associated with faster clinical development but similar approval times.  Targeted agents, particularly those with a biomarker-based approach, were developed faster than cytotoxic agents.  Response rates in early trials correlated with both registration trial response rates and total drug development time.",
        "metadata": {
            "identifier": "d0d34b63556601d9e32436c2d7a5909149c410c51bc440d54faceb99a1583b22",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:17:12.325940+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\An appraisal of drug development timelines in the Era of precision oncology.pdf",
            "name": "An appraisal of drug development timelines in the Era of precision oncology.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "drug development",
                "precision oncology",
                "biomarkers",
                "FDA approval",
                "personalized medicine",
                "oncology drugs",
                "clinical trials",
                "pharmacoeconomics"
            ],
            "author": "Denis Leonardo Jardim, Maria Schwaederle, David S. Hong, Razelle Kurzrock",
            "timestamp": "Published: July 13, 2016",
            "headings": [
                "AbstrAct",
                "INtrODUctION",
                "rEsULts",
                "Personalized therapy was associated with faster clinical development",
                "Access to FDA special programs",
                "response rates (rr) in early trials and drug approval time",
                "DIscUssION",
                "MAtErIALs AND MEtHODs",
                "search strategy",
                "Data extraction",
                "statistical analysis",
                "cONFLIcts OF INtErEst",
                "GrANt sUPPOrt",
                "rEFErENcEs"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Biosimilars_in_Oncology_in_the_United_States.pdf-46f2a9a4",
        "document": "This JAMA Oncology review article examines biosimilars in oncology within the United States, focusing on their regulatory pathways, cost implications, and potential for healthcare savings.  The authors highlight key differences between biosimilars and generic drugs, emphasizing the more complex approval process for biosimilars due to their inherent biological complexity.  The article discusses the potential for cost savings through biosimilar utilization, but also acknowledges uncertainties regarding market uptake and actual price reductions.  Finally, the authors address the impact of policy changes, such as the Affordable Care Act and MACRA, on biosimilar adoption in the US oncology market.",
        "metadata": {
            "identifier": "801dd39a6b23944e0c4c69f1560028e2096579696338502369702ae33a10524d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:17:17.412496+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Biosimilars in Oncology in the United States.pdf",
            "name": "Biosimilars in Oncology in the United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Biosimilars",
                "Oncology",
                "Generic Drugs",
                "Healthcare Costs",
                "FDA Regulation",
                "Value-Based Care",
                "Biologic Agents",
                "Cost Savings",
                "Extrapolation"
            ],
            "author": "Chadi Nabhan, MD, MBA; Sandeep Parsad, PharmD; Anthony R. Mato, MD, MSCE; Bruce A. Feinberg, DO",
            "timestamp": "July 20, 2017",
            "headings": [
                "IMPORTANCE",
                "OBSERVATIONS",
                "CONCLUSIONS AND RELEVANCE",
                "Commonly Asked Questions",
                "What Are the Regulatory Requirements to Approve a Biosimilar in the United States?",
                "Is Extrapolation to Additional Indications Appropriate?",
                "Can the Use of Biosimilars and Generics Save Money?",
                "How Are Biosimilars Paid For?",
                "Would Policy Changes in the United States Affect Biosimilars?",
                "Discussion",
                "Conclusions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Challenges_in_lung_cancer_therapy_during_the_COVID-19_pandemic.pdf-10e39ba5",
        "document": "This document comprises two articles published in The Lancet Respiratory Medicine in 2020, focusing on the challenges of lung cancer treatment during the COVID-19 pandemic.  The first article discusses the difficulties in distinguishing lung cancer progression from COVID-19 infection due to overlapping symptoms and radiological findings. The second article explores the potential benefits of immunomodulatory therapies, such as IL-6 inhibition, to control the hyperinflammatory response in severe COVID-19 cases. Both articles highlight the need for careful clinical management of lung cancer patients during the pandemic and emphasize the importance of COVID-19 testing for these patients.",
        "metadata": {
            "identifier": "06aaf774db065409bbfde5a10b549ca33b5233b6cdbc276023ea83edd207dd22",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:17:20.805136+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Challenges in lung cancer therapy during the COVID-19 pandemic.pdf",
            "name": "Challenges in lung cancer therapy during the COVID-19 pandemic.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Research",
            "keywords": [
                "COVID-19",
                "Lung Cancer",
                "Immunomodulation",
                "Pneumonitis",
                "Cytokine Storm",
                "SARS-CoV-2",
                "Radiological Findings",
                "Treatment Challenges"
            ],
            "author": "Luana Calabrò, Solange Peters, Jean-Charles Soria, Anna Maria Di Giacomo, Fabrice Barlesi, Alessia Covre, Maresa Altomonte, Virginia Vegni, Cesare Gridelli, Martin Reck, Naiyer Rizvi, Michele Maio",
            "timestamp": "April 9, 2020 and May 4, 2020",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Comparison_of_FDA_accelerated_vs_regular_pathway.pdf-79bfbe63",
        "document": "This research article compares FDA accelerated and regular pathway approvals for lung cancer treatments between 2006 and 2018.  The study analyzed FDA data to assess differences in study design, sample size, outcome measures, and effect size between the two pathways and the impact of Breakthrough Therapy Designation (BTD).  The findings reveal that accelerated pathway approvals rely more on single-arm studies with smaller sample sizes and surrogate endpoints, although effect sizes were not significantly different.  The authors conclude that accelerated approvals often involve uncertainties and emphasize the need for post-marketing validation and shared decision-making with patients.",
        "metadata": {
            "identifier": "e62aab7fb4fd64f6dcb6a887b3411f77467e24d36f5a903cc154fa167ccc16b7",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:17:26.997703+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Comparison of FDA accelerated vs regular pathway.pdf",
            "name": "Comparison of FDA accelerated vs regular pathway.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "FDA",
                "lung cancer",
                "accelerated approval",
                "regular approval",
                "Breakthrough Therapy Designation",
                "surrogate endpoints",
                "sample size",
                "effect size",
                "clinical trials",
                "evidence quality"
            ],
            "author": "Tatiane Bomfim Ribeiro, Lewis Buss, Cole Wayant, Moacyr Roberto Cuce Nobre",
            "timestamp": "July 24, 2020",
            "headings": [
                "Abstract",
                "Introduction",
                "Methods",
                "Data collection",
                "Magnitude of effect",
                "Statistical analysis",
                "Results",
                "Regulatory characteristics",
                "Study characteristics",
                "Elements related to the quality of evidence in lung cancer approvals",
                "Accelerated vs regular pathway",
                "Breakthrough therapy designation",
                "Discussion",
                "Limitations",
                "Conclusion",
                "Supporting information",
                "AuthorContributions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Drug_Resistance_Mechanisms_in_Non-Small_Cell_Lung_Carcinoma.pdf-e7f3064b",
        "document": "This scientific review article examines drug resistance mechanisms in non-small cell lung carcinoma (NSCLC), the most common type of lung cancer.  The authors discuss resistance to both targeted therapies (like EGFR and ALK inhibitors) and conventional chemotherapeutics, focusing on molecular mechanisms such as secondary mutations, pathway crosstalk, and the role of multidrug resistance proteins (ABC transporters).  The review highlights the importance of understanding these mechanisms to improve treatment efficacy and patient outcomes.  The authors conclude by emphasizing the need for further research, particularly regarding the role of ABC transporters and the development of more effective pharmacogenetic therapies.",
        "metadata": {
            "identifier": "325ff29c53ef2b7275541e17796f9a661a8b2df4461d2f4331d2a08cabf1923b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:17:40.792253+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.pdf",
            "name": "Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "EGFR",
                "EML4-ALK",
                "Tyrosine kinase inhibitors",
                "Drug resistance",
                "ABC transporters",
                "Chemotherapy",
                "Targeted therapy"
            ],
            "author": "Janet Wangari-Talbot and Elizabeth Hopper-Borge",
            "timestamp": "2013 October 31",
            "headings": [
                "Abstract",
                "Keywords",
                "INTRODUCTION",
                "RESISTANCE TO TARGETED AGENTS IN NSCLC",
                "Epidermal Growth Factor Receptor (EGFR)",
                "Increased PI3K/AKT Signaling",
                "Insulin-Like Growth Factor Receptor 1 (IGFR-1) Crosstalk",
                "KRAS Mutations",
                "Secondary Mutations in Acquired Resistance",
                "Epithelial to Mesenchymal Transition",
                "MET Amplification",
                "Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase (EML4-ALK)",
                "EML4-ALK Secondary Mutations",
                "ALK Copy Number Gain and Emergence of ALK - Fusion Negative Tumors",
                "Heat Shock Protein (Hsp90) Targeting in EMK4-ALK Positive Tumors",
                "Role of Multidrug Resistance Proteins in NSCLC",
                "ABCB1/MDR1/Pgp",
                "ABCC1/MRP1",
                "ABCC10/MRP7",
                "ABCG2/BCRP",
                "CONCLUSION",
                "Acknowledgments",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Drug_resistance_to_targeted_therapeutic_strategies_in_non-small_cell.pdf-ff34167f",
        "document": "This journal pre-proof article reviews drug resistance mechanisms in non-small cell lung cancer (NSCLC) targeted therapies.  The authors discuss on-target resistance (mutations in the targeted oncogene) and off-target resistance (changes in other signaling pathways).  Key oncogenes like EGFR, ALK, ROS1, and BRAF are examined, along with less common ones. The review also explores the role of epigenetic alterations (DNA methylation, histone modifications) and tumor microenvironment heterogeneity (CAFs, vascular cells, immune cells) in mediating drug resistance.",
        "metadata": {
            "identifier": "63d5eee431bf0848e5dd6f5776472b602d5693d02e78d03090e188a26f2f3a2b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:02.009359+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Drug resistance to targeted therapeutic strategies in non-small cell.pdf",
            "name": "Drug resistance to targeted therapeutic strategies in non-small cell.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "Drug resistance",
                "Targeted therapy",
                "Oncogenes",
                "Epigenetic alterations",
                "Tumor microenvironment",
                "EGFR",
                "ALK",
                "ROS1",
                "BRAF"
            ],
            "author": "Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu",
            "timestamp": "2019",
            "headings": [
                "Abstract",
                "Keywords",
                "Abbreviations",
                "1. Introduction",
                "2. Gene alterations associated with drug resistance",
                "2.1 EGFR-TKIs",
                "2.2 ALK-TKIs",
                "2.3 Other targetable molecular mutations",
                "2.3.1 Oncogenic ROS1 gene rearrangement",
                "2.3.2 Oncogenic BRAF mutation",
                "2.3.3 MET alteration",
                "2.3.4 KRAS mutation",
                "2.3.5 HER2 mutation",
                "2.3.6 Rearranged during transfection (RET)",
                "2.3.7 Neurotrophic tyrosine receptor kinase (NTRK)",
                "3. Epigenetic alterations and drug resistance",
                "3.1 DNA methylation",
                "3.2 Histone acetylation",
                "3.3 Histone methylation",
                "3.4 Chromosomal heterogeneity",
                "3.5 Noncoding RNA",
                "4. Tumor microenvironment heterogeneity and drug resistance",
                "4.1 Drug resistance induced by cancer-associated fibroblast",
                "4.2 Drug resistance induced by vascular and lymphatic endothelial cells",
                "4.3 Immune system-mediated drug resistance",
                "4.4 Cancer stem cell-mediated drug resistance",
                "5. Other therapeutic strategies",
                "6. Future perspectives",
                "Acknowledgments",
                "Contributions",
                "Conflict of interest statement",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Durvalumab_for_the_treatment_of_non-small_cell_cancer.pdf-b8584b4c",
        "document": "This expert review article focuses on durvalumab, an anti-PD-L1 antibody, and its use in treating non-small cell lung cancer (NSCLC).  The article covers durvalumab's pharmacological properties, clinical efficacy as a monotherapy and in combination with other drugs, and its safety profile.  Key clinical trials, including PACIFIC, MYSTIC, ARCTIC, and NEPTUNE, are discussed, highlighting durvalumab's success as a maintenance therapy after chemoradiotherapy for unresectable stage III NSCLC but mixed results in first-line treatment.  The article concludes by discussing future directions for durvalumab research and the importance of biomarker selection for optimal patient outcomes.",
        "metadata": {
            "identifier": "5041e36311ed6ad567574bd32f0699c04cda4f2153d753c6e8c0db2e78baf25a",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:09.387692+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Durvalumab for the treatment of non-small cell cancer.pdf",
            "name": "Durvalumab for the treatment of non-small cell cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Durvalumab",
                "Non-small cell lung cancer (NSCLC)",
                "Immune checkpoint inhibitors",
                "PD-L1",
                "Cancer therapy",
                "Clinical trials",
                "Immunotherapy",
                "Biomarkers",
                "Chemotherapy",
                "Tremelimumab"
            ],
            "author": "Shuji Murakami",
            "timestamp": "2019-11-29",
            "headings": [
                "Abstract",
                "Article highlights",
                "1. Introduction",
                "2. Overview of the market",
                "3. Introduction to durvalumab",
                "3.1. Chemistry",
                "3.2. Pharmacodynamics",
                "3.3. Pharmacokinetics and metabolism",
                "3.4. Clinical efficacy",
                "3.4.1. Second-line or Later Treatment",
                "3.4.2. First-line treatment",
                "3.4.3. Consolidation after Chemoradiotherapy",
                "3.4.4. Biomarkers",
                "3.5. Regulatory affairs",
                "4. Conclusion",
                "5. Expert opinion",
                "References",
                "Table 1. Ongoing phase II and III studies of durvalumab as monotherapy or in combination with other drugs"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Emerging_insights_of_tumor_heterogeneity_and_drug_resistance_mechanisms_in_lung_cancer_targeted_therapy.pdf-3de6f70c",
        "document": "This review article discusses emerging insights into tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.  The authors focus on the challenges of acquired drug resistance, highlighting the role of minimal residual disease (MRD) cells and intratumoral heterogeneity.  They explore various resistance mechanisms, including secondary mutations, bypass pathways, and phenotypic transformation.  The review proposes the use of advanced technologies like single-cell methods and liquid biopsies to identify and target MRD cells for more effective cancer treatment.",
        "metadata": {
            "identifier": "36cb1d2478a6fb9f11b70b115f8f592270a3d1137c36fe708c0e6d0a20850c19",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:18.489596+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.pdf",
            "name": "Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tumor heterogeneity",
                "Drug resistance",
                "Lung cancer",
                "Targeted therapy",
                "Minimal residual disease",
                "EGFR",
                "Liquid biopsy",
                "Single-cell analysis"
            ],
            "author": "Zuan-Fu Lim and Patrick C. Ma",
            "timestamp": "2019",
            "headings": [
                "Abstract",
                "Introduction",
                "Mechanisms of acquired drug resistance to lung cancer targeted therapy",
                "Understanding intratumoral heterogeneity in tumor evolution: the driving force behind minimal residual disease and drug tolerance-resistance",
                "Previous limitations and novel methods for linking intratumoral heterogeneity and drug resistance",
                "Molecular profiling for tumor-agnostic, driver-specific targeted therapy",
                "Conclusion",
                "Abbreviations",
                "Acknowledgments",
                "Authors’ contributions",
                "Funding",
                "Availability of data and materials",
                "Ethics approval and consent to participate",
                "Consent for publication",
                "Competing interests",
                "Author details",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Global_research_landscape_and_trends_of_lung_cancer.pdf-b0881031",
        "document": "This bibliometric analysis examines the global research landscape and trends in lung cancer immunotherapy from 2010 to July 1, 2022, using data from the Web of Science.  The study analyzes 2,941 publications, identifying key publications, journals, and research hotspots.  It reveals that anti-PD-(L)1 therapy has become a dominant area of research since 2015, with significant contributions from researchers in China and the USA. The findings suggest future research directions, including optimizing treatment strategies for various patient subgroups and developing novel immunotherapies.",
        "metadata": {
            "identifier": "d0a807d7cd4675d5a6c2a6bc42049ff10587f9eeaae192b52f7134483bc6cc49",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:33.373256+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Global research landscape and trends of lung cancer.pdf",
            "name": "Global research landscape and trends of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "bibliometric analysis",
                "lung cancer",
                "immunotherapy",
                "PD-1/PD-L1",
                "clinical trials",
                "nivolumab",
                "pembrolizumab",
                "tumor mutation burden",
                "SCLC",
                "NSCLC"
            ],
            "author": "Yanhao Liu, Xu Cheng, Xiaona Han, Xi Cheng, Shu Jiang, Yaru Lin, Zhen Zhang, Linlin Lu, Baozhen Qu, Yuxian Chen, and Xiaotao Zhang",
            "timestamp": "01 December 2022",
            "headings": [
                "Introduction",
                "Methods",
                "Database and paper selection",
                "Statistical analysis",
                "Results",
                "Journals",
                "Countries/regions",
                "Institutions",
                "Authors",
                "Keywords",
                "Research trends",
                "Anti–PD–(L)1 for NSCLC",
                "Anti–PD–(L)1 for previously treated advanced NSCLC",
                "First–line anti–PD–(L)1 therapy for advanced NSCLC",
                "Novel immunotherapy for advanced NSCLC",
                "Adjuvant anti–PD–(L)1 therapy",
                "Neoadjuvant anti–PD–(L)1 therapy",
                "Anti–PD–(L)1 for SCLC",
                "Anti–PD–(L)1 for previously treated extensive–stage SCLC",
                "First–line anti–PD–(L)1 for extensive–stage SCLC",
                "Other immunotherapies",
                "Journals, countries, institutions, and authors",
                "Research trends and hotspots",
                "Limitations",
                "Conclusions",
                "Data availability statement",
                "Publisher’s note",
                "Supplementary material",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_cancer_costs_by_treatment_strategy_and_phase_of_care_among.pdf-bcbc3761",
        "document": "This research article analyzes lung cancer treatment costs among Medicare patients in the US from 1998-2013.  Using the SEER-Medicare database, the authors allocated costs across different phases of care (prediagnosis, staging, surgery, initial, continuing, and terminal), considering treatment strategies, age, diagnosis stage, and histology.  They found that pre-diagnosis costs increased with age and year, while surgery costs decreased over time. Chemotherapy and radiation costs remained stable or increased.  The study concludes that these updated cost estimates are crucial for accurate cost-effectiveness analyses of lung cancer interventions.",
        "metadata": {
            "identifier": "f5830c7f6a8e4f10af63d10040cf01e8ecc0e847a36d8cc0f08a910c91961a90",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:39.633460+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Lung cancer costs by treatment strategy and phase of care among.pdf",
            "name": "Lung cancer costs by treatment strategy and phase of care among.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Healthcare Costs",
                "Treatment Costs",
                "Medicare",
                "SEER-Medicare Database",
                "Cost-Effectiveness Analysis",
                "Phase of Care",
                "Treatment Strategies"
            ],
            "author": "Deirdre F. Sheehan, Steven D. Criss, Yufan Chen, Andrew Eckel, Lauren Palazzo, Angela C. Tramontano, Chin Hur, Lauren E. Cipriano, Chung Yin Kong",
            "timestamp": "14 August 2018",
            "headings": [
                "Abstract",
                "1 | INTRODUCTION",
                "2 | MATERIALS AND METHODS",
                "2.1 | SEER‐Medicare data",
                "2.2 | Treatment strategies",
                "2.3 | Phases of care",
                "2.4 | Cancer‐attributable costs",
                "2.5 | Prescription drug costs",
                "2.6 | Statistical analysis",
                "3 | RESULTS",
                "3.1 | Costs during the prediagnosis and staging phases",
                "3.2 | Cost of initial cancer treatment",
                "3.3 | Costs during the continuing and terminal phases",
                "3.4 | Prescription drug costs",
                "4 | DISCUSSION",
                "ACKNOWLEDGMENTS",
                "CONFLICT OF INTEREST",
                "ORCID",
                "REFERENCES",
                "SUPPORTING INFORMATION"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_cancer_research_and_its_citation_on_clinical_practice_guidelines.pdf-20c99c44",
        "document": "This research article analyzes the citation patterns of lung cancer research papers within clinical practice guidelines (CPGs) from 16 countries and the Cochrane Collaboration.  The study compares the characteristics of papers cited in CPGs with the broader body of lung cancer research, revealing that CPG-cited papers are more clinically focused and often originate from smaller northern European countries, though leading institutions are primarily from the USA.  The analysis highlights the underrepresentation of certain research areas like genetics and palliative care in CPGs.  The authors propose CPG citation analysis as an alternative method for evaluating clinical research impact, offering a more clinically relevant perspective than traditional journal citations.",
        "metadata": {
            "identifier": "3af34539cde470bf1c840d4aaa7c5f0f4f66e9e83c063d49d56347f7c8e0fa06",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:46.953371+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Lung cancer research and its citation on clinical practice guidelines.pdf",
            "name": "Lung cancer research and its citation on clinical practice guidelines.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Clinical Practice Guidelines",
                "Research Citation Analysis",
                "Bibliometrics",
                "Clinical Trials",
                "Treatment Modalities",
                "Research Impact",
                "CPGs"
            ],
            "author": "Elena Pallari, Magnus Eriksson, Annika Billhult, Tommy Billhult, Ajay Aggarwal, Grant Lewison, Richard Sullivan",
            "timestamp": "5 February 2021",
            "headings": [
                "1. Introduction",
                "1.1. The burden from the disease, and previous studies",
                "1.2. Methods for research evaluation",
                "1.3. What this paper does",
                "2. Methodology",
                "2.1. Two sets of lung cancer research papers and means of analysis",
                "2.2. The clinical impact® and the KCL databases",
                "2.3. Description of analyses",
                "2.4. The comparison cohort of lung cancer research papers",
                "2.5. Statistical analysis",
                "3. Results",
                "3.1. Numbers of papers",
                "3.2. Countries of the researchers",
                "3.3. The leading research institutions in lung cancer",
                "3.4. The different types of lung cancer research",
                "3.5. The time gap between CPGs, and research papers, and their references",
                "4. Discussion",
                "5. Conclusions",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Mechanisms_of_immune_response_regulation_in_lung_cancer.pdf-340eab9d",
        "document": "This review article examines the mechanisms of immune response regulation in lung cancer, focusing on how the tumor microenvironment suppresses the host's anticancer immune response.  The article highlights the roles of regulatory T cells (Tregs), Th17 cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) in this suppression.  It also discusses the impact of cytokines like TGFβ and IL-10, and the potential of targeting these regulatory cells and molecules for new cancer treatments.  The authors emphasize the need for further investigation into these mechanisms to improve lung cancer therapies.",
        "metadata": {
            "identifier": "b26c239eae75d4b7901e18aa470dad2036ee994db222c9af12dd8980f09042e1",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:50.942657+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Mechanisms of immune response regulation in lung cancer.pdf",
            "name": "Mechanisms of immune response regulation in lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Immune response",
                "Regulatory T cells",
                "Th17 cells",
                "Myeloid-derived suppressor cells",
                "Tumor-associated macrophages",
                "TGFβ",
                "IL-10",
                "Immunotherapy"
            ],
            "author": "Joanna Domagala-Kulawik, Iwona Osinska, Grazyna Hoser",
            "timestamp": "2013-11-25",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Osimertinib_in_the_treatment_of_non-small-cell_lung_cancer_design_development_and_place_in_therapy.pdf-ce5bdbfb",
        "document": "This 2017 review article from Lung Cancer: Targets and Therapy, authored by Santarpia et al., focuses on osimertinib, a third-generation tyrosine kinase inhibitor (TKI) for non-small-cell lung cancer (NSCLC).  The authors detail osimertinib's design, development, and clinical efficacy, particularly in treating EGFR T790M mutation-positive NSCLC patients who have progressed after first-line EGFR TKI therapy.  The review covers preclinical findings, Phase I-III trial data, including efficacy against CNS metastases, and discusses mechanisms of resistance to osimertinib.  Finally, it provides an outlook on ongoing trials exploring osimertinib's use in combination therapies.",
        "metadata": {
            "identifier": "814250c5245ed1730091444c60e67f0cac2775f91b2a258ea0d7c9c16ca2943b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:18:59.386254+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Osimertinib in the treatment of non-small-cell lung cancer  design  development and place in therapy.pdf",
            "name": "Osimertinib in the treatment of non-small-cell lung cancer  design  development and place in therapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Osimertinib",
                "EGFR",
                "T790M mutation",
                "Non-small-cell lung cancer (NSCLC)",
                "Tyrosine kinase inhibitors (TKIs)",
                "Acquired resistance",
                "CNS metastases",
                "Liquid biopsy",
                "ctDNA"
            ],
            "author": "Mariacarmela Santarpia, Alessia Liguori, Niki Karachaliou, Maria Gonzalez-Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla & Rafael Rosell",
            "timestamp": "2017-08-18",
            "headings": [
                "Abstract",
                "Introduction",
                "Targeting EGFR in NSCLC",
                "Mechanisms of resistance to first-line EGFR TKI therapy",
                "Therapeutic strategies targeting EGFR T790M",
                "Osimertinib",
                "Design and mechanism of action",
                "Pharmacokinetics (PK)",
                "Development of the drug",
                "Phase I and II studies",
                "Phase III studies",
                "Activity of osimertinib against CNS metastases",
                "Cell-free ctDNA genotyping for EGFR T790M mutation",
                "Place in therapy",
                "Mechanisms of resistance to osimertinib",
                "Future perspectives: ongoing studies, novel agents and combination strategies",
                "Conclusion",
                "Disclosure",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Safety_and_antitumour_activity_of_durvalumab_plus.pdf-bdb30037",
        "document": "This phase 1b clinical trial investigated the safety and antitumor activity of the combined immunotherapy durvalumab and tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).  The study, conducted across five US cancer centers, enrolled 102 patients and assessed various dose combinations.  The maximum tolerated dose was determined, and the most frequent adverse events were identified.  The results showed evidence of clinical activity regardless of PD-L1 status, leading to the selection of a specific dose combination for further phase 3 trials.",
        "metadata": {
            "identifier": "fe6a0608efbe2c01975c20e20f60a36c53d5c66adcddf362a2eead7c8b0d56ec",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:05.605998+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Safety and antitumour activity of durvalumab plus.pdf",
            "name": "Safety and antitumour activity of durvalumab plus.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "durvalumab",
                "tremelimumab",
                "non-small cell lung cancer",
                "immunotherapy",
                "PD-L1",
                "CTLA-4",
                "phase 1b trial",
                "maximum tolerated dose",
                "adverse events",
                "antitumor activity"
            ],
            "author": "Scott Antonia*, Sarah B Goldberg*, Ani Balmanoukian, Jamie E Chaft, Rachel E Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson J Karakunnel, Naiyer A Rizvi",
            "timestamp": "February 5, 2016",
            "headings": [
                "Summary",
                "Introduction",
                "Research in context",
                "Methods",
                "Study design and participants",
                "Procedures",
                "Outcomes",
                "Statistical analysis",
                "Role of the funding source",
                "Results",
                "Discussion",
                "Contributors",
                "Declaration of interests",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Study_on_Medication_Rules_of_Modern_Chinese_Herbal_Medicine.pdf-a792518a",
        "document": "This research article investigates the medication rules of modern Chinese herbal medicine in treating non-small cell lung cancer (NSCLC).  Using data mining techniques on a dataset from Beijing 301 Hospital (2010-2017), the study analyzed the frequency, efficacy, meridian tropism, and properties of herbs used in 231 prescriptions.  Key findings revealed frequently used herbs, dominant properties (heat-clearing, qi-tonifying), and common herb combinations. The study concludes that NSCLC treatment in TCM focuses on clearing heat, detoxifying, tonifying the spleen, and regulating qi, aligning with the principle of strengthening the body and dispelling pathogens.",
        "metadata": {
            "identifier": "c2e19b9cf597a2e8f35a0e81a65dd4f3a58e1dc2ad11f6725dc2bf972c191eed",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:12.626002+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\Study on Medication Rules of Modern Chinese Herbal Medicine.pdf",
            "name": "Study on Medication Rules of Modern Chinese Herbal Medicine.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Data mining",
                "Traditional Chinese Medicine (TCM)",
                "Non-small cell lung cancer (NSCLC)",
                "Chinese herbal medicine",
                "Data analysis",
                "Prescription patterns",
                "Antitumor mechanisms",
                "Herb combinations"
            ],
            "author": "Li-Ting Liu, Cui-Yun Zhao, Tong Wu, Zi-Yang Yu, Yuan Sun, Jie Li",
            "timestamp": "20-02-2020",
            "headings": [
                "Abstract",
                "Introduction",
                "Search Methods",
                "Chinese Medicine Compound Screening and Entry",
                "Data processing and analysis",
                "Results and Analysis",
                "Discussion",
                "Conclusion",
                "Financial support and sponsorship",
                "Conflicts of interest",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_role_of_generic_medicines_and_biosimilars.pdf-61a4794e",
        "document": "This research article examines the role of generic and biosimilar medicines in oncology treatment within low-income countries, particularly focusing on Africa.  The authors highlight the significant cost savings these medications offer compared to brand-name drugs, which is crucial in settings with limited healthcare resources.  However, the article also addresses challenges related to quality assurance, supply chain integrity, and safety monitoring of generics and biosimilars.  The authors advocate for improved regulation, quality control, and the development of cost-effective treatment guidelines tailored to low-income countries.",
        "metadata": {
            "identifier": "06ae20972df48c06b15d91c26d9a768588972c598dc469e94f90669331997d95",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:16.158037+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\The role of generic medicines and biosimilars.pdf",
            "name": "The role of generic medicines and biosimilars.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Generic medicines",
                "Biosimilars",
                "Oncology",
                "Low-income countries",
                "Cancer care",
                "Cost-effectiveness",
                "Quality assurance",
                "Supply chain",
                "Treatment guidelines"
            ],
            "author": "L. Renner, F. A. Nkansah, A. N. O. Dodoo",
            "timestamp": "2013",
            "headings": [
                "The role of generic medicines and biosimilars in oncology in low-income countries",
                "challenges facing cancer control in Africa",
                "potential solutions to improve cancer control",
                "the case for generics",
                "potential problems with generics",
                "discussion",
                "disclosure",
                "references"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-TrendsinPricesofDrugsUsedtoTreatMetastaticNon_SmallCellLungCancer_intheUSFrom2015to2020.pdf-614d56ab",
        "document": "This cross-sectional study analyzed price changes in brand-name drugs for treating metastatic non-small cell lung cancer (NSCLC) in the US from 2015 to 2020.  The researchers found that prices increased across all drug classes, with minimal price competition among manufacturers.  This lack of competition resulted in price increases exceeding inflation and the consumer price index for prescription drugs. The study highlights the need for drug pricing reform to address the affordability concerns of these essential oncology medications.",
        "metadata": {
            "identifier": "207527823f8892e3509036b757a06c2f8e65abb5637240854e8040912abb314b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:19.969083+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Medicines and Related information\\TrendsinPricesofDrugsUsedtoTreatMetastaticNon–SmallCellLungCancer intheUSFrom2015to2020.pdf",
            "name": "TrendsinPricesofDrugsUsedtoTreatMetastaticNon–SmallCellLungCancer intheUSFrom2015to2020.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "drug pricing",
                "oncology",
                "non-small cell lung cancer (NSCLC)",
                "price competition",
                "inflation",
                "brand-name drugs",
                "healthcare disparities"
            ],
            "author": "Aakash Desai, MBBS, MPH; Caleb Scheckel, DO; Chelsee J. Jensen, PharmD, RPh; Jacob Orme, MD, PhD; Colt Williams, MD; Nilay Shah, MPH; Konstantinos Leventakos, MD, PhD; Alex A. Adjei, MD, PhD",
            "timestamp": "January 25, 2022",
            "headings": [
                "Abstract KeyPoints",
                "Introduction",
                "Methods",
                "StatisticalAnalysis",
                "Results",
                "Discussion",
                "Limitations",
                "Conclusions",
                "ARTICLEINFORMATION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-A_Review_of_the_Role_of_MRI_in_Diagnosis_and_Treatment_of_Early_Stage.pdf-9fd5e878",
        "document": "This review article examines the evolving role of magnetic resonance imaging (MRI) in the diagnosis and treatment of early-stage lung cancer.  While MRI has traditionally faced challenges due to lung tissue properties, advancements in technology, such as new sequences and functional MRI techniques (DWI, DCE), are increasing its clinical relevance.  The integration of MRI into radiation treatment delivery via MR-linacs offers real-time image guidance and adaptive radiotherapy, potentially improving treatment outcomes and reducing toxicities.  Despite limitations, MRI shows promise as a valuable tool for early lung cancer management.",
        "metadata": {
            "identifier": "21efa48f4fce007d80e0fff6d23fa9e22f479ed6b063f7ce116cc3eae6e7a070",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:25.568765+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\A Review of the Role of MRI in Diagnosis and Treatment of Early Stage.pdf",
            "name": "A Review of the Role of MRI in Diagnosis and Treatment of Early Stage.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Research",
            "keywords": [
                "MRI",
                "Lung Cancer",
                "Radiotherapy",
                "Image-Guided Radiotherapy",
                "Diffusion-Weighted Imaging",
                "Dynamic Contrast-Enhanced MRI",
                "MR-linac",
                "Early Stage Lung Cancer",
                "Treatment Response",
                "Oncology"
            ],
            "author": "Austin J. Sim, Evangelia Kaza, Lisa Singer, Stephen A. Rosenberg",
            "timestamp": "June 1, 2020",
            "headings": [
                "Abstract",
                "1. Introduction",
                "2. Barriers to lung MRI",
                "3. Advances in MRI technology",
                "4. Lung functional imaging",
                "5. MRI in radiation treatment",
                "6. Conclusion",
                "Figure Legends",
                "References",
                "Highlights"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Accuracy_of_Fine_Needle_Aspiration_Cytology_in_the_Pathological_Typing_of_Non-small_Cell_Lung_Cancer.pdf-296ee71f",
        "document": "This research article investigates the accuracy of fine needle aspiration cytology (FNAC) in typing non-small cell lung cancer (NSCLC) compared to histology.  The study analyzed 186 NSCLC cases with both cytology and histology results, finding an 88% concordance rate between the two methods.  The positive predictive value of FNAC was high for both adenocarcinoma (92%) and squamous cell carcinoma (82%). The authors conclude that FNAC, especially when performed by experts, is a valuable tool for NSCLC typing and treatment planning, particularly when more invasive procedures are not feasible.",
        "metadata": {
            "identifier": "574ae3ece688f6dad75f4dac746766aa62afe9e971a3179a0c2d4608f6648f11",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:29.812673+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer.pdf",
            "name": "Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Fine needle aspiration cytology",
                "FNAC",
                "Histology",
                "Adenocarcinoma",
                "Squamous cell carcinoma",
                "Accuracy",
                "Diagnosis",
                "Treatment planning"
            ],
            "author": "Rita Nizzoli, Marcello Tiseo, Francesco Gelsomino, Marco Bartolotti, Maria Majori, Lilia Ferrari, Massimo De Filippo, Guido Rindi, Enrico Maria Silini, Annamaria Guazzi, Andrea Ardizzoni",
            "timestamp": "March 2011",
            "headings": [
                "KeyWords",
                "Background",
                "Methods",
                "Results",
                "Conclusion",
                "PATIENTS AND METHODS",
                "Patients and Study Design",
                "Cytological Diagnosis",
                "Histological Diagnosis",
                "Statistical Analysis",
                "RESULTS",
                "DISCUSSION",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ALK-rearrangement_in_non-small-cell_lung_cancer_NSCLC_.pdf-58649d5d",
        "document": "This invited review article focuses on ALK-rearrangement in non-small-cell lung cancer (NSCLC), a significant driver mutation in a subset of NSCLC patients.  The authors discuss the different types of ALK gene mutations (rearrangement, amplification, and point mutation), their detection methods (FISH, IHC, RT-PCR, and NGS), and the use of ALK tyrosine kinase inhibitors (TKIs) like crizotinib for treatment.  The review highlights the advantages and limitations of each detection method, emphasizing the importance of accurate diagnosis for effective targeted therapy.  Finally, it explores the development of next-generation ALK inhibitors to overcome drug resistance.",
        "metadata": {
            "identifier": "d96688a79cd81ddcf3637298333c3719980c0b45bdc70fb6f6a4e0e91bda86ba",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:34.431631+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\ALK-rearrangement in non-small-cell lung cancer (NSCLC).pdf",
            "name": "ALK-rearrangement in non-small-cell lung cancer (NSCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ALK-rearrangement",
                "NSCLC",
                "ALK tyrosine kinase inhibitor",
                "Crizotinib",
                "FISH",
                "IHC",
                "RT-PCR",
                "NGS",
                "drug resistance"
            ],
            "author": "Xue Du, Yun Shao, Hai-Feng Qin, Yan-Hong Tai, Hong-Jun Gao",
            "timestamp": "2018",
            "headings": [
                "ALK-rearrangement in non-small-cell lung cancer (NSCLC)",
                "Types of oncogenesis in ALK",
                "ALK rearrangement in non-small cell lung cancer (NSCLC)",
                "ALK rearrangement detection methods in NSCLC patients",
                "ALK inhibitors",
                "Next generation ALK inhibitors",
                "Acknowledgment",
                "Disclosure",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ALK-rearrangements_and_testing_methods_in_non-small_cell_lung_cancer.pdf-a8d31b43",
        "document": "This scientific review article focuses on ALK-rearrangements in non-small cell lung cancer (NSCLC), their detection methods, and treatment strategies.  The authors discuss the ALK gene's role in various cancers, emphasizing its significance in NSCLC (4-9% of cases).  Different molecular diagnostic techniques for identifying ALK rearrangements, including FISH, IHC, and PCR, are compared.  The review also covers the use of crizotinib and second-generation ALK inhibitors, along with mechanisms of crizotinib resistance.",
        "metadata": {
            "identifier": "86d2a3b96a019726268749a3a003e0c1b1343ea2cbb6a43d2dabc7c8e9e4df16",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:42.461902+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\ALK-rearrangements and testing methods in non-small cell lung cancer.pdf",
            "name": "ALK-rearrangements and testing methods in non-small cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "ALK",
                "Non-small cell lung cancer",
                "Crizotinib",
                "EML4-ALK fusion",
                "Tyrosine kinase inhibitor",
                "Molecular diagnostics",
                "Cancer therapy",
                "IHC",
                "FISH",
                "PCR"
            ],
            "author": "Rodney E. Shackelford, Moiz Vora, Kim Mayhall, and James Cotelingam",
            "timestamp": "April 22, 2014",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "Anaplastic Lymphoma Kinase Gene Signaling",
                "ALK Mutations in Cancer",
                "ALK Activity in NSCLC",
                "Molecular Diagnostic Testing Methods for ALK-Fusions in NSCLC",
                "FISH",
                "ALK IHC",
                "PCR",
                "Other Methods of EML4-ALK Detection in NSCLC",
                "Alk-Inhibitor-Specific Therapy for NSCLC",
                "Molecular Mechanisms of Crizotinib Resistance",
                "Second Generation ALK Inhibitors",
                "HSP90 Inhibitors and EML-ALK Positive Lung Cancer",
                "CONCLUSION",
                "ACKNOWLEDGMENTS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Biomarkers_in_Lung_Cancer_Screening.pdf-b6be8203",
        "document": "This review article examines the use of molecular biomarkers in lung cancer screening, focusing on two key areas: improving risk assessment to select individuals for screening and characterizing indeterminate pulmonary nodules (IPNs) detected during computed tomography (CT) scans.  The authors discuss various promising biomarkers, including autoantibodies, complement fragments, microRNAs, circulating tumor DNA, and exhaled breath biomarkers.  They emphasize the importance of integrating different molecular technologies with imaging and artificial intelligence for enhanced diagnostic accuracy.  Finally, the authors propose a trial design to test the clinical utility of biomarker-based risk assessment strategies.",
        "metadata": {
            "identifier": "53f18fb05fc7dbbe488a0535ea1d6c77caeedc1c2b91866c1a935587518a8c67",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:50.300143+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Biomarkers in Lung Cancer Screening.pdf",
            "name": "Biomarkers in Lung Cancer Screening.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Biomarkers",
                "Lung Cancer",
                "Screening",
                "Indeterminate Pulmonary Nodules (IPNs)",
                "Risk Assessment",
                "Computed Tomography (CT)",
                "MicroRNAs",
                "Circulating Tumor DNA",
                "Exhaled Breath Biomarkers",
                "Artificial Intelligence"
            ],
            "author": "Luis M. Seijo, MD, PhD; Nir Peled, MD, PhD; Daniel Ajona, PhD; Mattia Boeri, PhD; John K. Field, PhD; Gabriella Sozzi, PhD; Ruben Pio, PhD; Javier J. Zulueta, MD, PhD; Avrum Spira, MD, MSc; Pierre P. Massion, MD; Peter J. Mazzone, MD, MPH; Luis M. Montuenga, PhD",
            "timestamp": "December 4, 2018",
            "headings": [
                "REVIEW ARTICLE",
                "Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges",
                "Lung Cancer Screening Challenges: Is Imaging Sufficient for Successful Screening? The Unmet Needs",
                "What Is a Good Biomarker?",
                "Optimizing Discovery of Lung Cancer Biomarkers",
                "The Metrics of Success",
                "Current Promising Molecular Biomarkers",
                "Emerging Biomarkers, New Technologies to Follow, and Future Directions. The Power of Integration",
                "EB Biomarkers",
                "Sputum Cell–Based Image Analysis",
                "Metabolomics",
                "Genetic Predisposition to Lung Cancer",
                "Integration of Molecular Biomarkers with Radiomics and Artificial Intelligence",
                "Integration of Multiple NGS Analysis in ctDNA",
                "Future Research Challenges",
                "The Future of Molecular Biomarkers in the Context of Lung Cancer Screening",
                "Acknowledgments",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Bronchoscopy_for_the_Diagnosis_and_Staging.pdf-be910c6b",
        "document": "This article reviews bronchoscopic techniques for diagnosing and staging lung cancer.  It covers established methods like forceps and brush biopsies, bronchoalveolar lavage, and transbronchial needle aspiration, detailing their accuracy based on tumor characteristics.  The article also introduces newer technologies such as autofluorescence bronchoscopy, narrow band imaging, and endoscopic ultrasound, highlighting their roles in early detection and staging.  The authors emphasize the potential of these advancements, particularly in minimally invasive mediastinal sampling, and discuss the future of bronchoscopy in lung cancer diagnosis.",
        "metadata": {
            "identifier": "e24a6316da743dfa2d9af4706c778171abb62d1fa206d11c48dfc15ed26c4288",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:19:56.258685+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Bronchoscopy for the Diagnosis and Staging.pdf",
            "name": "Bronchoscopy for the Diagnosis and Staging.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical",
            "keywords": [
                "Bronchoscopy",
                "Lung Cancer",
                "Diagnosis",
                "Staging",
                "Endobronchial Ultrasound",
                "Electromagnetic Navigation",
                "Autofluorescence Bronchoscopy",
                "Narrow Band Imaging"
            ],
            "author": "Ezzat El-Bayoumi, M.D. and Gerard A. Silvestri, M.D., M.S., F.C.C.P.",
            "timestamp": "2008",
            "headings": [
                "ABSTRACT",
                "BRONCHOSCOPIC TECHNIQUES for Endobronchial Disease",
                "ENDOBRONCHIAL DISEASE",
                "Bronchoscopy with Forceps Biopsy",
                "Bronchoscopy with Brush Biopsy",
                "Bronchoscopy with Bronchoalveolar Lavage or Wash",
                "Transbronchial Needle Aspiration",
                "Combining Techniques",
                "PERIPHERAL LUNG LESIONS",
                "Forceps Biopsy",
                "Brush Biopsy",
                "Bronchoscopy with Bronchoalveolar Lavage or Wash for Peripheral Lesions",
                "Computed Tomographic Fluoroscopy",
                "SAMPLING OF THE MEDIASTINUM",
                "Transbronchial Needle Aspiration for Sampling the Mediastinum",
                "Endoscopic Ultrasound with Fine Needle Aspiration",
                "Endobronchial ultrasound with Transbronchial Needle Aspiration",
                "EMERGING TECHNOLOGIES",
                "Autofluorescence Bronchoscopy",
                "Narrow Band Imaging Bronchoscopy",
                "Electromagnetic Navigation",
                "Optical Coherence Tomography and Confocal Laser Fluorescent Microscopy",
                "THE FUTURE",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Current_and_Future_Development_in_Lung_Cancer_Diagnosis.pdf-879c2e8f",
        "document": "This review article from the International Journal of Molecular Sciences discusses current and future developments in lung cancer diagnosis.  The authors highlight the critical need for earlier diagnosis due to the high mortality rate associated with late-stage detection.  Current methods like low-dose CT scans and sputum cytology are analyzed for their advantages and limitations.  The review focuses on the potential of liquid biopsies and novel biomarkers found in body fluids for improved early detection and personalized treatment strategies.",
        "metadata": {
            "identifier": "51119ea42426bdd9575de582620f76a1ee5b11fd614ee778ab7a9a33fa6c42e9",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:02.406759+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Current and Future Development in Lung Cancer Diagnosis.pdf",
            "name": "Current and Future Development in Lung Cancer Diagnosis.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "lung cancer",
                "diagnosis",
                "biomarkers",
                "liquid biopsy",
                "early detection",
                "screening",
                "imaging",
                "ctDNA"
            ],
            "author": "Reem Nooreldeen and Horacio Bach",
            "timestamp": "Published: 12 August 2021",
            "headings": [
                "Abstract",
                "1. Introduction",
                "2. Lung Cancer Staging",
                "3. Classification",
                "4. SCLC",
                "5. NSCLC",
                "6. Traditional Diagnosis and Screening",
                "7. Lung Tissue Biopsies",
                "8. Transition to Biomarker Applications",
                "9. Liquid Biopsies Use in Lung Cancer",
                "10. Applications of Biomarkers in Clinical Samples",
                "11. Conclusions and Future Venues",
                "Author Contributions",
                "Funding",
                "Conflicts of Interest",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Current_Challenges_and_Future_Advances_in_Lung_Cancer.pdf-eae70398",
        "document": "This editorial by Giovanni Vicidomini reviews ten articles on recent advances in lung cancer diagnosis and treatment.  The articles cover various aspects, including genetic mutations, novel biomarkers, targeted therapies like tyrosine kinase inhibitors (TKIs), and immunotherapy.  Challenges remain in treating rare lung cancers and overcoming resistance to existing therapies.  The editorial highlights the need for further research to improve prognosis and quality of life for lung cancer patients.",
        "metadata": {
            "identifier": "0a769e06cff8f51bd135f89042cea4853bfbf74fe1ec831fb42c9d1bfa2556b3",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:05.815461+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Current Challenges and Future Advances in Lung Cancer.pdf",
            "name": "Current Challenges and Future Advances in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Targeted Therapy",
                "Immunotherapy",
                "Biomarkers",
                "Genetics",
                "Diagnosis",
                "Treatment",
                "Prognosis",
                "Tyrosine Kinase Inhibitors (TKIs)",
                "Cell-free DNA"
            ],
            "author": "Giovanni Vicidomini",
            "timestamp": "2023-07-21",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Development_of_PD-1PD-L1.pdf-31a0dcb6",
        "document": "This scientific review article discusses the PD-1/PD-L1 pathway's role in non-small cell lung cancer (NSCLC) development and treatment.  The authors explore the pathway's mechanism in tumor immune escape and the clinical development of PD-1/PD-L1 inhibitors.  They analyze the efficacy, toxicity, and combination therapies involving these inhibitors, highlighting challenges and future research directions.  The review emphasizes the need for further research to optimize treatment strategies and identify predictive biomarkers for NSCLC patients.",
        "metadata": {
            "identifier": "12aed21610a415362a0dc7a56e69e08728f11fda526b4bdc28845fa8822b8c81",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:11.110960+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Development of PD-1PD-L1.pdf",
            "name": "Development of PD-1PD-L1.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "PD-1",
                "PD-L1",
                "Non-small cell lung cancer (NSCLC)",
                "Tumor immune microenvironment",
                "Immunotherapy",
                "Checkpoint inhibitors",
                "Cancer treatment",
                "Biomarkers"
            ],
            "author": "Jiabei He, Ying Hu, Mingming Hu & Baolan Li",
            "timestamp": "August 17, 2015",
            "headings": [
                "Immune checkpoint pathways and cancer",
                "The biological characteristics of PD-1/PD-L1 pathway and its role in tumor",
                "PD-1/PD-L1 mediate immune suppression by multiple mechanisms",
                "The clinical significance of PD-1/PD-L1 pathway in NSCLC",
                "Drugs targeting PD-1, PD-L1 and combination with other cancer treatments",
                "The combination therapy",
                "Safety of drugs",
                "Prospects and problems",
                "Conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Fine-needle_aspiration_biopsy_versus_core-needle_biopsy_in_diagnosing_lung_cancer.pdf-a46d7aa6",
        "document": "This systematic review compares fine-needle aspiration biopsy (FNAB) and core-needle biopsy (CNB) for diagnosing lung cancer.  The study analyzed eleven studies, finding insufficient evidence to definitively favor one technique over the other for overall diagnosis of lung malignancy.  However, CNB showed potentially higher specificity for benign lesions and accuracy in specific diagnoses.  No significant difference in complication rates (pneumothorax or hemoptysis) was observed between the two techniques.",
        "metadata": {
            "identifier": "3012e4d561b65a59ead3c0c0dbcc2115a96d0f1718a3041204bb236f26682012",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:17.410828+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Fine-needle aspiration biopsy versus core-needle biopsy in  diagnosing lung cancer.pdf",
            "name": "Fine-needle aspiration biopsy versus core-needle biopsy in  diagnosing lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Fine-Needle Aspiration Biopsy (FNAB)",
                "Core-Needle Biopsy (CNB)",
                "Diagnostic Accuracy",
                "Systematic Review",
                "Sensitivity",
                "Specificity",
                "Complications"
            ],
            "author": "X. Yao, M.M. Gomes, M.S. Tsao, C.J. Allen, W. Geddie, and H. Sekhon",
            "timestamp": "February 2012",
            "headings": [
                "ABSTRACT",
                "1. BACKGROUND",
                "2. METHODS",
                "2.1 Search Strategy",
                "2.2 Study Selection Criteria",
                "2.3 Data Abstraction",
                "2.4 Study Quality Assessment",
                "2.5 Data Analysis",
                "3. RESULTS",
                "3.1 Study Details and Quality",
                "3.2 Diagnostic Characteristics",
                "3.3 Overall Diagnostic Characteristics",
                "3.4 Specific Diagnostic Characteristics",
                "3.5 Image Guidance",
                "3.6 Lung Biopsy",
                "3.7 On-Site Cytopathologist",
                "3.8 FNAB and CNB Performed on the Same Patient",
                "3.9 Diagnostic Yields",
                "3.10 Complications",
                "4. DISCUSSION",
                "5. CONCLUSIONS",
                "6. ACKNOWLEDGMENTS",
                "7. CONFLICT OF INTEREST DISCLOSURES",
                "8. REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Liquid_biopsy_for_lung_cancer_early_detection.pdf-804becb9",
        "document": "This review article discusses the use of liquid biopsy for early detection of lung cancer.  It explores various circulating biomarkers, including cell-free circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and tumor-educated platelets (TEPs), and their potential roles in diagnosis.  The authors examine recent studies evaluating these biomarkers and the associated techniques, highlighting challenges and future directions in clinical application.  The goal is to identify sensitive and specific biomarkers to complement or replace current diagnostic methods like low-dose computed tomography (LDCT), which suffers from high false-positive rates.  Ultimately, the aim is to improve early detection and patient outcomes.",
        "metadata": {
            "identifier": "6358a0bf68aaec82586bab2972ae628e6a6ca1f1389c920a957c999c71b25973",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:24.816699+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Liquid biopsy for lung cancer early detection.pdf",
            "name": "Liquid biopsy for lung cancer early detection.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Liquid Biopsy",
                "Early Detection",
                "Circulating Tumor DNA (ctDNA)",
                "Circulating Tumor Cells (CTCs)",
                "Exosomes",
                "Tumor-Educated Platelets (TEPs)",
                "Biomarkers",
                "Low-Dose Computed Tomography (LDCT)"
            ],
            "author": "Mariacarmela Santarpia, Alessia Liguori, Alessandro D’Aveni, Niki Karachaliou, Maria Gonzalez-Cao, Maria Grazia Daffinà, Chiara Lazzari, Giuseppe Altavilla, Rafael Rosell",
            "timestamp": "February 26, 2018",
            "headings": [
                "Abstract",
                "Introduction",
                "Clinical applications of liquid biopsy",
                "Circulating cell-free tumor DNA",
                "Gene methylation in cell-free tumor DNA",
                "CTCs",
                "microRNAs",
                "Exosomes",
                "Tumor educated platelets (TEPs)",
                "Conclusions",
                "Acknowledgements",
                "Footnote",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Liquid_biopsy_in_lung_cancer_significance.pdf-1cf7074d",
        "document": "This review article from *Molecular Cancer* (2022) discusses the use of liquid biopsy in lung cancer diagnostics, prediction, and treatment monitoring.  The authors detail the research progress and clinical applications of various liquid biopsy components, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and microRNAs.  The non-invasive nature of liquid biopsy offers advantages over traditional tissue biopsies, enabling real-time monitoring of tumor status and guiding personalized treatment strategies.  However, limitations such as low biomarker concentrations and the need for standardized detection methods are also addressed.",
        "metadata": {
            "identifier": "0843c1b37e5ebfacc8808c98963728465abcc03325ef5f15d173f1e851e6d974",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:31.569919+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Liquid biopsy in lung cancer significance.pdf",
            "name": "Liquid biopsy in lung cancer significance.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Liquid Biopsy",
                "Circulating Tumor Cells (CTCs)",
                "Circulating Tumor DNA (ctDNA)",
                "Exosomes",
                "MicroRNAs (miRNAs)",
                "Diagnostics",
                "Treatment Monitoring",
                "Precision Medicine"
            ],
            "author": "Wen Li, Ji-Bin Liu, Li-Kun Hou, Fei Yu, Jie Zhang, Wei Wu, Xiao-Mei Tang, Feng Sun, Hai-Min Lu, Jing Deng, Jie Bai, Juan Li, Chun-Yan Wu, Qin-Lu Lin, Zhong-Wei Lv, Gao-Ren Wang, Geng-Xi Jiang, Yu-Shui Ma, Da Fu",
            "timestamp": "2022",
            "headings": [
                "Abstract",
                "Introduction",
                "Clinical application and technical research progress of liquid biopsy in lung cancer",
                "CTCs",
                "ctDNA",
                "Exosomes",
                "Other liquid biopsy components",
                "Conclusions",
                "Abbreviations",
                "Acknowledgements",
                "Authors’ contributions",
                "Funding",
                "Availability of data and materials",
                "Declarations",
                "Ethics approval and consent to participate",
                "Consent for publication",
                "Competing interests",
                "Author details",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Detection_using_CT_Scan_Images.pdf-b977869b",
        "document": "This research paper evaluates computer-aided techniques for lung cancer detection using CT scan images.  The authors analyze existing methods, highlighting their limitations, particularly in accuracy and the lack of benign/malignant classification.  A new model is proposed that incorporates median and Gaussian filtering for noise reduction, watershed segmentation for nodule detection, and support vector machines for classification.  The results show improved accuracy compared to previous models, although further improvements are suggested for future work.",
        "metadata": {
            "identifier": "60f696f2c4a193979b503d3f8fe06ce5ec7c3099b1dbc13edca7649c555bfea4",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:36.436369+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Lung Cancer Detection using CT Scan Images.pdf",
            "name": "Lung Cancer Detection using CT Scan Images.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer Detection",
                "CT Scan Image",
                "Image Processing",
                "Machine Learning",
                "Support Vector Machine",
                "Watershed Segmentation",
                "Computer-Aided Diagnosis",
                "Medical Imaging"
            ],
            "author": "Suren Makaju, P.W.C. Prasad, Abeer Alsadoon, A. K. Singh, A. Elchouemi",
            "timestamp": "2018",
            "headings": [
                "Abstract",
                "1. Introduction",
                "2. Literature Review",
                "3. Proposed Model",
                "3.2 Image Preprocessing",
                "3.3 Segmentation",
                "3.3 Features extraction",
                "3.4 Classification",
                "4. Implementation",
                "5. Result and Evaluation of Implementation",
                "6. Conclusion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Diagnosis_by_Fine_Needle.pdf-6440fe58",
        "document": "This study investigates the impact of pre-operative CT-guided fine needle aspiration (FNA) on the resection rate of non-malignant lung nodules in patients undergoing evaluation for lung cancer.  Researchers found that patients who underwent FNA before surgery had a significantly lower resection rate of non-malignant lesions (7.9%) compared to those without FNA (25.9%).  The study highlights the high diagnostic accuracy of FNA (97%) compared to PET scans (65%) and emphasizes the importance of preoperative FNA in reducing unnecessary surgeries.  The findings suggest that frequent use of FNA can improve the efficiency and safety of lung cancer diagnosis and treatment.",
        "metadata": {
            "identifier": "02394f3de6155d797fc9e3489af37505d4a5fe87121cf8d1e48bcb9ede4c7b6a",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:41.032483+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Lung Cancer Diagnosis by Fine Needle.pdf",
            "name": "Lung Cancer Diagnosis by Fine Needle.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Fine Needle Aspiration (FNA)",
                "Surgical Resection",
                "Non-malignant Nodules",
                "Diagnostic Accuracy",
                "Positron Emission Tomography (PET)",
                "Sensitivity",
                "Specificity"
            ],
            "author": "Julie A. Barta, MD, Claudia I. Henschke, PhD, MD, Raja M. Flores, MD, Rowena Yip, MPH, David F. Yankelevitz, MD, and Charles A. Powell, MD",
            "timestamp": "November 7, 2016",
            "headings": [
                "Background",
                "Methods",
                "Results",
                "Patient Characteristics",
                "Diagnosis and Clinical Outcomes",
                "Diagnostic Accuracy of FNA",
                "Predictive Factors for Malignant Disease",
                "Characteristics of the Nonmalignant Disease at Resection Cohort",
                "Comment",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Screening_with_CT_Mayo_clinic_experience.pdf-16fbc712",
        "document": "This study evaluated the effectiveness of low-dose spiral computed tomography (CT) screening for lung cancer in a large cohort of high-risk individuals.  Over three years, 40 cases of lung cancer were diagnosed, with a high rate of early-stage detection.  However, the study also revealed a high rate of benign nodule detection (false positives), raising concerns about overdiagnosis and the potential for unnecessary procedures.  The authors conclude that while CT can detect early-stage lung cancers, its effectiveness as a widespread screening tool remains unproven and requires further investigation.",
        "metadata": {
            "identifier": "0e8a15ecbff15f78ad4d7e4726c9c98fc0dff841f2be9535d8b400ed43b84d78",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:46.027018+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Lung Cancer Screening with CT Mayo clinic experience.pdf",
            "name": "Lung Cancer Screening with CT Mayo clinic experience.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "CT Screening",
                "Low-dose Spiral CT",
                "Early Detection",
                "Overdiagnosis",
                "False Positives",
                "Pulmonary Nodules",
                "Cancer Staging"
            ],
            "author": [
                "Stephen J. Swensen, MD",
                "James R. Jett, MD",
                "Thomas E. Hartman, MD",
                "David E. Midthun, MD",
                "Jeff A. Sloan, PhD",
                "Anne-Marie Sykes, MD",
                "Gregory L. Aughenbaugh, MD",
                "Medy A. Clemens, CCRP"
            ],
            "timestamp": "July 25, 2002",
            "headings": [
                "PURPOSE",
                "MATERIALS AND METHODS",
                "Participants",
                "Follow-up and Recommendations",
                "Imaging and Image Review",
                "RESULTS",
                "Enrollment",
                "DISCUSSION",
                "False-Positive Findings",
                "Overdiagnosis",
                "Potential Harms from False-Positive Findings and Overdiagnosis",
                "Additional Findings",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Magnetic_resonance_imaging_in_precision_radiation_therapy_for_lung_cancer.pdf-72a323bf",
        "document": "This review article discusses the use of magnetic resonance imaging (MRI) in precision radiation therapy for lung cancer.  It explores MRI's role in disease staging, target volume delineation, and adaptive radiotherapy, highlighting its advantages over traditional methods like CT scans. The authors focus on the integration of MRI with linear accelerators (MR-Linacs), a novel technology with challenges but significant potential for improving treatment outcomes.  The article also examines the use of functional MRI for dose painting and prediction of normal tissue toxicity.  The Atlantic MR-Linac Consortium's efforts to develop an adaptive workflow for lung cancer treatment are emphasized.",
        "metadata": {
            "identifier": "5df5c68ba4eb1809157b71605066effd57ff065f81aa3efd822c7264f7166493",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:53.066622+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Magnetic resonance imaging in precision radiation therapy for lung cancer.pdf",
            "name": "Magnetic resonance imaging in precision radiation therapy for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Radiotherapy",
                "Magnetic Resonance Imaging (MRI)",
                "MR-Linac",
                "Adaptive Radiotherapy",
                "Treatment Planning",
                "Disease Staging",
                "Organ at Risk (OAR)"
            ],
            "author": "Hannah Bainbridge, Ahmed Salem, Rob H. N. Tijssen, Michael Dubec, Andreas Wetscherek, Corinne Van Es, Jose Belderbos, Corinne Faivre-Finn, Fiona McDonald",
            "timestamp": "September 8, 2017",
            "headings": [
                "Abstract",
                "Background Searching strategy and selection criteria",
                "Disease staging and patient selection",
                "Target and OAR delineation",
                "Treatment planning",
                "Treatment verification",
                "Daily treatment plan adaptation",
                "Real-time target tracking",
                "Early assessment of treatment response",
                "Conclusions",
                "Acknowledgements",
                "Footnote",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-PD-L1_Expression_in_Lung_Cancer.pdf-e6e27c93",
        "document": "This article reviews the state-of-the-art in using PD-L1 expression as a biomarker to predict response to immunotherapy in lung cancer.  The authors discuss challenges in harmonizing PD-L1 detection methods due to variations in antibodies, scoring systems, and positivity cutoffs across different clinical trials.  They highlight the need for standardized methods and definitions to improve patient care and avoid misleading comparisons.  The review also explores other potential biomarkers, such as PD-L2 expression, tumor mutation burden, and other immune checkpoints, to better predict patient response to immunotherapy.",
        "metadata": {
            "identifier": "3b35a2623546aed5c1095e872b2f034813796ca320f229aa9e8eda458ce0dd89",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:20:59.651100+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\PD-L1 Expression in Lung Cancer.pdf",
            "name": "PD-L1 Expression in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "PD-L1",
                "Lung Cancer",
                "Immunotherapy",
                "Biomarker",
                "Immunohistochemistry",
                "Clinical Trials",
                "PD-L2",
                "Tumor Mutation Burden"
            ],
            "author": "Hui Yu, MD, PhD; Theresa A. Boyle, MD, PhD; Caicun Zhou, MD, PhD; David L. Rimm, MD, PhD; Fred R. Hirsch, MD, PhD",
            "timestamp": "April 23, 2016",
            "headings": [
                "Introduction",
                "PD-L1 Expression Emerges as a Biomarker in Early Studies",
                "Challenges and Pitfalls in Detecting PD-L1 by IHC Analysis",
                "Comparison of Different Antibodies",
                "Definitions of Positivity",
                "Challenges with Characterization of PD-L1 Expression by Cell Type",
                "Heterogeneity and Associated Risks for False-Positive and False-Negative Results",
                "Effect of Tissue Processing on PD-L1 Expression",
                "The Impact of Different Therapies on the Expression of PD-L1",
                "Role of Other PD-L1 Biomarkers",
                "Conclusion",
                "Acknowledgments",
                "References",
                "Update",
                "Erratum"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-PET_CT_imaging_in_different_types_of_lung_cancer.pdf-8fc80a67",
        "document": "This review article from the European Journal of Radiology (2012) examines the applications of PET/CT imaging in various types of lung cancer.  The authors discuss the use of different PET tracers, such as 18F-FDG, 68Ga-DOTA-peptides, and 18F-DOPA, for staging, treatment planning, and monitoring response to therapy in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bronchioloalveolar carcinoma (BAC), lung neuroendocrine tumors (NET), and solitary pulmonary nodules (SPN).  The review highlights the advantages and limitations of PET/CT compared to conventional imaging techniques like CT.  The overall aim is to provide a comprehensive overview of PET/CT's role in the diagnosis and management of lung cancer.",
        "metadata": {
            "identifier": "16987996590d4d8aae7f389a72f659c5b2dc2e21e758fca87b643eecdaf27d45",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:09.092915+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\PET,CT imaging in different types of lung cancer.pdf",
            "name": "PET,CT imaging in different types of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "PET/CT",
                "18F-FDG",
                "68Ga-DOTA-peptides",
                "18F-DOPA",
                "NSCLC",
                "SCLC",
                "Staging",
                "Treatment Response"
            ],
            "author": "Valentina Ambrosini, Silvia Nicolini, Paola Carolia, Cristina Nanni, Arianna Massaro, Maria Cristina Marzola, Domenico Rubello, Stefano Fanti",
            "timestamp": "2012",
            "headings": [
                "1. Introduction",
                "2. Non-small cells lung cancer (NSCLC)",
                "2.1. PET/CT for T detection",
                "2.2. PET/CT for N detection",
                "2.3. PET/CT for M detection",
                "2.4. Radiation therapy planning",
                "3. Small cell lung cancer",
                "4. Bronchioloalveolar carcinoma (BAC)",
                "5. Solitary pulmonary nodule (SPN)",
                "6. Neuroendocrine tumours (NET) of the lung",
                "7. Conclusions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-PET_CT_Versus_MRI_for_Diagnosis.pdf-8c3b475c",
        "document": "This review article compares PET/CT and MRI for diagnosing, staging, and following up lung cancer.  PET/CT, combining metabolic and morphologic data, shows higher sensitivity and accuracy for lung nodule characterization and metastasis detection than conventional methods. MRI, while initially challenging, is becoming a useful alternative with advancements in techniques like diffusion-weighted MRI (DWI) for distinguishing benign and malignant nodules and evaluating treatment response.  The article also explores the potential of PET/MRI hybrid systems, offering higher soft-tissue contrast and reduced radiation exposure.  Finally, the role of both modalities in early lung cancer detection is discussed.",
        "metadata": {
            "identifier": "1d8eb2dc1817a84d5968c06392adaa086e704ef1732afec6ae86ac726c938187",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:16.341728+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\PET,CT Versus MRI for Diagnosis.pdf",
            "name": "PET,CT Versus MRI for Diagnosis.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "PET/CT",
                "MRI",
                "Diagnosis",
                "Staging",
                "Follow-up",
                "Metastasis",
                "Treatment Response",
                "Diffusion-weighted MRI (DWI)",
                "PET/MRI"
            ],
            "author": "Hyun Su Kim, MD, Kyung Soo Lee, MD, Yoshiharu Ohno, MD, PhD, Edwin J.R. van Beek, MD, PhD, and Juergen Biederer, MD",
            "timestamp": "September 27, 2014",
            "headings": [
                "PET/CT Versus MRI for Diagnosis, Staging, and Follow-up of Lung Cancer",
                "Evaluation of patients with suspected lung cancer comprises PET/CT in Lung Cancer",
                "PET/CT in Solitary Pulmonary Nodule (SPN) Tissue Characterization",
                "Volume-Based Assessment of PET/CT in Lung Cancer",
                "PET/CT as a Follow-up Imaging Tool",
                "MRI in Lung Cancer",
                "Available Protocols",
                "MRI for the Detection of Pulmonary Nodules",
                "MRI for the Assessment of Malignancy and Tumor Viability",
                "Implementation of Lung MRI Into Hybrid Systems",
                "MRI as a Potential Tool for Early Detection of Lung Cancer",
                "PET/CT Versus MRI in Lung Cancer Staging",
                "TUMOR STAGING",
                "NODAL STAGING",
                "METASTASIS STAGING",
                "Performance Comparison in Cancer Staging Between PET/CT and WB MRI",
                "Conclusion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Sensitivity_and_Specificity_of_Chest_X-Ray_Screening.pdf-1f70dfcf",
        "document": "This review article by Gavelli and Giampalma examines the effectiveness of chest X-ray screening for early lung cancer detection.  While randomized controlled trials haven't shown a reduction in mortality rates, the authors argue that screening leads to earlier diagnosis, improved survival, and better disease staging. They acknowledge limitations of chest X-rays, including observer error and the difficulty in detecting small tumors, but advocate for its continued use as a secondary prevention method in high-risk populations.  The article also discusses the potential of computed tomography (CT) as a superior screening method.",
        "metadata": {
            "identifier": "d803d365b8e39b35139ad8af90043d6f37d0c76c4eb22eb5902899c1619488ab",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:19.263468+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Sensitivity and Specificity of Chest X-Ray Screening.pdf",
            "name": "Sensitivity and Specificity of Chest X-Ray Screening.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Research",
            "keywords": [
                "Lung Cancer",
                "Chest X-Ray",
                "Screening",
                "Early Detection",
                "Mortality",
                "Survival",
                "Computed Tomography (CT)",
                "Secondary Prevention",
                "Radiography"
            ],
            "author": "Giampaolo Gavelli, M.D. and Emanuela Giampalma, M.D.",
            "timestamp": "June 19, 2000",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Sensitivity_of_chest_X-ray_for_detecting_lung_cancer_in_people_presenting_with_symptoms.pdf-e921f51d",
        "document": "This systematic review assesses the sensitivity of chest X-rays in detecting lung cancer among symptomatic individuals.  The researchers analyzed 21 studies, finding that high-quality studies suggest a sensitivity of 77-80%, meaning chest X-rays miss lung cancer in at least 20% of cases.  This highlights the need for further investigation in high-risk patients with negative chest X-rays and raises questions about the limitations of chest X-rays as the primary diagnostic tool for lung cancer. The authors suggest that increased access to CT scans may improve early detection and outcomes, but further research is needed to balance the benefits against potential harms.",
        "metadata": {
            "identifier": "a31287e05aa502e63de9f612a318673c8df8ec04f3606e9c31ab12c46f371531",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:24.804122+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms.pdf",
            "name": "Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Chest X-ray",
                "Sensitivity",
                "Diagnostic Accuracy",
                "Systematic Review",
                "Early Diagnosis",
                "Computed Tomography (CT)",
                "Primary Care"
            ],
            "author": "Stephen H Bradley, Sarah Abraham, Matthew EJ Callister, Adam Grice, William T Hamilton, Rocio Rodriguez Lopez, Bethany Shinkins and Richard D Neal",
            "timestamp": "2 May 2019",
            "headings": [
                "Abstract",
                "Background",
                "Aim",
                "Method",
                "Design and setting",
                "Search strategy",
                "Inclusion and exclusion criteria",
                "Study selection",
                "Data extraction",
                "Analysis",
                "RESULTS",
                "Summary of eligible studies",
                "Quality assessment",
                "DISCUSSION",
                "Summary",
                "Strengths and limitations",
                "Comparison with existing literature",
                "Implications for research and practice",
                "Funding",
                "Ethical approval",
                "Provenance",
                "Competing interests",
                "Acknowledgements",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Future_of_Bronchoscopy_in_treatment_and_diagnosis_of_lung_cancer.pdf-dbdebef6",
        "document": "This 2006 thematic review article discusses the advancements and future directions of bronchoscopy in diagnosing, staging, and treating lung cancer.  It covers established techniques like forceps biopsy, needle aspiration, and brushing, alongside newer technologies such as endobronchial ultrasound and autofluorescence bronchoscopy.  The authors highlight the evolving role of bronchoscopy in minimally invasive procedures and multimodality treatment approaches for lung cancer.  The article also explores promising techniques like electromagnetic navigation and confocal fluorescence microendoscopy, emphasizing the need for greater integration of bronchoscopy in oncology.",
        "metadata": {
            "identifier": "5a265d1169cffc7124b95b55427c578362545d13681d9f5959bf53c12b29cf84",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:30.375867+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\The Future of Bronchoscopy in treatment and diagnosis of lung cancer.pdf",
            "name": "The Future of Bronchoscopy in treatment and diagnosis of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Bronchoscopy",
                "Lung Cancer",
                "Diagnosis",
                "Staging",
                "Treatment",
                "Endobronchial Ultrasound",
                "Autofluorescence Bronchoscopy",
                "Electromagnetic Navigation",
                "Confocal Fluorescence Microendoscopy"
            ],
            "author": "Felix J.F. Herth, Ralf Eberhardt, Armin Ernst",
            "timestamp": "2006",
            "headings": [
                "Abstract",
                "Introduction",
                "Current Techniques in Diagnostic Bronchoscopy",
                "Forceps Biopsy",
                "Transbronchial Needle Aspiration",
                "Brushing and Aspiration Cytology",
                "Current Techniques in Therapeutic Bronchoscopy",
                "Laser Therapy",
                "Electrocautery and Cryotherapy",
                "Stenting",
                "Recent Developments in Bronchoscopy",
                "Endobronchial Ultrasound",
                "Autofluorescence Endoscopy",
                "Electromagnetic Navigation",
                "Promising Techniques",
                "Magnification",
                "Narrow-Band Imaging",
                "Confocal Fluorescence Microendoscopy",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_Role_of_Artificial_Intelligence_in_Early_Cancer_Diagnosis.pdf-eb39638b",
        "document": "This review article examines the role of artificial intelligence (AI) in early cancer diagnosis.  The authors discuss how AI algorithms, particularly machine learning and deep learning, can assist clinicians in screening asymptomatic patients, investigating symptomatic patients, and diagnosing cancer recurrence.  Various data types, including electronic health records, medical images, and biopsy samples, are analyzed using AI to improve risk stratification and early detection.  The article also addresses challenges and ethical considerations associated with AI implementation in healthcare.",
        "metadata": {
            "identifier": "e3b70e5a36926feac1f635a0ce9e2bd47b4b66fae4ccff716cb8b1d7f8e5579c",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:45.620099+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\The Role of Artificial Intelligence in Early Cancer Diagnosis.pdf",
            "name": "The Role of Artificial Intelligence in Early Cancer Diagnosis.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Artificial Intelligence",
                "Machine Learning",
                "Deep Learning",
                "Early Cancer Diagnosis",
                "Cancer Screening",
                "Radiomics",
                "Digital Pathology",
                "Multi-Omics Data",
                "Clinical Applications"
            ],
            "author": "Benjamin Hunter, Sumeet Hindocha, Richard W. Lee",
            "timestamp": "Published: 16 March 2022",
            "headings": [
                "1. Introduction",
                "2. An Overview of Artificial Intelligence in Oncology",
                "2.1. Definitions and Model Architectures",
                "2.2. Data Types: Electronic Healthcare Records",
                "2.3. Data Types: Radiology",
                "2.4. Data Types: Digital Pathology",
                "2.5. Data Types: Multi-Omic Data",
                "3. Clinical Applications",
                "3.1. Risk-Stratified Screening of Asymptomatic Patients",
                "3.2. Symptomatic Patient Triage",
                "3.3. Diagnostic Workflow Triage",
                "3.4. Early Detection",
                "3.5. Early Detection of Recurrence",
                "4. Challenges and Future Directions",
                "5. Conclusions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_role_of_bronchoscopy_in_the_diagnosis_of_early_lung_cancer.pdf-d73553af",
        "document": "This review article discusses the role of bronchoscopy in the early diagnosis of lung cancer.  It highlights the limitations of traditional white light bronchoscopy and explores newer techniques like autofluorescence bronchoscopy (AFB), narrow band imaging (NBI), high magnification bronchovideoscopy (HMB), optical coherence tomography (OCT), confocal laser endomicroscopy (CLE), and laser Raman spectroscopy (LRS) to improve diagnostic accuracy.  The authors analyze the effectiveness and limitations of each technique, emphasizing the need for further research in some areas. Early detection is crucial for improving patient outcomes, and these advanced bronchoscopic methods offer promising advancements in this field.",
        "metadata": {
            "identifier": "b480b04bb50b0c30dd1597d48b3aba99f6fdd7f5f60afe736af6259c73a7295a",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:51.032644+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Related works\\The role of bronchoscopy in the diagnosis of early lung cancer.pdf",
            "name": "The role of bronchoscopy in the diagnosis of early lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Research",
            "keywords": [
                "Bronchoscopy",
                "Lung Cancer",
                "Early Diagnosis",
                "Autofluorescence Bronchoscopy",
                "Narrow Band Imaging",
                "Optical Coherence Tomography",
                "Confocal Laser Endomicroscopy",
                "Laser Raman Spectroscopy"
            ],
            "author": "Marco Andolfi, Rossella Potenza, Rosanna Capozzi, Valeria Liparulo, Francesco Puma, Kazuhiro Yasufuku",
            "timestamp": "October 20, 2016",
            "headings": [
                "Abstract",
                "Introduction",
                "AFB",
                "NBI",
                "HMB",
                "OCT",
                "CLE",
                "LRS",
                "EBUS",
                "Conclusions",
                "Acknowledgements",
                "Footnote",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Estimating_the_Prevalence_of_Cancer.pdf-b35e213f",
        "document": "This scientific article estimates the prevalence of cancer in the United States, using data from the Connecticut Tumor Registry.  The study found a significant increase in age-standardized prevalence rates between 1982 and 1994, particularly for breast, prostate, and lung cancers.  Based on Connecticut data, the authors project a substantial increase in the number of Americans who have ever been diagnosed with invasive cancer by 2030.  The findings highlight the need for cancer prevention and further research on cancer survivors.",
        "metadata": {
            "identifier": "c5731be0177d3199792b9e6a6d22732430045234b13b5277c553e581ff9e602a",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:21:55.053992+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Estimating the Prevalence of Cancer.pdf",
            "name": "Estimating the Prevalence of Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "cancer prevalence",
                "cancer incidence",
                "cancer survival",
                "age-standardized rates",
                "Connecticut Tumor Registry",
                "breast carcinoma",
                "prostate carcinoma",
                "lung carcinoma",
                "cancer survivors"
            ],
            "author": "Anthony P. Polednak, Ph.D.",
            "timestamp": "March 7, 1997",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "DISCUSSION",
                "Problems in Estimating Cancer Prevalence",
                "Temporal Trends in Estimated Prevalence Rates",
                "Projections of Prevalence",
                "Implications",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Genetics_of_lung-cancer_susceptibility.pdf-3b0ce865",
        "document": "This review article discusses the genetics of lung cancer susceptibility, focusing on the epidemiology of the disease, the role of tobacco smoking, and the identification of susceptibility genes through genome-wide association studies (GWAS).  The authors highlight three main susceptibility loci (5p15, 6p21, and 15q25) and discuss the implications of these findings for prevention, treatment, and personalized medicine.  While tobacco remains the primary risk factor, genetic factors contribute significantly to individual risk and disease progression.  Future research should focus on identifying additional rare variants and understanding the functional effects of identified genes.",
        "metadata": {
            "identifier": "8b69e15ac938266348d28aa6ff891dae31d85f197facca73da3fb67a87830162",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:04.723952+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Genetics of lung-cancer susceptibility.pdf",
            "name": "Genetics of lung-cancer susceptibility.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Genetics",
                "Genome-Wide Association Studies (GWAS)",
                "Susceptibility Genes",
                "Tobacco Smoking",
                "Epidemiology",
                "Risk Factors",
                "Telomerase",
                "Nicotinic Acetylcholine Receptors"
            ],
            "author": "Paul Brennan, Pierre Hainaut, Paolo Boffetta",
            "timestamp": "October 14, 2010",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Global_Epidemiology_of_Lung_Cancer.pdf-22d0464d",
        "document": "This review article examines the global epidemiology of lung cancer, focusing on international variations in incidence and mortality rates.  The authors analyze trends in industrialized and emerging economies, highlighting the strong correlation between smoking patterns and lung cancer statistics.  They also discuss the increasing incidence of adenocarcinoma, advancements in molecular profiling and targeted therapies, and the growing importance of lung cancer screening.  The review further explores the epidemiologic characteristics of specific groups, including women and never-smokers, and concludes by emphasizing the need for improved early detection and personalized treatment approaches.",
        "metadata": {
            "identifier": "a3fbb0cc865d12d29b635a98131972c329c8abc3fa2c02204050eb6a84e3e63a",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:12.036417+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Global Epidemiology of Lung Cancer.pdf",
            "name": "Global Epidemiology of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Epidemiology",
                "Global Trends",
                "Smoking",
                "Adenocarcinoma",
                "Molecular Profiling",
                "Targeted Therapies",
                "Lung Cancer Screening"
            ],
            "author": "Julie A. Barta, Charles A. Powell, Juan P. Wisnivesky",
            "timestamp": "22 January 2019",
            "headings": [
                "Global Epidemiology of Lung Cancer",
                "Burden of Disease Internationally",
                "Industrialized Countries",
                "Emerging Economies",
                "Developing Countries",
                "Histopathology",
                "Histology",
                "Molecular Markers",
                "Risk Factors and Environmental Exposures",
                "Cigarette Smoking, Secondhand Smoking, and E-cigarettes",
                "Domestic Biomass Fuels",
                "COPD and other Pulmonary Conditions",
                "Occupational Exposures",
                "Ambient Air Pollution and Other Environmental Exposures",
                "Diet and Nutrition",
                "Genetic Factors",
                "Measures of Lung Cancer Risk and Impact on Early Diagnosis",
                "Special Populations",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Incidence_and_mortality.pdf-09147b28",
        "document": "This scientific report analyzes global trends in lung cancer incidence and mortality, examining their correlation with socioeconomic factors.  The study uses data from GLOBOCAN and other sources to assess age-standardized rates and temporal patterns, revealing a strong correlation between lung cancer rates and the Human Development Index (HDI).  While declining trends are observed in men in many countries, increasing trends are prevalent among women, particularly in high-HDI nations. The authors highlight the need for targeted preventive measures, especially in light of these gender disparities and the projected increase in global lung cancer burden.",
        "metadata": {
            "identifier": "64c96bad5ae63360ed19ee6f92a8bc6c8ef91b68e2c2de1f745851520bb5c18d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:17.156432+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Incidence and mortality.pdf",
            "name": "Incidence and mortality.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Incidence",
                "Mortality",
                "Socioeconomic Status",
                "Human Development Index (HDI)",
                "Gross Domestic Product (GDP)",
                "Global Trends",
                "Gender Disparities"
            ],
            "author": "Martin C. S. Wong, Xiang Qian Lao, Kin-Fai Ho, William B. Goggins, Shelly L. A. Tse",
            "timestamp": "Published: xx xx xxxx",
            "headings": [
                "Received: 28 March 2017",
                "Accepted: 3 October 2017",
                "Methods",
                "Data Source",
                "Statistical Analysis",
                "Results",
                "Incidence and mortality of lung cancer in 2012",
                "The correlation between incidence/mortality of lung cancer and socioeconomic development",
                "Temporal trends in incidence of lung cancer",
                "Temporal trends in lung cancer mortality",
                "Discussion"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_-_A_Review.pdf-9a83e940",
        "document": "This review article from the International Journal of Health Sciences and Research provides a comprehensive overview of lung cancer.  It covers the epidemiology, classification (small-cell and non-small-cell lung cancers), detection methods, metastasis, and treatment options for this leading cause of cancer death globally.  The authors discuss various diagnostic techniques, including lymph node analysis and circulating tumor cell detection, and detail different treatment modalities such as surgery, chemotherapy, radiation, and targeted therapies. The review emphasizes the importance of early detection and the challenges in treating advanced-stage lung cancer, particularly in low- and middle-income countries.",
        "metadata": {
            "identifier": "9b185e6b3069a99a598959946b1569d3a83ed9e02e0f4b01325e9619118333d7",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:24.444734+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer - A Review.pdf",
            "name": "Lung Cancer - A Review.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "SCLC",
                "NSCLC",
                "Metastasis",
                "Chemotherapy",
                "Epidemiology",
                "Treatment",
                "Diagnosis",
                "WHO"
            ],
            "author": [
                "V. Sankar",
                "R. Kothai",
                "N. Vanisri",
                "Akilandeswari. S",
                "G. Anandharaj"
            ],
            "timestamp": "October 2023",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "Classification of lung cancer",
                "Small cell lung cancer (SCLC)",
                "Non-small cell lung cancer (NSCLC)",
                "Adenocarcinomas",
                "Squamous Cell Carcinomas",
                "Large Cell Carcinomas",
                "Epidemiology",
                "Clinical manifestation of Lung Cancer",
                "Detection Strategies",
                "METASTASIS",
                "Regional Lymph Node Metastases",
                "Metastasis and Its impact",
                "Treatment of lung cancer",
                "Surgery",
                "Chemotherapy",
                "Chemotherapy of lung cancer",
                "Chemotherapy for small cell lung cancer",
                "Chemotherapy for non-small cell lung cancer",
                "Chemotherapy after surgery",
                "Chemotherapy and radiotherapy",
                "Chemotherapy for locally advanced NSCLC or cancer that has spread",
                "Radiation",
                "CONCLUSION",
                "Declaration by Authors",
                "REFERENCE"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_and_Air_Pollution.pdf-d0d46c2b",
        "document": "This 1995 article by Cohen and Pope reviews epidemiological studies linking ambient air pollution, primarily from fossil fuel combustion, to increased lung cancer rates.  The authors analyze data from occupational groups, urban vs. rural populations, and case-control studies, highlighting a consistent association between exposure to respirable particles and lung cancer risk.  While acknowledging the significant role of cigarette smoking, they argue that current estimates of air pollution's contribution to lung cancer may be too low and advocate for improved epidemiological research methods to better quantify this risk.  The paper concludes that combustion-source air pollution contributes to lung cancer, although the effect is smaller than that of cigarette smoking.",
        "metadata": {
            "identifier": "0a694ae8562f640571fd035bfcf74c383a0e5ed539011a8da0cc6d01ea5e0fe6",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:29.424884+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer and Air Pollution.pdf",
            "name": "Lung Cancer and Air Pollution.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Air pollution",
                "Fossil fuels",
                "Respirable particles",
                "Epidemiology",
                "Combustion",
                "Relative risk",
                "Urban-rural differences",
                "Occupational exposure"
            ],
            "author": "Aaron J. Cohen and C. Arden Pope",
            "timestamp": "1995",
            "headings": [
                "Introduction",
                "Occupational Exposure",
                "Environmental Exposure",
                "Case-Control and Recent Prospective Cohort Studies",
                "Plausibility ofAmbient Air Pollution-Lung Cancer Effect",
                "Epidemiology Research Needs",
                "Conclusions",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Epidemiology_Risk_Factors_and_Prevention.pdf-97852d8b",
        "document": "This article reviews the epidemiology, risk factors, and prevention strategies for lung cancer.  It highlights the strong correlation between lung cancer and cigarette smoking, emphasizing the significant increase in adenocarcinoma rates.  The text also discusses other risk factors such as environmental tobacco smoke, pollution, radon exposure, and genetic predisposition.  Finally, it explores prevention methods including tobacco cessation, tobacco control legislation, HPV vaccination, radon control, and dietary modifications.",
        "metadata": {
            "identifier": "8baed7d2f95f8a2065d79b5cd78f5ae3987861247efa30be0fb094323cf1316f",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:35.837081+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer Epidemiology, Risk Factors, and Prevention.pdf",
            "name": "Lung Cancer Epidemiology, Risk Factors, and Prevention.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Epidemiology",
                "Risk Factors",
                "Prevention",
                "Cigarette Smoking",
                "Adenocarcinoma",
                "Radon",
                "HPV",
                "Genetics",
                "Environmental Factors"
            ],
            "author": "Patricia deGroot, MD and Reginald F. Munden, MD, DMD, MBA",
            "timestamp": "2012",
            "headings": [
                "EPIDEMIOLOGY",
                "Trends in Incidence and Mortality",
                "Lung Cancer in Never-Smokers",
                "Histopathology of Lung Cancer",
                "RISK FACTORS",
                "Genetic Factors",
                "Heredity and genetic susceptibility",
                "Genomic instability",
                "Age",
                "Gender",
                "Race",
                "Behavioral Factors",
                "Tobacco and smoking",
                "Composition of tobacco smoke",
                "Nicotine",
                "Cannabis sativa",
                "Socioeconomic status",
                "Diet",
                "Macronutrients",
                "Micronutrients",
                "Preexisting lung disease",
                "Human papillomavirus",
                "Human immunodeficiency virus",
                "Environmental Factors",
                "Second-hand tobacco smoke",
                "Other environmental pollutants",
                "Radon",
                "Asbestos",
                "Other occupational exposures",
                "PREVENTION",
                "Tobacco Cessation",
                "Tobacco-Control Legislation",
                "Vaccination",
                "Radon Control",
                "Diet",
                "SUMMARY",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_Risk_and_Workplace_Exposure.pdf-48cb630d",
        "document": "This scientific article presents a meta-analysis of 22 studies investigating the link between workplace exposure to environmental tobacco smoke (ETS) and lung cancer risk.  The analysis revealed a 24% increased lung cancer risk among workers exposed to ETS, rising to a 2-fold increase for those highly exposed.  A strong correlation was found between lung cancer risk and duration of ETS exposure. The authors conclude that workplace ETS exposure is a significant risk factor for lung cancer, reinforcing public health concerns and supporting stricter workplace smoking regulations.",
        "metadata": {
            "identifier": "fd4d3caf15fb65db27a668933c659901c767fea99a7276a9fa904383c01bc61e",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:40.725486+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Lung Cancer Risk and Workplace Exposure.pdf",
            "name": "Lung Cancer Risk and Workplace Exposure.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Environmental Tobacco Smoke",
                "Workplace Exposure",
                "Meta-analysis",
                "Relative Risk",
                "Public Health",
                "Occupational Safety",
                "Epidemiology"
            ],
            "author": "Leslie Stayner, James Bena, Annie J. Sasco, Randall Smith, Kyle Steenland, Michaela Kreuzer, and Kurt Straif",
            "timestamp": "March 2007",
            "headings": [
                "Objectives",
                "Methods",
                "Results",
                "Conclusions",
                "Data Abstraction",
                "Meta-regression",
                "Exposure–Response Analyses",
                "Sensitivity and Influence Analyses",
                "Evaluation of Publication Bias",
                "DISCUSSION",
                "Limitations",
                "Conclusions",
                "About the Authors",
                "Contributors",
                "Acknowledgments",
                "Institutional Review Board",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Molecular_and_Genetic_Aspects_of_Lung_Cancer.pdf-816d4de2",
        "document": "This scientific article reviews the molecular and genetic aspects of lung cancer, focusing on its cellular mechanisms and the role of environmental factors like cigarette smoking.  The authors discuss various molecular abnormalities, including mutations in tumor suppressor genes (p53, Rb, p16) and oncogenes (ras, myc), and their implications for cell cycle regulation and tumorigenesis.  The article also explores diagnostic approaches, the potential of gene therapy, and the use of transgenic mice models to study lung cancer development.  Finally, it highlights the importance of understanding cell cycle networking in developing effective treatment strategies.",
        "metadata": {
            "identifier": "6f907a9fad40b86e5939aa8ac62e775f2406a164295dd7373b73d49055e8e8f5",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:49.012302+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Molecular and Genetic Aspects of Lung Cancer.pdf",
            "name": "Molecular and Genetic Aspects of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Molecular Genetics",
                "Cell Cycle",
                "Tumor Suppressor Genes",
                "Oncogenes",
                "Gene Therapy",
                "Cigarette Smoking",
                "Environmental Carcinogens"
            ],
            "author": "WILLIAM N. ROM, JOHN G. HAY, THEODORE C. LEE, YIXING JIANG, and KAM-MENG TCHOU-WONG",
            "timestamp": "September 24, 1999",
            "headings": [
                "Introduction",
                "Diagnosis (Clinical Approaches)",
                "Cigarette Smoking and Molecular Epidemiology of Lung Cancer",
                "Molecular Abnormalities in Lung Cancer: A Disease of the Cell Cycle",
                "Role of p53 as the Guardian of the Genome and Protector of the Lung from Environmental Carcinogens",
                "The p16 Tumor Suppressor Pathway",
                "Transforming Growth Factor-b Induces p15",
                "Role of Activated Oncogenic ras in the Genesis of Lung Cancer",
                "Oncogenic Pathways: c-Myc in Lung Cancer",
                "Chromosomal Abnormalities: Preneoplastic Changes in Bronchial Epithelial Cells",
                "Chromosomal Abnormalities: Telomeres and Telomerases in Lung Cancer",
                "Modeling Lung Cancer Genetic Lesions in Transgenic Mice",
                "Gene Therapy for Lung Cancer",
                "Gene Delivery Systems",
                "Monitoring, Therapeutics, and Delivering Toxins via Gene Therapy",
                "Summary: Cell Cycle Networking",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Non-small_cell_lung_cancer_NSCLC_.pdf-5189b9ab",
        "document": "This narrative review article discusses non-small cell lung cancer (NSCLC), focusing on risk factors, diagnosis, and treatment options.  It covers various treatment modalities including surgery, radiation, chemotherapy, targeted therapies (EGFR, ALK, ROS1, KRAS, NTRK, BRAF, MET exon 14 skipping, and RET fusion inhibitors), and immunotherapy (PD-1, PD-L1, and CTLA-4 pathway inhibitors). The authors emphasize the importance of personalized treatment based on patient-specific factors and accurate NSCLC sub-classification according to WHO standards.  Despite advancements, the overall progression-free survival rate remains poor, highlighting the need for continued research.",
        "metadata": {
            "identifier": "db3174a58c1173134ec6d3944647a130afd2ace5276011fc4deb9b30adfaa00e",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:22:53.872306+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Non-small cell lung cancer (NSCLC).pdf",
            "name": "Non-small cell lung cancer (NSCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "Treatment",
                "Targeted therapy",
                "Immunotherapy",
                "Diagnosis",
                "Risk factors",
                "WHO Classification",
                "EGFR",
                "ALK"
            ],
            "author": "Yaser Alduais, Haijun Zhang, Fan Fan, Jing Chen, Baoan Chen",
            "timestamp": "Received: 4 January 2023 / Accepted: 19 January 2023",
            "headings": [
                "Abstract",
                "Abbreviations",
                "Keywords",
                "1. Introduction",
                "2. Factors",
                "3. Classification",
                "4. Diagnosis",
                "5. Treatment",
                "6. Surgery",
                "7. Radiation therapy",
                "8. Chemotherapy",
                "9. Targeted therapy",
                "10. Immunotherapy",
                "11. Conclusions",
                "Acknowledgments",
                "Author contributions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-NoneSmall_Cell_Lung_Cancer.pdf-8f70b596",
        "document": "This thematic review from Mayo Clinic Proceedings focuses on non-small cell lung cancer (NSCLC), covering epidemiology, screening, diagnosis, and treatment advancements.  It details the role of low-dose CT scans in screening high-risk individuals and discusses the evolution of treatment, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The article highlights the significant impact of ICIs, their use in first-line therapy, and considerations for patients with brain metastasis or autoimmune disorders.  Finally, it addresses palliative care and survivorship issues.",
        "metadata": {
            "identifier": "4943259b6db43e91741ec1de7fdab28dc7fab68b9a1f46981f24f72c00129050",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:02.530008+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\NoneSmall Cell Lung Cancer.pdf",
            "name": "NoneSmall Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Medical Oncology",
            "keywords": [
                "Non-small cell lung cancer (NSCLC)",
                "Lung cancer screening",
                "Tyrosine kinase inhibitors (TKIs)",
                "Immune checkpoint inhibitors (ICIs)",
                "EGFR mutations",
                "ALK translocations",
                "Brain metastasis",
                "Chemoimmunotherapy",
                "Palliative care"
            ],
            "author": "Narjust Duma, MD; Rafael Santana-Davila, MD; and Julian R. Molina, MD, PhD",
            "timestamp": "8/1/2019",
            "headings": [
                "EPIDEMIOLOGY",
                "CLASSIFICATION",
                "SCREENING",
                "DIAGNOSIS",
                "TREATMENT",
                "Surgery",
                "Neoadjuvant Chemotherapy",
                "Adjuvant Chemotherapy",
                "Immunotherapy Use in Unresectable Stage III NSCLC",
                "OLIGOMETASTATIC DISEASE",
                "METASTATIC NSCLC",
                "Chemotherapy for Advanced Disease",
                "TARGETED THERAPY",
                "Epidermal Growth Factor Receptor Inhibitors",
                "Resistance to EGFR TKIs",
                "Anti-EGFR Monoclonal Antibodies",
                "ALK and ROS1 Translocations",
                "Vascular Endothelial Growth Factor Receptor Inhibitors",
                "Other Targetable Alterations",
                "IMMUNOTHERAPY",
                "Immunotherapy Monotherapy",
                "Combination Chemoimmunotherapy",
                "Combination Immunotherapy",
                "Immunotherapy for Progressive Disease After Chemotherapy",
                "Biomarkers of Activity",
                "Patients With Genetic Driver Abnormalities",
                "Brain Metastasis",
                "Patients With Preexisting Autoimmune Conditions",
                "Palliative Care and End of Life",
                "SURVIVORSHIP",
                "CONCLUSION",
                "Abbreviations and Acronyms"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Occupational_exposure_and_lung_cancer.pdf-939d3088",
        "document": "This mini-review article examines the link between occupational exposure to carcinogens and lung cancer.  It highlights lung cancer as a leading cause of cancer death globally, emphasizing the role of occupational and environmental factors beyond smoking. The authors discuss various carcinogenic agents, their association with lung cancer, and the importance of occupational hygiene and detailed occupational history taking in diagnosis and prevention.  The article also categorizes carcinogenic agents based on their potential and presents a list of agents causally linked to lung cancer.",
        "metadata": {
            "identifier": "618c19c47260ead7cba1c19bb767acea7c72326a1b04fe77c322da8f6701874e",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:06.767429+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Occupational exposure and lung cancer.pdf",
            "name": "Occupational exposure and lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Occupational exposure",
                "Carcinogenic agents",
                "Environmental exposure",
                "Occupational disease",
                "IARC",
                "Risk factors",
                "Mortality",
                "Epidemiology"
            ],
            "author": "Dionysios Spyratos, Paul Zarogoulidis, Konstantinos Porpodis, Kosmas Tsakiridis, Nikolaos Machairiotis, Nikolaos Katsikogiannis, Ioanna Kougioumtzi, Georgios Dryllis, Anastasios Kallianos, Aggeliki Rapti, Chen Li, Konstantinos Zarogoulidis",
            "timestamp": "July 4, 2013",
            "headings": [
                "ABSTRACT",
                "KEY WORDS",
                "Table 1. Classification of carcinogenetic agents according to the International Agency for Research on Cancer.",
                "Table 2. Carcinogenetic agents related with development of lung cancer according to IARC"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Occupational_Exposures_and_Lung_Cancer.pdf-15cb53e2",
        "document": "This article by David C. Christiani discusses the significant global public health problem of lung cancer, focusing on occupational exposures as a major risk factor.  Two studies, analyzing a large pooled dataset, demonstrate increased lung cancer risk from occupational exposure to diesel exhaust and crystalline silica, even among non-smokers, highlighting the need for stronger preventative measures. The author emphasizes the importance of primary prevention through identifying and eliminating carcinogenic agents in the workplace to reduce lung cancer morbidity and mortality.  Despite progress in some regions, the global number of workers exposed to these carcinogens continues to rise.",
        "metadata": {
            "identifier": "e7c55ea96111e7c368684ced3357050e4ad4bfc5b4710b1e5d45fa0ef037574e",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:09.750317+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Occupational Exposures and Lung Cancer.pdf",
            "name": "Occupational Exposures and Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Occupational Exposures",
                "Diesel Exhaust",
                "Crystalline Silica",
                "Carcinogen",
                "Public Health",
                "Primary Prevention",
                "Epidemiology",
                "Case-Control Studies",
                "Risk Assessment"
            ],
            "author": "David C. Christiani, MD, MPH",
            "timestamp": "May 12, 2020",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pollution_and_regional_variations_of_lung_cancer_mortality_in_the_United.pdf-f1f02a20",
        "document": "This research article investigates regional variations in lung cancer mortality across the United States from 2004-2014.  The study identifies a 'lung cancer mortality belt' spanning from eastern Oklahoma through central Appalachia, characterized by high particulate matter pollution and socioeconomic disadvantages.  Researchers used geospatial autocorrelation methods to identify clustered counties with high mortality rates and compared them to non-clustered counties.  The findings highlight the significant impact of air pollution and socioeconomic factors on lung cancer mortality, emphasizing the need for interventions in both urban and rural areas.",
        "metadata": {
            "identifier": "31b45989ae5d818c72411ca9825d4eb395189d49d9c12f16c4e779ac4df1e443",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:17.117299+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Pollution and regional variations of lung cancer mortality in the United.pdf",
            "name": "Pollution and regional variations of lung cancer mortality in the United.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Mortality",
                "Air Pollution",
                "Particulate Matter (PM2.5)",
                "Socioeconomic Factors",
                "Geospatial Analysis",
                "Regional Disparities",
                "Public Health"
            ],
            "author": "Justin Xavier Moore, Tomi Akinyemiju, Henry E. Wang",
            "timestamp": "May 29, 2017",
            "headings": [
                "Introduction",
                "Methods",
                "2.1. Study design",
                "2.2. County-level particulate matter exposure",
                "2.3. County-level demographic characteristics",
                "2.4. County-level community characteristics",
                "2.5. Identification of lung cancer deaths",
                "2.6. Defining lung mortality clusters",
                "2.7. Statistical analysis",
                "2.8. Ethical statement",
                "Results",
                "3.1. LISA, EB, and GI* analyses",
                "3.2. Demographic characteristics",
                "3.3. Community characteristics",
                "3.4. Lung cancer mortality rates",
                "3.5. Odds of lung cancer mortality clustering",
                "3.6. Odds of lung cancer mortality clustering by urban status",
                "Discussion",
                "4.1. Conclusion",
                "Conflict of interest statement",
                "Author contributions",
                "Acknowledgements and funding",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Racial_and_Socioeconomic_Disparities_in_Lung_Cancer.pdf-af4577e4",
        "document": "This systematic review examines racial and socioeconomic disparities in lung cancer screening (LCS) in the United States.  The authors analyzed 21 studies to identify disparities in LCS eligibility, utilization, and post-screening care, finding that Black and socioeconomically disadvantaged individuals experience significant barriers to accessing and benefiting from LCS.  These disparities contribute to higher lung cancer mortality rates in these groups. The authors recommend implementing prospective trials to evaluate eligibility criteria and interventions to improve utilization and follow-up care.",
        "metadata": {
            "identifier": "a2627edc8452b54878531fc86791edf8c956d2dd3a4b4807174abb4ef766a1ee",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:27.981165+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Racial and Socioeconomic Disparities in Lung Cancer.pdf",
            "name": "Racial and Socioeconomic Disparities in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer Screening",
                "Racial Disparities",
                "Socioeconomic Disparities",
                "Health Equity",
                "Lung Cancer Mortality",
                "Systematic Review",
                "USPSTF Guidelines",
                "Low-Dose Computed Tomography (LDCT)"
            ],
            "author": "Ernesto Sosa, Gail D’Souza, Aamna Akhtar, Melissa Sur, Kyra Love, Jeanette Duffels, Dan J. Raz, Jae Y. Kim, Virginia Sun, Loretta Erhunmwunsee",
            "timestamp": "2021",
            "headings": [
                "Abstract",
                "Introduction",
                "Methods",
                "Search Strategy",
                "Article Review Process",
                "Data Abstraction",
                "Study Quality Assessment",
                "Results",
                "LCS Eligibility",
                "LCS Utilization, Perception, and Utility",
                "LCS not offered or used",
                "Negative perceptions/understanding of LCS",
                "Late- stage diagnosis",
                "Postscreening Behavior and Care",
                "Failure to quit smoking",
                "Lack of follow- up care/loss to follow- up",
                "No surgery",
                "Post- LCS mortality",
                "Discussion",
                "Eligibility",
                "Utilization, Perception, and Utility",
                "Postscreening Behavior and Care",
                "Future Recommendations",
                "Address gaps in eligibility",
                "Address gaps in utilization and utility",
                "Address gaps in follow- up care",
                "Strengths and Limitations",
                "Conclusions",
                "Acknowledgments"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Rural-Urban_Differences_in_Cancer_Incidence_and_Trends_in_the_United_States.pdf-f3141f92",
        "document": "This study analyzes rural-urban cancer incidence and trends in the US using data from the North American Association of Central Cancer Registries.  Researchers found that while overall cancer incidence was higher in urban areas, rural populations exhibited higher rates of tobacco- and HPV-associated cancers, as well as lung, colorectal, and cervical cancers.  These disparities were observed across various demographic and geographic factors. The study highlights the need for targeted interventions to address modifiable risk factors and improve cancer outcomes in rural communities.",
        "metadata": {
            "identifier": "8fee3bd38a28b6a526590a13e90c50aa01068f13c6e1f3fdf7c9684f2d9fdf64",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:34.565568+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Rural-Urban Differences in Cancer Incidence and Trends in the United States.pdf",
            "name": "Rural-Urban Differences in Cancer Incidence and Trends in the United States.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "cancer incidence",
                "rural health",
                "urban health",
                "cancer disparities",
                "tobacco",
                "HPV",
                "cancer screening",
                "epidemiology"
            ],
            "author": "Whitney E. Zahnd, Aimee S. James, Wiley D. Jenkins, et al.",
            "timestamp": "July 27, 2017",
            "headings": [
                "Abstract",
                "Introduction",
                "Materials and Methods",
                "Results",
                "Discussion",
                "Strengths and Limitations",
                "Conclusions",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Small-cell_lung_cancer_SCLC_.pdf-d8b87c75",
        "document": "This document presents ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of small-cell lung cancer (SCLC).  It covers various aspects, including staging, risk assessment, treatment strategies for localized and metastatic disease, and follow-up care.  The guidelines emphasize the importance of a multimodality approach, including chemotherapy and radiotherapy, tailored to the patient's stage and performance status.  Smoking cessation is highlighted as a crucial factor in reducing the risk and improving outcomes.",
        "metadata": {
            "identifier": "751a3d186af04b1a9e6514657a6837caf5319bb443a1a11f93f7d9aa5dbc18cb",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:38.653977+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\Small-cell lung cancer (SCLC).pdf",
            "name": "Small-cell lung cancer (SCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Small-cell lung cancer",
                "SCLC",
                "ESMO Clinical Practice Guidelines",
                "diagnosis",
                "treatment",
                "chemotherapy",
                "radiotherapy",
                "staging",
                "prognosis",
                "follow-up"
            ],
            "author": "M. Früh1, D. De Ruysscher2, S. Popat3, L. Crinò4, S. Peters5 & E. Felip6, on behalf of the ESMO Guidelines Working Group",
            "timestamp": "May 2013",
            "headings": [
                "incidence and epidemiology",
                "diagnosis and pathology/molecular biology",
                "staging and risk assessment",
                "management of localised disease",
                "management of metastatic disease",
                "first-line treatment",
                "second-line treatment",
                "personalised medicine",
                "follow-up and long-term implications",
                "note",
                "conflict of interest",
                "references"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_economic_burden_of_lung_cancer.pdf-3464cb1d",
        "document": "This study examines the economic burden of lung cancer in the United States using a large database of inpatient, outpatient, and pharmacy claims.  Researchers found significantly higher healthcare costs for lung cancer patients compared to a control group, with hospitalization and outpatient office visits being the main cost drivers.  Treatment failure was associated with dramatically increased costs, highlighting the need for preventative measures and new therapies. The study's findings underscore the significant economic impact of lung cancer on the US healthcare system.",
        "metadata": {
            "identifier": "5d0839d29b14c0a0c57915983e7b1f224626d373022f8a815ee0a14ec0f8b840",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:43.711025+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\The economic burden of lung cancer.pdf",
            "name": "The economic burden of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Treatment Failure",
                "Healthcare Costs",
                "Economic Burden",
                "Hospitalization",
                "Outpatient Visits",
                "Case-Control Study",
                "Treatment Phases"
            ],
            "author": "Lucie Kutikova, Lee Bowman, Stella Chang, Stacey R. Long, Coleman Obasaju, William H. Crown",
            "timestamp": "Received 24 January 2005; accepted 14 June 2005",
            "headings": [
                "1. Introduction",
                "2. Methods",
                "2.1. Cancer severity",
                "2.2. Assignment by treatment phase",
                "2.3. Designation of treatment failure",
                "2.4. Study outcomes",
                "2.5. Statistical analysis",
                "3. Results",
                "3.1. Direct health care utilization and costs: patients versus controls",
                "3.2. Costs by treatment phase in lung cancer patients",
                "3.3. Costs of treatment failure",
                "4. Discussion",
                "5. Conclusion",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-The_epidemiology_of_lung_cancer.pdf-509ecabe",
        "document": "This review article examines the epidemiology of lung cancer, focusing on incidence, mortality, and risk factors.  While lung cancer mortality is decreasing in the US due to tobacco control, it's increasing globally.  The article highlights the significant role of smoking, but also explores other risk factors like passive smoke, radon, occupational exposures, and genetic susceptibility.  Disparities in lung cancer burden are noted across racial and socioeconomic groups, with concerns raised about the emerging challenges posed by marijuana and e-cigarette use.",
        "metadata": {
            "identifier": "2e6bc0c6acf71e69043a444f48b5148f2e93230005328b8a551d623e189220aa",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:50.385294+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Topics Brief\\The epidemiology of lung cancer.pdf",
            "name": "The epidemiology of lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Epidemiology",
                "Smoking",
                "E-cigarettes",
                "Risk factors",
                "Mortality",
                "Incidence",
                "Marijuana"
            ],
            "author": "Patricia M. de Groot, Carol C. Wu, Brett W. Carter, Reginald F. Munden",
            "timestamp": "May 07, 2018",
            "headings": [
                "Introduction",
                "Lung cancer statistics",
                "Incidence",
                "Mortality and survival",
                "Global trends in lung cancer epidemiology",
                "Demographic factors in US lung cancer",
                "Race/ethnicity",
                "Geography",
                "Education/occupation/income",
                "Age",
                "Gender",
                "Behavioral risk factors for lung cancer",
                "Tobacco and smoking: historical perspective",
                "Tobacco and smoking: carcinogenesis",
                "Other smoking products",
                "Electronic nicotine delivery systems (ENDS)",
                "Environmental risk factors for lung cancer",
                "Radon",
                "Asbestos",
                "Pollution and air quality",
                "Infection",
                "Genetic risk factors for lung cancer",
                "Lung cancer in never smokers (LCINS)",
                "Conclusions",
                "Acknowledgements",
                "Footnote",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-_ALK_inhibitors_in_the_treatment.pdf-c0b66975",
        "document": "This accepted manuscript reviews anaplastic lymphoma kinase (ALK) inhibitors used in treating ALK-driven lung cancers.  It details the structure and function of ALK, focusing on its role in cancer pathogenesis and the mechanisms of action of various ALK inhibitors like crizotinib, ceritinib, alectinib, brigatinib, entrectinib, and lorlatinib.  The review also discusses the development of drug resistance and different strategies to overcome it.  Finally, it classifies protein kinase inhibitors based on their drug-enzyme complex structures.",
        "metadata": {
            "identifier": "a2833525ba2bb82b627d8fdab92224d1e9bff246ae1d80e50263a181d4208bbe",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:23:59.428121+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\(ALK) inhibitors in the treatment.pdf",
            "name": "(ALK) inhibitors in the treatment.pdf",
            "document_type": "pdf",
            "domain_themes": "Oncology/Pharmacology",
            "keywords": [
                "ALK inhibitors",
                "Lung cancer",
                "Crizotinib",
                "Ceritinib",
                "Alectinib",
                "Drug resistance",
                "Protein kinase",
                "Targeted therapy",
                "EML4-ALK fusion protein",
                "NSCLC"
            ],
            "author": "Robert Roskoski Jr.",
            "timestamp": "2017-01-06",
            "headings": [
                "Overview of lung cancers",
                "1.1 Incidence",
                "1.2 Small cell lung cancer",
                "1.3 Non-small cell lung cancer",
                "Role of ALK and ALK-fusion proteins in the pathogenesis of malignancies",
                "2.1 Discovery and architecture of Anaplastic Lymphoma Kinase (ALK)",
                "2.2 Primary structure of the ALK protein-tyrosine kinase domain",
                "2.3 Secondary and tertiary structure of ALK and the K/E/D/D signature",
                "2.4 The hydrophobic spines of inactive ALK and active insulin receptor protein kinase",
                "Structure of ALK-drug complexes",
                "Mechanisms of ALK-based drug resistance",
                "Classification of protein kinase-drug complexes",
                "Epilogue"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Chemotherapy_advances_in_small-cell_lung_cancer.pdf-ad8f9529",
        "document": "This review article discusses the advances in chemotherapy for small-cell lung cancer (SCLC), a disease with limited treatment progress in the past 30 years.  The authors provide a historical overview of chemotherapeutic regimens, highlighting the current standard platinum-etoposide doublet.  They then examine recent clinical trial data on novel agents like amrubicin and belotecan, which show promise as potential alternatives or additions to existing treatments.  The article also explores second-line chemotherapy options and discusses future directions for research, including the potential of combination therapies with targeted agents.",
        "metadata": {
            "identifier": "3dd8ee0378b0ec12df97359311327af59b60e988f9e3db3b2a10ee1cbf52c24d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:05.812134+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Chemotherapy advances in small-cell lung cancer.pdf",
            "name": "Chemotherapy advances in small-cell lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Small-cell lung cancer",
                "SCLC",
                "Chemotherapy",
                "Amrubicin",
                "Belotecan",
                "Picoplatin",
                "Relapsed SCLC",
                "Platinum-etoposide"
            ],
            "author": "Bryan A. Chan, Jermaine I. G. Coward",
            "timestamp": "July 30, 2013",
            "headings": [
                "Introduction",
                "SCLC: histology and staging",
                "Evolution of combination chemotherapy",
                "First-line chemotherapy",
                "Irinotecan",
                "Belotecan",
                "Amrubicin",
                "Maintenance and consolidation therapy",
                "Second-line chemotherapy",
                "Amrubicin",
                "Picoplatin",
                "Belotecan",
                "Future directions and closing remarks"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-COMPARISON_OF_FOUR_CHEMOTHERAPY_REGIMENS_FOR_ADVANCED_NON_SMALL-CELL_LUNG_CANCER.pdf-c2ed169c",
        "document": "This randomized clinical trial by the Eastern Cooperative Oncology Group (ECOG) compared four chemotherapy regimens for advanced non-small-cell lung cancer.  The study involved 1207 patients, evaluating cisplatin and paclitaxel against three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel.  No significant survival differences were found among the regimens, though cisplatin and gemcitabine showed a longer time to disease progression but with increased renal toxicity.  Patients with a performance status of 2 had significantly lower survival rates.",
        "metadata": {
            "identifier": "bf936743237e16cd429a39e0ac3aee317194c3e33e2b91090c572d88bad2b2b6",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:10.050549+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER.pdf",
            "name": "COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Non-small cell lung cancer",
                "Chemotherapy",
                "Cisplatin",
                "Paclitaxel",
                "Gemcitabine",
                "Docetaxel",
                "Carboplatin",
                "Survival",
                "Toxicity",
                "ECOG"
            ],
            "author": "Joan H. Schiller, M.D., David Harrington, Ph.D., Chandra P. Belani, M.D., Corey Langer, M.D., Alan Sandler, M.D., James Krook, M.D., Junming Zhu, Ph.D., and David H. Johnson, M.D., FOR THE EASTERN COOPERATIVE ONCOLOGY GROUP",
            "timestamp": "January 10, 2002",
            "headings": [
                "ABSTRACT",
                "METHODS",
                "Stratification Variables",
                "Regimens",
                "Eligibility Criteria",
                "Statistical Analysis",
                "RESULTS",
                "DISCUSSION"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Comparison_of_gefitinib_erlotinib_and_afatinib_in_non-small_cell_lung.pdf-9dbf64fb",
        "document": "This meta-analysis compares the efficacy and safety of three epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)—gefitinib, erlotinib, and afatinib—in treating non-small cell lung cancer (NSCLC).  The study synthesized data from 90 studies involving over 17,000 patients. Gefitinib and erlotinib showed comparable efficacy in first-line treatment of EGFR-mutant NSCLC, but gefitinib had a better safety profile. Afatinib demonstrated superior efficacy to erlotinib as a second-line treatment for advanced squamous cell carcinoma. These findings provide valuable insights for clinical decision-making in NSCLC treatment.",
        "metadata": {
            "identifier": "9135476530c9d17ab7cef9ed67dfadd23bf7a3cc859ee3e448e8161c831606ae",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:18.654925+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Comparison of gefitinib, erlotinib and afatinib in non-small cell lung.pdf",
            "name": "Comparison of gefitinib, erlotinib and afatinib in non-small cell lung.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Gefitinib",
                "Erlotinib",
                "Afatinib",
                "Non-small cell lung cancer",
                "EGFR TKIs",
                "Meta-analysis",
                "Efficacy",
                "Safety",
                "Adverse events"
            ],
            "author": "Zuyao Yang et al.",
            "timestamp": "N/A",
            "headings": [
                "Novelty and Impact",
                "ABSTRACT",
                "BACKGROUND",
                "METHODS",
                "Data sources and literature search",
                "Study selection",
                "Data extraction",
                "Risk of bias assessment",
                "Data synthesis and analysis",
                "RESULTS",
                "Study selection and characteristics",
                "Gefitinib versus erlotinib: efficacy",
                "Gefitinib versus erlotinib: safety",
                "Comparison of afatinib with gefitinib and erlotinib",
                "Subgroup, sensitivity and publication bias analyses",
                "DISCUSSION",
                "Funding support",
                "Conflicts of interest statement",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Crizotinib_A_comprehensive_review.pdf-2126bd4a",
        "document": "This article provides a comprehensive review of Crizotinib, a tyrosine kinase inhibitor used in treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).  The review details Crizotinib's mechanism of action, clinical trial results demonstrating its efficacy and safety, and common adverse effects.  It also discusses emerging resistance mechanisms and the development of second-generation ALK inhibitors to overcome resistance.  The authors highlight Crizotinib's significance as a targeted therapy for ALK-positive NSCLC and its potential applications in other ALK-related cancers.",
        "metadata": {
            "identifier": "daebde06238da1b6e6b25cd02af63da9a0b29afa0988ad007b1b05d413acaf80",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:24.258549+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Crizotinib A comprehensive review.pdf",
            "name": "Crizotinib A comprehensive review.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Crizotinib",
                "ALK",
                "Non-small cell lung cancer",
                "Tyrosine kinase inhibitor",
                "Targeted therapy",
                "Cancer treatment",
                "Drug resistance",
                "Clinical trials"
            ],
            "author": "Arvind Sahu, Kumar Prabhash, Vanita Noronha, Amit Joshi, Saral Desai",
            "timestamp": "April-June 2013",
            "headings": [
                "Abstract",
                "Introduction",
                "Molecular pathogenesis",
                "Chemistry",
                "Mechanism of action",
                "Detection of EML4-ALK Mutation",
                "History",
                "Overview of Clinical Trials",
                "Indications",
                "Dosing",
                "In renal impairment",
                "In hepatic impairment",
                "Dose adjustment for toxicity",
                "Adverse reactions",
                "Resistance to crizotinib",
                "Future Possibilities (Ongoing Cinical Trials)",
                "Conclusions",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Crizotinib_versus_Chemotherapy_in_Advanced_ALK-Positive_Lung_Cancer.pdf-b27177b1",
        "document": "This New England Journal of Medicine article reports on a phase 3 clinical trial comparing crizotinib to standard chemotherapy in treating advanced ALK-positive non-small cell lung cancer.  The study found crizotinib significantly improved progression-free survival and response rates compared to chemotherapy. While overall survival wasn't significantly different at the interim analysis, the high crossover rate from chemotherapy to crizotinib may have confounded this result. Crizotinib also led to better patient-reported outcomes, including symptom reduction and improved quality of life, although it had more frequent adverse events.",
        "metadata": {
            "identifier": "ed440d58bafb04bc43d1a23de12f91b14665294e1628207f2f8ab5955598357d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:29.555410+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.pdf",
            "name": "Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Crizotinib",
                "Chemotherapy",
                "ALK-positive lung cancer",
                "Non-small cell lung cancer",
                "Progression-free survival",
                "Clinical trial",
                "Phase 3 trial"
            ],
            "author": "Alice T. Shaw et al.",
            "timestamp": "June 1, 2013",
            "headings": [
                "ABSTRACT",
                "Background",
                "Methods",
                "Patients",
                "Study Oversight",
                "Study Design and Treatment",
                "Assessments",
                "Statistical Analysis",
                "Results",
                "Patients",
                "Efficacy",
                "Safety and Adverse Events",
                "Patient-Reported Outcomes",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-CURRENT_LANDSCAPE_OF_TARGETED_THERAPY_IN_LUNG_CANCER.pdf-5252427b",
        "document": "This review article discusses the current state of targeted therapy in lung cancer treatment.  It highlights the success of biomarker-driven approaches, where patients are matched to therapies based on their tumor's genetic profile.  The article details various targeted therapies for oncogenic drivers like EGFR, ALK, ROS1, and BRAF mutations, outlining their efficacy, limitations, and ongoing research into overcoming resistance.  Challenges such as drug resistance, toxicity, and tumor heterogeneity are addressed, along with strategies like combination therapies and drug repurposing.  The authors emphasize the importance of molecular profiling for improved patient outcomes.",
        "metadata": {
            "identifier": "35f3806162cdac38b76b1e909fdbf3c6153a36c558d9157783af5a459b90ed52",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:35.777488+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\CURRENT LANDSCAPE OF TARGETED THERAPY IN LUNG CANCER.pdf",
            "name": "CURRENT LANDSCAPE OF TARGETED THERAPY IN LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Targeted Therapy",
                "Oncogenic Drivers",
                "Biomarker",
                "EGFR",
                "ALK",
                "ROS1",
                "BRAF",
                "Drug Resistance",
                "Molecular Profiling"
            ],
            "author": "Manasi K. Mayekar and Trever G. Bivona",
            "timestamp": "N/A",
            "headings": [
                "ABSTRACT",
                "INTRODUCTION",
                "ACTIONABLE GENETIC ALTERATIONS",
                "EGFR-activating genetic lesions",
                "ALK rearrangements",
                "ROS1 rearrangements",
                "RET rearrangements",
                "NTRK rearrangements",
                "BRAF mutations",
                "OTHER ONCOGENIC ALTERATIONS",
                "HER2 mutations",
                "MET activating genetic lesions",
                "KRAS activating mutations",
                "DISCUSSION",
                "References",
                "Table 1"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Effectiveness_and_safety_of_nivolumab_in_advanced_non-small_cell_lung.pdf-635c5584",
        "document": "This real-world study evaluates the effectiveness and safety of nivolumab in treating advanced non-small cell lung cancer (NSCLC) in 260 Israeli patients.  The median overall survival was 5.9 months, lower than clinical trial results, with ECOG performance status being the most significant predictor of survival.  The safety profile was generally consistent with previous reports, though some new adverse events were observed.  The study highlights the need for real-world data to complement clinical trial results in guiding treatment decisions, particularly for patients with poor prognoses.",
        "metadata": {
            "identifier": "8dd3f25462b66b3e642157b8eba89f3aab7f7811baf3a48b3c91a914b0c783d4",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:40.505056+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Effectiveness and safety of nivolumab in advanced non-small cell lung.pdf",
            "name": "Effectiveness and safety of nivolumab in advanced non-small cell lung.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Nivolumab",
                "Non-small cell lung cancer (NSCLC)",
                "Overall survival (OS)",
                "ECOG performance status",
                "Real-world data",
                "Safety",
                "Toxicity",
                "Immunotherapy"
            ],
            "author": "Elizabeth Dudnik et al.",
            "timestamp": "November 17, 2017",
            "headings": [
                "Introduction",
                "Materials and methods",
                "Results",
                "3.1. Patients",
                "3.2. Treatment",
                "3.3. Effectiveness",
                "3.4. Safety",
                "Discussion",
                "Conclusions",
                "Funding",
                "Conflict of interest",
                "Acknowledgments",
                "Appendix A. Supplementary data",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-ESTIMATING_THE_NEED_FOR_RADIOTHERAPY_FOR_LUNG_CANCER.pdf-72d83f0c",
        "document": "This 2001 clinical investigation by Tyldesley et al. uses an evidence-based, epidemiologic approach to estimate the need for radiotherapy (RT) in lung cancer patients.  The study systematically reviewed literature to identify RT indications and their evidence levels, then estimated the incidence of each indication in a typical North American population.  Results showed a significant percentage of lung cancer patients requiring RT, varying by cancer type and stage.  The authors propose this method for long-term planning of radiation services and auditing access to RT at the population level.",
        "metadata": {
            "identifier": "cf04f9765a9bfa07a06af96bc93350a5a46ad7e3151ca59d509fe372ac951f04",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:46.799043+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\ESTIMATING THE NEED FOR RADIOTHERAPY FOR LUNG CANCER.pdf",
            "name": "ESTIMATING THE NEED FOR RADIOTHERAPY FOR LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Radiotherapy",
                "Lung Cancer",
                "Needs Assessment",
                "Treatment Guidelines",
                "Epidemiology",
                "Small-Cell Lung Cancer",
                "Non-Small-Cell Lung Cancer",
                "Evidence-Based Medicine"
            ],
            "author": "Scott Tyldesley, Chris Boyd, Karleen Schulze, Hugh Walker, William J. Mackillop",
            "timestamp": "2001",
            "headings": [
                "Introduction",
                "Describing indications for radiotherapy",
                "Estimating the incidence of indications for radiotherapy",
                "Estimating the incidence of attributes that define indications for radiotherapy",
                "Estimates of error",
                "Results",
                "Indications for radiotherapy for lung cancer",
                "Small-cell lung cancer",
                "Stage I and II non-small-cell lung cancer",
                "Stage III non-small-cell lung cancer",
                "Stage IV non-small-cell lung cancer",
                "Estimated appropriate radiotherapy rate for lung cancer",
                "Discussion",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Gefitinib_a_review_of_its_use_in_adults.pdf-fd2909fd",
        "document": "This article reviews the efficacy and tolerability of gefitinib, a selective EGFR tyrosine kinase inhibitor, in treating adults with advanced non-small cell lung cancer (NSCLC).  Large clinical trials demonstrated that gefitinib significantly prolonged progression-free survival and improved response rates in patients with activating EGFR mutations, particularly in never-smokers and Asian patients.  While overall survival wasn't significantly increased, this may be due to confounding post-study treatments. Gefitinib was generally well-tolerated, with common side effects including skin reactions and gastrointestinal issues, and a rare but serious risk of interstitial lung disease.",
        "metadata": {
            "identifier": "5b95d50862aa1ed0ac88cc90ac0e6d23168270ec8f344179ed21f40c20f91b29",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:56.159971+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Gefitinib a review of its use in adults.pdf",
            "name": "Gefitinib a review of its use in adults.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Gefitinib",
                "EGFR",
                "Non-small cell lung cancer",
                "Tyrosine kinase inhibitor",
                "NSCLC",
                "EGFR mutation",
                "Progression-free survival",
                "Interstitial lung disease"
            ],
            "author": "Sohita Dhillon",
            "timestamp": "Received: 21 September 2014 / Accepted: 18 December 2014",
            "headings": [
                "Abstract",
                "Introduction",
                "Pharmacodynamic properties",
                "Mechanism of action",
                "Predictors of efficacy",
                "Drug resistance",
                "Diagnostic studies",
                "Pharmacokinetic properties",
                "Therapeutic efficacy",
                "In chemotherapy-experienced patients",
                "Versus placebo",
                "Versus chemotherapy",
                "Versus docetaxel",
                "Versus pemetrexed",
                "Versus other EGFR TKIs",
                "In chemotherapy-naïve patients",
                "In clinically selected patients",
                "Versus carboplatin plus paclitaxel",
                "Versus gemcitabine plus cisplatin",
                "In patients with activating EGFR mutations",
                "Versus carboplatin plus paclitaxel",
                "Versus cisplatin plus docetaxel",
                "In Caucasian patients with activating EGFR mutations",
                "In patients with poor performance status and activating EGFR mutations",
                "Real-world evidence",
                "Tolerability",
                "General profile",
                "Versus chemotherapy",
                "Versus other EGFR TKIs",
                "Interstitial lung disease",
                "Place of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Introduction_to_Cancer_Chemotherapeutics.pdf-008d77e3",
        "document": "This Chemical Reviews issue focuses on cancer chemotherapeutics, exploring their development from the 1940s to current advancements.  The articles cover various aspects, including mechanisms of action, drug resistance, combination therapies, and targeting specific pathways like angiogenesis.  The authors discuss the challenges of balancing efficacy with minimizing side effects in cancer treatment, highlighting the need for innovative approaches.  The issue also examines the role of natural products, nanotechnology, and the potential of cancer stem cells as therapeutic targets.",
        "metadata": {
            "identifier": "cb5bae23e2cad539218b85cbcbb8f8a5db8e88d8fae38098b9e595fdf9b48f8e",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:24:58.776936+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Introduction to Cancer Chemotherapeutics.pdf",
            "name": "Introduction to Cancer Chemotherapeutics.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Cancer Chemotherapy",
                "Antimetabolites",
                "DNA Replication",
                "Angiogenesis",
                "Drug Resistance",
                "Combination Therapy",
                "Natural Products",
                "Cancer Stem Cells"
            ],
            "author": "Donna S. Shewach and Robert D. Kuchta",
            "timestamp": "07/08/2009",
            "headings": [],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_cancer_immunotherapy.pdf-f00d09ad",
        "document": "This review article from Molecular Cancer (2023) by Lahiri et al. focuses on the progress, challenges, and future prospects of lung cancer immunotherapy.  It covers various immunotherapeutic approaches, including cancer vaccines, immune checkpoint inhibitors (ICIs), adoptive cell therapies (CAR T, TCR, TIL), and oncolytic viruses.  The authors discuss the clinical trials and obstacles associated with each approach, highlighting the need for combination therapies and personalized medicine.  The role of nanomedicine and nutraceuticals in enhancing immunotherapy is also explored.",
        "metadata": {
            "identifier": "a274b7159cdb9e02a7195e7dcf4eef07ababd420d69ff6e05bd796e502dfe2f7",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:14.794022+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Lung cancer immunotherapy.pdf",
            "name": "Lung cancer immunotherapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Immunotherapy",
                "Checkpoint Inhibitors",
                "Adoptive Cell Therapy",
                "Cancer Vaccines",
                "Nanomedicine",
                "SCLC",
                "NSCLC"
            ],
            "author": "Aritraa Lahiri, Avik Maji, Pravin D. Potdar, Navneet Singh, Purvish Parikh, Bharti Bisht, Anubhab Mukherjee, Manash K. Paul",
            "timestamp": "2023",
            "headings": [
                "Abstract",
                "Introduction",
                "NSCLC and immunotherapy",
                "Tumor-specific vaccines",
                "Adoptive cell therapy",
                "Oncolytic viruses for lung cancer immunotherapy",
                "Targeted antibodies for lung cancer",
                "Immune checkpoint inhibitors and NSCLC",
                "Immunotherapy in SCLC",
                "Combination immunotherapy approaches",
                "Immunotherapy with Anti-angiogenic agents for targeting NSCLC",
                "Chemo-immunotherapy in NSCLC",
                "Chemo-immunotherapy in SCLC",
                "Radiation and immunotherapy",
                "Immunomodulatory nanomedicine for use in lung cancer",
                "Immunomodulatory nutraceuticals in lung cancer",
                "Ongoing clinical trials for immunotherapeutics",
                "Major obstacle and future perspective for lung cancer treatment",
                "Conclusion",
                "Abbreviations",
                "Acknowledgements",
                "Authors’ contributions",
                "Funding",
                "Availability of data and materials",
                "Declarations",
                "Ethics approval and consent to participate",
                "Consent for publication",
                "Competing interests",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Lung_Cancer_in_the_Era_of_Precision_Medicine.pdf-50bb645f",
        "document": "This article discusses the advancements in lung cancer treatment in the era of precision medicine.  It highlights the importance of molecular profiling to identify actionable mutations and match patients to targeted therapies.  The authors emphasize the challenges of drug resistance and the need for repeat biopsies to understand tumor evolution.  New clinical trial designs, such as basket and umbrella trials, are also discussed as crucial for accelerating the development of effective treatments.  The ultimate goal is to improve patient outcomes and potentially cure metastatic lung cancer.",
        "metadata": {
            "identifier": "f1be3932cbcb0e55da9059df640d6e452c7b61ed608be19b6ff824c3a07b70c6",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:19.748042+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Lung Cancer in the Era of Precision Medicine.pdf",
            "name": "Lung Cancer in the Era of Precision Medicine.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Precision Medicine",
                "Molecular Profiling",
                "Targeted Therapies",
                "Drug Resistance",
                "Repeat Biopsies",
                "EGFR Mutations",
                "ALK Rearrangements",
                "Immunotherapy"
            ],
            "author": "Katerina Politi and Roy S. Herbst",
            "timestamp": "May 15, 2015",
            "headings": [
                "Abstract",
                "Introduction",
                "Molecular Profiling of Lung Cancer",
                "Is there a role for molecular profiling in lung squamous cell carcinoma and SCLC?",
                "Lung cancer-omics and new targets",
                "Beyond mutations: the future of molecular profiling for lung cancer",
                "Tackling Drug Resistance",
                "Repeat biopsies in lung cancer",
                "Incorporating rebiopsies at disease progression into clinical practice",
                "Clinical Trial Design in the Era of Precision Medicine",
                "Conclusions",
                "Disclosure of Potential Conflicts of Interest",
                "Authors' Contributions",
                "Grant Support",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Nivolumab_for_the_Treatment_of_Metastatic_Non-Small_Cell_Lung_Cancer_With_Progression_On_or_After_Platinum-Based_Chemotherapy.pdf-774e7b4b",
        "document": "This FDA approval summary details the expanded indication of nivolumab for treating metastatic non-small cell lung cancer (NSCLC) patients whose disease progressed after platinum-based chemotherapy.  The approval was based on the CheckMate 057 trial, demonstrating improved overall survival compared to docetaxel.  While a statistically significant improvement in objective response rate was also observed, progression-free survival showed no significant difference.  The FDA's decision considered the overall benefit-risk profile, including the drug's toxicity profile and the need for further studies to clarify its role in patients with specific genetic alterations.",
        "metadata": {
            "identifier": "591f2701f775aea9b3ead47bdc3e196d9f8811da1e70bcaff4934bf45cebb137",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:25.055013+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.pdf",
            "name": "Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Nivolumab",
                "Non-small cell lung cancer",
                "NSCLC",
                "FDA approval",
                "Immunotherapy",
                "PD-1 inhibitor",
                "Docetaxel",
                "Overall survival",
                "CheckMate 057"
            ],
            "author": "Dickran Kazandjian, Daniel L. Suzman, Gideon Blumenthal, Sirisha Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur",
            "timestamp": "March 16, 2016",
            "headings": [
                "Regulatory Issues: FDA",
                "FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy",
                "Key Words",
                "ABSTRACT",
                "Implications for Practice",
                "INTRODUCTION",
                "Trial Design",
                "RESULTS",
                "DISCUSSION",
                "CONCLUSION",
                "AUTHOR CONTRIBUTIONS",
                "DISCLOSURES",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Osimertinib_As_First-Line_Treatment_of_EGFR.pdf-506b3a5a",
        "document": "This article reports on the AURA study, which investigated the efficacy and safety of osimertinib as a first-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC).  The study included two cohorts of treatment-naive patients receiving either 80mg or 160mg of osimertinib daily.  Results showed a robust objective response rate (ORR) and prolonged progression-free survival (PFS) across both dose groups, with no evidence of acquired EGFR T790M mutation.  The 80mg dose demonstrated better tolerability.  The findings suggest osimertinib is a promising first-line treatment option for this patient population.",
        "metadata": {
            "identifier": "df27b1759b92da91db352dc28e33fb1638611d165fa3122d29a6d088740857e9",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:31.588135+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Osimertinib As First-Line Treatment of EGFR.pdf",
            "name": "Osimertinib As First-Line Treatment of EGFR.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Osimertinib",
                "EGFR",
                "Non-small-cell lung cancer (NSCLC)",
                "First-line treatment",
                "Objective response rate (ORR)",
                "Progression-free survival (PFS)",
                "EGFR T790M",
                "AURA study",
                "Clinical trial"
            ],
            "author": "Suresh S. Ramalingam, James C.-H. Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, and Pasi A. Ja¨nne",
            "timestamp": "March 20, 2018",
            "headings": [
                "Purpose",
                "Patients and Methods",
                "Results",
                "Conclusion",
                "INTRODUCTION",
                "ASSOCIATED CONTENT",
                "PATIENTS AND METHODS",
                "Patients",
                "Study Design and Treatment",
                "Study Assessments",
                "Clinical assessments",
                "Translational assessments",
                "Study Oversight",
                "StatisticalAnalysis",
                "RESULTS",
                "Patients and Treatment",
                "Clinical Activity",
                "Translational Analysis",
                "Baseline central tissue versus plasma EGFR genotyping",
                "Mechanisms of resistance to osimertinib",
                "Safety and AEs",
                "DISCUSSION",
                "AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST",
                "AUTHOR CONTRIBUTIONS",
                "REFERENCES",
                "Prior Presentation",
                "Acknowledgment"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Osimertinib_for_Patients_With_Non_Small-Cell.pdf-cc4bf444",
        "document": "This multicenter, open-label, phase II clinical trial (KCSG-LU15-09) investigated the efficacy and safety of osimertinib in treating non-small-cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations.  The study enrolled 37 patients, demonstrating an objective response rate of 50% and a median progression-free survival of 8.2 months.  Adverse events were manageable, primarily rash, pruritus, and decreased appetite.  The results suggest osimertinib as a potential treatment option for NSCLC patients with uncommon EGFR mutations.",
        "metadata": {
            "identifier": "72c27441390c1e58b64a11783dbf1d573d7f09485f2262ab0adf2f531ea0b525",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:36.205675+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Osimertinib for Patients With Non–Small-Cell.pdf",
            "name": "Osimertinib for Patients With Non–Small-Cell.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Osimertinib",
                "Non-small-cell lung cancer (NSCLC)",
                "Epidermal growth factor receptor (EGFR)",
                "Uncommon EGFR mutations",
                "Phase II clinical trial",
                "Objective response rate (ORR)",
                "Progression-free survival (PFS)"
            ],
            "author": "JangHo Cho et al.",
            "timestamp": "December 11, 2019",
            "headings": [
                "abstract",
                "INTRODUCTION",
                "PATIENTS AND METHODS",
                "Study Design and Participants",
                "Procedures",
                "Outcomes",
                "Statistical Analysis",
                "RESULTS",
                "Demographics",
                "Efficacy",
                "Safety",
                "DISCUSSION",
                "AFFILIATIONS",
                "CLINICAL TRIAL INFORMATION",
                "AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT",
                "AUTHOR CONTRIBUTIONS",
                "ACKNOWLEDGMENT",
                "REFERENCES",
                "APPENDIX"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pembrolizumab_for_the_Treatment_of_Non_Small-Cell_Lung_Cancer.pdf-b9925ed0",
        "document": "This New England Journal of Medicine article details a phase 1 clinical trial evaluating pembrolizumab, a PD-1 inhibitor, in treating advanced non-small-cell lung cancer.  The study assessed efficacy, safety, and the correlation between PD-L1 expression and treatment response.  Results showed pembrolizumab had an acceptable safety profile and demonstrated antitumor activity, with improved efficacy observed in patients exhibiting high PD-L1 expression (at least 50% of tumor cells).  The study concludes that PD-L1 expression is a potential biomarker for predicting pembrolizumab's effectiveness.",
        "metadata": {
            "identifier": "7140dcb9c41ea2cdd3ba4e4f05b1460134ff804aed15f17a3106dc504b058789",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:42.674019+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Pembrolizumab for the Treatment  of Non–Small-Cell Lung Cancer.pdf",
            "name": "Pembrolizumab for the Treatment  of Non–Small-Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Pembrolizumab",
                "Non-small-cell lung cancer",
                "PD-1 inhibitor",
                "PD-L1 expression",
                "Immunotherapy",
                "Clinical trial",
                "Biomarker",
                "Antitumor activity",
                "Efficacy",
                "Safety"
            ],
            "author": "Edward B. Garon, M.D. et al. for the KEYNOTE-001 Investigators",
            "timestamp": "April 19, 2015",
            "headings": [
                "Abstract",
                "Background",
                "Methods",
                "Results",
                "Conclusions",
                "Pembrolizumab for Non–Small-Cell Lung Cancer",
                "Study Oversight",
                "Study Design and Treatment",
                "Patients",
                "Study Assessments",
                "Biomarker Analysis for Patient Eligibility",
                "Biomarker Cutoff Selection",
                "Biomarker Validation",
                "Statistical Analysis",
                "Adverse Events",
                "Overall Efficacy",
                "Biomarker Selection",
                "Biomarker Validation",
                "Estimated Prevalence of PD-L1",
                "Longitudinal Outcomes on the Basis of PD-L1 Staining",
                "Discussion",
                "Appendix",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pembrolizumab_plus_Chemotherapy_in_Metastatic_Non_Small-Cell_Lung_Cancer.pdf-42282b56",
        "document": "This article reports on a phase 3 clinical trial (KEYNOTE-189) evaluating the efficacy and safety of pembrolizumab in combination with chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC).  The study found that adding pembrolizumab to standard chemotherapy significantly improved overall survival and progression-free survival compared to chemotherapy alone, regardless of PD-L1 expression levels.  While adverse events were common in both groups, the addition of pembrolizumab did not significantly increase the frequency of serious side effects.  The results suggest that pembrolizumab plus chemotherapy is a beneficial first-line treatment option for this type of lung cancer.",
        "metadata": {
            "identifier": "e4a4bbb449bd2489617885a240068b0e6b6c291fe47a8aff91c06f21907b67c2",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:49.222243+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Pembrolizumab plus Chemotherapy  in Metastatic Non–Small-Cell Lung Cancer.pdf",
            "name": "Pembrolizumab plus Chemotherapy  in Metastatic Non–Small-Cell Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Pembrolizumab",
                "Chemotherapy",
                "Non-small cell lung cancer (NSCLC)",
                "Metastatic cancer",
                "PD-L1",
                "Overall survival",
                "Progression-free survival",
                "KEYNOTE-189",
                "Clinical trial",
                "Immunotherapy"
            ],
            "author": "L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, et al. for the KEYNOTE-189 Investigators",
            "timestamp": "April 16, 2018",
            "headings": [
                "ABSTRACT",
                "BACKGROUND",
                "METHODS",
                "Patients",
                "Trial Design and Treatment",
                "Assessments",
                "End Points",
                "Trial Oversight",
                "Statistical Analysis",
                "RESULTS",
                "Patients and Treatment",
                "Overall Survival",
                "Progression-free Survival",
                "Tumor Response",
                "Adverse Events",
                "Discussion",
                "Appendix",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Personalized_medicine_for_lung_cancer.pdf-42747266",
        "document": "This review article discusses the challenges and opportunities in personalized medicine for lung cancer, focusing on the importance of accurate subtyping of non-small-cell lung cancer (NSCLC).  The author highlights the limitations of traditional morphological diagnosis using small biopsy samples and advocates for the increased use of immunohistochemistry (IHC) to improve diagnostic accuracy.  Specific biomarkers and their association with various targeted therapies are reviewed, emphasizing the need for standardized testing methods and careful interpretation of results.  The article concludes by stressing the crucial role of pathologists in guiding treatment decisions through accurate diagnosis and biomarker testing.",
        "metadata": {
            "identifier": "023226e0fb5be55106b03cf6c1e45f0f0f3ebffaa303dd0b4d02b2d75e21431c",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:25:55.750733+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Personalized medicine for lung cancer.pdf",
            "name": "Personalized medicine for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Non-small-cell lung cancer (NSCLC)",
                "Personalized Medicine",
                "Immunohistochemistry (IHC)",
                "Biomarkers",
                "Targeted Therapy",
                "EGFR Mutation",
                "Pathology"
            ],
            "author": "Keith M Kerr",
            "timestamp": "2012",
            "headings": [
                "Introduction",
                "Subtyping NSCLC: why does it matter?",
                "Subtyping NSCLC: the challenges for pathologists",
                "Dealing with the morphological challenge: the NSCLC–NOS category",
                "NSCLC–NOS: how many cases?",
                "NSCLC–NOS: the solution becomes the problem",
                "What would be a reasonable rate for NSCLC–NOS diagnosis?",
                "Molecular predictive markers in NSCLC",
                "EGFR mutation testing",
                "Other mutations in adenocarcinomas",
                "Biomarkers and cytotoxic drugs",
                "Newer drug classes and biomarkers",
                "Delivering on this promise: challenges and opportunities for pathology",
                "Conclusion",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Pneumonectomy_for_lung_cancer_Contemporary_national_early_morbidity_and_mortality_outcomes.pdf-8773d547",
        "document": "This study analyzes contemporary early morbidity and mortality outcomes associated with pneumonectomy for lung cancer using a nationally representative French database (EPITHOR).  The researchers identified several risk factors for major adverse events, including age, low BMI, and ASA score.  Interestingly, induction therapy and overweight BMI were found to be protective factors, potentially due to selection bias and improved perioperative management. The study highlights the importance of patient selection and perioperative care in minimizing risks associated with pneumonectomy.",
        "metadata": {
            "identifier": "bdb083eb1a9e8e31313e9dfff2be12010528d9280cac0f60b627f6c66127f6cb",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:00.962037+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Pneumonectomy for lung cancer Contemporary national early morbidity and mortality outcomes.pdf",
            "name": "Pneumonectomy for lung cancer Contemporary national early morbidity and mortality outcomes.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Pneumonectomy",
                "Lung Cancer",
                "Morbidity",
                "Mortality",
                "Risk Factors",
                "Induction Therapy",
                "BMI",
                "EPITHOR database",
                "Propensity Score Analysis"
            ],
            "author": "Pascal A. Thomas et al.",
            "timestamp": "October 16, 2014",
            "headings": [
                "Objective",
                "Methods",
                "Results",
                "Conclusions",
                "MATERIALS AND METHODS",
                "The French National Database EPITHOR",
                "Patient Population and Clinical Variables",
                "Outcome Definition",
                "Statistical Analysis",
                "RESULTS",
                "DISCUSSION",
                "Study Limitations",
                "CONCLUSIONS",
                "References",
                "Discussion",
                "EDITORIAL COMMENTARY"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Radiotherapy_treatment_for_lung_cancer.pdf-26c9ab04",
        "document": "This invited review article examines the current status and future directions of radiotherapy treatment for lung cancer.  It discusses advancements in radiotherapy technologies, such as stereotactic ablative body radiotherapy (SABR) and intensity-modulated radiotherapy (IMRT), which have improved targeting accuracy and reduced side effects. The review also covers the role of radiotherapy in various stages of lung cancer, including stage I-II, stage III, and stage IV, and explores the use of concurrent chemotherapy and immunotherapy.  Finally, it highlights the potential of big data and machine learning to personalize radiotherapy treatment decisions.",
        "metadata": {
            "identifier": "7b2d0b4cdbf84c90d2775a37ac36d0dd57ffcf537419fc88df791ec2a704f624",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:06.516454+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Radiotherapy treatment for lung cancer.pdf",
            "name": "Radiotherapy treatment for lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Radiotherapy",
                "Stereotactic Ablative Body Radiotherapy (SABR)",
                "Intensity-Modulated Radiotherapy (IMRT)",
                "Chemotherapy",
                "Immunotherapy",
                "Oligometastases",
                "Big Data",
                "Machine Learning"
            ],
            "author": "Shalini K. Vinod and Eric Hau",
            "timestamp": "18 May 2020",
            "headings": [
                "ABSTRACT",
                "ADVANCES IN RADIOTHERAPY TECHNOLOGIES",
                "INTRODUCTION",
                "RADIOTHERAPY FOR STAGE I AND II NSCLC",
                "RADIOTHERAPY FOR STAGE III NSCLC",
                "RADIOTHERAPY FOR STAGE IV NSCLC",
                "RADIOTHERAPY FOR STAGE I–III (LIMITED STAGE) SCLC",
                "RADIOTHERAPY FOR STAGE IV (EXTENSIVE STAGE) SCLC",
                "FUTURE DIRECTIONS",
                "CONCLUSIONS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Segmentectomyor_lobectomy_forearlystage_lung_cancer.pdf-dc7acc89",
        "document": "This meta-analysis investigates the efficacy of segmentectomy versus lobectomy for early-stage lung cancer.  The study analyzed 22 observational studies, comparing overall and cancer-specific survival rates.  Results indicate that lobectomy is superior for Stage I, Stage IA, and Stage IA tumors larger than 2cm but smaller than 3cm. However, for tumors 2cm or smaller, segmentectomy showed equivalent survival to lobectomy.  The authors caution that these findings should be interpreted cautiously due to limitations inherent in meta-analyses of retrospective studies.",
        "metadata": {
            "identifier": "a3862dbfa0a2a4e943414fe4c620137dacd0193fcb08ed5237ef80dce826bc66",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:11.217329+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Segmentectomyor lobectomy forearlystage lung cancer.pdf",
            "name": "Segmentectomyor lobectomy forearlystage lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung cancer",
                "Segmentectomy",
                "Lobectomy",
                "Survival",
                "Meta-analysis",
                "Stage I NSCLC",
                "Tumor size",
                "Surgical treatment"
            ],
            "author": "Feichao Bao, Peng Ye, Yunhai Yang, Luming Wang, Chong Zhang, Xiayi Lv, and Jian Hu",
            "timestamp": "21 October 2013",
            "headings": [
                "Summary",
                "INTRODUCTION",
                "MATERIALS AND METHODS",
                "Eligibility criteria",
                "Collection of published studies",
                "Statistical analysis",
                "RESULTS",
                "Selected articles and description of the studies",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage I NSCLC patients",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage IA NSCLC patients",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage IA NSCLC patients with tumours larger than 2cm but smaller than 3cm",
                "Effect of operative approach on the overall survival/cancer-specific survival of Stage IA NSCLC patients with tumours of 2cm or smaller",
                "DISCUSSION",
                "Funding",
                "Conflictof interest"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Sleeve_Lobectomy_Versus_Pneumonectomy_for_Lung_cancer.pdf-590523c1",
        "document": "This study compares sleeve lobectomy (SL) and pneumonectomy (PN) for lung cancer treatment, analyzing survival rates and recurrence sites in 1230 patients.  SL showed significantly lower operative mortality (1.6% vs 5.3%) and better 5-year survival (52% vs 31%).  The study found that SL resulted in better long-term survival and local control, particularly for stages I and II, when complete resection was achieved.  However, the authors acknowledge potential biases due to the retrospective nature of the study.",
        "metadata": {
            "identifier": "cf8a358cb70ae709cdd027c3f8b85b2c4788e560e32f707d124f7060afc6262d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:14.752416+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Sleeve Lobectomy Versus Pneumonectomy for Lung cancer.pdf",
            "name": "Sleeve Lobectomy Versus Pneumonectomy for Lung cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Sleeve Lobectomy",
                "Pneumonectomy",
                "Lung Cancer",
                "Survival Rate",
                "Recurrence",
                "Operative Mortality",
                "NSCLC",
                "Bronchoplasty"
            ],
            "author": "Jean Deslauriers, MD, Jocelyn Gre´goire, MD, Louis F. Jacques, MD, Michel Piraux, MD, Liu Guojin, MD, and Yves Lacasse, MD",
            "timestamp": "2004",
            "headings": [
                "ORIGINAL ARTICLES: GENERAL THORACIC",
                "Background",
                "Methods",
                "Results",
                "Patient Profile",
                "Operative Risk",
                "Survival Rates",
                "Sites of Recurrences",
                "Comment",
                "References",
                "DISCUSSION"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Small_cell_lung_cancer_Treatment_review.pdf-b3558a2f",
        "document": "This review article discusses the treatment of small cell lung cancer (SCLC), focusing on chemotherapy and radiotherapy.  The authors highlight the importance of considering various treatment options and regimens, emphasizing that age should not be a contraindication to therapy for elderly patients who are otherwise fit.  The article also covers prognostic factors, staging, and quality of life considerations in SCLC treatment.  Despite initial responsiveness to chemo-radiotherapy, relapse is common, and the authors explore second-line treatment options and the role of prophylactic cranial irradiation.",
        "metadata": {
            "identifier": "87b0e7bc32ba0a510d5087c3c1decd93e41c277f90e9ccc68dd18da083d83066",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:20.218559+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Small cell lung cancer Treatment review.pdf",
            "name": "Small cell lung cancer Treatment review.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Small cell lung cancer",
                "SCLC",
                "Chemotherapy",
                "Radiotherapy",
                "Treatment review",
                "Prognostic factors",
                "Elderly patients",
                "Quality of life",
                "Relapse",
                "Prophylactic cranial irradiation"
            ],
            "author": "S Cooper and SG Spiro",
            "timestamp": "2006",
            "headings": [
                "PREVALENCE",
                "SYMPTOMS AND SIGNS",
                "STAGING AND PROGNOSTIC FACTORS",
                "TREATMENT",
                "CHEMOTHERAPY",
                "First-line chemotherapy",
                "Second-line chemotherapy",
                "Granulocyte colony stimulating factor",
                "Oral versus i.v. chemotherapy",
                "RADIOTHERAPY",
                "Dose",
                "Timing",
                "Prophylactic cranial irradiation",
                "SURGERY",
                "QUALITY OF LIFE",
                "ELDERLY"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Stereotactic_body_radiation_therapy_for_lung_metastases.pdf-ff75ffc9",
        "document": "This study evaluates the efficacy and safety of stereotactic body radiation therapy (SBRT) for treating lung metastases.  Researchers retrospectively analyzed 61 patients treated between 2003 and 2009, finding high local control rates (89% at 2 years) and acceptable toxicity.  Overall survival and cancer-specific survival rates were also reported, with tumor volume significantly associated with survival outcomes.  The study concludes that SBRT is a viable and safe treatment option for selected patients with lung metastases.",
        "metadata": {
            "identifier": "b626e1a8eede66b8a138c62891f6d90671026ba751be634d5fae1cec65e04731",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:24.913704+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Stereotactic body radiation therapy for lung metastases.pdf",
            "name": "Stereotactic body radiation therapy for lung metastases.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung metastases",
                "Stereotactic body radiation therapy (SBRT)",
                "Oligometastases",
                "Local control",
                "Survival",
                "Toxicity",
                "Radiation oncology",
                "Cancer treatment"
            ],
            "author": [
                "Umberto Ricardi",
                "Andrea Riccardo Filippi",
                "Alessia Guarneri",
                "Riccardo Ragona",
                "Cristina Mantovani",
                "Francesca Giglioli",
                "Angela Botticella",
                "Patrizia Ciammella",
                "Cristina Iftode",
                "Lucio Buffoni",
                "Enrico Ruffini",
                "Giorgio Vittorio Scagliotti"
            ],
            "timestamp": "2011-04-26",
            "headings": [
                "Introduction",
                "Materials and methods",
                "2.1. Patients",
                "2.2. Treatment technique",
                "2.3. Follow-up and statistics",
                "3. Results",
                "4. Discussion",
                "5. Conclusion",
                "Conflict of interest statement",
                "References"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-SURVIVAL_AND_FUNCTION_AFTER_SLEEVE_LOBECTOMY_FOR_LUNG_CANCER.pdf-0d4e7480",
        "document": "This 1996 article by Gaissert et al. presents a retrospective study comparing sleeve lobectomy and pneumonectomy for lung cancer treatment.  The study analyzed 72 patients who underwent sleeve lobectomy between 1962 and 1991, comparing their outcomes to a control group of 56 pneumonectomy patients.  The findings suggest comparable survival rates between the two procedures, with sleeve lobectomy showing lower mortality and morbidity rates.  The authors conclude that sleeve lobectomy is a superior procedure for selected patients, particularly those with compromised lung function.",
        "metadata": {
            "identifier": "8f8fc4340a3fb17cc5c4be367bcda66b83f5b97945035273dfe2b0375b38d582",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:29.470464+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\SURVIVAL AND FUNCTION AFTER SLEEVE LOBECTOMY FOR LUNG CANCER.pdf",
            "name": "SURVIVAL AND FUNCTION AFTER SLEEVE LOBECTOMY FOR LUNG CANCER.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Sleeve Lobectomy",
                "Pneumonectomy",
                "Lung Cancer",
                "Surgical Outcomes",
                "Survival Rate",
                "Morbidity",
                "Mortality",
                "Pulmonary Function"
            ],
            "author": "Henning A. Gaissert, Douglas J. Mathisen, Ashby C. Moncure, Alan D. Hilgenberg, Hermes C. Grillo, John C. Wain",
            "timestamp": "1996",
            "headings": [
                "Patients and methods",
                "Statistical methods",
                "Preoperative evaluation",
                "Surgical technique",
                "Results",
                "Age and sex",
                "Staging and histology",
                "Indication for sleeve lobectomy",
                "Type of resection",
                "Mortality and morbidity",
                "Sleeve lobectomy",
                "Pneumonectomy",
                "Radiotherapy",
                "Follow-up and survival",
                "Prediction of postoperative FEV1",
                "Ventilation-perfusion scans",
                "Discussion",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Targeted_Therapies_in_Lung_Cancer.pdf-07cf4e0e",
        "document": "This review article discusses the mechanisms of tyrosine kinase inhibitor (TKI) resistance in oncogene-driven lung cancers, focusing on non-small cell lung cancer (NSCLC).  The authors explore both primary (intrinsic) and secondary (acquired) resistance mechanisms, including mutations within the target kinase, activation of bypass signaling pathways, and phenotypic transformations.  They highlight the complexity of TKI resistance, emphasizing the role of genetic heterogeneity and the existence of drug-tolerant persister cells.  The review concludes by discussing strategies to overcome TKI resistance, such as next-generation TKIs and combination therapies.",
        "metadata": {
            "identifier": "a86631e3a1ee9b89daa127ad1c0e9efa648d036b3b60d1cba4d3a6e276a0d86d",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:36.828238+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Targeted Therapies in Lung Cancer.pdf",
            "name": "Targeted Therapies in Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Tyrosine kinase inhibitors",
                "TKI resistance",
                "Lung cancer",
                "Non-small cell lung cancer",
                "Oncogene addiction",
                "Drug resistance mechanisms",
                "Genetic heterogeneity",
                "Persister cells",
                "Combination therapies"
            ],
            "author": "Jessica J. Lin and Alice T. Shaw",
            "timestamp": "July 2016",
            "headings": [
                "Resisting Resistance: Targeted Therapies in Lung Cancer",
                "TKI Resistance: A Pervasive Challenge",
                "Overview of Oncogenic Drivers in NSCLC",
                "Primary Resistance",
                "Secondary Resistance",
                "Target Amplification",
                "Bypass Signaling Pathway Activation",
                "Downstream Effector Activation",
                "Phenotypic and Histological Transformation",
                "Drug-Tolerant Persister Cells",
                "Heterogeneity and Polyclonal Resistance",
                "Strategies Targeting TKI Resistance",
                "Concluding Remarks",
                "Outstanding Questions"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Ten-Year_Survey_of_Lung_Cancer.pdf-39453f6d",
        "document": "This 1999 American Cancer Society report analyzes lung cancer treatment and survival trends in US hospitals from 1985-1995 using data from the National Cancer Data Base (NCDB).  The study reveals demographic shifts (more older, female, and African-American patients, increased adenocarcinoma cases), minimal changes in treatment (more lymph node dissection, increased chemotherapy use), and a consistently poor overall survival rate (7% at 10 years).  Despite some improvements in staging and treatment, the authors emphasize the need for enhanced prevention and treatment strategies, particularly for improving outcomes in later-stage diagnoses.",
        "metadata": {
            "identifier": "1160ca42644bf52539ffb6635ff6423784bc2aaa5a1188a1a0671979e8675f0b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:41.355763+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Ten-Year Survey of Lung Cancer.pdf",
            "name": "Ten-Year Survey of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Scientific Article",
            "keywords": [
                "Lung Cancer",
                "Treatment",
                "Survival",
                "National Cancer Data Base (NCDB)",
                "Adenocarcinoma",
                "Chemotherapy",
                "Radiation Therapy",
                "Staging",
                "Demographics"
            ],
            "author": [
                "Willard A. Fry, M.D.",
                "Jerri Linn Phillips, M.A., C.T.R.",
                "Herman R. Menck, M.B.A."
            ],
            "timestamp": "July 20, 1999",
            "headings": [
                "BACKGROUND",
                "METHODS",
                "RESULTS",
                "Patient Characteristics",
                "Treatment",
                "Survival Outcome",
                "DISCUSSION",
                "Demographic Trends",
                "Treatment Trends",
                "Survival Implications",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Treatment_of_Lung_Cancer.pdf-a3ba8c8e",
        "document": "This article reviews the treatment of lung cancer, focusing on both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).  Treatment strategies for NSCLC vary depending on the stage of the disease, ranging from surgical resection for early stages to chemotherapy and radiotherapy for advanced stages.  Molecularly targeted therapies are also discussed for patients with specific genetic mutations.  For SCLC, the treatment approach depends on whether the cancer is limited-stage or extensive-stage, with combined modality therapy being the standard for limited-stage disease.",
        "metadata": {
            "identifier": "2491e996e49ae1e486a2e3ee0ab9c18ac174caf58c61502e1e6660e279e554d5",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:47.134371+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Treatment of Lung Cancer.pdf",
            "name": "Treatment of Lung Cancer.pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Lung Cancer",
                "Non-small cell lung cancer (NSCLC)",
                "Small cell lung cancer (SCLC)",
                "Chemotherapy",
                "Radiotherapy",
                "Surgery",
                "Molecular therapy",
                "Targeted therapy"
            ],
            "author": "Shirish M. Gadgeel, Suresh S. Ramalingam, Gregory P. Kalemkerian",
            "timestamp": "2012",
            "headings": [
                "NON–SMALL CELL LUNG CANCER",
                "Stage I/II NSCLC",
                "Surgery",
                "Nonsurgical therapy",
                "Adjuvant therapy",
                "Stage III NSCLC",
                "Stage IV NSCLC",
                "First-line chemotherapy",
                "Maintenance therapy",
                "Salvage chemotherapy",
                "Targeted therapy",
                "EGFR mutation",
                "ALK gene rearrangement",
                "Antiangiogenic therapy",
                "Future Directions",
                "SMALL CELL LUNG CANCER",
                "Treatment",
                "Radiotherapy",
                "Chemotherapy",
                "Recurrent disease",
                "Future Directions",
                "ACKNOWLEDGMENTS",
                "REFERENCES"
            ],
            "llm_status": "success"
        }
    },
    {
        "id": "unstructured-Treatment_of_non-small_cell_lung_cancer_NSCLC_.pdf-ba10cf2e",
        "document": "This review article discusses the treatment of non-small cell lung cancer (NSCLC), focusing on various stages and treatment strategies.  It covers surgical interventions, adjuvant therapies like chemotherapy and radiotherapy, and the use of targeted therapies such as EGFR and VEGF inhibitors.  The article also explores the role of biomarkers in predicting treatment response and the benefits of concurrent versus sequential chemo-radiotherapy.  Treatment options are detailed for different stages of NSCLC, from early-stage surgical resection to advanced-stage multidisciplinary approaches.",
        "metadata": {
            "identifier": "f2a64fcec91675fd88ed2f9f5d99e6c97c2049eb19b1335899725340f427cf6b",
            "data_type": "unstructured",
            "source_type": "file",
            "collection_time": "2025-06-25T11:26:52.884793+00:00",
            "original_file_path": "C:\\Users\\karti\\OneDrive\\Desktop\\RAG\\Document\\Unstructured\\Lung Cancer\\Treatment\\Treatment of non-small cell lung cancer (NSCLC).pdf",
            "name": "Treatment of non-small cell lung cancer (NSCLC).pdf",
            "document_type": "pdf",
            "domain_themes": "Healthcare",
            "keywords": [
                "Non-small cell lung cancer",
                "NSCLC",
                "cancer treatment",
                "chemotherapy",
                "radiotherapy",
                "targeted therapy",
                "EGFR inhibitors",
                "VEGF inhibitors",
                "surgical resection",
                "biomarkers"
            ],
            "author": [
                "Konstantinos Zarogoulidis",
                "Paul Zarogoulidis",
                "Kaid Darwiche",
                "Efimia Boutsikou",
                "Nikolaos Machairiotis",
                "Kosmas Tsakiridis",
                "Nikolaos Katsikogiannis",
                "Ioanna Kougioumtzi",
                "Ilias Karapantzos",
                "Haidong Huang",
                "Dionysios Spyratos"
            ],
            "timestamp": "July 5, 2013",
            "headings": [
                "ABSTRACT",
                "Introduction",
                "Management of NSCLC according to the extent of the disease",
                "Early disease stage I-IIIA",
                "Stage IA",
                "Stage IB",
                "Stage II",
                "Locally advanced IIIA and selected IIIB",
                "Stage IIIB",
                "Management of advanced non-small cell lung cancer stage IIIB-IV",
                "Chemotherapy vs. best supportive care (BSC)",
                "Number of chemotherapy pts",
                "Concurrent vs. sequential chemo radiotherapy",
                "Treatment according to prognostic and predictive factors",
                "Excision repair cross-complementation group 1 and regulatory subunit of ribonucleotide reductase (ERCC1, RRM1)",
                "Thymidylate synthase expression (TS)",
                "Biological agents",
                "Acknowledgements",
                "References"
            ],
            "llm_status": "success"
        }
    }
]